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Abstract  
There is lim ited scient ific evidence of herbal and dietary supplem ent  (HDS)  
safet y am ongst  pat ients with renal insufficiency, including the prevalence, 
pat terns and reasons for  HDS use. The prim ary object ive of this thesis was to 
determ ine any associat ions between HDS use and the fast  progression of chronic 
kidney disease (CKD)  in Thai outpat ients with CKD. The other object ives were to 
determ ine 1)  any associat ions between HDS use and CKD com plicat ions;  2)  
pat terns of any other r isk factors of CKD progression and it s com plicat ions;  3)  
the prevalence, t ypes, pat terns and reasons for  HDS use;  4)  the dem ographic 
characterist ics of Thai pat ients with CKD using HDS, com pared with non-users;  
5)  any associat ion between HDS use and the level of adherence to prescribed, 
convent ional m edicat ion;  6)  pat ients’ experiences of the beneficial and adverse 
effect s from  using HDS;  and 7)  rate of non-disclosure of HDS use to a doctor 
and the reasons for that  non-disclosure. 
Following ethical approval in Thailand, a survey recruited 421 outpat ients with 
stages 3 to 5 CKD from  two kidney clinics in cent ral Thailand, from  January to 
June 2012. A prospect ive cohort  study followed up these respondents, in 
part icular not ing their serum  creat inine, as well as serum  levels of potassium 
and phosphate, for  12 m onths. Three hundred and fift y-seven respondents were 
com pletely followed up. The exposed group was defined as the current  and 
regular users of HDS and the prim ary outcom e of the cohort  study was defined 
as either a decline in the est im ated glom erular filt rat ion rate of at  least  5 
m l/ m in/ 1.73m 2/ year or the init iat ion of renal replacem ent  therapy. Sixteen HDS 
users were recruited from  the survey to be interviewed about  their reasons for  
using HDS, using open-ended quest ions to elicit  inform at ion in the qualitat ive 
study. Exclusion criteria were those with had received renal replacem ent  therapy 
before the recruitm ent .  
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Pat ients were interviewed face to face regarding dem ographics, use and 
disclosure of HDS, and adherence to prescribed, convent ional m edicine, which 
was assessed by the Thai version of the 8- I tem  Morisky Medicat ion Adherence 
Scale® . Their co-m orbidit ies, current  use of convent ional m edicine and 
laboratory results were ext racted from  their m edical notes. Univariate and 
m ult ivariate analyses were perform ed to determ ine the associat ions using Chi-
squared tests and m ult iple logist ic regressions for dichotom ous independent  and 
dependent  variables. Tests were 2- tailed and a p- value <  0.05 was considered 
stat ist ically significant .  
The prevalence of HDS use during the previous year in Thai pat ients with CKD 
was 45%  (95% CI  40% -50% )  and 99%  of these used HDS together with 
convent ional m edicine. Most  respondents used HDS for m aintaining well-being 
(61% )  whilst  30%  used HDS for kidney diseases. Kariyat , turm eric and horse 
radish t ree were the m ost  com m only used HDS. The m ost  frequent ly reported 
influences on HDS use in the survey and the qualitat ive study were fam ily 
m em bers, fr iends and percept ion of benefit s gained from  using HDS. Seventy-
two percent  did not  inform  their doctor about  their HDS use. Those report ing a 
m edium  level of convent ional m edicine adherence (adjusted OR 0.53, 95%  CI  
0.32-0.87)  were less likely to use HDS, com pared with those report ing poor 
adherence.  
An associat ion between HDS use and CKD progression was not  found (adjusted 
OR 1.16, 95% CI  0.66 – 2.03) . Exist ing proteinuria at  baseline had the st rongest  
associat ion with the fast  progression of CKD (adjusted OR 4.22, 95%  CI  2.52 – 
7.05) , followed by younger age (adjusted OR 1.91, 95%  CI  1.14 – 3.18) . Two 
respondents (0.6% )  had acute kidney injury, which m ay be related to the use of 
unknown Chinese herbal m edicines or r iver spiderwort  com bined with diclofenac;  
issues which were reported by their doctor in their m edical note. Addit ionally, 
HDS use was associated with uncont rolled hyperphosphatem ia (adjusted OR 
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3.53, 95% CI  1.20 – 10.43) , possibly due to t he HDS used in the cohort  study 
which contained phosphate or vitam in D. Meanwhile, no associat ion between 
HDS use and uncont rolled hyperkalem ia was found (adjusted OR 0.59, 95% CI  
0.25 – 1.38) .  
Health care providers, part icularly in Thailand, should be aware of the high 
num ber of CKD pat ients using HDS;  in part icular that  m any m ay not  inform  their  
doctor about  their HDS use. For this reason it  is suggested enquir ies about  HDS 
use should be included in guidelines for CKD m anagem ent . They should also 
closely m onitor CKD pat ients using Chinese herbal m edicine, r iver spiderwort  or  
HDS containing phosphorus or vitam in D. Proteinuria raises m ore concerns about  
the fast  progression of CKD than HDS use in Thai pat ients with CKD. A lim itat ion 
of this cohort  study was that  it  considered all HDS use and had a lim ited sam ple 
size. Further studies need to extend the follow-up period of this cohort  study to 
5 years to invest igate any long- term  effects of HDS, in a populat ion-based 
cohort  study, in order to confirm  this present  study’s findings and to exam ine 
renal adverse effects of specific herbal m edicines, part icularly in relat ion to acute 
kidney injury.   
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1 . I nt roduct ion to the study 
The prevalence of the use of herbal and dietary supplem ents (HDS)  has been 
increasing worldwide, part icularly in Asian populat ions.1 Pat ients with stages 3 to 
5 chronic kidney disease (CKD)  are m ore vulnerable to renal adverse effect s of 
HDS and there are several report s of nephropathy from  using HDS in general 
populat ions.2-7 Therefore, health professionals have raised safety concerns about  
HDS use in pat ients with CKD.8-10 The US Nat ional Kidney Foundat ion Kidney 
Disease Outcom es Qualit y I nit iat ive in 2012 (NKF-KDOQI ® ) , and the Thai 
guideline for CKD m anagem ent  in 2009, have both recom m ended pat ients with 
CKD should avoid using herbal m edicines, although they have only a few case 
report s of products containing aristolochic acid use related to acute kidney injury 
to support  this recom m endat ion.11,12 Case reports are the m ain source of 
evidence regarding renal adverse effect s from  HDS use2,3 although there have 
been cross-sect ional and case-cont rol studies in Thailand and Taiwan report ing 
the use of herbal m edicine relat ing to individuals newly diagnosed with CKD or 
end stage renal disease.4,5,7 There is lim ited evidence of HDS use being 
associated with progression of CKD and it s com plicat ions am ongst  pat ients with 
advanced CKD, part icularly in prospect ive studies.13 
Despite the high prevalence of HDS use in Asian populat ions, there is a lack of 
studies invest igat ing the use and effects of HDS am ongst  pat ients with CKD.14 
Most  epidem iological studies in Thailand and Taiwan have invest igated general 
populat ions using herbal m edicines and have m easured end-stage renal disease 
or developing CKD as an outcom e.4-7,13 There is lim ited inform at ion from  a sm all 
num ber of surveys about  HDS use in Western populat ions with CKD.15,16 These 
issues need to be invest igated in order for health care professionals to be aware 
of likely HDS use in such pat ients, and to ident ify and m onitor the effects of HDS 
in those pat ients. 
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The associat ion between HDS use and adherence to prescribed, convent ional 
m edicat ion is unknown. Literature reports HDS use being associated with poor 
adherence to convent ional m edicat ion or that  there is no relat ionship between 
these two variables.17-19 Further studies are required to ascertain any associat ion 
as convent ional m edicat ion adherence is a crucial factor related to the 
achievem ent  of pharm acotherapeut ic outcom es in pat ients.  
The prim ary aim  of this thesis, in a prospect ive cohort  study, was to determ ine 
any associat ions between HDS use and the progression of CKD, including it s 
com plicat ions in Thai pat ients with advanced CKD. This would provide further 
evidence of the safety of HDS in these pat ients and provide evidence for health 
care providers, when advising on the use of HDS with this populat ion. The other 
aim s were to determ ine 1)  the pat terns of any other r isk factors of CKD 
progression and it s com plicat ions;  2)  the prevalence, types, pat terns, and 
reasons for  HDS use;  3)  the dem ographic characterist ics of Thai pat ients with 
CKD using HDS, com pared with non-users;  4)  any associat ion between HDS use 
and the level of adherence to prescribed, convent ional m edicat ion;  5)  pat ients’ 
experiences of the beneficial and adverse effect s from  using HDS;  and 6)  rate of 
non-disclosure of HDS use to a doctor and reasons for non-disclosure. 
Structure  of the thesis 
Following this int roduct ion, this thesis consists of a further nine chapters and 
these chapters are sum m arised below.  
Chapters 2  to 4  present  the literature review, gaps in research and content  of 
each chapter is as follows:   
Chapter 2 presents an overview of herbal and dietary supplem ents – definit ions 
of HDS, the prevalence of HDS use in pat ients with CKD and dem ographic 
characterist ics of those using HDS. This chapter then presents about  at t itudes 
towards HDS use and disclosure of HDS use. Evidence for  relat ionships between 
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HDS use and adherence to prescribed convent ional m edicine is exam ined. 
Finally, this chapter presents the regulat ions regarding availabilit y and 
recom m ended use of HDS, and details of a post -m arket ing surveillance system  
for adverse effects from  HDS use in Thailand.  
Chapter 3 gives an overview of chronic kidney disease, including it s definit ion 
and classificat ion of CKD. Then the prevalence of CKD in Thailand is described, 
together with the sym ptom s and com plicat ions of CKD, r isk factors for and the 
m easurem ent  of the progression of CKD and CKD com plicat ions. This is followed 
by the presentat ion of t reatm ent  opt ions in CKD, and recom m endat ions for HDS 
use, based on guidelines for the m anagem ent  of CKD. 
Chapter 4 describes the negat ive and posit ive effects of HDS use on the renal 
system . 
Chapters 5  and 6  present  the study’s aim s and an overview of the m ethods 
used. There are two m ain studies described in this thesis;  a cross-sect ional 
survey of CKD pat ients at tending an outpat ient  clinic and these pat ients then 
form ed a cohort  which was followed prospect ively for one-year.  The survey 
determ ined the prevalence, types, pat terns and reasons for HDS use;  the 
dem ographic characterist ics of Thai pat ients with CKD using HDS com pared with 
non-users;  any associat ion between HDS use and the level of adherence to 
prescribed, convent ional m edicat ion;  pat ients’ experiences of the beneficial and 
adverse effects from  using HDS;  and the rate of non-disclosure of HDS use to a 
doctor and reasons for  such non-disclosure. Meanwhile the cohort  study 
determ ined associat ions between HDS use, the progression of CKD and it s 
com plicat ions, and the pat terns of any other r isk factors of CKD progression and 
it s com plicat ions. The m ethod chapter explains the reasons for the inclusion and 
exclusion criteria, and selected set t ings for both studies. 
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Chapter  7  describes the developm ent  and test ing of researcher adm inistered 
quest ionnaires regarding dem ographics, types, pat terns, purposes and disclosure 
of HDS use, percept ion of benefit s and adverse effect s of HDS for a survey, and 
researcher adm inistered open-ended quest ions about  at t itudes towards HDS use 
for  a qualitat ive study. The validity and reliabilit y of the Thai-version of the 8-
item  Morisky Medicat ion Adherence Scale®  and the Rest r ict ion of Protein, 
Potassium , Phosphate and Salt  Diet  (RPPPS)  Quest ionnaire for pre-dialysis 
pat ients were tested with a group of Thai CKD pat ients. Further aim s were to 
test  the recruitm ent  process, to est im ate the t im e needed to recruit  for the m ain 
study, and to analyse the com pleteness of rout inely collected inform at ion from  
pat ients’ records in the two set t ings. 
Chapter  8  presents t he findings from  the survey of the prevalence, types, 
pat terns, and disclosure of HDS use;  the dem ographic characterist ics of Thai 
pat ients with CKD using HDS, com pared with non-users;  percept ions of benefit s 
and adverse effects of HDS use am ongst  Thai outpat ients with CKD, including 
analysis of the associat ion between HDS use and adherence to prescribed 
convent ional m edicine. Reasons for HDS use are presented based on data from  
both the survey and the qualitat ive study. This chapter supports the other aim s 
of the thesis and explains the reasons for the study’s design.  
Chapter  9  presents the findings from  the cohort  study, which invest igated any 
associat ions between HDS use, the progression of CKD and it s com plicat ions. 
There are explanat ions concerning reasons for study design and definit ions of 
exposed and unexposed groups, r isk factors and study outcom es.  
Chapter 1 0  sum m arises and concludes the thesis – key findings, sum m ary of 
discussion, st rengths and weaknesses of the study, im plicat ions for clinical 
pract ice and policy, and recom m endat ions for further studies.    
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2 . Herbal and dietary supplem ents 
There is widespread usage of herbal and dietary supplem ent  (HDS) . The World 
Health Organisat ion (WHO)  reports over 75%  of the populat ion, in som e Asian 
count ries, use herbal m edicine whilst  38-75%  of Western populat ions use 
com plem entary and alternat ive m edicine.1 I n the last  decade research in this 
field has been increasing. Many Asian count r ies have established a research 
inst itut ion of herbal m edicine, such as China, South Korea, Thailand, I ndonesia 
and Viet  Nam .1 Funding for alternat ive m edicine research has been increasing in 
both the US and UK.1 Various definit ions of HDS have been reported in the 
literature and are discussed in this chapter.  An overview of com plem entary, 
alternat ive and integrat ive m edicine, the prevalence of HDS use, at t itudes about  
and influences on HDS use, and the regulatory and safety environm ent  for  HDS 
in Thailand, are presented in this chapter.  
2 .1  Overview  of com plem entary, a lternat ive and 
integrat ive m edicine 
2 .1 .1  Definit ions of com plem entary, a lternat ive and 
integrat ive m edicine 
There are two term s com m only used to describe non-convent ional medicine:  i)  
com plem entary and alternat ive m edicine (CAM)  and ii)  integrat ive m edicine 
( IM) . CAM is used m ore often to describe a new choice of therapy, instead of 
convent ional m edicine, whilst  IM refers to integrated use of alternat ive m edicine 
with convent ional m edicine.20,21   
CAM has been defined by WHO, the Nat ional Center for  Com plem entary and 
Alternat ive Medicine (NCCAM)  in the US and the House of Lords in the UK. The 
definit ions are sim ilar in their m eanings and enable them  to be used worldwide.  
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“CAM are used to refer t o a broad set  of health care pract ices that  are not  part  of 
a count ry’s own t radit ion, or not  integrated into it s dom inant  health care system ”  
(World Health Organizat ion, 2002: 7) .1  
NCCAM defines CAM as “a group of diverse m edical and health care system s,  
pract ices and products that  are not  generally  considered part  of convent ional 
m edicine” .22 Sim ilarly, the House of Lords defines CAM as “a diverse group of 
health- related therapies and disciplines which are not  considered to be a part  of 
m ainst ream  m edical care” .23 These definit ions are defined from  a Western 
perspect ive. From  an Asian perspect ive, the term  ‘t radit ional m edicine’ (TM)  is 
m ore likely to be used rather than CAM, as in m ost  Asian count ries TM is 
em bedded in health care system s as a m ainstay or self- care m anagem ent  of a 
wide variety of condit ions. I n such count ries as India, China and Thailand, 
individuals are likely to turn to TM before t reatm ent  is sought  from  Western or 
convent ional m edicine.21 
I n Thailand, the Pract ice of the Arts of Healing Act  1999 defined Thai t radit ional 
m edicine as “ the m edical processes dealing with the exam inat ion, diagnosis, 
therapy, t reatm ent , or  prevent ion of diseases, or  prom ot ion and rehabilitat ion of 
the health of hum ans or anim als, m idwifery, Thai m assage, as well as the 
preparat ion, product ion of Thai t radit ional m edicines and the m aking of devices 
and inst rum ents for  m edical purposes. All of these are based on the knowledge 
or t extbooks that  were passed on and developed from  generat ion to 
generat ion” .24 Recent ly, the Nat ional Health Care System  in Thailand has 
included alternat ive m edicine, i.e. herbal m edicine, acupuncture and m assage, 
and therefore m ost  Thai people consider CAM with convent ional m edicine as a 
m ainst ream  m edicine and they will rout inely use such t reatm ents.   
  
Chapter 2:  Herbal and dietary supplements 
7 
2 .1 .2  Types of CAM 
The House of Lords (2000)  classified CAM into three groups.23 First ly, 
professionally organised alternat ive therapies which claim  to have an individual 
diagnost ic approach including acupuncture, chiropract ic, herbal m edicine, 
hom eopathy and osteopathy.23 This group is the m ost  frequent ly used in the UK. 
Secondly, com plem entary therapies, which are added to convent ional m edicine:  
the Alexander technique, arom atherapy, Bach and other flower rem edies, body 
work therapies, including m assage, counselling st ress therapy, hypnotherapy, 
m editat ion, reflexology, Shiatsu, healing, Maharishi Ayurvedic m edicine, 
nut r it ional m edicine and yoga. Finally, alternat ive disciplines are divided into 
long-established and t radit ional system s of healthcare, and other alternat ive 
disciplines, which have lim ited evidence of effect iveness. Within the final group 
the first  subgroup consists of anthroposophical, Ayurvedic m edicine, Chinese 
herbal m edicine, Eastern m edicine, naturopathy and t radit ional Chinese 
m edicine. The second subgroup is crystal therapy, dowsing, iridology, 
kinesiology and radionics.23 A nat ional survey in the UK found that  herbal 
m edicine was the m ost  frequent ly used CAM (34% ) , com pared with 
arom atherapy (21% ) , hom eopathy (17% ) , acupuncture or acupressure (14% )  
and m assage (6% ) .23 
NCCAM classified types of CAM into natural products, m ind and body m edicine, 
m anipulat ive and body-based pract ices, and other CAM pract ices.22 Natural 
products refer to herbal m edicines or dietary supplem ents. Mind and body 
m edicine consists of m editat ion and acupuncture whilst  m anipulat ive and body-
based pract ices include spinal m anipulat ion, such as chiropract ic and m assage. 
Exam ples of other CAM pract ices are the Alexander technique and Feldenkrais 
m ethod. A nat ional survey in the US showed natural products were the m ost  
frequent ly used (22% ) , followed by chiropract ic (8% ) , yoga (5% )  and m assage 
(5% ) .25 
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In Thailand, types of Thai t radit ional m edicine are herbal m edicine, Thai 
m assage, hot  herbal com presses and herbal steam  baths, and m editat ion.26 A 
survey of hospital pat ients in Thailand reported that  folk rem edies or herbal 
m edicine was the m ost  frequent ly used (72% ) , followed by m assage (31% )  and 
dietary supplem ents (12% ) .27 
Therefore, herbal m edicines and dietary supplem ents fall within the definit ions of 
CAM and are the m ost  frequent ly used types of CAM.  
2 .2  Definit ion of herbal and dietary supplem ent 
use 
There are various term s and definit ions of HDS across studies of HDS 
usage.4,10,14,15,28-30 ‘Natural products’ was the term  used by Grabe and Garrison 
(2004)  and Laliberte et  al. (2007) , whilst  ‘natural herbs’ was used by Kennedy 
(2005)  and Gardiner et  al. (2007) . Grabe and Garrison (2004)  defined ‘natural 
products’ as herbal or  dietary supplem ents.15 Likewise, Kennedy (2005)  and 
Gardiner et  al. (2007)  used ‘natural herbs’, which include dietary 
supplem ents.28,29 The term  ‘dietary supplem ents’, which includes herbs, was 
used by Tim bo et  al. (2006) .10 However, Laliberte et  al. (2007)  did not  define the 
term  in their study.30 
I n Asian count ries, som e herbs are part  of diet  or are added to flavour food, 
rather than used for health reasons. Studies of herbal m edicine use in Turkey 
and Taiwan4,14 did not  include herbal food consum pt ion in their definit ion of 
herbal m edicine usage. Therefore, studies of herbal m edicine from  Asian 
count ries are less likely to include herbal food consum pt ion, as this m ay 
overest im ate prevalence of herbal m edicine use.  
There are widely used definit ions of herbal m edicine and dietary supplem ents 
defined by the WHO and the US Food and Drug Adm inist rat ion (US FDA) , 
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respect ively. The WHO defines a herbal m edicine as “a plant -derived m aterial or  
preparat ion with therapeut ic or other hum an health benefit s which contains 
either raw or processed ingredients from  one or m ore plants. I n som e t radit ions 
m aterials of inorganic or anim al origin m ay also be present "  (World Health 
Organizat ion, 2000:  27) .31 Dietary supplem ents are defined by the US FDA as 
products containing ingredients in order to supplem ent  diet .32 Dietary ingredients 
include vitam ins, m inerals, herbs or other botanicals, am ino acids and 
substances, such as enzym es, organ t issues, glands and m etabolites.32 The Thai 
Drug Act  1967 defined herbal m edicine as “ m edicine [ that ]  is derived from  a 
plant , anim al and m ineral in a raw state” .33 
I n the present  study, HDS was defined as products containing plant -derived 
m aterial, which m ay be raw or processed ingredients from  one or m ore plants;  
or  products containing dietary ingredients, such as vitam ins, m inerals, am ino 
acids and substances, for  exam ple enzym es, organ t issues, glands and 
m etabolites, which com bines the US FDA and WHO definit ions.31,32 Addit ionally, 
this study focused on HDS use for the t reatm ent  of illnesses or health prom ot ion 
rather than consum pt ion as daily food intake or for  cosm et ic purposes, due to 
HDS being less likely to be frequent ly used. Also the study did not  include 
prescribed dietary supplem ents, which were a standard t reatm ent  for  CKD. 
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2 .3  The prevalence of CAM and HDS use and their 
characterist ics 
There is lim ited evidence report ing the prevalence and dem ographic 
characterist ics of CAM or HDS use am ongst  pat ients with CKD, whilst  large 
num bers of surveys have reported this inform at ion in both the general and other 
pat ient  populat ions.  
2 .3 .1  The prevalence of HDS and CAM use in pat ients w ith 
CKD 
The prevalence of current  HDS use am ongst  pat ients with CKD in Canada and 
the US ranges from  29 to 45% , see Table 2.1.15,16 However, there is no evidence 
from  Asian populat ions. I n the US, the prevalence of HDS use am ongst  pat ients 
with CKD (29% ) 15 was lower than pat ients with cardiovascular disease (57% ) 34 
and the general populat ion (52-73% ) .10,35 Sim ilarly, the prevalence of herbal use 
in dialysis pat ients (28% )  in Turkey14 was lower than the general populat ion 
(55% ) .36 Whereas there was no difference in the prevalence of dietary 
supplem ent  use between pat ients with CKD (45% )  in Canada16 and the general 
populat ion (40% ) .37   
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Table 2.1 Studies report ing the prevalence of HDS or CAM use in pat ients with 
CKD, pat ients receiving dialysis or kidney t ransplant  recipients (n= 5)  
Authors and country Definit ion Populat ion and 
sample size 
Prevalence 
(% )  
Kara (2009) , 
Turkey14 
Herbal product  use was 
defined as ‘having ever used 
them for health maintenance 
or t reatment of health 
problems rather than for food 
consumpt ion’ 
114 
haemodialysis 
pat ients 
28.1 
Hess et al. (2009) , 
Switzer land38 
CAM defined by I nst itute of 
Medicine of the Nat ional 
Academ ies 
356 kidney 
t ransplant  
recipients 
11.8 (CAM use) 
1.9 (herbal 
use)  
Nowack et  al. 
(2009) , Germany39 
-  CAM use was defined as 
‘having regular ly consumed 
CAM in the last  12 months’ 
-  CAM use were herbal or 
dietary supplements 
119 dialysis 
pat ients 
57 
 
45 kidney 
t ransplant  
recipients 
49  
Spanner and Duncan 
(2005) , Canada16 
-  DS use defined as ‘current  
daily consumpt ion’ 
-  DS defined by the Dietary 
Supplement  Health and 
Educat ion Act (1994)*  
100 pat ients with 
CKD 
45 
Grabe and Garr ison 
(2004)  US15 
-  Natural products use defined 
as ‘current  use’ 
-  Natural products were defined 
as ‘herbal or dietary 
supplements’ 
250 pre-dialysis 
pat ients 
29 
*  Dietary supplement defined as a product intended to supplement the diet and not a convent ional 
food16 
2 .3 .2  The prevalence of CAM and HDS use in the general 
and pat ient  populat ions  
There are large num bers of studies m easuring the prevalence of CAM or HDS use 
in the general populat ion (n= 15) 4,10,25,35-37,40-48, com pared with such prevalence 
in pat ients with CKD (n= 5) .14-16,38,39 The prevalence of CAM or HDS use varies 
considerably across both general and pat ient  populat ions.17-19,27,34,49-68 Som e of 
the variat ion can be explained by the different  periods used to m easure 
prevalence and by the various definit ions of CAM, dietary supplem ent  (DS)  or 
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HDS use, see Tables 2.2 and 2.3. ‘One-year ’ is m ost  frequent ly reported in the 
literature regarding the prevalence of HDS or CAM use in both general and 
pat ient  populat ions (n= 19, 48% ) . Definit ions of CAM, DS or herbal use in the 
literature were m ainly based on the NCCAM definit ion (n= 11, 28% ) . However, 
33%  (n= 13)  and 25%  (n= 10)  of surveys of such prevalence did not  define a 
period of use and definit ion of CAM or HDS, respect ively. Sixty-eight  percent  
(n= 27)  of these surveys reported the prevalence of CAM use and 55%  (n= 22)  
showed the prevalence of HDS use.  
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Table 2.2 Studies report ing the prevalence of CAM and/ or HDS use in general populat ions (n= 15)  
Authors and country Definit ion and per iod for prevalence  Sample size Prevalence (% ) 
Thomson et  al. (2012) , 
Aust ralia48 
CAM use was not  defined 1,261 61.7 
Hunt  et  al. (2010) , UK47 CAM use in the last  12 months 7,630 26.3 
Marques-Vidal et  al. 
(2009) , Switzer land44 
DS defined by authors*  6,188 25.7 (DS use, including 
plant  ext racts)  
Ock et  al. (2009) , South 
Korea45 
-  CAM use in the last  12 months 
-  CAM defined by NCCAM 
3,000 74.8 (CAM use) 
65.4 (HDS use)  
Aziz and Tey (2009) , 
Malaysia46 
-  Herbal use in the last  12 months 
-  Herbal medicine defined by authors* *  
1,601 33.9 
Guo et  al. (2009) , 
Canada37 
Vitam in and m ineral supplements use in the last  month 35,107 40.1 
Aydin et al. (2008) , 
Turkey36 
-  Herbal use in the last  12 months 
-  Herbal medicine defined by NCCAM 
873 55.4 
Guh et  al. (2007) , Taiwan4 -  Herbal use was not  defined 1,740 21.6 
Xue et  al. (2007) , 
Aust ralia43 
CAM use in the last  12 months 1,067 68.9 
Timbo et  al. (2006) , US10 -  DS use in the last  12 months 
-  DS defined by the Dietary Supplement  Health and Educat ion Act (1994)* * *  
2,743 73 (DS use, including 
herbal medicine) 
Barnes et  al. (2004) , US25 -  CAM use in the last  12 months 
-  CAM defined by NCCAM 
31,044 36 (CAM use) 
18.9 (HDS use)  
Radimer et  al. (2004) , 
US35 
-  Dietary supplements (DS)  use in the last  month 
-  DS defined by the Dietary Supplement  Health and Educat ion Act (1994)* * *  
4,862 52 (DS use, including 
herbal medicine) 
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Table 2.2 (cont inued)  
Authors and country Definit ion and per iod for prevalence  Sample size Prevalence (% ) 
Singh et al. (2004) , South 
Afr ica42 
-  CAM use in the last  12 months 
-  CAM defined by the American Nat ional I nst itute of Health’s Office of 
Alternat ive Medicine 
200 38.5 
Al-Windi et al. (2000) , 
Sweden40 
      Herbal use in the last  12 months 1,312 31.8 
Balluz et  al. (2000) , US41 -  Vitam in and m ineral supplements use in the last  month 
-  They defined by the Dietary Supplement  Health and Educat ion Act  (1994)* * *  
33,905 40 
*  Dietary supplements were defined as all possible dietary components not usually included in a regular diet , including herbal tea and plant  and animal ext racts. 
* *  Herbal medicine was defined as all plant -der ived products which contain either raw or processed ingredients from one or more plants used to prevent  or t reat  diseases.  
* * *  Dietary supplements were defined as a product  (other than tobacco)  intended to supplement the diet that  bears or contains one or more of the following dietary 
ingredients:  a vitam in, a m ineral, an herb or other botanical, an am ino acid, or  a dietary substance for use to supplement  the diet  by increasing the total dietary intake, or a 
concentrate, metabolite, const ituent , ext ract , or  combinat ion of the above ingredients. 
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The prevalence of CAM use within a year in general populat ions ranges from  
26%  to 75% , see Table 2.2.25,42,43,45,47 A sim ilar range of prevalence is seen in 
studies am ongst  pat ients with chronic illnesses, which varies from  23%  to 88% , 
see Table 2.3.19,49,52,53,58,59  
Use of CAM is generally higher in Asian populat ions com pared with Western 
populat ions. The prevalence in Western populat ions varies from  26%  to 36%  
25,47
,  whereas am ongst  Asian populat ions, the prevalence ranges from  38%  to 
75% .42,45  
The one-year prevalence of HDS use am ongst  general populat ions ranges from  
19%  to 73%  in the US and South Korea.10,25,45 I t  would seem  that  the one-year 
prevalence of CAM and HDS use in general populat ions is quite sim ilar (26-75%  
versus 19-73% ) .25,42,43,45,47 Thus, this indicates that  HDS is m ore likely to be 
used than other CAMs. However, it  is not  possible to accurately com pare the 
one-year prevalence of HDS use between Western and Asian populat ions due to 
the low num ber of studies in both populat ions, and inconsistent  prevalence of 
HDS use in the US, due to differences of HDS definit ions. Likewise, there are 
insufficient  studies to com pare the one-year prevalence of HDS use between 
general and pat ient  populat ions. 
The one-year prevalence of herbal use am ongst  the general populat ion in 
Sweden, Turkey and Malaysia ranges from  32%  to 55% , see Table 2.2.36,40,46   
Kennedy (2005)  in the US reported that  the Asian populat ion was m ore likely to 
use herbal m edicine in the last  12 m onths com pared with the Caucasian 
populat ion (25%  versus 19% ) .29 However,  there is lim ited evidence about  the 
prevalence of herbal use in Thailand and two previous studies have not  defined a 
period of herbal use.5,69 These two studies were conducted by Ingsathit  et  al. 
(2010)  and Satyapan (2010) , and found that  the prevalence of herbal use in 
Thailand and Bangkok were 33%  and 29% , respect ively. The m ain object ive of 
I ngsathit ’s study was to determ ine r isk factors influencing chronic kidney disease 
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(CKD) , rather than the prevalence of herbal use in the Thai populat ion.5 
Although Satyapan’s study was to determ ine the prevalence of herbal use in 
Bangkok, respondents were recruited from  Thai people at tending or working at  
the Phram ongkutklao hospital in Bangkok, and therefore, this m ay not  represent  
the general populat ion in Bangkok.69 
Table 2.3 Studies report ing the prevalence of CAM and/ or HDS use in pat ient  
populat ions (n= 25)  
Authors and 
country 
Definit ion and per iod for 
prevalence 
Populat ion and sample 
size 
Prevalence (% ) 
Strej ilevich et  al. 
(2013) , Argent ina 
and Colombia68 
CAM defined by Barnes 
and Ernst (1997) a 
200 outpat ients with 
bipolar disease 
46.7 (CAM use 
together with 
convent ional 
medicine)  
Ali-Shtayeh (2012) , 
Palest inian 
terr itor ies66 
Herbal medicine was not 
defined 
1,883 diabet ic 
pat ients 
51.9 
Weizman et  al. 
(2012) , Canada18 
CAM defined by Zollman 
and Vicker (1999) b 
380 pat ients with 
inflammatory bowel 
disease 
56 
Braun and Cohen 
(2011) , Aust ralia65 
CAM use in the last  2 
weeks before hospital 
adm ission 
161 elect ive cardiac 
surgery inpat ients 
51 
Krousel-Wood et al. 
(2010) , US17 
-  CAM use was defined as 
the use of CAM at  least 
several t imes or on a 
regular basis in the 
year before the 
baseline survey 
-  CAM defined by NCCAM 
2,000 elder ly pat ients 
with hypertension 
26.5 
Shorofi and Arbon 
(2010) , Aust ralia67 
-  Herbal medicine have 
used daily 
-  Defined by NCCAM 
353 inpat ients 38.2 
Lambert  et  al. 
(2010) , UK63 
CAM defined by 
Eisenberg et al. (1993) c 
92 outpat ients with 
headache 
32 (CAM use) 
13 (herbal use) 
10.9 (DS use) 
Ogbera et  al. 
(2010) , Niger ia64 
-  CAM use was defined as 
the use of CAM more 
than once for any 
per iod of t ime 
-  CAM defined by NCCAM 
263 diabet ic pat ients 46 
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Table 2.3 (cont inued)  
Authors and 
country 
Definit ion and per iod for 
prevalence 
Populat ion and sample 
size 
Prevalence (% ) 
Hasan et al. 
(2009) , Malaysia61 
CAM was defined by 
authorsd 
321 outpat ients 63.9 
Wilk inson and 
Jelinek (2009) , 
Aust ralia62 
-  CAM use in the last  12 
months 
-  CAM defined by NCCAM 
102 elder ly pat ients 
with chronic illnesses 
78 (CAM use) 
54 (Vitam in and 
m ineral use) 
28 (herbal use) 
Gohar et al. (2008) , 
UK19 
-  CAM use in the last  12 
months 
-  CAM defined by NCCAM 
153 pat ients with 
hypertension 
43.1 
Hor i et  al. (2008) , 
Japan59 
-  CAM use in the last  12 
months 
-  CAM defined by NCCAM 
496 outpat ients 50 (CAM use) 
28.4 (DS use) 
Rossi et  al. (2008) , 
I taly60 
CAM use in the last 12 
months 
100 pat ients with 
headache 
10 
Kumar et  al. 
(2006) , I ndia56 
CAM defined by NCCAM 493 diabet ic pat ients 67.7 
Saw et al. (2006) , 
Malaysia57 
Herbal medicine defined 
by WHO guidelines for 
the appropr iate use of 
herbal medicines 
(1998) e 
250 inpat ients 42.4 
Yeh et  al. (2006) , 
US58 
-  CAM use in the last  12 
months 
-  Biological based 
therapies defined by 
authorsf 
10,572 pat ients with 
CVD 
68 (CAM use) 
21.8 (biological 
based therapies) 
Barraco et  al. 
(2005) , US53 
-  CAM use in the last  12 
months 
-  Listed types of CAM 
223 inpat ients with 
acute coronary 
syndrome 
63 
Hyodo et  al. 
(2005) , Japan54 
CAM defined by WHO 
(2002) 
3,100 pat ients with 
cancer 
44.6 
Molassiot is et al. 
(2005) ,  
14 countr ies in 
Europe55 
-  Past  and current  use of 
CAM 
-  CAM defined by Ernst et 
al. (1995) g 
956 pat ients with 
cancer 
35.9 
Moolasarn et al. 
(2005) , Thailand51 
-  CAM use in the last  3 
months 
-  CAM defined by 
Eisenberg et al. (1993) c 
159 diabet ic pat ients 
 
47.8 (CAM use) 
32 (herbal use) 
Lee et  al. (2004) , 
Singapore52 
CAM use in the last 12 
months 
488 pat ients with 
chronic illnesses 
22.7 
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Table 2.3 (cont inued)  
Authors and 
country 
Definit ion and per iod for 
prevalence 
Populat ion and sample 
size 
Prevalence (% ) 
Stys et al. (2004) , 
US34 
-  Naturoceut ical use in 
the last  12 months 
-  Naturoceut ical agents 
were vitam in, m ineral 
or supplements. 
187 pat ients with CVD 
 
57 ( including 
herbal medicine) 
Moolasarn et al. 
(2003) , Thailand50 
CAM defined by 
Eisenberg et al. (1993) c 
180 pat ients with 
cancer 
41.1 (CAM use) 
31.7 (herbal use)  
Jiaranaikajorn et al. 
(2002) , Thailand27 
CAM defined by 
Eisenberg et al. (1993) c 
200 inpat ients and 
outpat ients 
52.5 (CAM use) 
38 (herbal use) 
Mat thees et al. 
(2001) , US49 
-  CAM use in the last  12 
months 
-  CAM defined by NCCAM 
99 lung transplant  
recipients 
88 
CVD =  Cardiovascular disease 
a
 CAM was defined as a heterogenous group of pract ices which include several medical and health 
care pract ices and products that  are not  an integral part  of convent ional medicine due to insufficient 
proof of their  safety and effect iveness.70 
b
 CAM was defined as a therapy that  falls beyond the realm  of convent ional medicine and is not 
based on r igorous scient if ic evidence for a part icular indicat ion.71 
c
 CAM was defined as medical intervent ions and techniques that  have neither been t radit ionally  
taught  in medical schools nor included in residency training and that  are not generally used in 
hospitals.72 
d
 CAM was defined as a pract ice for  an holist ic approach other than convent ional medicine. 
e
 Herbal medicine was defined as plant  der ived mater ials or products with therapeut ic or other 
human health benefits, which contain either raw or processed ingredients from one or more plants. 
f
 Biological based therapies were chelat ion therapy, folk medicine, herbal products, large-dose 
vitam ins, special diets, such as vegetar ianism  and macrobiot ics. 
g
 CAM was defined as any diagnosis t reatment  or prevent ion that  complements mainst ream medicine 
by contr ibut ing to a common whole, by sat isfy ing a demand not met  by orthodoxy or by diversify ing 
the conceptual framework of medicine.73 
Som e surveys have reported the prevalence of CAM or HDS use am ongst  elderly 
people, see Table 2.4.74-76 Com paring the one-year prevalence of CAM use 
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between general and elderly populat ions in the US, prevalence in elderly 
populat ions was m ore likely to be higher than the general populat ion (63%  
versus 36% ) .25,74 
Table 2.4 Studies report ing the prevalence of CAM and/ or HDS use in elderly 
populat ions (n= 3)  
Authors and country Definit ion and per iod for 
prevalence 
Sample 
size 
Prevalence (% ) 
Levine et  al. (2009) , 
Canada76 
Natural health products (NHPs)  
use in the last 12 months 
NHPs defined by authors*  
1,206 51 (NHP use) 
Qato et  al. (2008) , 
US75 
DS use at  least  daily or weekly 2,976 49 (DS use, including 
plant  ext racts)  
Cheung et  al. (2007) , 
US74 
-  CAM use in the last 12 
months 
-  CAM defined by NCCAM 
445 62.9 (CAM use) 
44.3 (nut r it ional 
supplements) 
28.3 (mega vitam ins)  
20.7 (herbal use)  
*  NHPs were defined as medicinal products der ived from botanical or  other natural sources (herbal 
products, v itam in, and m ineral supplements.  
2 .3 .3  Dem ographic character ist ics of CAM and HDS users 
A large num ber of cross- sect ional surveys, am ongst  general populat ions 
worldwide, reported dem ographic characterist ics related to the use of CAM, 
including HDS (n= 18) , see Table 2.5. Most  studies in the general populat ion 
have reported that  older people and fem ales are m ore likely to use CAM or HDS. 
There is inconsistent  evidence that  those who are highly educated or who take 
regular exercise are m ore likely to use CAM or HDS. There is evidence to suggest  
educated people in the US, Switzerland and the UK are m ore likely to use CAM or  
HDS29,35,44,47,77,78, whereas those with a lower level of educat ion are m ore likely 
to use them , am ongst  both Asian general and Asian pat ient  populat ions in 
Turkey, South Korea and Thailand.45,50,79 However, other studies have found no 
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relat ionship between educat ional level and CAM or HDS use in Japan, South 
Korea and Turkey.36,80,81    
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Table 2.5 Studies report ing characterist ics of CAM or HDS users in general populat ions (n= 18)  
Authors and country Study design and types of CAM Sample 
size 
Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )   
No associat ion  
Thomson et  al. 
(2012) , Aust ralia48 
-  An interview survey 
-  CAM use 
1,261 -  Age (Ref. age <  65 yrs.)  
Age >  65 yrs. (AOR 0.65, 0.47-0.89) 
-  Male (AOR 0.69, 0.54-0.87) 
-  Not  marr ied (AOR 0.78, 0.61-0.99)  
-  Unemployed (AOR 0.76, 0.56-0.97)  
Educat ion, smoking 
Health status, BMI  
Physical act iv it ies 
Rural/ urban areas 
Chung et  al. (2011) , 
Hong Kong82 
-  Secondary analysis from the Hong 
Kong populat ion representat ive 
themat ic household survey 2007 
dataset  
-  Use of Chinese medicine 
25,208 Age (Ref. age 15-29 yrs.)  
30-39 yrs. (AOR 2.19, 1.28-3.72) 
40-49 yrs. (AOR 2.68, 1.60-4.48) 
50-59 yrs. (AOR 1.94, 1.11-3.41) 
60-69 yrs. (AOR 2.17, 1.15-4.09) 
>  70 yrs. (AOR 2.04, 1.07-3.88) 
-  Male (AOR 0.7, 0.54-0.90) 
-  Educat ion (Ref. Pr imary school)  
Higher educat ion (AOR 2.77, 1.78-4.30) 
-  Self- reported health status (Ref. poor health status)  
Good (AOR 0.39, 0.29-0.51) 
-  Having chronic illnesses (AOR 2.62, 1.96-3.49) 
Personal income 
Secondary school 
educat ion 
Hunt  et  al. (2010) , 
UK47 
-  Secondary analysis from the 
Health Survey for England 2005 
-  CAM use 
7,630 -  Male (OR 0.49, 0.42-0.58)  
-  University educat ion (OR 1.29, 1.09-1.54) 
-  Employed (OR 1.42, 1.18-1.71)  
-  Anxiety/ depression (OR 1.34, 1.07-1.67) 
-  Chronic illnesses (OR1.41, 1.19-1.66) 
Household income 
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Table 2.5 (cont inued)  
Authors and country Study design and types of CAM Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
Araz et  al. (2009) , 
Turkey79 
-  A survey using a quest ionnaire 
-  CAM use 
988 -  Educat ion (Ref. Pr imary school)  
College degree (OR 0.36, 99% CI  0.20-0.63) 
Age, sex, income 
Having chronic 
illnesses 
Guo et  al. (2009) , 
Canada37 
-  A nat ional survey 
-  Use of v itam in and m ineral 
supplements 
35,107 -  Female was more likely to use CAM. 
-  Educat ion (Ref. <  secondary school)  
College degree (AOR 1.37, 1.17-1.61)  
University educat ion (AOR 1.41, 1.18-1.69) 
-  Physical act iv it ies (Ref. act ive)  
Moderate (AOR 0.75,0.63-0.90)  
I nact ive (AOR 0.64, 0.54-0.76)  
Smoking, dr inking 
BMI  
Chronic illnesses 
Lee and Kim  (2009) , 
South Korea81 
-  Secondary analysis from the 
nat ionwide cross-sect ional 
survey 2005 
-  Use of DS 
4,775 Having higher household income was more 
likely to use DS.  
Age, sex, educat ion 
Smoking, dr inking 
Health status 
Employment  
BMI , physical act iv it ies 
Levine et  al. (2009) , 
Canada76 
-  A telephone interview survey 
-  Use of NHPs 
1,206 elder ly 
people 
-  Younger (AOR 0.96, 0.94-0.98)  
-  Smoking (Ref.-never smoking)  
Current  smoking (AOR 0.62, 0.42-0.91) 
Sex 
Educat ion 
Health status  
Marques-Vidal et  al. 
(2009) , Switzer land44 
-  A cross-sect ional survey using 
interviews 
-  HDS use 
6,188 Elder ly, female, higher educated people, 
having regular physical act iv it ies, having 
anxiety/ depression and having normal BMI  
were more likely to use HDS 
Alcohol consumpt ion 
AOR =  Adjusted odds rat io;  CI  =  confidence interval, BMI  =  Body mass index 
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Table 2.5 (cont inued)  
Authors and country Study design and types of 
CAM 
Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
Ock et  al. (2009) , 
South Korea45 
-  A nat ional survey using 
interviews 
-  CAM use 
3,000 People aged 50-59 yrs., female, having less 
than high school educat ion, having high 
household income, being marr ied, being 
unemployed and liv ing in an urban area were 
more likely to use CAM. 
-  
Aydin et  al. (2008) , 
Turkey36 
-  A cross-sect ional populat ion 
based study using interviews 
-  CAM use 
873 -  Female (OR 1.42, 1.08-1.87) 
-  Health status (Ref. good health)  
Fair  (OR 1.36, 1.02-1.82)  
Bad (OR 2.35, 1.18-4.67)  
-  Having chronic disease (OR 1.27, 1.54-2.49) 
Educat ion 
Smoking, dr inking 
Marital status 
I ncome 
BMI  
Cheung et  al. (2007) , 
US74 
-  A mailed survey 
-  CAM use 
445 elder ly 
people 
-  Sex, educat ion 
Marital status 
Annual income 
Xue et  al. (2007) , 
Aust ralia43 
-  A nat ional populat ion based 
survey 
-  CAM use 
1,067 People aged 18-34 yrs., female, higher 
educated people and being employed were 
more likely to use CAM. 
Health status 
I mai et al. (2006) , 
Japan80 
-  An interview survey 
-  HDS use 
2,259 aged 
40-82 yrs 
Middle aged people, female and having poor 
health status were more likely to use HDS. 
Educat ion 
Marital status 
Smoking 
Household income, 
BMI  
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Table 2.5 (cont inued)  
Authors and country Study design and types of CAM Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
Honda and Jacobson 
(2005) , US78 
-  A nat ional survey using both telephone 
interviews and mailed quest ionnaires 
-  CAM use 
4,242 Female and college educated people were 
more likely to use CAM. 
Age 
Marital status 
Kennedy (2005) , US29 -  Secondary analysis from the Nat ional 
Health I nterview Survey 2002 
-  HDS use 
30,412 People aged 45-64 yrs., female, higher 
educated people, having high household 
income, having good health status, former 
smokers and having regular exercise were 
more likely to use HDS. 
-  
Radimer et  al. (2004) , 
US35 
-  Secondary analysis from the Nat ional 
Health and Nutr it ion Exam inat ion 
Survey 1999-2000 
-  DS use 
4,862 -  Age (Ref. age 20-39 yrs.)  
40-59 (OR 1.7, 1.4-2.1) 
> 60 (OR 2.7, 2.2-3.3)  
-  Female (OR 1.6, 1.3-1.8) 
-  Educat ion (Ref. less than high school)  
High school diploma (OR 1.5, 1.2-1.9)  
>  High school (OR 2.4, 1.9-3.2)  
-  BMI  ( ref. normal BMI ) 
BMI  > 30 (OR 0.7, 0.6-0.9) 
Health status 
BMI  25-  <  30 
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In cont rast  with general populat ions, age, sex and educat ional level did not  
affect  CAM or HDS use in pat ient  populat ions reported by the m ajority of studies, 
see Table 2.6.16,19,34,50,51,53,59,66,68 
With respect  to m ost  studies in both general and pat ient  populat ions, there were 
no differences between CAM or HDS users and non-users regarding sm oking, 
drinking, household incom e, m arital status and body m ass index (BMI ) , see 
Tables 2.5 and 2.6. Am ongst  general populat ions, there were inconsistencies in 
associat ions of living in urban or rural areas, self- reported health status and 
having chronic disease between CAM or HDS users and non-users. For instance, 
Ock et  al. (2009)  in South Korea reported that  people living in an urban area 
were m ore likely to use CAM45;  whilst  Thom son et  al. (2012)  in Aust ralia found 
that  there were no associat ions between the users and non-users regarding 
living in urban or rural areas.48 Three studies indicated that  people who 
perceived poor health status were m ore likely to use CAM.36,80,82 On the other 
hand, Kennedy et  al. ( 2005)  reported people with perceived good health status 
were m ore likely to use HDS.29 Other studies found no associat ion of health 
status and the users.43,48,76,81 
Only one study reported dem ographic characterist ics related to HDS use 
am ongst  pat ients with CKD.16 There were no associat ions between the users and 
non-users regarding age, sex, educat ion levels, sm oking status, household 
incom e, the num ber of concurrent  chronic illnesses and the num ber of prescribed 
m edicat ions. 
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Table 2.6 Studies report ing characterist ics of CAM or HDS use in pat ient  populat ions (n= 13)  
Authors and country Study design and types of 
CAM  
Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
St rej ilevich et  al. (2013) 
Argent ina and 
Colombia68 
-  A survey using  
a quest ionnaire 
-  CAM use 
200 pat ients with 
bipolar disease 
-  Age, sex, educat ion 
Marital status, employment 
No. of medicat ions 
Ali-Shtayeh et  al. (2012) 
Palest inian terr itor ies66 
-  An interview survey 
-  Herbal use 
1,883 diabet ic pat ients -  Age, sex, educat ion 
Marital status 
Having chronic illnesses 
Weizman et  al. (2012) 
Canada18 
-  A survey using  
a quest ionnaire 
-  CAM use 
380 pat ients with 
inflammatory bowel 
disease 
 
-  University educat ion (AOR 1.72, 1.05-
2.82)  
-  Exper ienced adverse effects from using 
CM (AOR 2.54, 1.59-4.06) 
Sex, smoking 
Marital status, employment 
Quality of life 
Gohar et  al. (2008) UK19 -  A survey using  
a quest ionnaire 
-  CAM use 
153 pat ients with 
hypertension 
 
-  Age, sex, educat ion 
Marital status 
Hor i et  al. (2008) 
Japan59 
-  A survey using  
a quest ionnaire 
-  CAM use 
496 outpat ients 
 
Female was more likely to use CAM. Age, educat ion 
Financial status 
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Table 2.6 (cont inued)  
Authors and country Study design and types of CAM  Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
Yeh et  al. (2006) 
US58 
-  Secondary analysis from the 
Nat ional Health I nterview 
Survey (NHI S)  2002 
-  The use of CAM or herbal 
medicine 
10,572 pat ients 
with CVD 
 
CAM use 
-  Age >  65 yrs. compared with age <  30 (AOR 0.5, 0.4-0.7) 
-  Female (AOR 1.7, 1.5-1.9) 
-  Completed high school compared with less than high school 
(AOR 1.4, 1.2-1.7) 
-  Higher household income (AOR 1.2, 1.1-1.5) 
-  Asian populat ion compared with whites (AOR 2.1, 1.4-3.1)  
-  Poor health status compared with excellent  health (AOR1.3, 
1.1-1.6)  
Age 30-64 yrs. 
Employment  
Fair  health 
status 
 
 Herbal use 
-  Female (AOR 1.4, 1.2-1.6) 
-  Completed high school compared with less than high school 
(AOR 1.3, 1.1-1.6) 
-  Higher household income (AOR 1.2, 1.1-1.5) 
-  Asian populat ion compared with whites (AOR 2.5, 1.7-3.9)  
Age 
Barraco et  al. (2005) 
US53 
-  An interview survey 
-  Herbal use 
223 inpat ients 
with ACS 
-  Age, educat ion 
Marital status 
I ncome, BMI  
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Table 2.6 (cont inued)  
Authors and country Study design and types of 
CAM  
Sample size Character ist ics related to use CAM or HDS 
(AOR or OR, 95%  CI )  
No associat ion  
Molassiot is et  al. (2005) , 
14 countr ies in Europe55 
-  A survey using a 
quest ionnaire 
-  CAM use 
956 pat ients with cancer Younger people, female and higher 
educated people were more likely to use 
CAM. 
-  
Moolasarn et al. (2005) 
Thailand51 
-  An interview survey 
-  CAM use 
159 diabet ic pat ients 
 
-  Age, sex, educat ion 
Marital status, income 
Quality of life 
Spanner and Duncan 
(2005)  Canada16 
-  An interview survey 
-  HDS use 
100 pat ients with CKD 
 
-  Age, sex, educat ion 
Smoking, household 
income 
No. of concurrent  
chronic illnesses 
No. of prescr ibed 
medicat ions 
Stys et  al. (2004) US34 -  A cohort study over 
one year 
-  HDS use 
187 pat ients with CVD 
 
-  Age, sex 
Smoking 
Moolasarn et al. (2003) 
Thailand50 
-  An interview survey 
-  CAM use 
180 pat ients with cancer -  Educat ion (Ref. having high educated) 
Less educated (OR 0.043, 0.004-0.415) 
-  Having side effects from using CM (OR 
3.054, 1.400-6.662)  
Age, sex 
Marital status 
I ncome 
Mat thees et al. (2001) 
US49 
-  A mailed survey 
-  CAM use 
99 lung t ransplant  
recipients 
 
-  Female (OR 2.68, 1.02-7.03) 
-  College degree compared to high school 
(OR 6.07, 1.62-22.73) 
-  
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2 .4  Reasons for HDS use 
There are large num bers of surveys of at t itudes towards reasons for HDS or CAM 
use worldwide (n= 46) . Meanwhile, qualitat ive studies about  this issue are lim ited 
(n= 4) . Although m ost  studies have been conducted am ongst  CAM users, no 
dist inct ion was m ade between HDS and m ore generic CAM. Both the general 
populat ion and pat ients with chronic illnesses, such as cardiovascular diseases, 
diabetes, hypertension, cancer,  and arthrit is, have been explored, regarding 
their at t itudes towards HDS use. There are m ainly no differences in at t itudes 
across the populat ions using CAM or HDS. However, there are only lim ited 
studies of such at t itudes am ongst  pat ients with CKD (n= 1) .  
Quant itat ive studies show that  the reasons m ost  frequent ly reported for using 
CAM are the percept ion of benefit  and safety ;  followed by dissat isfact ion with 
convent ional m edicine (CM) ;  willingness to t ry them ;  hope to gaining benefit s 
from  using them , including the use of CAM as a last  resort ;  at t itudes towards 
internal health locus of cont rol and an holist ic approach;  and cultural and 
spir itual beliefs. CAM is perceived as a support  for cont rol over health whilst  
people who believe in a holist ic approach to their wellbeing, perceive that  CAM 
supports both physical and m ental health. Cultural and spiritual beliefs are 
associated with decision-m aking in CAM use because they are em bedded in the 
part  of self-m edicat ion am ongst  cit izens in som e count ries, such as China. These 
findings are consistent  with the qualitat ive studies. Table 2.7 sum m arises 
seventeen studies of such at t itudes in general populat ions. 
I n cont rast , the percept ion of scept icism  around the efficacy and safet y of CAM, 
and sat isfact ion of CM, are m ost  frequent ly reported in people who are unlikely 
to use CAM.55,57,60,74 
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Table 2.7 Studies report ing at t itudes towards reasons for CAM or HDS use in general populat ions (n= 17)  
Authors and country Study design and populat ion At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
DS use  
Conner et  al. (2001) , 
UK83  
Database of self- reported  
DS use 
Qualitat ive analysis 
303 female adults 
-  Perceived benefits of DS Benefit  
-  Prevent ion of illnesses  
-  I ntent ions to use DS Willingness to use DS 
-  Highly perceived value of health and suscept ibility to illness -  
Use of herbal medicine or natural products  
Aziz and Tey (2009) , 
Malaysia46 
Survey 
1,601 adults 
Agreed that  herbal medicine was effect ive and safe Benefit  and safety 
Levine et  al. (2009) , 
Canada76 
Survey 
1,206 elder ly people 
-  I mprovement  of their  health (73% ) Benefit  
-  Prevent ion of illnesses (47% )  
-  Last  resort  for  chronic illness (10% )   
-  Be able to tolerate more than CM (17% ) Safety 
-  Less expensive than CM (4% ) -  
Bruno and Ellis 
(2005) , US84 
Database of the 2002 Nat ional 
Health I nterview Survey  
31,044 elder ly people 
-  Combinat ion of herbal medicine and CM would help (48.8% ) Benefit  
-  Willingness to t ry (45.6% ) Willingness to use 
-  I neffect iveness of CM (20% ) Dissat isfact ion with CM 
-  CM was too expensive (10.2% )  
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Table 2.7 (Cont inued)  
Authors and country Study design and populat ion At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
CAM use  
Thomson et  al. 
(2012) , Aust ralia48 
Survey 
1,261 adults 
-  Treatment  of their  chronic illnesses (75.5% ) 
-  Prevent ion of illnesses (60% ) 
Benefit  
McFadden et  al. 
(2010) , US85 
Survey 
65 healthy graduate students aged 
22-45 years  
-  Holist ic balance (r= 0.52, p< 0.001) I nternal health locus of 
cont rol and holist ic 
approach 
-  I nternal health locus of cont rol related to CAM use ( r= 0.33, p= 0.007) 
-  Dissat isfact ion with CM ( r= 0.25, p= 0.045) Dissat isfact ion with CM 
-  Philosophical congruence with CAM ( r= 0.41, p= 0.001)  -  
Araz et al. (2009) , 
Turkey79 
Survey 
988 adults 
-  Perceived efficacy of CAM related to regular use of CAM (OR 1.74, 
99% CI  1.06-2.85) 
Benefit  
-  There was no associat ion between regular CAM use and internal health 
locus of cont rol 
I nternal health locus of 
cont rol 
Ock et  al. (2009) , 
South Korea45 
Nat ional survey 
3,000 aged 30-69 years 
-  Health prevent ion and promotion (78.8% ) Benefit  
-  Treatment  of illnesses (20.3% )  
Aydin et  al. (2008) , 
Turkey36 
Cross-sect ional populat ion based 
survey 
873 adults 
-  Perceived that  herbs complemented CM (47.4% ) Benefit  
-  Prevent ion of illnesses (37.4% ), t reatment  of illnesses (25.6% )  
-  Perceived that  herbs were safe as they were natural (29.4% ) Safety 
Sm ith et al. (2008) , 
US86 
Survey 
276 undergraduate students 
-  Significant  associat ion between willingness to use herbs and spir ituality 
and mood at tent ion ( r2= 0.078, F= 11.48)  
Willingness 
-  Significant  associat ion between willingness to use vitam in and 
opt im ism (r2= 0.026, F= 7.29)  
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Table 2.7 (Cont inued)  
Authors and country Study design and populat ion At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
CAM use  
Cheung et  al. (2007) , 
US74 
Survey 
445 elder ly people 
-  Maintaining their  general health (73.7% ) Benefit  
-  Treatment  of illnesses (59.6% )  
-  Had more personal cont rol over their health (50.2% ) I nternal health locus of 
cont rol 
Vickers et  al. (2006) , 
UK87  
Qualitat ive study 
the 18 female adults 
-  Natural and having no or lit t le side effects. Safety 
-  Exper ienced side effects of CM Dissat isfact ion of CM 
-  Last  resort  Benefit  
-  Had personal cont rol over their  health I nternal health locus of 
cont rol 
Honda and Jacobson 
(2005) , US78 
Nat ional survey 
4,242 people aged 25-74 years 
A personal t rait  of CAM users was more likely to have an open m ind. Willingness 
Barnes et  al. (2004) , 
US25 
Nat ional survey 
31,044 adults 
-  Combined CAM with CM would help (54.9% ) Benefit  
-  Want ing to t ry (50.1% ) Willingness to t ry 
-  Belief in ineffect iveness of CM (28% ) Dissat isfact ion with CM 
-  CM were too expensive (13% )  
Singh et  al. (2004) , 
South Afr ica42 
Survey 
200 people aged 26-60 years 
-  CAM was natural (61% ) Safety 
-  Perceived that  natural products were safe (23.4% )  
-  Exper ienced or were concerned about  side effects of CM (15.6% ) Dissat isfact ion with CM 
Thomas and Coleman 
(2004) , UK88 
Nat ional survey 
1,794 adults 
-  Treatment  of illnesses (62% ) Benefit  
-  Maintaining general health or prevent  illnesses (34% )  
Ast in (1998) , US89 Survey 
1,035 adults 
Perceived benefits of CAM Benefit  
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Table 2.8 shows twenty-nine studies of at t itudes towards reasons for CAM or HDS use am ongst  pat ient  populat ion worldwide. 
Table 2.8 Studies report ing at t itudes towards reasons for CAM or HDS use in pat ients with chronic illnesses (n= 29)  
Authors and country Study design, populat ion and 
types of CAM use 
At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
Yu et al. (2012) , 
China90 
Qualitat ive study 
26 cancer pat ients  
Use of Chinese medicine 
-  Last  resort  Benefit  
-  Perceived good exper ience   
-  safe and cheap Safety 
-  Desire to use Willingness to use 
-  Understanding of Chinese medicine due to their cultural and histor ical 
context 
Cultural belief 
Rausch et  al. (2011) , 
US91 
Survey 
153 cancer pat ients  
Use of herbal medicine 
-  Being used to taking it  (19% ) -  
-  Being interested in herbs (<  5% )  
-  Dissat isfact ion with CM (<  5% ) Dissat isfact ion with CM 
Sewitch et  al. (2011) , 
Canada92 
Survey 
103 cancer pat ients  
Use of natural health products 
-  I mproving quality of life (98.8% ) Benefit  
-  Treatment  of illnesses or maintenance of good health (20.7% )  
-  Cure for cancer (9.8% )  
-  Relief of symptoms or t reatment  of side effects from using CM (9.8% )   
Hyodo et al. (2005) , 
Japan54 
Survey 
3,100 cancer pat ients  
CAM use 
Expectat ion for CAM use Benefit  
-  Dealing with cancer (67.1% ), cure for cancer (44.5% )  
-  Relieving symptoms (27.1% ), combined CAM with CM (20.7% )  
Molassiot is et  al. 
(2005) , 14 countr ies in 
Europe55 
Survey  
956 cancer pat ients  
CAM use 
-  I mproving their  immune system (50.7% ) Benefit  
-  I mproving physical health (40.6% )  
-  I mproving emot ional health (35.2% )  
Chapter 2:  Herbal and dietary supplements 
34 
Table 2.8 (cont inued)  
Authors and country Study design, populat ion and 
types of CAM use 
At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
Verhoef et al. (2005) 93 Systemat ic review 
52 eligible quant itat ive studies 
dur ing 1994-2004 
Cancer pat ients 
CAM use 
-  Perceived benefits of CAM (38.4% ) Benefit  
-  Last  resort  (9.6% ), having hope (9.6% )  
-  Want ing to control their  health (17.3% ) I nternal health locus of cont rol 
-  A strong belief in CAM (17.3% ) -  
-  Disappointment  to CM (3.8% ) Dissat isfact ion with CM 
Wilk inson et  al. 
(2002) , US94 
Survey 
1,099 cancer pat ients  
CAM use 
-  Believed that  CAM would extend life span and improvement  of 
their  quality of life (90% ), having hope (81% ) 
Benefit  
-  Relieved symptoms (60% ), Expectat ion of disease cures (47% )  
-  Had control over their disease (63% ) I nternal health locus of cont rol 
Chen et  al. (2009) , 
China95 
Qualitat ive study 
29 HI V pat ients, CAM use 
-  Relieving side effects of CM, dealing with other discomforts Benefit  
-  Enhancing good health  
Mat thees et  al.  
(2001) , US49 
Survey, 99 lung t ransplant  
recipients, CAM use 
-  Dealing with weight  gain Benefit  
-  Maintaining good health or the immune system healthy  
Ali-Shtayeh et  al. 
(2012) , Palest inian 
terr itor ies66 
Survey 
1,883 diabet ic pat ients 
Use of herbal medicine 
-  Slowing progression of their disease (45.7% ) Benefit  
-  Relieving their  symptoms (35% ), cure for their disease (22.9% )  
-  Decreased side effects of CM (12.6% )  
Kumar et  al. (2006) , 
I ndia56 
Survey 
493 diabet ic pat ients  
CAM use 
-  Rapid and addit ional relief of their  disease (86.8% ) Benefit  
-  CAM was no side effects (26.1% ) Safety 
-  There is low cost and easy availability (16.8% ) -  
Yeh et  al. (2006) , US58 Survey 
10,572 pat ients with 
cardiovascular disease, CAM use 
-  Combinat ion of CAM and CM would help (59% ) Benefit  
-  Trying (50% ) Willingness to t ry 
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Table 2.8 (Cont inued)  
Authors and country Study design, populat ion and 
types of CAM use 
At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
Moolasarn et al. 
(2005) , Thailand51 
Survey 
159 diabet ic pat ients, CAM use 
Perceived that  CAM complemented CM (13.2% ) Benefit  
Kara (2009) ,  Turkey14 Survey 
114 hemodialysis pat ients   
Use of herbal medicine 
-  Treatment  of their  disease (81.3% ) Benefit  
-  Prevent ion of disease (12.5% )  
Spanner and Duncan 
(2005) , Canada16 
Survey 
100 pat ients with CKD, DS use 
-  Prevent ion of illnesses (44% ) Benefit  
-  Treatment  of illnesses (38% )  
Weizman et  al. 
(2012) , Canada18 
Survey 
380 outpat ients with I BD 
CAM use 
-  I neffect iveness of CM (40% ), perceived side effects of CM (18% ) Dissat isfact ion with CM 
-  Safety of CAM (28% ) Safety 
-  Sense of cont rolling their  disease (30% ) I nternal health locus of 
cont rol 
Rawsthorne et al. 
(1999) , US, Canada, 
I reland, Sweden96 
Survey 
289 pat ients with I BD 
CAM use 
-  Dissat isfact ion with CM Dissat isfact ion with CM 
-  Perceived their  medical condit ion was hopeless  
Lambert et al. (2010) , 
UK63 
Survey 
92 outpat ients with headache, 
CAM use 
-  Last  resort  (48% ), belief in efficacy of CAM (21% ) Benefit  
-  Unhappy with CM (17% ) Dissat isfact ion with CM 
Rossi et  al. (2008) , 
I taly60 
Survey 
100 pat ients with headache 
CAM use 
-  Perceived benefits of CAM (44.8% ) Benefit  
-  Perceived that  CAM was safer than CM or had fewer side effects than 
CM (27.5% ) 
Safety 
-  Cur iosity (24.1% ) -  
-  Holist ic approach to health (10.3% ) Holist ic approach 
-  Dissat isfact ion with CM (4.6% ) Dissat isfact ion with CM 
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Table 2.8 (Cont inued)  
Authors and country Study design, populat ion and 
types of CAM use 
At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
Strej ilevich et  al. 
(2013) , Argent ina and 
Colombia68 
Survey 
200 outpat ients with bipolar 
disorder, CAM use 
-  Relieving their  illness Benefit  
Braun and Cohen 
(2011) , Aust ralia65 
Survey 
161 inpat ients, CAM use 
-  I mproving their  good health (71% ), t reatment  of disease (30% ) Benefit  
-  Prevent ion of disease (20% )  
Hasan et  al. (2009) , 
Malaysia61 
Survey 
321 outpat ients  
CAM use 
-  Belief in safety of CAM (66.3% ) Safety 
-  Perceived efficacy of CAM and it  was fewer side effects (15% ) Benefit  and safety 
-  Trying new alternat ive therapy (63.9% ) Willingness to t ry 
-  Be used to take CAM (17.6% ) -  
-  Exper ienced side effects of CM (7.8% ) Dissat isfact ion with CM 
-  Failure of CM to control their illnesses (2.9% )  
-  Lack of t rust in CM (4.9% )  
-  Cultural belief (5.9% ) Cultural belief 
Bishop et  al. (2007)97 Systemat ic review dur ing 
1995-2005 
94 eligible quant itat ive and 
qualitat ive studies in pat ients  
CAM use 
-  Belief in cont rol and part icipat ion I nternal health locus of cont rol 
and willingness 
-  I llness percept ion -  
-  Causes of illness  
-  Major ity of the studies was among cancer pat ients  
-  Belief about  holism  and natural t reatment  Holist ic approach 
-  Cultural or spir itual belief Cultural or spir itual belief 
Saw et al. (2006) , 
Malaysia57 
Survey, 250 inpat ients  
Use of herbal medicine 
-  Maintaining good health (51.3% ) Benefit  
-  Treatment  of chronic illnesses (42.1% )  
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Table 2.8 (Cont inued)  
Authors and country Study design, populat ion and 
types of CAM use 
At t itudes towards reasons for CAM or HDS use I nterpretat ion of at t itudes 
Kuo et  al. (2004) , US98 Survey 
322 pr imary care pat ients  
Use of herbal medicine 
-  Believed that combinat ion of herbs and CM would be superior to using 
either alone 
Benefit  
-  Believed that  herbs were super ior to CM  
-  Using herbs for  t reatment  and prevent ion of illnesses   
-  Rapid relief of symptoms (47% )  
-  Trying (33% ) Willingness to t ry 
-  Having their own t reatment  (20% ) I nternal health locus of cont rol 
Jiaranaikajorn et  al. 
(2002) , Thailand27 
Survey 
200 outpat ients and 
inpat ients, CAM use 
-  Believed in efficacy of CAM (77.1% ),  Benefit  
-  Alleviat ing m inor ailments (27.6% )  
-  Failure to be treated by CM (13.3% ) Dissat isfact ion with CM 
Sirois and Gick 
(2002) , Canada99 
Survey 
199 pat ients at  health clinics 
CAM use 
-  Trying new things Willingness to t ry 
-  Medical need -  
-  Perceived ineffect ive of CM Dissat isfact ion with CM 
Klepser et  al. (2000) , 
US100 
Survey 
794 outpat ients, HDS use 
-  Posit ive at t itude towards herbal effects on their  health (p<  0.05)  Benefit  
-  Perceived benefits and safety of HDS (p <  0.05)  Benefit  and safety 
Kappauf et al. (2000) , 
Germany101 
Survey 
131 outpat ients and 
inpat ients, CAM use 
Perceived that  CAM complemented CM (75% ) Benefit  
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2 .4 .1  Perceived benefits from  CAM and HDS use  
The percept ion of CAM or HDS benefit s has been reported as a reason for  CAM or 
HDS use am ongst  both the general populat ion and pat ients with chronic 
illnesses.27,46,60,61,63,79,83,89,90,93,100 A survey in Turkish adults found that  the 
percept ion of benefit s was posit ively associated with regular use of CAM (Odds 
rat io (OR)  1.74, 99%  CI  1.06-2.85) .79 The studies have also described benefit s 
of CAM or HDS in term s of purposes of use, such as the t reatm ent  or prevent ion 
of illnesses, and the percept ion of gaining benefit  when people com bined CAM or 
HDS use with convent ional m edicat ion. 
Treatm ent  or  prevent ion of illnesses and m aintaining good health are the m ost  
frequent ly reported reason for  using CAM or HDS in both the general and pat ient  
populat ions.14,16,36,46,48,49,57,65,66,68,76,83,88,92,94,95,98 Som e pat ients with diabetes, 
cancer, hum an im m unodeficiency virus (HIV)  or receiving lung t ransplant  have 
perceived that  CAM relieved their sym ptom s, im proved their im m une system , 
physical and em ot ional health, or dealt  with other discom forts or weight  
gain.27,49,55,66,92,94,95 Pat ients with life- threatening illnesses, such as cancer, have 
reported using CAM to im prove their qualit y of life.92,94 Moreover, respondents 
with either cancer or  diabetes have t r ied herbal m edicine in order to cure their 
disease.66,92 Som e pat ients have reported using HDS or CAM to t reat  side effects 
from  convent ional m edicine.66,92,95 
The use of CAM or herbal m edicine has been perceived to supplem ent  
convent ional m edicat ion, or  that  their  com binat ion would be m ore effect ive than 
using either alone.25,36,51,58,84,98,101 Moreover, som e users perceive that  herbal 
m edicine is superior t o convent ional m edicine, or it  rapidly relieves their 
sym ptom s.56,98  
Pat ients with life threatening illnesses hope or expect  to gain benefit s from  using 
CAM.54,93,94 Although both the general and pat ient  populat ions want  to use CAM 
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as a last  resort  for  their chronic illnesses63,76,87,90,93,  it  appears that  this reason is 
m ore likely to be reported by pat ients rather than the general populat ion.  
2 .4 .2  The percept ion of safety of CAM and HDS 
Respondents perceived that  CAM or herbal m edicine was safe.18,46,61,90 CAM or 
herbal m edicine has been perceived as being natural, leading to the belief that  
they are safe am ongst  both the general populat ion and pat ients with chronic 
illnesses.36,42,87 Som e respondents thought  that  CAM had no, or fewer, adverse 
effect s than convent ional m edicat ion56,60 and they could tolerate them  m ore than 
those from  CM.76 
2 .4 .3  Dissat isfact ion w ith convent ional m edicat ion 
Four studies in the general populat ion25,42,84,85 and nine studies in pat ient  
populat ions have reported the percept ion of dissat isfact ion with CM as a reason 
for CAM use.18,27,60,61,63,91,93,96,99 A survey in healthy graduate students has 
reported a significant  associat ion between dissat isfact ion with convent ional 
m edicat ion and CAM use ( r= 0.25, p= 0.04) .85 However, Ast in’s study in the 
general populat ion, and Eisenberg’s study in adults who saw a doctor, t ested this 
hypothesis and rejected it .89,102 Despite inconsistencies with this reason for using 
CAM in the general populat ion, it  would seem  that  pat ients with chronic illnesses 
are likely to perceive dissat isfact ion with CM as a reason for using CAM or herbal 
m edicine, see Table 2.8.18,27,60,61,63,91,93,96,99 
Dissat isfact ion with CM was also described by both the general populat ion and 
pat ients in term s of the ineffect iveness of CM, having either exper ienced or 
becom e concerned about  adverse effect s of CM, and the high costs of 
CM.18,25,27,42,61,84,87,99 Som e pat ients with inflam m atory bowel disease ( IBD)  felt  
that  “Their m edical situat ion was hopeless” , and thus they decided to use CAM.96 
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However, dissat isfact ion with doctor-pat ient  interact ion was not  related to CAM 
use.52 
2 .4 .4  W illingness to t ry CAM and HDS  
Willingness to t ry has been reported as a reason for  using CAM or HDS in both 
the general populat ion25,84 and pat ients with chronic illnesses.58,61,98,99 Having an 
open m ind is a possible personalit y t rait  of CAM or HDS users, as they are willing 
to t ry new things.61,78,99  
Som e respondents desire to use CAM or HDS.83,90 Pat ients using CAM are likely 
to act ively search inform at ion on alternat ive medicine and discuss CAM with their 
fr iends and fam ily in order t o decide whether or not  they will actually use CAM.97 
2 .4 .5  At t itudes tow ards internal health locus of control, 
holist ic approaches, cultural and spir itual beliefs 
There are fewer studies of the relat ionship between CAM use and at t itudes 
towards health locus of cont rol, holist ic approaches, cultural and spiritual beliefs. 
Percept ion of health locus of cont rol is reported as a reason for  CAM use in both 
the general and pat ient  populat ions.18,74,85,87,93,94,97 A survey in healthy graduate 
students shows a significant  associat ion between CAM use and internal health 
locus of cont rol ( r= 0.33, p< 0.01) .85 However, this at t itude is inconsistent  with 
Araz et  al. (2009) 79, Conner et  al. (2001) 83 and Sirois and Gick (2002) .99 
At t itudes towards a holist ic approach is posit ively associated with CAM use in the 
general populat ion ( r= 0.52, p< 0.01) .85 This is consistent  with Bishop and Rossi’s 
studies of pat ient  populat ions.60,97  
There are cultural and spir itual beliefs linked to CAM use am ongst  pat ients with 
chronic illnesses.61,97 Cultural belief related to CAM use is supported by Yu et  al. 
(2012)  who stated that  Chinese pat ients with cancer use Chinese m edicine, due 
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to their understanding of Chinese m edicine, based on their cultural context .90 
Meanwhile Sm ith et  al. (2008)  in the UK reported that  spir itual belief is 
significant ly associated with CAM use am ongst  t he general populat ion.86  
2 .4 .6  At t itudes tow ards CAM in people w ho are unlikely to 
use CAM 
Negat ive at t itudes towards CAM and the sat isfact ion of CM benefit s prevent  both 
general and pat ient  populat ions from  using CAM.55,57,60,74 The negat ive at t itudes 
are doubts regarding the efficacy and safety of CAM, and having either 
experienced or been concerned about  the negat ive effect s of CAM.55,74 Saw et  al.  
(2006)  also report  that  non-users perceive that  efficacy of herbal m edicine is 
inferior to CM.57 
2 .5  HDS users’ social netw orks and the m edia 
influence on HDS use 
HDS users’ social networks and the m edia are the m ost  frequent ly reported 
sources of inform at ion or recom m endat ions for the use of CAM or HDS, in both 
the general populat ion and pat ients with chronic illnesses. This is supported by  a 
large num ber of surveys (n= 21) , see Tables 2.9 and 2.10, but  there is lim ited 
literature from  qualitat ive research in the general populat ion83 and pat ients with 
CKD.16  
Three quarters of the surveys in the general populat ion report  at  least  40%  of 
the users’ social network influencing their decision m aking in CAM or HDS use, 
see Table 2.9.45,74,76,88,103,104 Sim ilarly, one of the top reasons why Brit ish people 
take CAM is because their fam ily m em bers recom m end it .105 
  
Chapter 2:  Herbal and dietary supplements 
42 
Table 2.9 Surveys of sources of inform at ion or recom m endat ion for  CAM or HDS 
use in the general populat ion (n= 8)  
Authors and 
countr ies 
The populat ion, types of alternat ive 
medicine  
Types and rates of sources 
Chung et  al. 
(2011) , Hong 
Kong82 
Secondary analysis of the Hong 
Kong Populat ion Representat ive 
Themat ic Household Survey 
2007 dataset  
25,208 people aged >  15 years  
Use of t radit ional Chinese 
medicine (TCM) 
-  TCM pract it ioners (59.5% ) 
-  Pharmacy sales personnel 
(24.6% ) 
-  Fr iends and relat ives (19.8% ) 
-  Chinese herbal dispensers 
(12.2% ) 
-  Leaflets (10.4% ) 
McCrea and 
Pr itchard (2011) 
in the US103 
305 college students aged 18-
50 years 
Use of herbal medicine 
-  Self- recommendat ion (60% ) 
-  Fr iends (40% ) 
Levine et al. 
(2009)  in 
Canada76 
1,206 elders  
Use of natural health products  
-  Fr iends and fam ily (49% ) 
-  Self-exper imentat ion (23% ) 
-  Advert isement  (20% ) 
-  Doctors (18% ) 
-  Purveyor of the products (3% ) 
Ock et al. (2009) 
in South Korea45 
3,000 adults  
CAM use 
-  Fr iends and fam ily (66.9% ) 
-  The media (11.7% ) 
-  Doctors (4.1% ) 
-  Pharmacists (3% ) 
-  CAM pract it ioners (2.1% ) 
-  Dist r ibutor of CAM (1.8% ) 
Cheung et al. 
(2007) in the 
US74 
445 elders  
CAM use 
Fr iends and fam ily (46.7% ) 
 
Alkhateeb et  al. 
(2006) in the 
US104 
456 adults  
Use of herbal medicine  
 
-  Fr iends and fam ily (61.6% ) 
-  Newspapers/  magazine (43.8% ) 
-  TV and radio (37% ) 
-  Doctors or pharmacists (32.9% ) 
-  I nternet (31.5% ) 
-  Herb professional (30.1% ) 
Singh et al. 
(2004)  in South 
Afr ica104 
200 adults  
CAM use 
 
-  Advised by someone or 
influenced by advert isement in 
newspapers, books or 
magazines (52% ) 
Thomas and 
Coleman (2004) 
in the UK88 
1,794 people aged >  16 years 
CAM use 
-  Fr iends or relat ives (59% ) 
-  Health care providers (18% ) 
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Am ongst  pat ients with chronic illnesses, half of the studies report  m ore than 
50%  of CAM or HDS users regard fam ily and fr iends as sources of inform at ion or 
recom m endat ion, see Table 2.10.50,51,54,55,60,63,106 However, am ongst  pat ients 
with CKD, Spanner and Duncan’s survey in the US report  the lowest  rate of 
fr iends and fam ily as an inform at ion source, because m ost  respondents received 
inform at ion from  their doctor (27% ) .16 This is consistent  with Kappauf’s study in 
Germ any101, Wilkinson and Jelinek’s study in Aust ralia62, and Braun and Cohen’s 
study in Aust ralia.65 A doctor or pharm acist ’s recom m endat ion for CAM use has 
been m ost  frequent ly reported as influencing CAM use (41 to 53% ) .62,65,101 
Com paring health care professionals’ recom m endat ions for CAM or HDS use, 
between the general and pat ient  populat ions, pat ients (8 to 53% )  are m ore 
likely to receive recom m endat ions from  their health care providers, than the 
general populat ion (3 to 33% ) , see Tables 2.9 and 2.10. 
  
Chapter 2:  Herbal and dietary supplements 
44 
Table 2.10 Surveys of sources of inform at ion or recom m endat ion for CAM or HDS 
use in pat ients with chronic illnesses (n= 13)  
Authors and 
country 
Populat ion, types of CAM Types and rates of sources 
Ali-Shtayeh et al. 
(2012) , 
Palest inian 
terr itor ies66 
1,883 diabet ic pat ients 
Use of herbal medicine 
-  Fam ily (40.2% ) 
-  Fr iends (37.1% ) 
-  Herbalists (16.4% ) 
-  The media (TV,radio)  (12.3% ) 
-  Doctors and pharmacists (7.5% ) 
-  I nternet , advert isement  and text  
messages (5.6% ) 
Braun and Cohen 
(2011) , 
Aust ralia65 
161 inpat ients 
CAM use 
-  Pharmacists (44% ) 
-  Doctors (41% ) 
-  Health food store staff (23% ) 
-  CAM pract it ioners (22% ) 
-  Books or magazines (22% ) 
-  Fr iends and fam ily (15% )  
Lambert et al. 
(2010) , UK63 
92 outpat ients with headache 
CAM use 
-  Fr iend or relat ives (72% ) 
-  Doctors (16% ) 
-  Nurses (8% ) 
-  Self- recommendat ion (4% ) 
Hasan et  al. 
(2009) , 
Malaysia61 
321 outpat ients  
CAM use 
 
-  Fr iends (32.5% ) 
-  Health care professionals 
(25.9% ) 
-  Fam ily (20.2% ) 
-  Advert isement  (15.8% ) 
-  Folks or culture beliefs (4.4% ) 
Wilk inson and 
Jelinek (2009) , 
Aust ralia62 
102 elder ly people with 
chronic illnesses 
CAM use 
-  Doctors and pharmacists (53% ) 
-  Fr iends and fam ily (28% ) 
-  Popular magazines (23% ) 
-  CAM pract it ioners (22% ) 
-  I nternet (10% ) 
-  Medical/ scient if ic journals (10% ) 
Rossi et  al. 
(2008) , I taly60 
100 pat ients with headache 
CAM use 
-  Fr iends or relat ives (54% ) 
-  Doctors (26% ) 
-  Self- recommendat ion (20% ) 
Kumar et al. 
(2006) , I ndia56 
493 diabet ic pat ients 
CAM use 
-  Fr iends (36.4% ) 
-  Neighbours (25% ) 
-  Relat ives or fam ily members 
(18.2% ) 
-  Doctors (17.9% ) 
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Table 2.10 (cont inued)  
Authors and 
country 
Populat ion, types of CAM Types and rates of sources 
Howell et  al. 
(2006) , US106 
620 outpat ients  
Use of herbal medicine  
Fam ily (66% ) 
Hyodo et al. 
(2005) , Japan54 
3,100 cancer pat ients 
CAM use 
-  Fr iends or fam ily (77.7% ) 
-  Self- recommendat ion (23.3% ) 
Molassiot is et al. 
(2005) , 14 
countr ies in 
Europe55 
956 cancer pat ients 
CAM use 
-  Fr iends (56.5% ) 
-  Fam ily (29.1% ) 
-  The media (28.4% ) 
-  Doctors (18.6% ) 
-  CAM pract it ioners (12.9% ) 
-  I nternet (9.3% ) 
Moolasarn et  al. 
(2005) , 
Thailand51 
159 diabet ic pat ients  
CAM use  
 
-  Fr iends, media and relat ives 
(57.9% ) 
-  Doctors (28.9% ) 
Moolasarn et  al. 
(2003) , 
Thailand50 
180 pat ients with cancer  
Use of herbal medicine 
 
Fr iends, relat ives and fellow pat ients 
(55.5% ) 
Kappauf et  al. 
(2000) , 
Germany101 
131 outpat ients and 
inpat ients  
CAM use 
-  Doctors (41% ) 
-  Fr iends and relat ives (21% ) 
-  Books and media (21% ) 
-  CAM pract it ioners (15% ) 
-  Fellow pat ients (2% ) 
 
Fam ily and fr iends’ recom m endat ions influencing CAM or HDS use was m ost  
frequent ly reported in all studies am ongst  Asian pat ients, whilst  60%  of studies 
am ongst  Western pat ients reported it .50,51,54-56,60,61,63,106 I t  would seem  that  the 
Asian pat ient  populat ions are m ore likely to receive inform at ion or 
recom m endat ions from  their social network, com pared with Western pat ient  
populat ions. However, t here is no difference in the general populat ions between 
Asian and Western count ries, as fam ily and fr iends are m ost  frequent ly reported 
as sources of inform at ion or recom m endat ions in both contexts, see Table 2.10. 
The m edia, such as books, m agazine, TV, radio and internet ,  as well as 
advert isem ents, seem s to influence a person’s decision to use CAM or HDS 
am ongst  both the general and pat ient  populat ions, see Tables 2.9 and 2.10. No 
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m ore than one quarter of respondents reported this as a source, with the 
except ion of Alkhateeb’s study.16,45,55,61,62,65,66,76,82,101  
Posit ive or negat ive effects of CAM have been reported by the m edia;  Bubela et  
al. (2008)  reviewed newspaper’s percept ions of the efficacy and safet y of herbal 
m edicine during 1995-2005.107 They reviewed the m edia in the UK, the US, 
Aust ralia, New Zealand and Canada and found that  90%  of newspapers reported 
benefit s of herbal m edicine, whilst  no benefits were reported in only 4%  of 
art icles. The m edia under reported the side effects of herbal products.107 This is 
consistent  with a system at ic review of the m ass m edia and CAM use, in which 
the m ass m edia was found to be m ore likely to report  posit ive effect s of CAM, 
rather than their r isks.108   
2 .6  Disclosure of HDS use to health care providers 
Herbal and dietary supplem ent  use m ay affect  convent ional health m anagem ent , 
part icularly in pat ients with chronic illnesses. Theoret ically, HDS users should 
inform  their health care providers about  their usage, in order t o have their 
health properly m anaged. However, large num bers of surveys, worldwide, have 
reported high rates of non-disclosure of HDS or CAM use to health care 
professionals (HCP)  in both the general populat ion (n= 10)  and pat ients with 
chronic illnesses (n= 12) , see Tables 2.11 and 2.12, respect ively.  
Three surveys of general populat ions42,74,82 and seven surveys of t he pat ient  
populat ions have reported reasons for  the non-disclosure, 53,61,63,65,68,101,102 whilst  
only two qualitat ive studies have reported them  in the general populat ion and 
pat ients.87,109 The reasons are presented in sect ion 2.6.2 below. 
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Table 2.11 Surveys of the non-disclosure of CAM or HDS use to HCP in the 
general populat ion (n= 10)  
Authors and 
country 
Populat ion and types of 
CAM 
Rates of the 
non-
disclosure 
Reasons for the non-disclosure 
HDS use 
Chung et  al. 
(2011) , Hong 
Kong82 
Secondary analysis of the 
Hong Kong Populat ion 
Representat ive Themat ic 
Household Survey 2007 
dataset  
25,208 people aged >  15 
years  
Use of tradit ional Chinese 
medicine (TCM) 
59.3%  -  No interact ion between CM 
and TCM (62.7% ) 
-  Doctors don’t  ask (25.9% ) 
-  Doctors don’t  understand 
(5.9% ) 
-  TCM wasn’t  based on 
modern, medical 
knowledge (4.5% ) 
-  Doctors would discourage 
from using TCM (4.1% ) 
McCrea and 
Pr itchard (2011) ,  
US103 
305 college students aged 
18-50 years  
HDS use 
75%  -  
Chao et  al. 
(2008) , US110 
Secondary analysis from the 
2002 Nat ional Health 
I nterview Survey and 2001 
Health Care Quality Survey 
Use of folk medicine 
67%  -  
Mehta et  al. 
(2008) , US111 
Secondary analysis from the 
2002 NHI S Sample Adult  
Core and the Alternat ive 
Medicine Supplement 
HDS use 
66.7%  -  
Kennedy (2005) , 
US29 
31,044 adults  
Use of natural herbs 
66.6%  -  
CAM use 
Thomson et  al. 
(2012) , 
Aust ralia48 
1,261 adults  
CAM use 
39.7%  -  
Aydin et  al. 
(2008) ,  Turkey36 
873 adults  
CAM use 
73.6%  -  
Cheung et al. 
(2007) , US74 
445 elders  
CAM use 
46.7%  -  Their  pract it ioners don’t  
ask (38.5% ) 
-  Unnecessary (22% ) 
Singh et  al. 
(2004) , South 
Afr ica42 
200 adults  
CAM use 
57.5%  -  Unnecessary (53.6% ) 
-  Their  doctor don’t  ask 
(28.6% ) 
-  The doctor may be upset 
(7.1% ). 
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Table 2.11 (cont inued)  
Authors and country Populat ion and 
types of CAM 
Rates of the non-
disclosure 
Reasons for the non-
disclosure 
CAM use 
Thomas and 
Coleman (2004) , 
UK88 
1,794 adults  
CAM use 
52%  -  
Table 2.12 shows rates of the non-disclosure of CAM or HDS use to health care 
providers in pat ients, but  the studies did not  explore the reasons. 
Table 2.12 Surveys of t he non-disclosure of CAM or HDS use to HCP in pat ients 
(n= 12)  
Authors and country Populat ion and types of CAM Rates of the non-
disclosure 
Ali-Shtayeh et al. (2012) , 
Palest inian terr itor ies66 
1,883 diabet ic pat ients  
Use of herbal medicine 
68%  
Rausch et  al. (2011) , US91 153 cancer pat ients  
CAM use 
47%  
Sewitch et  al. (2011) , 
Canada92 
103 cancer pat ients  
CAM use 
31.7%  
Shorofi and Arbon (2010) , 
Aust ralia67 
353 inpat ients  
Use of herbal medicine 
51.6%  
Wilk inson and Jelinek 
(2009) ,  Australia62 
102 elder ly people with chronic 
illnesses  
CAM use 
40%  
Rossi et al. (2008) , I taly60 100 pat ients with headache  
CAM use 
62%  
Yeh et  al. (2006) , US58 10,572 pat ients with 
cardiovascular disease  
Use of herbal medicine 
56%  
Moolasarn et  al. (2005) , 
Thailand51 
159 diabet ic pat ients  
CAM use 
64.4%  
Spanner and Duncan 
(2005) , Canada16 
100 pat ients with kidney disease  
Use of dietary supplement 
33%  
Grabe and Garr ison 
(2004) , US15 
491 pat ients in pr imary care and 
nephrology units  
Use of natural products 
67%  for pat ients in 
pr imary care  
45%  for pat ients with 
kidney disease 
Moolasarn et  al. (2003) , 
Thailand50 
180 pat ients with cancer  
Use of herbal medicine 
51.3%  
Mat thees et  al. (2001) , 
US49 
41 lung t ransplant  recipients  
HDS use 
36.6%  
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Table 2.13 indicates both rates of the non-disclosure and the reasons am ongst  
pat ients using CAM or HDS. 
Table 2.13 Surveys of the non-disclosure of CAM or HDS use to HCP and it s 
reasons in pat ients (n= 7)  
Authors and 
country 
Populat ion and 
types of CAM 
Rates of the 
non-disclosure 
Reasons for the non-disclosure 
Strej ilevich et  al. 
(2013) , Argent ina 
and Colombia68 
200 outpat ients with 
bipolar disorder  
CAM use 
48%  Pat ients were afraid that  their doctor 
may ask them to stop using them 
(32% ) 
Braun and Cohen 
(2011) , Aust ralia65 
161 inpat ients  
CAM use 
56%  -  Doctors didn’t  ask (67% ) 
-  Unnecessary (54% ) 
-  Doctors would not understand 
(5% ) 
-  Didn’t  want  to be judged 
negat ively (5% ) 
Lambert et  al. 
(2010) , UK63 
92 pat ients with 
headache  
CAM use 
42%  -  A doctor or nurse has never 
asked (80% ). 
-  Unnecessary (10% ) 
-  They wouldn’t  understand (10% ) 
Hasan et  al. 
(2009) , Malaysia61 
321 outpat ients  
CAM use 
54.5%  -  A doctor or pharmacist has never 
asked (45.5% ). 
-  Unnecessary (37.3% ) 
-  A doctor may disapprove 
(12.7% ). 
Barraco et  al. 
(2005) , US53 
223 inpat ients with 
acute coronary 
syndrome 
CAM use 
35.9%  -  Doctors didn’t  ask (48% ) 
-  Other reasons 
-  Unnecessary 
-  They forgot  
-  Felt  uneasy talk ing about  it  
Eisenberg et al. 
(2001) , US102 
831 outpat ients  
CAM use 
-  -  HCP may be unable to 
understand their  CAM use. 
-  “ I t ’s not  important  for  the doctor 
to know”  
Kappauf et  al. 
(2000) , Germany101 
131 outpat ients and 
inpat ients  
CAM use 
44%  -  Their  use may be disapproved. 
-  Pat ient -doctor relat ionship may 
be interrupted. 
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2 .6 .1  Com parison of rates of non- disclosure of CAM and 
HDS use to health care providers betw een general and 
pat ient  populat ions 
Forty t o seventy- five percent  of people using CAM or natural herbs do not  
disclose their CAM or HDS use to health care providers, see Table 
2.9.29,36,42,48,74,82,88,103,110,111 Am ongst  pat ients with chronic illnesses, the rate of 
the non-disclosure varies from  32%  to 68% , see Tables 2.12 and 2.13.49-51,53,58-
63,65-68,91,92,101
 The rate of non-disclosure in the general populat ion is likely to be 
higher than that  in pat ients as they have no, or only m inor illnesses, so they 
m ay think that  they do not  need to inform  their  doctor, see Table 2.11.    
Pat ients with life threatening illnesses, such as cancer, lung t ransplantat ion or 
CKD in Western populat ions, including Aust ralian, are m ore likely to inform  their 
health care providers about  their CAM or HDS use (53 to 68% ) , com pared with 
pat ients with other illnesses (33%  to 64% )  or the general populat ion (25%  to 
60% ) .15,16,49,91,92 However, cancer pat ients in Thailand were less likely to inform  
their doctor (49% ) , com pared with Western count ries.50 
Asian populat ions, either  general populat ions or pat ients with chronic illnesses, 
are less likely to inform  their health care providers about  their HDS or CAM use, 
com pared with Western populat ions.98,110,111 Nearly seventy per cent  of Asian 
pat ients do not  disclose their herbal use to their health care providers, com pared 
with 33%  of whites.98 However, there is a lack of evidence on the rate of the 
non-disclosure in Asian pat ients with CKD, so the com parison between both 
populat ions cannot  be m ade. 
  
Chapter 2:  Herbal and dietary supplements 
51 
2 .6 .2  Reasons for  non- disclosure of CAM and HDS use to 
health care providers 
Surveys have reported the reasons why HDS or CAM users do not  inform  their 
use to health care providers in both the general populat ion and pat ients with 
chronic illnesses (although not  for  CKD) , see Tables 2.11 and 2.13. Am ongst  
pat ient  populat ions, the m ost  frequent ly reported reasons for the non-disclosure 
are that  doctors do not  ask them  about  CAM or HDS use (46%  to 80% ) , followed 
by report ing ‘it  is not  im portant  for  their doctor t o know’ (10%  to 54% ) .53,61,63,65 
The lat ter reason (22%  to 54% )  is m ore frequent ly reported than the form er 
(29%  to 39% )  in the general populat ion.42,74  
Another reason for non-disclosure is concerns about  receiving a negat ive 
response from  health care providers, such as disapproval about  their use of HDS 
or CAM, asking them  to stop using HDS or CAM, or being upset  by their 
use.42,61,65,68,87,101 Moreover, som e users thought  that  their doctor would not  
understand so they did not  inform  them .63,65,82,102 However, there is a lack of 
literature about  such reasons am ongst  pat ients with CKD. 
I t  appears that  the m ain types of reasons for  the non-disclosure are likely to 
relate to a doctor’s pract ice and their ant icipated response.  
2 .6 .3  Reasons for  disclosure of CAM and HDS use to doctors 
Only three studies have reported reasons for disclosure of CAM or HDS use to a 
doctor.53,87,109 Vickers et  al. (2006)  report  the m ain reasons why Brit ish fem ales 
inform  their doctor about  their herbal use is because their doctor is open-m inded 
about  herbal m edicine and that  there is good relat ionship between the pat ient  
and doctor.87 Farooqui et  al. (2012)  in Malaysia found that  pat ients with cancer 
disclosed their CAM use to their doctor as their doctor advised well on CAM 
use.109 Barraco et  al. (2005)  in the US found that  the reasons for disclosure in 
pat ients were that  respondents believe CAM affected their m edical care, and 
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their doctor asked and is willing to listen to t heir ideas about  CAM use.53 This 
evidence seem s to indicate that  doctor ’s at t itudes towards CAM use, and their 
response, play an im portant  part  in the disclosure, or lack thereof.  
2 .7  Associat ion betw een HDS use and 
convent ional m edicat ion adherence 
Fewer studies have reported an associat ion between CAM or HDS use and 
convent ional m edicat ion adherence am ongst  pat ients with chronic illnesses, see 
Table 2.14.19,68,112,113. Other surveys have shown differences in adherence levels 
between the users and non-users.17,18,49,64 The Morisky scale is the m ost  
frequent ly used to assess levels of adherence to convent ional m edicat ion (CM) . 
There are inconsistencies with such associat ions, differences am ongst  pat ients 
with chronic illnesses and a lack of literature in pat ients with CKD.  
CAM or herb users are m ore likely to be non-adherent  to CM. Gohar et  al. (2008)  
report  that  there was a significant  associat ion between fem ale users of CAM and 
poor adherence.19 Herbal use has been found to related to non-adherence to 
ant iret roviral agents (adjusted OR 6.67, 95%  CI  3.12-14.24) .112 Afr ican-
Am erican users of CAM are likely to have poor adherence to CM (prevalence rat io 
1.56, 95%  CI  1.14-2.15)  whilst  the adherence in whites was not  different  
between CAM users and non-users.17 Bailey et  al. (2012)  report  that  a reason for  
non-adherence was CAM use (10% ) .114 Only Krousel-Wood et  al. (2010)  explain 
possible reasons for  such associat ions:  depressive sym ptom s, high costs of CM 
and dissat isfact ion with the doctor-pat ient  relat ionship.17 Gohar et  al. (2008)  
suggest  that  further studies should invest igate reasons why fem ale CAM users 
have poorer adherence to CM.19 
I n cont rast , five surveys found no associat ion between CAM or HDS use and 
m edicat ion adherence in pat ients with different  diseases.18,49,64,68,113 Ogbera et  al 
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(2010)  and Cherniack (2011)  did not  define how they m easured m edicat ion 
adherence.64,113 The evidence suggests that  CAM or HDS use m ay not  influence 
CM adherence. Weizm an et  al. (2012)  support s this posit ion and explains that  
CAM users have m ore severe disease, and t rust  their doctor, so they are likely to 
adhere to their CM.18 Despite the fact  that  Mat thees’s study also found no 
difference in levels of CM adherence between CAM users and non-users, the 
sm all num ber of CAM users (n=  30)  and non-users (n= 11)  in that  study m eans 
they cannot  m ake this conclusion.49 However, the rem aining studies do not  
explain, or have unclear reasons, for such findings. 
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Table 2.14 Studies of any associat ions between CAM or HDS use and adherence to convent ional m edicat ion (n= 9)  
Authors Study design and populat ion Measurement  of  Adherence Results 
St rej ilevich et  al. (2013) ,  
Argent ina and Colombia68 
Survey 
200 outpat ients with bipolar disorder 
Developed self- reported 
measurement  of adherence 
No associat ion of adherence between CAM users and non-users (p >  
0.05)  
Bailey et al. (2012) , US114 Survey 
59 diabet ic pat ients 
MMAS-8- I tem ®  Reasons for non-adherence:  CAM use (10% ) 
Weizman et  al. (2012) , 
Canada18 
Survey 
380 outpat ients with inflammatory 
bowel syndrome 
4- item  Morisky medicat ion 
adherence scale 
No difference of adherence between CAM users and non-users 
(p= 0.26) 
Cherniack (2011) , US113 Retrospect ive survey 
300 charts in a ger iat r ic clinic 
Not  defined No associat ion of adherence between CAM users and non-users (p =  
0.46)  
Krousel-Wood et  al. 
(2010) , US17 
Survey 
2,000 pat ients using hypertensive 
agents 
MMAS-8- I tem ®  -  Prevalence rat io of poor adherence in Afr ican-American CAM users 
=  1.56 (95% CI  1.14-2.15) 
-  The prevalence rat io in Whites =  0.95 (95%  CI  0.70-1.29) 
Ogbera et  al. (2010) , 
Niger ia64 
Survey 
263 diabet ic pat ients 
Not  defined No difference of a percentage of adherence between herbal users 
and non-users (p >  0.05)  
Peltzer et  al. (2010) , 
South Afr ica112 
Cohort  study 
735 HI V pat ients 
The 30-day visual analog 
scale 
Herbal use associated with non-adherence to ant iret roviral agents 
(adjusted OR 6.67, 95%  CI  3.12-14.24) 
Gohar et  al. (2008) , UK19 Survey 
153 pat ients with hypertension 
 
The Hill-Bone compliance -  Female CAM users related to non-perfect adherence (p =  0.02) 
-  No associat ion of adherence between CAM users and non-users (p 
=  0.11)  
Mat thees et  al. (2001) , 
US49 
Survey 
41 lung t ransplant  recipients 
4- item  Morisky medicat ion 
adherence scale 
No difference of a percentage of report ing levels of adherence 
between CAM users and non-users 
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2 .8  HDS situat ion in Thailand during the last  tw o 
decades and the surveillance system  for their  
adverse effects 
Herbal m edicine has been em bedded in the Thai health system  since the 11 t h 
century.26 Thai herbal m edicine has been influenced by India and China;  som e 
herbal m edicines used by Thai people originate from  Indian or Chinese herbal 
m edicine, such as ‘Tri pala’ and ginseng.26,115 However, this has declined as 
Western m edicine has influenced the Thai health system  since the 19 th 
Century.26 
The use of herbal m edicine has becom e popular again in Thailand since 1999,  
because the governm ent  has prom oted its use for self- reliance on health, in 
place of pharm aceut icals in order to decrease drug im port s from  Western 
count ries.116 The Act  on the Protect ion and Prom ot ion of Thai Tradit ional 
Medicine Wisdom  1999 is to prom ote the use of herbal m edicine, and protect  and 
develop knowledge of herbal m edicine.33 These issues have been established in 
Thai Public Health Developm ent  Plans since 2002. The Inst itute of Thai 
Tradit ional Medicine has also developed herbal products, dissem inated 
knowledge of Thai herbal m edicines, and prom oted rat ional use of t hem  since 
1993.117 The Medicinal Plant  Research Inst itute in Thailand has developed herbal 
m edicine knowledge, a standard of herbal m edicine and Thai herbal 
pharm acopoeia since 1997.118 Over 10,000 products have been produced during 
1983-2004 and expenditure on herbal m edicines was approxim ately 176 m illion 
GBP in 2005.116 
I n the past , m ost  Thai herbal m edicines were a m ixture of herbal m edicines 
called ‘t radit ional m edicine’, such as ‘Ya hom ’ for faint ing and ‘Ka sai’ for m uscle 
pain, but  since the 20 th century, single herbal m edicines have been m ore popular 
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influenced by the philosophy of m odern m edicine. Clinical t r ials have been 
conducted on the first  four herbal m edicines:  kariyat  for pharyngotonsillit is, 
turm eric for dyspepsia, Senna alata for const ipat ion and Zingiber cassum unar  for 
m uscle pain.26 Recent ly, pat terns of herbal m edicine use in Thailand have been 
both herbal com binat ions and single herbal m edicines. I n general, herbal 
m edicine plays an im portant  role in self- reliance to health in Thai society. Kariyat  
for sore throats and com m on colds, turm eric for dyspepsia, and ginger for  
flatulence are m ost  com m only used in Thailand;  conclusions supported by data 
from  a bus stop survey, see Appendix 1, and Satyapan’s study.69,119 There are 
lim ited studies about  HDS use in Thailand, so the bus stop survey was conducted 
and aim ed to determ ine the prevalence and pat tern of HDS use am ongst  the 
Thai general populat ion. This survey shows that  the prevalence of HDS use is 
52% ;  the m ain purpose of herbal m edicine use is t reat ing illnesses, whilst  
dietary supplem ents are used for m aintaining well-being.   
I n the last  decade, use of dietary supplem ents (DS)  has frequent ly been used 
influenced by the US and beverages of DS im ported from  Japan;  however there 
is a lack of evidence to report  m ore on this situat ion. 
2 .8 .1  Legislat ion relat ing to HDS 
There has been a general debate on whether herbal and dietary supplem ents 
should be categorized as food or m edicine, and whether they fall under the 
governing laws of food or m edicine. I n Thailand, herbal products are required by 
the Drug Act  1967 to be registered.33 This Act  has classified the products as 
either registered herbal products or over- the-counter t radit ional rem edies. 
Meanwhile, dietary supplem ents are under the food law 1979.33 I f dietary 
supplem ents contain medicine or claim  to prevent , cure or t reat  disease, or  
m odify, restore or correct  physiological funct ion, they have to com ply with the 
drug law. 
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To register the m arket ing authorisat ion of the products, both herbal products 
and dietary supplem ents m ust  be tested to ident ify them , and assess m axim um 
perm issible levels of contam inants, am ounts of bacter ia, heavy m etals and 
pest icides.120 Herbal m edicines m ust  have proved their  efficacy and safety by 
using scient ific evidence or t radit ional m edical pharm acopoeia,120 whilst  dietary 
supplem ents are required to prove their safety by using acute toxic and chronic 
toxic experim ents in anim al m odels.121 Therefore, the regist rat ion of dietary 
supplem ents is less rest r icted than herbal products. However, the regist rat ion of 
herbal products is not  subject  to the sam e rest r ict ions as for convent ional 
m edicine. For instance, com panies which plan to register their herbal products 
are not  required to prove efficacy and safety of their products by clinical t rials, if 
up- to-date scient ific evidence or t radit ional m edical pharm acopoeia does not  
report  serious side effects. As a result , there is a lack of safety evidence 
am ongst  herbal products and dietary supplem ents, part icularly relat ing to 
pat ients with kidney and liver insufficiency.    
Com paring the legislat ion of HDS in Thailand with the EU laws and WHO 
guidelines, HDS can be classified as either a m edicine or food, depending on 
certain criteria under t he EU laws. The European Direct ive 2004 has classified 
herbal m edicines and dietary supplem ents as a m edicine if they can “…..prevent ,  
t reat , or cure of a condit ion…., or can be adm inistered with a view to restoring, 
correct ing or m odifying physiological funct ions in hum an beings”  (Gulat i and 
Ot taway, 2006: 77) .122 However, they are defined as a food if they are intended 
to m aintain the funct ion of healthy organs and t issues and are regarded as a 
food ingredient .122 I f the products are ident ified as a food, they m ust  be included 
under the EU food law. On the cont rary, if they are defined as a m edicat ion, they 
m ust  com ply with the EU m edicines law. Therefore, registered dietary 
supplem ents under the EU laws are m ore rest r icted than their legislat ion in 
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Thailand, in case som e dietary supplem ents are classified as m edicat ion. I f they 
are classified into food, the legislat ion, in both the EU and Thai laws, is sim ilar. 
Regarding legislat ion of safety of herbal products, the EU food law established 
the guidance on safet y assessm ent  of botanical preparat ions in 2009. These 
preparat ions m ust  be tested for the ident ificat ion of their scient ific nam es and 
botanical parts. Moreover, m anufacturers have to provide specific toxicity data 
as follows:  genotoxicity data, reproduct ive toxicity, im munotoxicity and 
carcinogenicity. I n the case of historic herbs, if they have no report s on toxic 
inform at ion, they need not  t o com ply with this criterion.123 Likewise, WHO 
guidelines for  t radit ional m edicine have suggested herbs, which have been 
t radit ionally used without  any evidence of harm , do not  have to provide any 
toxic data.31 Am ongst  t radit ional herbal medicines, this is sim ilar to the 
legislat ion in Thailand.  
2 .8 .2  Post - m arket ing surveillance of HDS products 
Post -m arket ing surveillance of herbal and dietary products under the Thai law is 
m onitored by the Thai Health Product  Vigilance Center and consum er com plaint  
system . Init ially, the center intensively m onitored the side effects of five herbal 
products in 2000 and revealed m inor side effects, which are described in herbal 
m onographs.124 I n 2007, this intensive m onitoring system  has included eight  
herbal m edicines:  Kariyat , turm eric, Zingiber officinale, Senna alata, Centella 
asiat ica, Clinacanthus nutans, Capsicum  frutescens, and Zingiber purpureum ,  
and found no renal adverse effects from  using them .125 The Nat ional 
spontaneous report ing system  has also been established to m onitor adverse 
effect s from  HDS products in Thailand since 1997 126 and has encouraged both 
health care providers and consum ers to report  them . However, there is under 
report ing of adverse effect s from  HDS;  for  exam ple there was only one report  
from  dietary supplem ents in a m onthly sum m ary of the reports in 2012.127   
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The Thai Health Product  Vigilance Center database, between 2000 and 2008, has 
reported that  m ost  side effects from  using herbal m edicines are gast rointest inal 
problem s, with som e are serious side effects, such as Stevens-Johnson 
syndrom e and anaphylact ic shock.128 However, there are lim ited report s on any 
renal side effects from  using HDS.    
2 .8 .3  Accessibility to HDS products in Thailand 
Registered herbal products are available at  prim ary and secondary hospitals, 
health service centers, Thai t radit ional clinics and drug stores, but  not  in general 
shops.116 Legislat ion of drug stores in Thailand has classified the stores as 
convent ional m edicine drug stores and t radit ional m edicine drug stores. People 
who are likely to take herbal products can consult  pract it ioners at  these places. 
Addit ionally, general shops can sell over- the-counter t radit ional rem edies. 
Medicinal plants in a raw state need not  be registered as herbal products and are 
sold at  t radit ional m edicine drug stores. Many Thai people also grow m edicinal 
plants in their garden. Therefore, raw herbal m edicines are easy to access in 
Thailand, which m ay do harm  if there is a lack of inform at ion on how to use 
them  safely.  
More than 1,000 dietary supplem ent  products have been registered as a food in 
Thailand and can be categorised into 8 types of products:  vitam ins and m inerals,  
ant ioxidant  agents, ant i-aging agents, laxat ives, herbal ext racts, cereal ext racts, 
the agents of decreased lipid absorpt ion and the agents of increased 
m etabolism .129 They are available at  drug stores, dietary supplem ent  stores and 
departm ent  stores. 
  
Chapter 2:  Herbal and dietary supplements 
60 
2 .8 .4  Thai Nat ional List  of Herbal Medicine Products 
Since 2006, the Thai nat ional drug com m it tee has launched the Nat ional List  of 
Herbal Medicine Products based on t radit ional knowledge, scient ific evidence and 
Thai Herbal Pharm acopoeia in order to encourage good pract ice of t he use of 
m edicinal herbs.124 Herbal m edicines in the list  are to alleviate m inor ailm ents, 
such as fever, cold, gast rointest inal problem s and m uscle pain. 
Seventy-one item s of Thai herbal products, both herbal com binat ions (n= 50)  
and single herbal m edicines (n= 21) , are in the Thai Nat ional List  of Herbal 
Medicine Products (2011) :  for exam ple turm eric (Curcum a longa) , ginger 
(Zingiber officinale) ,  senna (Senna alata,  Cassia alata) ,  kariyat  (Andrographis 
paniculata) . Also included are Thai folk rem edies such as ‘Ya hom ’ and ‘Ka sai’.119 
Appendix 2 shows com m only used herbal m edicines in Thailand, their pictures 
and their m edical purposes, which are either recom m ended by the Thai Nat ional 
List  of Herbal Medicine Products or approved by Thai FDA. 
2 .8 .5  Thai Nat ional Health System  and t radit ional m edicine 
The Thai Nat ional Health System , called ‘the Universal coverage of healthcare 
schem e’, has been im plem ented nat ionwide since 2002.130 Pat ients with 
advanced CKD in Thailand are referred from  prim ary and secondary hospitals to 
tert iary hospitals, such as teaching hospitals, which provide a specialist , such as 
a nephrologist  or cardiologist . Thus, these places are the prim ary source of 
advanced CKD health care in Thailand. 
Herbal m edicines in the Thai Nat ional List  of Herbal Medicine Products are 
covered by Thai Nat ional Health System . However, only 3%  of herbal products in 
governm ent  hospitals have been prescribed in 2012.131 
Thai t radit ional m edicine pract it ioners have to register  under the Pract ice of the 
Art  of Healing Act  1999.33 There are two educat ional system s of Thai t radit ional 
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m edicine, which are apprent iceship and undergraduate program m es.24 However, 
m ost  use of herbal m edicine in Thailand is not  under supervision by the 
pract it ioners as Thai people use it  for self-  care, such as t reat ing com m on cold, 
dyspepsia and const ipat ion. 
2 .8 .6  The spect rum  of herbal research in Thailand 
Most  studies of herbal m edicines in Thailand have been conducted by 
researchers in Thai universit ies, the Medicinal Plant  Research Inst itute, and the 
Inst itute of Thai Tradit ional Medicine. Most  herbal research in Thailand has 
explored efficacy and toxicity of herbal m edicine in anim al m odels and in vit ro.132 
Few clinical t rial studies have been conducted. Exam ples of herbal m edicines, 
which are studied are:  Curcum a longa, Andrographis paniculata, Centella 
asiat ica, Boesenbergia pandurata, Zingiber officinale, Eugenia caryophyllus, 
Psidium  guajava.132 The purposes of these herbal m edicines are t reatm ent  of 
m inor ailm ents, such as dyspepsia, diarrhoea, wound healing and the com m on 
cold. Addit ionally, research regarding the efficacy of well- known herbs such as 
Mom ordica charant ia, Allium  sat ivum  and Pueraria m ir ifica, has been conducted 
frequent ly, com pared with others, because they are consum ed frequent ly. People 
have used them  for diabetes, dyslipidaem ia and breast  enlargem ent ,  
respect ively.133 There are lim ited clinical t r ials of benefits and adverse effects of 
herbal m edicine in Thailand.134-138 Case reports are the m ain inform at ion sources 
of side effects from  use of herbal m edicine in Thailand, and these have been 
lim ited.139   
With respect  to findings of herbal inform at ion supported by postgraduate 
research in Thailand, the m ajorit y of research areas are sim ilar to the studies as 
described above. Many studies have exam ined ant i-oxidant  and ant i-m icrobial 
effect s of plants and have focused on m edicinal plants for t reat ing osteoarthrit is, 
diabetes m ellitus, cancer and acquired im m une deficiency syndrom e.140 Beliefs 
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and at t itudes regarding herbal products have been surveyed in m any regions of 
Thailand.141-143 
Despite plenty of anim al studies on the beneficial effect s of herbal m edicine, 
there is a lack of hum an studies regarding posit ive and negat ive effect s of herbal 
m edicines in Thailand.  
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3 . Chronic k idney disease 
Chronic kidney disease (CKD)  is an im portant  condit ion, as it  leads to an 
increase in m orbidity and m ortalit y worldwide. An overview of CKD, prevalence 
of this disease and assessm ent  of kidney funct ion are now presented. 
3 .1  Definit ion and classificat ion of CKD 
Chronic kidney disease is defined as either kidney dam age or a glom erular 
filt rat ion rate of less than 60 m l/ m in/ 1.73m 2 for  at  least  3 m onths.144 The United 
States (US)  Nat ional Kidney Foundat ion Kidney Disease Outcom es Qualit y 
I nit iat ive (NKF-KDOQI ® )  in 2002, the Kidney Disease Im proving Global 
Outcom es (KDIGO)  in 2012, and the Nat ional I nst itute for  Health and Clinical 
Excellence (NICE)  guideline for  CKD in 2008, have classified the severity of CKD 
into five stages, see Table 3.1.11,144,145 Stage one of CKD has the lowest  kidney 
dam age whilst  stage five denotes the highest  severity of CKD. The Thai guideline 
for  CKD in 2009, which defined CKD and it s classificat ion, is based on the NKF-
KDOQI ®  guideline.12 
Table 3.1 Classificat ion of CKD 
Stage Descr ipt ion GFR (m l/ m in/ 1.73m 2)  
1 Kidney damage with normal or an increase in GFR >  90 
2 Kidney damage with a slight  decline in GFR 60-89 
3   
   3a Mild to moderate decline in GFR 45-59 
   3b Moderate to severe decline in GFR 30-44 
4 Severe decline in GFR 15-29 
5 Kidney failure or end-stage renal disease <  15 (or dialysis)  
 References:  Nat ional Kidney Foundat ion. Definit ion and Classificat ion of Stages of Chronic Kidney 
Disease. Am J Kidney Dis 2002; 39(2 Suppl 1) : S46. 
 
Kidney Disease:  I mproving Global Outcome (KDI GO) CKD Work Group. The KDI GO 
2012 Clinical Pract ice Guideline for  the Evaluat ion and Management  of Chronic Kidney 
Disease. Kidney I nt  Suppl 2012; 3(1) : 27. 
 
The Nat ional Collaborat ing Centre for Chronic Condit ions (Great Br itain) . Chronic 
Kidney Disease:  Nat ional Clinical Guideline for Ear ly ident ificat ion and Management  in 
Adults in Pr imary and Secondary Care. 1st  ed. London:  Royal College of Physicians, 
2008. 
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This thesis is focused on CKD stages 3 to 5, as classified by GFR and defined as 
advanced CKD. Stage 1 to 2 CKD is classified by kidney dam age – either 
st ructural or funct ional abnorm alit y of the kidney.144 The m ore GFR decreases, 
the m ore kidney funct ion declines. Pat ients who either have less than 15 
m l/ m in/ 1.73m 2 of GFR or are receiving dialysis therapy are defined as having 
end-stage renal disease (ESRD) , m eaning their kidneys fail to elim inate body 
waste. 
3 .2  Prevalence of CKD and characterist ics of 
pat ients w ith CKD in Thailand 
The prevalence of pat ients with less than 60 m l/ m in/ 1.73m 2 of est im ated 
glom erular filt rat ion rate ( eGFR)  in Thailand has ranged from  8.9-14.0% .5,146,147 
I t  appears that  the prevalence of CKD in the Thai populat ion, aged 35 years or 
older (8.9% ) ,147 was higher than the m edian prevalence of CKD worldwide in a 
populat ion aged 30 years or over (7.2% ) .148 Perkovic’s study also showed that  
the prevalence of stage 3 CKD in Thailand was higher than in both the US and 
Taiwan.147  
I n Thailand, stage 3 of CKD has the highest  prevalence, com pared with stages 4 
and 5, see Table 3.2.5,146,147 Northeast  Thailand has a high prevalence of CKD, 
whilst  it s prevalence in Bangkok is inconsistent :  one study found the highest  
prevalence of CKD in Bangkok (23.9% ) 5 and a nat ional survey in 2000 showed 
the lowest  prevalence (9.7% ) .147 
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Table 3.2 Prevalence of CKD in each stage and region am ongst  Thai pat ients 
Authors Study  design Populat ion Measurement  of 
eGFR 
Prevalence (% ) 
Perkovic et al. 
(2008) 147 
A nat ional survey in 
2000 using a 
st rat if ied, 
mult istage, cluster-
sampling method 
(n= 7,909) 
Thai populat ion 
aged 35 years or 
over 
MDRD equat ion Stage 3:  13.2 
Stage 4:  0.6 
Northeast :  16.9 
North:  15.1 
Central:  13.7 
Bangkok:  9.7 
South:  9.7 
Ong-Ajyooth et  al. 
(2009) 146 
A nat ional health 
survey in 2004 
(n= 3,117)   
Thai populat ion 
aged 15 years or 
over 
Chinese 
modified MDRD 
equat ion 
Stage 3:  8.1 
Stage 4:  0.2 
Stage 5:  0.2 
I ngsathit  et  al. 
(2010) 5 
The populat ion-
based Thai 
Screening and Ear ly 
Evaluat ion of 
Kidney Disease 
(SEEK) study in 
2007 (n= 3,459) 
Thai populat ion 
aged 18 years or 
over 
MDRD Stage 3:  7.5 
Stage 4:  1.1 
Bangkok:  23.9 
Northeast :  22.2 
North:  20.4 
South:  13.7 
Central:  13.4 
eGFR =  Est imated glomerular f ilt rat ion rate 
MDRD =  Modificat ion of Diet  in Renal Disease study 
There are four relevant  studies which reported characterist ics of stages 3 to 5 
CKD populat ions in four count r ies:  Ong-Ajyooth’s study (2009)  in Thailand146;  
Zhang’s study (2012)  in China149;  Im ai’s study (2010)  in Japan150;  and Mart inez-
Castelao’s study (2011)  in Spain151, see Table 3.3. The m ean age from  the Thai 
survey (56.8)  is younger than others. Most  of the CKD populat ion in Thailand 
and China is fem ale, whilst  those in Japan and Spain are m ale. The Thai 
populat ion with CKD has the lowest  proport ion of hypertension and diabetes.  
There is no significant  difference in m ean BMI  am ongst  Asian populat ions, which 
is lower than in Spain (28.4 kg/ m 2) . Fewer than 20%  of CKD pat ients in Japan 
and China current ly sm oke, whilst  26%  are either current  or form er sm okers, as 
reported by the Thai survey. I t  appears that  the characterist ics of the Thai 
populat ion are consistent  with those in China. 
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Table 3.3 Characterist ics of populat ions with stages 3 to 5 CKD aged 15-18 or 
over in several count r ies 
Survey Thailand146 China149 Japan150 Spain151*  
 (n= 3,117) (n= 47,204) (n= 2,977) (n= 1,129) 
Mean age 56.8 63.6 60.8 68 
Female (% )  69.6 61.9 37.9 36.0 
Mean BMI  (kg/ m 2)  24.4 24.4 23.5 28.4 
Diabetes (% ) 14.6 19.1 38.0 40.8 
Hypertension (% ) 50.0 60.5 92.0 92.7 
Current  smoking (% )  26.0* *  19.4 16.4 -  
*  Stage 3-4 CKD populat ion;  * *  Current or former smoking 
3 .3  Causes, sym ptom s of CKD and its 
com plicat ions 
3 .3 .1  Causes of CKD and rate of CKD progression  
There are several causes of CKD. Diabetes and hypertension are the m ain causes 
of CKD worldwide, followed by chronic glom erulonephrit is, chronic interst it ial 
nephrit is and renovascular disease.152 Chronic glom erulonephrit is is a m ore 
com m on cause in Asia.152 I n Thailand, high num bers of renal tubular acidosis 
have been reported, part icularly in northeast  Thailand153, which m ay lead to a 
high prevalence of CKD in northeast  Thailand. There is an ongoing survey of CKD 
causes in Thailand – the populat ion-based Thai screening and early evaluat ion of 
kidney disease (SEEK)  study 2.  
Several diseases can lead to CKD, such as hum an im m unodeficiency virus (HIV) , 
cancer and cirrhosis. Pat ients with HIV are six t im es m ore likely to develop 
kidney im pairm ent  than non-HIV pat ients, which m ainly causes HIV-associated 
nephropathy.154,155 CKD can be caused by cancer, due to paraneoplast ic 
nephropathy and side effect s from  chem otherapy or radiat ion.156 CKD in cirrhosis 
is related to hepatorenal syndrom e im paired renal perfusion.157 
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Various causes of CKD have a different  rate of decline in GFR, see Table 3.4.18,19 
Diabetes and chronic glom erulonephrit is has a faster progression of CKD, 
com pared to other causes. Fast  progression has been defined as a decline in GFR 
of at  least  5 m l/ m in/ year.11,145 There is a lack of evidence relat ing to the 
progression of CKD regarding those with cancer or cirrhosis.  
Table 3.4 Mean rate of decline in GFR for various causes of CKD am ongst  
pat ients with stage 3-5 CKD158,159 
Causes of CKD Mean GFR at  baseline (m l/ m in)  Rate of decline in GFR 
(m l/ m in/ year)  
Diabetes 36 7.9 
Hypertension 39 4 
Chronic glomerulonephr it is 43 4.6 
Tubulointerst it ial diseases 41 2 
Polycyst ic k idney disease 47 3.8 
HI V <  60 2.3-2.6 
References:  Nat ional Kidney Foundat ion. St rat if icat ion of Risk for  Progression of Kidney Disease and 
Development  of Cardiovascular Disease. Am J Kidney Dis 2002; 39(2 Suppl1) : S173. 
 Campbell LJ, I brahim  F, Fisher M, Holt  SG, Hendry BM, Post  FA. Spectrum of chronic 
kidney disease in HI V- infected pat ients. HI V Med 2009; 10(6) : 329-36. 
3 .3 .2  Sym ptom s and com plicat ions of CKD 
Pat ients with early stage CKD are asym ptom at ic, whilst  those with stages 3 to 5 
CKD are likely to have sym ptom s of CKD com plicat ions:  fat igue, weakness, a 
poor appet ite, swollen feet , dry and it chy skin and frequent  urinat ion at  
night .160,161  
Pat ients with less than 60 m l/ m in of GFR are m ore likely to develop 
com plicat ions of CKD, such as anem ia, hypertension, hyperphosphatem ia, 
hyperkalem ia and m etabolic acidosis. The prevalence of hypertension, am ongst  
those with advanced CKD is over 70% , whilst  the prevalence of anem ia or  
hyperphosphatem ia is less than 10% .162 The m ore severe the CKD, the m ore 
com plicat ions of CKD pat ients suffer . Hyperkalem ia is likely to occur when 
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pat ients have stages 4 to 5 of CKD.163 The prevalence of hyperkalem ia (serum  
potassium  level >  5 m Eq/ L)  in pat ients with stage 5 CKD is 54% .164 
This thesis is focused on hyperphosphatem ia and hyperkalem ia, because herbal 
and dietary supplem ents m ay lead to these com plicat ions. CKD causes 
hyperphosphatem ia and hyperkalem ia as kidneys decline in elim inat ing 
phosphate and potassium .163,165 However, pat ients with advanced CKD can 
develop hyperkalem ia if they partake of a diet  containing high am ounts of 
potassium .163 A high serum  level of potassium  (>  6.0 m Eq/ L)  m ay cause 
elect rocardiogram  abnorm alit y and is life- threatening. Severe hyperkalem ia can 
induce vent r icular arrhythm ias, skeletal m uscle weakness and respiratory 
failure.157 Advanced CKD is linked to an abnorm alit y of calcium -phosphate 
hom eostasis leading to hyperparathyroidism . Hypercalcem ia and 
hyperphosphatem ia can increase cardiovascular calcificat ion in pat ients with 
CKD.166 
3 .4  Risk factors related to progression of CKD and 
its com plicat ions 
3 .4 .1  Risk factors linked to CKD progression 
There are known factors that  increase suscept ibilit y to CKD, including older age,  
fam ily history of CKD, diabetes, obesity, hypertension and dyslipidaem ia, as well 
as nephrotoxic agents, such as non-steroidal ant i- inflam m atory drugs 
(NSAIDs) .167 Likewise, two surveys in Thailand have revealed factors related t o 
CKD, which are being elderly, diabetes, hypertension, high body m ass index 
(BMI )  and a history of k idney stones.5,168 
Established factors related to the progression of CKD have been younger age, 
m ale, obesity, sm oking, proteinuria, high protein intake, hypertension, systolic 
blood pressure of m ore than 130 m m Hg, hyperlipidaem ia, and exposure to 
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nephrotoxic agents.157,167 There have been m any relevant  cohort  studies that  
have reported factors linked to the progression of CKD in pat ients with advanced 
CKD, see Table 3.5.169-173  
These studies defined the progression of CKD as either a decline in eGFR of 5 
m l/ m in/ year or end-stage renal disease (ESRD) . Levin et  al. (2008)  report  a 
younger age has a faster progression (p- value <  0.01) 169 and Eriksen and 
Ingebretsen (2006)  found that  an increase of 10 years in age has less ESRD (HR 
0.75, 95% CI  0.63-0.89) .173 Males are m ore likely to experience CKD progress in 
term s of severity, than fem ales.173 Proteinuria indicates a high r isk of CKD 
progression169 or ESRD170,171, com pared with diabetes, hypertension, sm oking 
history and uncont rolled blood pressure.170 Non-select ive NSAIDs and rofecoxib 
are linked to ESRD in newly diagnosed CKD pat ients.174 
 
Chapter 3:  Chronic kidney disease 
70 
Table 3.5 Factors related to the progression of CKD 
Authors Study design Populat ion Definit ion of progression of CKD Risk factors 
Er iksen and 
I ngebretsen 
(2006) , Norway173 
A 10-year populat ion-based 
study 
Pat ients with stage 3 CKD 
(n= 3,047)   
End-stage renal disease Age (10 year increase) :  HR 0.75, 95% CI  
0.63-0.89 
Female:  HR 0.35, 95% CI  0.21-0.59 
Levin et  al. (2008) , 
US169 
Cohort  analysis from PROMI S*  
database 
Median follow-up:  31 months 
Pat ients with <  30 m l/ m in of 
eGFR (n= 4,231)  
Fast  progression defined as  
-5 m l/ m in/ yr of decline in eGFR  
Younger age 
Proteinur ia (>  1 g/ day) 
Higher level of SBP 
Obi et al. (2010) , 
Japan170 
Histor ical cohort  study 
Median follow-up:  3.2 years 
Pat ients with stage 3-5 CKD 
(n= 461) 
End-stage renal disease Overt  proteinur ia (>  1 g/ day) :  SHR 9.1, 
95% CI  4.2-19.7 
Diabetes:  SHR 2.1, 95% CI  1.2-3.4 
Hypertension:  SHR 10.7, 95% CI  1.5-76.0 
Smoking history:  SHR 2.0, 95% CI  1.2-3.4 
Nicola et  al. 
(2011) , I taly171 
Prospect ive cohort  study for 5 
years 
Pat ients with stage 3-5 CKD 
(n= 1,248) 
End-stage renal disease Proteinur ia (>  0.5 g/ day) 
  Stage 3:  HR 3.17, 95% CI  1.76-5.72 
  Stage 4:  HR 2.02, 95% CI  1.41-2.88 
  Stage 5:  HR 1.13, 95% CI  0.73-1.76 
Goeij  et  al. (2011) ,  
Nether land172 
Cohort  analysis for  a year from  
PREPARE-1 study 
Pat ients with stage 4-5 CKD 
(n= 508) 
Rate of decline in eGFR BP >  130/ 80:  Adjusted addit ional decline 
in eGFR 0.31 m / m in/ month, 95% CI  0.08-
0.53 
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Table 3.5 (cont inued)  
Authors Study design Populat ion Definit ion of progression of CKD Risk factors 
Samuelsson et  al. 
(1997) , Sweden175 
 A prospect ive, observat ional 
study 
Average follow-up:  3.2 years 
Pat ients with GFR 15-75 
m l/ m in/ 1.73m 2 and non-
diabetes and (n= 73)  
 
Rate of decline in GFR The more level of LDL increased, the more 
rate of GFR declined (p-value =  0.01)    
LDL level of 88-140 mg/ dl had -4.7 of 
annual decline in GFR. 
Kuo et  al. (2010) ,  
Taiwan174 
A cohort  study Newly diagnosed CKD pat ients 
(n= 19,163) 
End-stage renal disease Non-select ive NSAI Ds:  adjusted* *  HR 
1.56, 95% CI  1.32-1.85 
Aspir in:  adjusted HR 1.96, 95% CI  1.62-
2.36 
Rofecoxib:  adjusted HR 1.98, 95% CI  1.15-
3.40 
*  Pat ient  Regist rat ion and Outcomes Management  I nformat ion System;  eGFR =  Est imated glomerular f ilt rat ion rate;  SBP =  Systolic blood pressure 
   SHR =  Subdistr ibut ion hazard rat io;  HR =  Hazard rat io, CI  =  Confidence intervals;  PREPARE-1 =  PREdialysis Pat ient  Record-1 study 
* *  Adjusted for age, sex. Comorbidit ies, such as diabetes and hypertension and use of other analgesics 
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There is lim ited evidence to support  high protein intake relat ing to a progression 
of CKD in pat ients with advanced CKD. The Modificat ion of Diet  in Renal Disease 
(MDRD)  study in 2004 has been the cornerstone of the recom m endat ion for  low 
protein intake in pat ients with CKD, and reports slight ly slowed progression of 
CKD in a group with low protein intake (0.6-0.8 g/ kg of body weight / day)  
am ongst  pat ients with 55-25 m l/ m in of eGFR, com pared with a group of usual 
protein intake (1.0-1.2 g/ kg of body weight / day) .176 There is no significant  
benefit  in pat ients with less than 25 m l/ m in of eGFR and very low protein intake 
(0.4-0.6 g/ kg of body weight / day) , com pared with a group of low protein intake.  
3 .4 .2  Factors related to hyperkalem ia and 
hyperphosphatem ia 
Theoret ically, hyperkalem ia in pat ients with CKD is caused by high potassium 
intake and/ or drug- induced hyperkalem ia, such as angiotensin-convert ing 
enzym e inhibitors (ACEIs) , angiotensin I I  receptor antagonists (ARBs) , NSAIDs 
or cyclooxygenase-2 (COX-2)  inhibitors.163,177 However, ACEI s or ARBs related to 
hyperkalem ia in these pat ients are less likely to be clinically significant .178 High 
phosphate intake m ainly results in hyperphosphatem ia am ongst  pat ients with 
advanced CKD.179 Vitam in D also increases intest inal absorpt ion of phosphate 
from  60%  to 86%  in pat ients with advanced CKD.165 
There are lim ited studies of the associat ion between risk factors and 
hyperkalem ia and hyperphosphatem ia. There is one cohort  study with an 
average durat ion of 2.6 years, in the US, that  report  pat ients with CKD taking 
ACEIs or ARBs are m ore likely to have hyperkalem ia.180     
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3 .5  Measurem ent of k idney funct ion, 
hyperkalem ia and hyperphosphatem ia 
3 .5 .1  Measurem ent  of k idney funct ion and progression of 
CKD 
Kidney funct ion is assessed by m easuring the glom erular filt rat ion rate (GFR) . 
Norm al values of GFR in an adult  are 120 m l/ m in for  m en and 100 m l/ m in for 
wom en. A decline in GFR represents worsening kidney funct ion, part icularly if 
less than 60 m l/ m in of GFR. Inulin is a gold standard m arker for evaluat ing 
kidney funct ion, as this substance is filt rated from  renal tubules, and is not  
absorbed and secreted by renal tubules. I n clinical pract ice, serum  creat inine is a 
recom m ended m arker for assessing kidney funct ion due to being cheap and 
convenient . This is calculated to predict  kidney funct ion using the Cockcroft -
Gault  equat ion (CG equat ion) , the MDRD equat ion or the Chronic Kidney Disease 
Epidem iology Collaborat ion equat ion (CKD-EPI  equat ion) , see Table 3.6.  
Unt il 2005, the Cockcroft -Gault  equat ion had been calculated to predict  the 
creat inine clearance rate, which was assum ed to be equal to GFR. This equat ion 
had been the m ost  com m only used in clinical pract ice;  nevertheless, it  
overest im ates eGFR due to the fact  that  15-20%  of creat inine is secreted by 
renal tubules.157  
To date, est im ated GFR calculated using the MDRD equat ion has been 
recom m ended for adult  pat ients with less than 60 m l/ m in/ 1.73m 2 of GFR by the 
Nat ional Kidney Disease Educat ion Program  in the US, the NI CE guideline for 
CKD in UK and the Thai guideline for CKD.12,145,181 This is adjusted for body 
surface area and is m ore accurate than the Cockcroft -Gault  equat ion in pat ients 
with advanced CKD.145 Meanwhile, the Chronic Kidney Disease Epidem iology 
Collaborat ion equat ion (CKD-EPI  equat ion)  has been recom m ended for those 
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with at  least  60 m l/ m in/ 1.73m 2 of GFR.11 Recent ly, epidem iologic studies are 
m ore likely to est im ate kidney funct ion using the MDRD equat ion, rather than 
the Cockcroft -Gault  equat ion.148 
Table 3.6 Equat ions of est im ated glom erular filt rat ion rate 
eGFR equat ion Formulas 
Cockcroft -Gault  equat ion 
(m l/ m in)  
(140-Age) X Body weight / 72 X Scr (m l/ m in)  
Female (X 0.72) 
Reexpressed MDRD equat ion 
(m l/ m in/ 1.73 m 2)  
(175 X Scr -1.154 X Age-0.203)  
Female (X 0.742) 
Thai MDRD equitat ion 
(m l/ m in/ 1.73 m 2)  
(175 X Scr -1.154 X Age-0.203)  
Female (X 0.742)  X Thai (X 1.129)  
CKD-EPI  equat ion 
(m l/ m in/ 1.73 m 2)  
Male:  with Scr <  0.9 mg/ dL 
     141163 X (Scr/ 0.9) -0.411 X (0.993) Age 
Male:  with Scr >  0.9 mg/ dL 
     141163 X (Scr/ 0.9) -1.209 X (0.993) Age 
Female:  with Scr <  0.7 mg/ dL 
     144166 X (Scr/ 0.7) -0.329 X (0.993) Age 
Female:  with Scr >  0.7 mg/ dL 
     144166 X (Scr/ 0.7) -1.209 X (0.993) Age 
References: Cir illo M. Evaluat ion of Glomerular Filt rat ion Rate and of Album inur ia/ Proteinur ia. J 
Nephrol 2010; 23(2) : 127. 
Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the 
Modificat ion of Diet in Renal Disease Study Equat ion for Est imat ion Glomerular Filt rat ion 
Rate with Standardized Serum Creat inine Values. Clin Chem  2007; 53(4) : 771. 
Praditpornsilpa K, Townamchai N, Chawatanarat T, Tiranathanagul K, Katawat in P, 
Susant itaphong P, et  al. The Need for Robust  Validat ion for  MDRD-Based Glomerular 
Filt rat ion Rate Est imat ion in Var ious CKD Populat ions. Nephrol Dial Transplant  
2011; 26(9) : 2780-85. 
Scr =  Serum creat inine 
However, the MDRD equat ion has been validated in Caucasian populat ions and 
underest im ates eGFR am ongst  Asian populat ions, such as Chinese people, due to 
a difference in m uscle m ass.182 The Thai MDRD equat ion has been developed and 
recom m ended for  Thai pat ients, see Table 3.6.183 The lim itat ion of the MDRD 
equat ion is that  it  should not  be used for unstable serum  creat inine and there 
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should be caut ion in using it  for people aged over 70 years and those individuals 
with ext rem es of m uscle m ass, such as the obese or bodybuilders. 
To est im ate progression of CKD, based on eGFR, fast  progression of CKD is 
current ly defined as a decline in an eGFR of at  least  5 m l/ m in/ 1.73m 2/ year11,145 
although there is no conclusive definit ion as som e studies define it  as -3 or -4 
m l/ m in/ 1.73m 2/ year.161,184 The NKF-KDOGI ®  guideline in 2002 has suggested 
that  the CKD progression is est im ated by a slope of the best  fit  linear regression 
line, which is plot ted on a graph of eGFR levels and t im e under the assum pt ion 
of a constant  decline in kidney funct ion over a period.158 Both the NKF-KDOGI ®  
guideline in 2002, and the NICE guideline for CKD in 2008, have recom m ended 
at  least  three m easures of serum  creat inine over a period in order t o est im ate 
GFR and precisely predict  the progression of CKD;  part icularly slow rates of this 
progression.145,158  
3 .5 .2  Measurem ent  of hyperkalem ia and hyper-
phosphatem ia 
Serum  levels of potassium  and phosphate indicate abnorm alit y of these 
elect rolytes. Hyperkalem ia is m ore than 5.5 m Eq/ L (m m ol/ l)  of a serum  
potassium  level185 and hyperphosphatem ia is m ore than 4.6 and 5.5 m g/ dl (1.5 
and 1.7 m m ol/ l)  of a serum  phosphate level for  stages 3 to 4 CKD and stage 5 
CKD, respect ively.186   
3 .6  Slow ing the progression of CKD and 
m anagem ent  of its com plicat ions  
Managem ent  in slowing the progression of CKD has involved cessat ion of 
sm oking, body weight  loss for  obesity, st r ict  blood sugar cont rol in diabetes, 
st r ict  blood pressure cont rol, use of ACEIs or ARBs for  CKD with proteinuria and 
rest r icted protein intake.145,158 The Thai guideline for  CKD m anagem ent  in 2009, 
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and the NKF-KDOQI ®  for diabetes in 2007, have recom m ended cont rolled blood 
sugar of less than 7%  of glycated haem oglobin (A1C)  for diabetes and cont rolled 
blood pressure of equal or under 130/ 80 m m Hg to slow the progression of 
CKD.12,187 The NI CE guideline for  CKD m anagem ent  in 2008 has suggested 
cont rolled blood pressure of lower than 140/ 90 and 130/ 80 m m Hg for non-
diabetes and diabetes, respect ively.145 The Thai guideline for  CKD m anagem ent  
in 2009 has recom m ended 0.6-0.8 and 0.6 g of protein/ kg of body weight / day 
for  stage 3 and stages 4 to 5 of CKD, respect ively, whilst  the KDI GO guideline in 
2012 has suggested 0.8 g of protein/ kg of body weight / day for stages 4 to 5 of 
CKD.11 A dietary protein rest r ict ion, of 0.6 g/ kg/ day, prevented 32%  of non-
diabet ic pat ients from  reaching end-stage renal disease.188  
The principal m anagem ent  of CKD com plicat ions, hyperkalem ia and 
hyperphosphatem ia, has been the avoidance of potassium  and phosphate r ich 
foods.12 Potassium - rich foods are fruit , such as oranges and bananas, dried fruit  
and potatoes, and phosphate- r ich foods such as cereal, dairy products and 
coffee.12,163 I f a pat ient  with CKD cannot  cont rol their serum  potassium  or 
phosphate levels under these diets, their  doctor will consider prescribed 
m edicat ion therapy, such as sodium  or calcium  polystyrene sulfonate for  
hyperkalem ia and phosphate binders, such as calcium  carbonate or acetate, for  
hyperphosphatem ia.12,185 
There are com m on m edicat ions for other CKD com plicat ions, such as loop 
diuret ics for  peripheral oedem a, iron supplem ents, folic acid, vitam in B12 and 
erythropoiet in for anaem ia, sodam int  for m etabolic acidosis and allopurinol for  
hyperuricem ia.185 
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3 .7  Use of nephrotoxic agents, herbal m edicine 
and dietary supplem ents in pat ients w ith 
advanced CKD 
NSAI Ds and COX-2 inhibitors have been known as a nephrotoxic agent .157 Both 
the NKF-KDOQI ®  guideline in 2002, and the Thai guideline for CKD m anagem ent  
in 2009, have recom m ended avoiding nephrotoxic agents for pat ients with CKD, 
such as NSAIDs and COX-2 inhibitors, in order to prevent  acute kidney injury on 
top of CKD.158 The NICE guideline for CKD m anagem ent  in 2008 has suggested 
prolonged use of these m edicat ions only with caut ion for those with CKD, 
com bined with close m onitoring of their GFR.145 There have been inconsistencies 
in the associat ion between aspir in and progression of CKD. In case-cont rol 
studies, aspir in is likely to be associated with end-stage renal disease (ESRD)  in 
pat ients with newly diagnosed CKD174,189;  however Perneger et  al. in 1994 report  
no associat ion.190 Am ong pat ients with stages 4 to 5 of CKD, there is a posit ive 
associat ion between aspirin and the progression of CKD in a prospect ive cohort  
study of 5-7 years durat ion.191 However, this has been the only study report ing 
the posit ive associat ion, so further studies are required to confirm  and explain 
this result .  
Pat ients with CKD should not  use herbal m edicine, as som e Chinese herbal 
m edicines m ay contain aristolochic acid, which can induce renal failure. Such 
pat ients should use dietary supplem ents only under the supervision of a doctor 
or pharm acist , as suggested by the KDI GO guideline in 2012.11 The 2009 Thai 
guideline for  CKD m anagem ent  has recom m ended using herbal m edicine with 
caut ion.12 However, neither guidelines have provided conclusive evidence to 
support  their recom m endat ion;  in part icular the KDI GO recom m endat ion for  
herbal use is supported by only one Chinese herbal m edicine related to kidney 
injury. The 2008 NICE guideline for CKD m anagem ent  did not  m ent ion herbal 
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m edicine. Such guidelines suggest  that  there is only lim ited scient ific evidence 
regarding the safet y of herbal m edicine for pat ients with CKD. 
The 2011 Thai Nat ional List  of Essent ial Medicines has advised pat ients with CKD 
to avoid senna for  const ipat ion, rosella flower for a diuret ic effect , j ava tea for a 
diuret ic effect  and ‘Ya hom ’ for faint ing and ‘Ka sai’ for  m uscle pain, the last  two 
being Thai folk rem edies.119 This is because high doses of senna m ay induce 
nephrit is and it s prolonged use affect s water and elect rolyte im balance, 
part icularly potassium im balance. Java tea also contains high am ounts of 
potassium  and m ay cause water and elect rolyte im balance. Prolonged use of ‘Ya 
hom ’ and ‘Ka sai’ accum ulates cam phor in the body leading to renal toxicit y;  
part icularly urinary retent ion, albuminuria and anuria.192 Moreover, ‘Ya hom ’ and 
‘Ya khom ’, which are Thai folk rem edies, contain Aristolochia, which is related to 
renal failure and has a carcinogenic effect , so this ingredient  has been withdrawn 
from  these rem edies in Thailand since 2013.193 
The Nat ional Kidney Foundat ion in the US has suggested avoiding herbal 
m edicine, which m ay be toxic or harm ful to the kidneys, see Table 3.7.194 
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Table 3.7 Herbal m edicines related to renal dam age 
Herbal medicine may injure the kidneys 
Artem isia absinthium (wormwood plant )  Per iwinkle 
Autumn crocus Sassafras 
Chuifong tuokuwan (Black pear l)  Tung shueh 
Horse chestnut  Vandelia cordifolia 
Herbal medicine may be harmful in CKD 
Alfalfa Ginger 
Aloe Ginseng 
Bayberry Horsetail 
Blue Cohosh Mate 
Broom Net t le 
Buckthorn Noni juice 
Capsicum Rhubarb 
Cascara Senna 
Coltsfoot Vervain 
Dandelion  
Reference:  Nat ional k idney foundat ion. Use of herbal supplements in chronic kidney disease, 2013. 
www.kidney.org/ atoz/ content / herbalsupp.cfm . (accessed 17 th December 2013) . 
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4 . Negat ive and posit ive effects of HDS on 
kidneys 
This thesis is focused on invest igat ing any adverse effects of herbal and dietary 
supplem ent  on kidneys, rather than renal benefit s of HDS.  
4 .1  Renal adverse effects of HDS 
Adverse effects of HDS on renal funct ion can be associated with their act ive 
ingredient  which can cause kidney injury, adulterat ion of HDS with heavy m etals 
and convent ional m edicines, or herbs/ dietary supplem ents-drug interact ions. 
4 .1 .1  Herbal m edicine- induced nephropathy 
There are known herbal m edicines which direct ly dam age the kidneys, see Table 
4.1.2 Thai surveillance of herbal m edicine also report s Hout tuynia cordata Thunb 
can induce acute renal failure.195 There is a case report  that  ‘Ya hom ’ caused the 
renal failure and death of a 2- year-old gir l, as it  contained Magnolia officinalis 
which is associated with renal failure.196 I t  appears that  m ost  of the inform at ion 
regarding m edicine- induced nephropathy has been provided by case reports.  
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Table 4.1 Plants and herbal m edicines and negat ive effect s on renal funct ion 
Herbal medicine Common 
name 
Toxic component  Potent ial effects on renal 
funct ion 
Aristolochia spp. -  Ar istolochic acid Chronic interst it ial nephr it is 
Renal tubular defects 
Urothelial malignancies 
Lorrea tr identata Chapparal Nordihydroguaiaret ic 
acid 
Renal cysts, renal cell 
carcinoma 
Ephedra sinica Ma-Huang, 
ephedra 
Ephedr ine Nephrolithiasis 
Obstruct ive nephropathy 
Pithecolobium lobatum  
P. j ir inga 
Djengkol Djenkolic acid Nephrolithiasis 
Obstruct ive nephropathy 
Averrhoa carambola Star fruit  Oxalic acid Nephrolithiasis 
Obstruct ive nephropathy 
Vaccinium 
macrocarpon 
Cranberry Oxalic acid Nephrolithiasis 
Obstruct ive nephropathy 
Salix daphnoides Willow bark Salicin Renal papillary necrosis 
Pausinystalia yohimbe Yohimbe Yohimbe Lupus nephr it is 
Rhizoma Rhei Rhubarb Anthraquinone Chronic interst it ial nephr it is 
Echinacea spp. Coneflower Arabinogalactan Renal tubular acidosis 
Reference:  Jha V. Herbal medicines and chronic kidney disease. Nephrology 2010; 15(Suppl S2) : 11. 
A few observat ional studies in Taiwan and Thailand have reported a relat ionship 
between herbal products and new cases of CKD or end-stage renal disease 
(ESRD) , see Table 4.2.4-7,197,198 There are lim ited studies regarding this issue, 
part icularly cohort  studies or research involving populat ions with exist ing CKD. 
Most  studies have been conducted in Taiwan and their focus is on those newly 
diagnosed with CKD ( five out  of six studies) . Most  studies have not  reported the 
types of herbal m edicines because m ost  pat ients do not  know the nam es of the 
herbal m edicine or it s act ive ingredients. There has been inconsistent  associat ion 
between herbal use and the progression of CKD.   
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Table 4.2 Studies of the associat ion between herbal use and new cases of CKD or ESRD 
Authors Study design Number of general 
populat ion 
Methods Outcomes Results 
Guh et  al. (2007) , 
Taiwan4 
Cross-sect ional study 1,740 I nterview CKD Com parator: non-herbal users 
Herb users: adjusted OR =  1.4 (95%  CI  =  1.2-1.7) 
Lin et  al. (2013) ,  
Taiwan198 
Cross-sect ional study 3,352 I nterview CKD Com parator: non-herbal users 
Chinese herb users: adjusted OR =  0.8 (95%  CI  =  0.6-
1.1)  
I ngsathit  et  al. (2010) ,  
Thailand5 
Cross-sect ional study 3,459 I nterview CKD Com parator: non-herb users 
Herb users: mult ivar iate OR =  1.20 (95%  CI  =  1.02-
1.42)  
Hsieh et  al. (2012) ,  
Taiwan6 
Case-control study 424 I nterview CKD Com parator: non-herbal users 
Prescribed Chinese herb use:  
   Occasional use:  adjusted OR =  1.9 (95%  CI  =  0.9-4.1) 
   Regular use:  adjusted OR =  1.2 (95%  CI  =  0.6-2.4) 
Non-prescribed Chinese herb use:  
   Occasional use:  adjusted OR =  6.2 (95%  CI  =  1.8-21.6)  
   Regular use:  adjusted OR =  3.1 (95%  CI  =  0.8-12.2) 
Tsai et  al. (2009) ,  
Taiwan7 
Case-control study 200 cases and 200 
controls 
I nterview ESRD Com parator: non-herbal users 
Herbal users* : crude OR =  6.26 (95%  CI  =  3.85-10.19) 
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Table 4.2 (cont inued)  
Authors Study design Number of general 
populat ion 
Methods Outcomes Results 
Lai et  al. (2010) ,  
Taiwan197 
Populat ion-based 
case-control study 
25,843 cases and 
184,851 controls 
Database 
analysis 
ESRD Com parator: 0 g of Mu tong 
1 0 1 - 2 0 0  g of Mu tong* * : 
Mult ivar iate OR =  2.42 (95%  CI  =  1.45-4.05) 
>  2 0 0  g of Mu tong* * : 
Mult ivar iate OR =  6.17 (95%  CI  =  3.62-10.53) 
Com parator: 0 g of Fangchi 
>  2 0 0  g of Fangchi* * :  
Mult ivar iate OR =  2.40 (95%  CI  =  1.43-4.04) 
Note:  CKD =  chronic kidney disease, OR =  odds rat io, CI  =  confidence intervals,  ESRD =  end-stage renal disease, *  =  regular herb used for 5 years before 
diagnosed with ESRD, * *  =  used herbal medicines more than once a week for at  least  3-6 months 
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Both Guh et  al. (2007)  and Ingsathit  et  al. (2010)  report  that  herbal products 
are associated with a sm all increased risk of developing CKD.4,5 Tsai et  al (2009)  
show herbal m edicines are linked to a large increase in the r isk of new cases of 
ESRD ( crude OR =  6.26;  95%  CI  =  3.85-10.19) .7 Lai’s study is the only art icle 
which specified the type of herbs involved and addit ionally, they found a dose 
related increase in r isk of developing new cases of ESRD.197  
I n cont rast , Lin et  al. (2013)  and Hsieh et  al. (2012)  report  no associat ion 
between Chinese herbal use, or prescribed Chinese herbal m edicine, and new 
cases of CKD.6,198 Despite occasional use of non-prescribed Chinese herbal 
m edicine related to CKD, there is no clear pat tern to this relat ionship. 
4 .1 .2  Renal adverse effects of dietary supplem ents 
Few studies have reported dietary supplem ents being associated with 
nephrotoxicity, see Table 4.3.199-201 Creat ine supplem ents, L-glutam ine, ascorbic 
acid and cranberry have all been shown to be related to kidney problem s. Three 
case reports,  together with a clinical t r ial, report  creat ine supplem ents resulted 
in a deteriorat ion of renal funct ion.202-205 L-glutam ine decreased eGFR200, whilst  
ascorbic acid increased 20%  and 33%  of urinary oxalate in norm al subjects and 
kidney stone form ers, respect ively.201 Finally, cranberry increased am ounts of 
calcium  oxalate in urine.199 
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Table 4.3 Dietary supplem ents related to nephrotoxicity 
Authors Study design Number of part icipants I ntervent ion Outcomes Results 
Gualano et al. 
2008203 
12-week, double 
blind, random ised, 
placebo-controlled 
t r ial 
18 healthy men  0.3 g of creat ine supplements/ kg/ day 
for 1st week and then 0.15 g/ day/ kg 
for the next 11 weeks 
Scr I ncrease in Scr among 
creat ine group 
Gualano et al. 
(2010) 202 
Case report  20-year-old-man having 
a single kidney 
20 g/ day of creat ine monohydrate for  
5 days and then took 5 g/ day for the 
next  30 days 
Scr Scr increased from  1.03 to 
1.27 m l/ m in 
Pr itchard and 
Kara (1998) 204 
Case report  25-year-old man with 
focal segmental 
glomerulosclerosis 
Creat ine of 5 g t id per week and then a 
maintenance dose of 2 g/ day for 7 
weeks 
eGFR Decrease in eGFR 
Thorsteinsdot t ir  
et  al. (2006) 205 
Case report  24-year-man 5 g of creat ine monohydrate 3 t imes 
per week 
Renal biopsy He had acute interst it ial 
nephr it is 
Galera et  al. 
(2010) 200 
Controlled, 
random ised, 
double-blind, 
crossover study 
30 residents of a long-
term-care inst itut ion 
x 0.5 g of L-glutam ine/ kg/ day for 14 
days  
x 0.5 g of calcium caseinate/ kg/ day 
(control group) 
eGFR Decrease of 13.3%  in eGFR 
among group of L-glutam ine 
Traxer et  al. 
(2003) 201 
Randomised, 
double-blind, 
crossover study 
12 normal subjects and 
12 stone formers*  
x Ascorbic acid 1 g twice a day for 6 
days 
x Placebo containing excipient  twice a 
day 
x Scr 
 
x ur inary 
oxalate 
x No differences of Scr in both 
groups 
x I ncrease in ur inary oxalate 
in both groups, compared 
with placebo phrase 
Terr is et al. 
(2001) 199 
Clinical t r ial 5 healthy volunteers A cranberry tablet  twice a day for a 
week 
UA I ncrease in 50%  of  amounts 
of calcium oxalate in ur ine 
Abbreviat ion:  g =  gram, kg =  kilogram, Scr =  Serum creat inine, t id =  three t imes a day, UA =  ur inalysis,  eGFR=  est imated glomerular f ilt rat ion rate, *  =  part icipants 
having the history of k idney stones 
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4 .1 .3  Herbal and dietary supplem ents related to 
com plicat ions of CKD 
Som e HDS leads to worsening com plicat ions focused on hyperkalem ia and 
hyperphosphatem ia, because HDS m ay direct ly induce m ore severe 
com plicat ions or HDS m ay contain large am ounts of potassium  and phosphate. 
For instance, taking herbal diuret ics, such as alfalfa, dandelion, horsetail, 
m ilkweed and net t le, m ay result  in hyperkalem ia.163 Several HDS containing high 
am ounts of potassium , such as Noni j uice, Lam p wick herb, Herba ecliptae, Rice 
paper plant  pith, Red stem  worm wood, Cyathula root  and Cardam on, St . John’s 
Wort  and psyllium , can lead to worsening hyperkalem ia.30,206-208 Likewise, 
liquorice and m ult ivitam in supplem ents consist  of large am ounts of phosphate, 
so they m ay induce deteriorat ing hyperphosphatem ia. However, such 
inform at ion has been reported based upon low level evidence, such as case 
report s, or theoret ical inform at ion30,206,208,209 and there is a lack of evidence 
regarding the associat ion between HDS and CKD com plicat ions. 
4 .1 .4  Adulterat ion of herbal products 
Not  only can the act ive ingredients in HDS dam age the kidneys, but  so can 
contam inants. Heavy m etals, adulterat ion of convent ional m edicines, fake herbs 
and excessive levels of m icroorganism s are the principal contam inants 
associated with renal failure.210-212 Som e herbal products contain lead, cadm ium 
and m ercury, which m ay lead to the loss of renal funct ion.213,214 An exam ple of 
adulterat ion with convent ional m edicat ions are Tung Shueh pills, a Taiwanese 
herbal product , which was contam inated with m efenam ic acid, known to cause 
drug- induced nephropathy.210 There have also been cases of fake herbs. Chan 
(2003)  reports that  a slim ming herbal product  contained Aristolochia fangchi 
rather than Stephania tet randra;  and as a result , a large num ber of people 
taking it  suffered from  renal failure.212 
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A report  on nat ional qualit y surveillance of dietary products by the Thai Food and 
Drug Adm inist rat ion (FDA)  in 2012, shows that  18%  of herbal m edicines, such 
as turm eric products, or  Thai folk rem edies were contam inated with steroids, 
excessive levels of bacteria or heavy m etals, and 2%  of im ported Chinese herbal 
m edicines were contam inated with arsenic and m icroorganism s.215 Three 
sam ples of m ixed Chinese herbal m edicines were contam inated with sildenafil 
and/ or tadalafil,  m edicat ions for sexual dysfunct ion and a cont raindicat ion for a 
person with renal insufficiency;  these exam ples were reported by the Thai alert  
system  for safety of health products.216 
4 .1 .5  Herb and nut r ient - drug interact ions 
Herb-drug interact ions m ay cause renal effects, part icularly in pat ients 
undergoing renal replacem ent  therapy, such as dialysis or kidney t ransplant . A 
cross- sect ional study am ongst  114 pat ients receiving haem odialysis in Turkey 
reported four possible herb-drug interact ions. These were:  garlic -  ant icoagulant  
agents, garlic -  NSAI Ds, garlic – insulin, and liquorice -  ant ihypertensive 
agents.14 However, these interact ions do not  have negat ive or beneficial effect s 
on renal funct ion. A case report  has revealed that  three pat ients with kidney 
t ransplants took herbal tea with cyclosporin – an im m unosuppressant  agent , and 
had a decrease in the level of cyclosporin, which m ay lead them  to reject  their 
kidney graft .217   
I n general, reports on herb or dietary supplem ent -drug interact ions are based on 
inform at ion from  theoret ical data, in vit ro, anim al studies, a few case reports 
and clinical t r ials. They focus on com m on HDS, such as garlic, ginkgo biloba, 
ginseng, St . John’s Wort  and liquorice.218,219 These papers report  adverse effects 
related to bleeding problem s, neurological problem s and hyper/ hypotensive 
effect s. Current ly, herb or dietary supplem ent -drug interact ions leading to the 
loss of renal funct ion, or  deteriorated com plicat ions of CKD are unknown.  
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4 .2  Renal benefits from  HDS 
There is lim ited evidence of posit ive effects on chronic kidney disease from  HDS 
use, part icularly from  clinical t r ials. Chinese herbal m edicine is the m ost  
frequent ly researched t reatm ent  of CKD despite the sm all num ber of clinical 
t r ials and sam ple sizes.220 Only three Chinese herbal m edicines have proven 
effect ive on decreasing proteinuria caused by diabetes, nephrot ic syndrom e and 
IgA nephropathy. Such data are supported by work with cellular m echanism s, 
anim al and hum an studies, involving Ast ragalus and it s com binat ion with 
Angelica sinensis, Rheum  or it s com binat ion, and the decoct ion nam ed ‘Saireito’ 
containing Radix bupleuri.220,221 Other herbal m edicines for CKD t reatm ent  have 
been m ainly studied in vit ro and in vivo experim ents, such as Cordyceps 
sinensis,  shallots, turm eric, and onion.220,222-224  
Regarding other effects on kidneys, a system at ic review has reported that  only 
three herbal m edicines have diuret ic effect s when used in human studies 
invest igat ing increasing urinary volum e and urinary excret ion of sodium ;  the 
m edicines involve Equisetum  bogotense, Phyllanthus am arus and Withania 
som nifera.225 However, each herbal m edicine has been supported by only one 
sm all, non- random ised, non-cont rolled study. A sm all cont rolled t r ial in Thailand 
showed that  roselle (Hibiscus sabdariffa)  increased urinary excret ion of uric acid 
in pat ients with renal stones.226 
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5 . Aim s and object ives 
This thesis is com prised of two m ain studies:  i)  a survey of the prevalence, 
pat terns and reasons for HDS usage in Thai pat ients with CKD and, ii)  the 
associat ion between HDS use, the fast  progression of CKD and it s com plicat ions. 
The m ain research quest ion of this study was “ I s HDS associated with the fast  
progression of CKD in Thai pat ients with stages 3 to 5 CKD?”  
The prim ary aim  of this thesis was to invest igate any relat ionships between HDS 
use and the progression of CKD and it s com plicat ions am ongst  Thai outpat ients 
with stages 3 to 5 CKD. Specific object ives of each study are as follows. 
The f irst  study: A survey of the prevalence and pat terns of HDS usage in Thai 
outpat ients with CKD together with a qualitat ive study regarding reasons for  
HDS use 
1. To determ ine the prevalence of HDS usage in the previous 12 m onths in 
outpat ients with CKD at  two teaching hospitals in Thailand. 
2. To determ ine the types and pat terns of HDS use am ongst  this populat ion. 
3. To ident ify the dem ographic characterist ics of Thai pat ients with CKD who 
are using HDS, com pared with non-users. 
4. To determ ine the associat ion between HDS use and a level of adherence 
to prescribed, convent ional m edicat ion. 
5. To determ ine the reasons for HDS use in this populat ion. 
6. To determ ine pat ients’ experiences of the beneficial and adverse effects 
from  using HDS.  
7. To determ ine the rate of non-disclosure of HDS use to a doctor and it s 
reasons.  
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The second study: The associat ion between HDS use, the fast  progression of 
CKD and it s com plicat ions am ongst  Thai outpat ients with CKD in a prospect ive,  
cohort  study 
1. To determ ine any associat ions between HDS use and the fast  progression 
of CKD. 
2. To determ ine any associat ions between HDS use and CKD com plicat ions 
3. To determ ine the pat terns of any other r isk factors of CKD progression 
and it s com plicat ions. 
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6 . Study m ethods 
Details of study m ethods, set t ings for data collect ion, part icipant  inclusion and 
exclusion criteria, sam ple size determ inat ion, ethical approval and funding are 
presented in this chapter.  An overview of the study design and recruitm ent  
process of the two m ain studies is shown in Flowchart  6.1.  
Flowchart  6.1 Schem at ic diagram  of the study 
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6 .1  Pilot  study 
The obj ect ives of this pilot  study were to i)  develop and test  quest ionnaires, ii)  
determ ine the com pleteness of rout inely collected inform at ion in pat ient  records 
in both hospitals, and iii)  to test  the suitabilit y of the data ext ract ion sheet  from  
m edical notes. Medical inform at ion from  records were ext racted and recorded on 
the form , see Appendix 5 and Chapter 7.  
A researcher-adm inistered quest ionnaire for  the survey and cohort  study, 
together with open-ended quest ions for the qualitat ive study, were developed 
and piloted from  Septem ber to Decem ber 2011. The first  quest ionnaire consisted 
of quest ions regarding dem ographic characterist ics of HDS users, pat terns of 
HDS usage, reasons for  HDS use, sources of inform at ion and HDS products, and 
disclosure of HDS use to a doctor. This quest ionnaire also included the Thai 
version of the 8- item  Morisky Medicat ion Adherence Scale®  (MMAS-8-
I t em ® ) 227,228,  and the Rest r ict ion of Protein, Potassium , Phosphate and Salt  diet  
(RPPPS)  quest ionnaire for pre-dialysis pat ients.229 The last  two quest ionnaires 
were to m easure potent ial factors related to the cohort  study outcom es. This 
quest ionnaire was adm inistered with sam ples of HDS and types of food pictures 
in order t o assist  respondents with understanding what  HDS is. Also, each type 
of food rest r ict ion in pat ients with CKD, such as being aware of food r ich in 
potassium , phosphate or salt , was explained, see Appendix 3. This pilot  study 
tested understanding of the quest ions. 
The Thai versions of t he MMAS-8- I tem ®  and the RPPPS quest ionnaire were 
tested for their validit y and reliabilit y, as the form er quest ionnaire had not  been 
tested for validity and reliabilit y in Thai pat ients with CKD and the lat ter was 
m odified from  the dialysis diet  and fluid non-adherence quest ionnaire (DDFQ) .229  
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The eight  open-ended quest ions gathered inform at ion about  at t itudes towards 
reasons for  HDS use, which served as a qualitat ive study, t ested for  face validity, 
see Appendix 4. 
The first  pilot  study tested the clarit y of the quest ionnaire for  the survey and 
cohort  study and the validity and reliabilit y of the Thai version of the 8- I tem  
Morisky Medicat ion Adherence Scale®  (MMAS-8- I tem ® )  and the Rest r ict ion of 
Protein, Potassium , Phosphate and Salt  Diet  quest ionnaire for pre-dialysis 
pat ients (RPPPS) . The second pilot  study tested the revised RPPPS quest ionnaire 
and pat ients’ understanding of the researcher adm inistered open-ended 
quest ions. 
6 .2  Survey of the prevalence and pat terns of HDS 
use and qualitat ive study regarding reasons 
for HDS use 
This study consisted of two parts -  a survey and a qualitat ive study. 
Part  one: The cross-sect ional survey was conducted using the first  researcher-
adm inistered quest ionnaire, from  January to June 2012, see Appendix 6. All 
outpat ients with CKD, who at tended one of two teaching hospitals in Thailand, 
were approached to take part  and those who consented were interviewed.  
Part  tw o: To determ ine the reasons for  HDS use, the qualitat ive study was 
conducted. Respondents who part icipated in the survey were recruited for this 
part  using purposive sam pling from  both set t ings. They were interviewed face-
to- face, using eight  open-end quest ions which were audio recorded, see 
Appendix 4. The findings were used to bet ter  understand the responses to the 
quest ions. 
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6 .3  Prospect ive, cohort  study 
This study was to determ ine any associat ions of HDS use, and the progression of 
CKD, or CKD com plicat ions. I t  consisted of two parts:  the baseline data collect ion 
and follow-up data collect ion over one year.   
Part  one: Baseline inform at ion was provided by responses to the survey. 
Part icipants were ident ified as exposed or unexposed to HDS. The exposed group 
was defined as current , regular herbal users and/ or dietary supplem ent  users, 
who had taken herbs and/ or dietary supplem ents at  least  three t im es a week 
during the previous m onth prior t o the index date:  the interview date in the 
survey. The unexposed group was defined as those who have never taken herbs 
or dietary supplem ents (non-users of HDS)  or who have stopped using them  in 
the previous m onth before the index date ( form er users of HDS)  or who have 
taken them  less than three t im es per week in the m onth before the index date 
(occasional or rare users of HDS) . 
From  respondents’ m edical notes, data were ext racted regarding their chronic 
illnesses, current  m edicat ion use and laboratory results on the index date to 
form  the baseline data, see Appendix 5. 
Part  tw o: These respondents were followed up regarding their HDS and over-
the-counter m edicat ion use, and their laboratory results ext ract ing from  their  
m edical notes over one year. Appendix 7 shows a data sheet  for the telephone 
interview and a data ext ract ion sheet  for the m edical notes for the follow-up 
study. Respondents were interviewed over the telephone regarding HDS usage, 
reasons for cont inuing or stopping using HDS and use of over- the-counter 
m edicines during a 12 m onth period after t he index date. I nform at ion was 
ext racted from  pat ients’ m edical notes over one year in the sam e as the baseline 
data was established.  
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Regarding outcom es of this study, progression of CKD was ident ified by a change 
of m ean est im ated glom erular filt rat ion rate (eGFR)  over one year.  The outcom e 
was com pared between the exposed and unexposed groups. CKD com plicat ions 
were also m easured, i.e. serum  potassium  levels and serum  phosphate levels in 
order t o classify uncont rolled hyperkalem ia and hyperphosphatem ia. These 
param eters were com pared between exposed and unexposed groups.  
6 .4  I nclusion criteria  
1. Pat ients who were diagnosed as having chronic kidney disease and who had 
eGFR levels of less than 60 m l/ m in/ 1.73 m 2 at  baseline calculated by the Thai 
Modificat ion of Diet  in Renal Disease equat ion.183  
2. Pat ients aged 18 years or over.  
3. Outpat ients at tending a kidney clinic. 
4. Pat ients who could verbally com m unicate and were able to give inform ed 
consent .  
Outpat ients were selected to be recruited in this study as their kidney funct ion 
was m ore likely to be stable than inpat ients, reflect ing valid kidney funct ion 
rather than in an em ergency state.   
6 .5  Exclusion criteria 
1. Pat ients receiving dialysis or kidney t ransplant  at  baseline 
2. Pat ients who could not  rem em ber m ost  of their inform at ion, especially 
regarding herbal products and dietary supplem ents. 
Pat ients receiving dialysis or kidney t ransplant  at  baseline, were excluded 
because they have different  outcom es of their t reatm ent  and different  factors 
related to their outcom es, com pared to pre-dialysis pat ients. For instance, the 
m ain therapeut ic outcom e am ongst  these pat ients is to slow the progression of 
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CKD, whilst  dialysis pat ients require support ive t reatm ent  for their com plicat ions, 
such as water and sodium  retent ion. Am ongst  kidney t ransplant  recipients, poor 
adherence to im m unosuppressant  drugs affect s kidney funct ion.  
6 .6  Set t ings 
The study set t ings were the outpat ient  kidney clinic in King Chulalongkorn 
Mem orial Hospital, which is also known as ‘the hospital of Chulalongkorn 
University (CU) ’, in Bangkok, and the HRH Princess Maha Chakri Sirindhorn 
Medical Center, which is also known as ‘t he hospital of Srinakharinwirot  
University (SWU) ’, in Nakhon-Nayok province. These set t ings were purposively 
selected as they are tert iary hospitals, which provide health services for 
com plicated diseases, such as CKD and cancer. The target  populat ion is referred 
to these hospitals by their GP under the Thai Nat ional Health System  and they 
are the prim ary source of CKD health care in Thailand. These are two out  of the 
12 m edical school hospitals in Thailand. Bangkok has the highest  prevalence of 
CKD (24% ) , com pared with other regions of Thailand.5 The CU hospital serves 
an urban populat ion, whereas the SWU hospital serves a rural populat ion.  
6 .7  Recruitm ent  process 
The principal invest igator (MT)  approached all Thai pat ients with CKD who m et  
the inclusion criteria and inform ed them  about  the purpose, m ethods and 
potent ial benefit s of the study and provided each prospect ive candidate with a 
part icipant  inform at ion sheet  and consent  form , see Appendices 8 and 9. I t  was 
explained to the pat ients that  ent ry into the study was ent irely voluntary and 
that  their t reatm ent  and care would not  be affected by their decision. I t  was also 
explained that  they could withdraw at  any t im e but  at tem pts were m ade to avoid 
this occurrence. Their  inform at ion was regarded as confident ial. Pat ients 
providing consent  were recruited for the survey and cohort  study. 
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Som e respondents who reported using HDS in the survey, and seem ed able to 
provide m ore inform at ion about  reasons for  HDS use, were invited to be 
interviewed using the researcher adm inistered open-ended quest ions about  their  
at t itudes to HDS use. This was for the qualitat ive study, which was audio 
recorded with perm ission. Those who consented to part icipate in the qualitat ive 
study were recruited. 
6 .8  Sam ple size determ inat ion 
The cohort  study was to serve the prim ary object ive of this thesis, so sam ple 
size determ inat ion was based on this study.  
The null hypothesis was the absence of a relat ionship between HDS and the fast  
progression of CKD. The sam ple size was calculated to ensure that  t his study 
had sufficient  power to detect  the effect  size, which was a difference in a decline 
in eGFR of at  least  5 m l/ m in/ 1.73m 2/ year between exposed and unexposed 
groups. A decline in eGFR of at  least  5 m l/ m in/ 1.73m 2/ year defined the fast  
progression of CKD in this study, which was a dependent  variable.145 Sam ple size 
was calculated to com pare two m eans using the form ula from  Kirkwood and 
Sterne.230 Ong-Ajyooth et  al. (2009)  reported 78.9 m l/ m in of m ean eGFR and 
0.3 standard error of eGFR in Thai residents. Therefore, the standard deviat ion 
of eGFR in Thai pat ients with CKD was 16.75.146 Drop out  was est imated to be 
5% , as a previous study using face- to- face interviews with a sim ilar populat ion 
reported a 2%  drop out  rate.29 The study was designed for  a two- tailed 
hypothesis. The stat ist ically significant  level and the power were 5%  and 80% , 
respect ively. The allocat ion rat io between exposed and unexposed groups was 
1: 2 because 33%  of Thai people have reported using herbs.5 Kirkwood and 
Sterne have recom m ended an adjustm ent  factor for use to com pare unequal 
sized groups. I f  a rat io of larger to sm aller group is 2, ¾  is the adj ustm ent  to the 
sam ple size of the sm aller group.230 The est im ated sam ple size of this study was 
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140 in the exposed group and 280 in the unexposed group. Therefore, at  least  
420 pat ients were aim ed to be recruited in this study.  
After  com plet ing the follow-up period, 8%  of part icipants init iated dialysis 
therapy, which was likely to be due to the fast  progression of CKD. As a result , 
the dependent  variable was newly defined as either a decline in eGFR of at  least  
5 m l/ m in/ 1.73m 2/ year11,145 or  init iated renal replacem ent  therapy during the 
follow-up period. This was a dichotom ous var iable defined as having the fast  
progression of CKD or no fast  progression. Post  hoc determ inat ion of t he sam ple 
size for  non-param et ric stat ist ical analyses, using the com parison of two 
proport ions of the fast  progression of CKD,230,231 suggested that  this cohort  study 
required a sam ple size at  least  72 and 144 num bers of the exposed and 
unexposed groups, respect ively.   
6 .9  Ethical approval and funding 
Ethical approval was obtained from  the Inst itut ional Review Board for Research 
in Hum an Subjects at  the Faculty of Medicine, Chulalongkorn University (CUIRB 
No. 297/ 54)  and Srinakharinwirot  University (SWUEC/ Ex No. 43/ 2554) , Thailand, 
and the Medical School Research Ethics Com m it tee, University of Not t ingham , 
UK for the pilot  study and the m ain study in Septem ber 2011 ( reference No. 
CHS22082011) , see Appendix 10. 
The Royal Thai governm ent  funded MT’s PhD study. 
 
Chapter 7:  Pilot  study 
99 
7 . Pilot  study 
The first  pilot  study tested the clarit y of the quest ionnaire and the validity and 
reliabilit y of the Thai version of the 8- I t em  Morisky Medicat ion Adherence Scale®  
(MMAS-8- I tem ® )  and the Rest r ict ion of Protein, Potassium , Phosphate and Salt  
Diet  quest ionnaire for  pre-dialysis pat ients (RPPPS) .  
The second pilot  study tested the revised RPPPS quest ionnaire and the 
respondents’ understanding of the researcher adm inistered open-ended 
quest ions in the qualitat ive study, regarding the at t itudes towards reasons for  
HDS use. 
7 .1  Object ives 
The prim ary object ives of the pilot  study were to test  the validity and reliabilit y 
of the Thai version of t he 8- I t em  Morisky Medicat ion Adherence Scale®  (MMAS-
8- I tem ® )  and the Rest r ict ion of Protein, Potassium , Phosphate and Salt  diet  
quest ionnaire for pre-dialysis pat ients (RPPPS) . Addit ionally, self-designed 
researcher adm inistered open-ended quest ions about  at t itudes towards reasons 
for  herbal and dietary supplem ent  use were tested for face validity. 
The second object ive was to test  the clarit y of the quest ions in the 
quest ionnaire, the feasibilit y of the recruitm ent  process and to m easure the 
num ber of pat ients at t ending the kidney clinics. The data ext ract ion sheet  for the 
outpat ient  records was also tested regarding the com pleteness of rout inely 
collected inform at ion in pat ient  records in both hospitals. 
7 .2  Developm ent  of the quest ionnaire 
The quest ionnaire for  t he survey was adapted from  Kuo’s quest ionnaire,98 with 
som e added quest ions in order t o achieve the object ives of this study. The new 
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quest ions asked about  reasons for  HDS use, experiences of posit ive and negat ive 
effect s from  using HDS, and non-disclosure of HDS use to a doctor, see 
Appendix 3. Kuo’s quest ionnaire was well suited to the present  survey as it  
consisted of dem ographics, pat terns of herbal use, people’s recom m endat ions for  
their use, and inform at ion sources for herbal m edicine, see Appendix 11.  
The Thai-version of the 8- I tem  Morisky Medicat ion Adherence Scale®  (MMAS-8-
I t em ® )  was chosen to m easure adherence to convent ional m edicat ion in the 
present  survey, as it  is relat ively short  and has been validated in m any count ries 
around the world, including Thailand and is widely used.227,232-234 The m ain focus 
of this study was not  adherence and therefore a sim ple m ethod that  gave a 
broad m easure of adherence was wanted. Other quest ionnaires that  m easure 
adherence included the Sim plified Medicat ion Adherence Quest ionnaire (SMAQ) , 
which has been used for dialysis pat ients;  however, it  is developed from  the 
Morisky scale235 and does not  have a validated Thai version. A num ber of 
m easures are specific to individual diseases, such as the Medicat ion Adherence 
Rat ing Scale (MARS) , which is appropriate for pat ients with psychiat r ic 
illnesses236, or the Hill-Bone com pliance quest ionnaire which is a specific 
m easure of adherence for  pat ients with hypertension.237 Other m easures focus 
on a part icular aspect  of adherence, such as the Adherence Est im ator which 
m easures intent ional non-adherence238;  whereas the present  study aim ed to 
m easure both intent ional and non- intent ional non-adherence. The Brief 
Medicat ion Quest ionnaire (BMQ)  does have a Thai version, but  shows lower 
sensit ivit y and specificit y com pared with the original, which m ay be due to 
cultural differences in understanding of quest ions about  m edicat ion 
adherence.239 I t  was decided to use a quest ionnaire in order to m easure 
adherence to convent ional m edicat ion rather than other tools, such as pill counts 
and elect ronic m onitoring system s, as it  would form  part  of a larger 
quest ionnaire and therefore be convenient , inexpensive and pract ical for use in 
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the study. However, there are som e disadvantages of using a quest ionnaire t o 
m easure adherence, including recall and social desirabilit y bias, and pat ients 
overest im at ing their adherence.240 
To m easure the degree of protein, potassium  and phosphate intake, the dialysis 
diet  and fluid non-adherence quest ionnaire (DDFQ) 229 was the only validated 
quest ionnaire which seem ed to be relevant  to the object ives of the present  
study, see Appendix 12. This quest ionnaire was adapted and som e quest ions 
were added in order to achieve the desired outcom es of the present  study, which 
was nam ed the Rest r ict ion of Protein, Potassium , Phosphate and Salt  Diet  
quest ionnaire (RPPPS) , see Appendix 3. Dietary intake assessed by a food 
frequency quest ionnaire is com m only used in epidem iological research, due to 
such a tool being convenient  and feasible. However, such an approach m ay 
involve sm all inaccuracies in the est im ate am ount  of food for an individual, 
com pared with other t ools, such as 24-hour dietary recall and food diaries.241 
Both Kuo’s quest ionnaire and the DDFQ were t ranslated from  English into Thai 
by MT who is fluent  in both languages, and then these were developed into Thai 
language. The process of backward t ranslat ion of these quest ionnaires was not  
perform ed as the quest ions in both inst rum ents were st raight forward.  
The researcher adm inistered open-ended quest ions about  at t itudes towards the 
reasons for  HDS use am ongst  pre-dialysis pat ients, see Appendix 4. These 
quest ions were developed in the Thai language by the author, based on the 
literature89,242 in order t o achieve the object ive of this study.  
The Thai version of the researcher adm inistered quest ionnaire in the present  
survey and open-ended quest ions in the present  qualitat ive study is the original. 
This thesis also presented the English version of such quest ionnaires, in 
Appendices 3 and 4 in order to com m unicate to internat ional readers.  
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7 .3  Method 
7 .3 .1  The first  pilot  study 
The first  pilot  study was conducted between 28 Septem ber and 26 October 2011. 
Forty- two pat ients, who m et  the inclusion criteria and provided their consent , 
were recruited and interviewed face- to- face, using the researcher adm inistered 
quest ionnaire, together with sam ples of HDS and types of food pictures, see 
Appendix 3. The pat ients were recruited from  each hospital;  20 to 50 are 
accepted as the general num bers of respondents appropriate for  the pilot  t r ial of 
a quest ionnaire.243 The reason why pat ients from  both hospitals were recruited 
for the pilot  study was that  the populat ions in each hospital are different  and it  
was im portant  that  the quest ionnaire was shown to be suitable for both sites.  
Validity test  
Validity assessm ent  of the MMAS-8- I tem ®  and the RPPPS quest ionnaire, see 
Appendix 3, was required, as the form er was only validated in Thai pat ients with 
diabetes227,  so needed validat ion for  a different  group of pat ients:  nam ely those 
with CKD.244 The RPPPS quest ionnaire also needed to be validated as it  is 
adapted from  the dialysis diet  and fluid non-adherence quest ionnaire229 and was 
t ranslated from  English into Thai. The MMAS-8- I tem ®  classifies convent ional 
m edicat ion adherence into three categories, i.e. a low, m edium  or high levels of 
adherence to prescribed, convent ional medicat ion, whilst  the RPPPS 
quest ionnaire classifies degrees of consum pt ion of protein, potassium , phosphate 
and salt  diets into two categories:  low or high level of diet  intake. Concurrent  
validat ion, which is the subtype of criterion validity and the validity between the 
new quest ionnaire and an exist ing criterion m easure at  the sam e t im e, was 
conducted on both quest ionnaires as the two scales have indirect  criterion 
m easurem ents.244 Est im ated GFR levels are the criterion m easurem ent  of the 
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MMAS-8- I t em ® ,  because if pat ients adhere to their prescribed, convent ional 
m edicat ion regim e, part icularly angiotensin convert ing enzym e inhibitors (ACEI s)  
or angiotensin receptor blockers (ARBs) , they will slow the progression of 
CKD.245-247 Therefore, if pat ients have a decrease in a difference of m ean eGFR 
during 3 m onths, com pared with those with either an increase, or no change, it  
indicates non-adherence to their convent ional m edicat ion regim e. However, an 
increase in an eGFR level m ay be caused by other factors, such as high protein 
consum pt ion and taking nephrotoxic agents.  
The indirect  criterion m easurem ent  of the RPPPS quest ionnaire is a serum  level 
of potassium  and phosphate, and level of blood pressure. This is because diet  is 
the m ain factor influencing the serum  levels of potassium  and phosphate in 
pat ients with CKD, due to the decreased elim inat ion of potassium  and 
phosphate165,248, whilst  a high salt  diet  can result  in uncont rolled high blood 
pressure.249 I f these levels are outside the target  of t reatm ent ,  it  could be that  
the pat ients with CKD consum e high potassium , phosphate and salt  diets. The 
target  t reatm ent  of blood pressure, and a serum  potassium  level, is equal to or  
less than 130/ 80 m m / Hg and 5 m Eq/ L (m m ol/ l) , respect ively.185 The target  of a 
serum  phosphate level is equal to or less than, 4.6 and 5.5 m g/ dl (1.5 and 1.7 
m m ol/ l)  for stages 3 to 4 CKD and stage 5 CKD, respect ively.186  
Next ,  the outcom es of the two criterion m easurem ents were classified into a 
dichotom ous scale. Non-adherence to prescribed, convent ional m edicat ions was 
defined as a decrease in a difference of m ean eGFR during 3 m onths, whereas 
adherence was an increase or no change of m ean eGFR in the sam e period. High 
potassium , phosphate and salt  consum pt ion were defined as higher m ean levels 
of potassium , phosphate or blood pressure, respect ively than the goal of their 
therapy. Correlat ion between the exist ing m easurem ents and the quest ionnaires 
was analysed using Chi-squared test .  
Reliability test  
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The Thai version of the MMAS-8- I t em ®  was tested for internal consistency using 
Cronbach’s alpha, because this quest ionnaire consists of 8 item s, which m easure 
one outcom e, that  of convent ional m edicat ion adherence. Due to this, the 
quest ionnaire needs to be tested for correlat ions between each item  and the 
outcom e.230 Addit ionally, t est - retest  reliabilit y of the two quest ionnaires, which 
m easures the agreem ent  between repeated m easurem ents taken at  different  
t im es, was conducted.230 Respondents were interviewed at  the ent ry into the 
pilot  study in Septem ber 2011 and then 2 weeks later,  as the RPPPS 
quest ionnaire was designed to explore the previous 14-day dietary intake. 
Moreover, the periods between the first  and the second m easurem ent  should be 
2 to 14 days.244 The second interview was conducted over the telephone. The 
int raclass correlat ion coefficient  ( ICC) , which m easures the agreem ent  of 
num erical variables230, was calculated using two-way m ixed effects m odel250,  and 
was calculated for  the Thai version of MMAS-8- I tem ® ,  because this quest ionnaire 
classifies the degree of convent ional m edicat ion adherence using a num erical 
scale. The interpretat ion of the ICC is that  an ICC >  0.75 is an excellent  
agreem ent ;  0.4 <  ICC <  0.75 is a fair to good agreem ent  and an ICC <  0.4 is a 
poor agreem ent .251 The Kappa coefficient , which tests the proport ion of 
responses in the agreem ent  of a dichotom ous scale, was used for t he RPPPS 
quest ionnaire, because it  classifies either a low level of dietary intake, or a 
m oderate to high level of dietary intake. From  0.81 to 1.00 of Kappa coefficient  
represents very good agreem ent ;  0.61 and 0.80 indicates good agreem ent ;  
between 0.41 and 0.60 shows m oderate agreem ent ;  between 0.21 and 0.40 
shows fair agreem ent ,  whilst  a Kappa coefficient  under 0.20 shows poor 
agreem ent .252 
7 .3 .2  The second pilot  study 
The second pilot  study was conducted in Decem ber 2011 and recruited 21 
pat ients in order to assess the test - retest  reliabilit y of the revised RPPPS 
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quest ionnaire. This inst rum ent  was designed to m easure the degree of dietary 
consum pt ion in the last  14 days, as the first  pilot  study was found to have poor  
reliabilit y, part icularly regarding the m easurem ent  of protein and phosphate 
consum pt ion. This m ay be because the quest ions did not  specify types of protein 
or phosphate diets and respondents m ay change their diet  behaviour during the 
14-day period. Therefore, the RPPPS quest ionnaire was revised, see Appendix 6. 
The period between the first  and the second m easurem ent  was 7 days due to i)  
the lim ited t im e of the study and ii)  the researcher being concerned that  
respondents m ay change their diet  if their diet  is m easured far from  the first  
m easurem ent .  
Face validity of researcher adm inistered open- ended quest ions about  
reasons for  HDS use 
After the respondents who used HDS had part icipated in the survey, they were 
invited to be interviewed regarding their at t itudes towards the reasons for HDS 
use. These sessions were to be audio- recorded. I f they consented, they were 
recruited. This face to face interview was to t est  the clarit y of the quest ions. The 
audio recordings were t ranscribed and t ranslated from  Thai into English based on 
m eaning.253 The t ranscr ipts were analysed by a brief induct ive them at ic analysis 
in order to assess the findings to som e extent  and to fulfil the research 
object ive. Key words, which seem ed to be related to reasons for HDS use from  
all t ranscripts, were coded and grouped based on the sam e m eaning in each 
group, and then a t it le of each group indicated their them e. Therefore, such 
them es were built  up from  the data.  
7 .4  Results of the first  pilot  study 
Fifty five pat ients in two hospitals were recruited, although 13 pat ients (25% )  
were then excluded. Three had received hem odialysis, eight  had stage 1 or 2 
CKD and two pat ients had com m unicat ion problem s. Therefore, the total number 
Chapter 7:  Pilot  study 
106 
of respondents was 42, of which 22 were recruited from  CU hospital and 20 were 
recruited from  SWU hospital. The rate of recruitm ent  was 10 pat ients per week. 
7 .4 .1  Character ist ics of respondents 
The 42 respondents had a m ean age of 66 years (SD 12, range 25-86)  and 43%  
were m en. The characterist ics of respondents are shown in Table 7.1.  
Table 7.1 Characterist ics of respondents (n= 42)  
Character ist ics Number of respondents Percent Missing data (% ) 
Age (>  60 years) 31 73.8 -  
Educat ion levels   -  
     Uneducated  1 2.4  
     Pr imary school 21 50.0  
     Secondary school 6 14.3  
     Vocat ional degree 5 11.9  
     Undergraduate degree 8 19.0  
     Higher than undergraduate degree 1 2.4  
Household income (baht  per month)    20 (47.6% ) 
     <  10,000 (£200/ month)  24 57.1  
     10,000-50,000 (£200-1000/ month)  17 40.5  
     >  50,000 (£1000/ month)  1 2.4  
Occupat ion   -  
     Unemployed 2 4.8  
     Ret ired 24 57.1  
     Housewife 6 14.3  
     Employee 6 14.3  
     Farmer 2 4.8  
     Business owner 1 2.4  
     Pr iest 1 2.4  
Smoking status   -  
     Never 34 81.0  
     Former smoker 8 19.0  
Alcoholic consumpt ion   -  
     Never 34 81.0  
     Current consumer 6 14.3  
     Former consumer 2 4.8  
BMI  (kg/ m 2)    1 (2.4% ) 
<  18.5 3 7.3  
18.5 – 26.9 in men or 18.5 – 24.9 
in women 
21 51.2  
>  27 in men or >  25 in women 17 41.5  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
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Twenty respondents (48% )  did not  provide household incom e because som e 
could not  est im ate their incom e and others refused to disclose this inform at ion. 
The num ber of respondents who had never sm oked (81% )  or consum ed 
alcoholic beverages (81% )  was high because the interviewer asked all 
respondents “Do you sm oke or drink alcoholic beverages?”  and m ost  of them  
said “no” . Seventeen respondents (42% )  were obese, whilst  three respondents 
were underweight  defined as less than 18.5 kg/ m 2 of BMI .254 Table 7.2 shows 
severity of CKD, CKD com plicat ions, co-m orbidity and the follow-up appointm ent  
t im e. 
Table 7.2 Stages of chronic kidney disease and co-m orbid condit ions (n= 42)   
Types Number of respondents Percent Unknown data (% ) 
Stages of CKD   -  
     3 26 61.9  
     4 15 35.7  
     5 1 2.4  
Hyperkalem ia 16 39.0 2 (4.8% )*  
Hyperphosphatem ia 11 32.3 8 (19.0% )*  
Hypertension 41 97.6 -  
Per ipheral oedema 7 20.0 7 (16.7% )*  
Diabetes 32 76.2 -  
Heart  diseases 8 19.0 -  
Dyslipidaem ia 34 81.0 -  
Exist ing proteinur ia 19 48.7 3 (7.1% )*  
Proteinur ia tests    
1. Random ur ine protein and 
ur ine creat inine rat io 
17 43.6  
2. Total protein (24 hr ur ine 
collect ion)  
3 7.7  
3. The dipst ick protein 
measurement  
19 48.7  
Follow-up of physician’s 
appointment 
  1 (2.4% ) 
     <  3 months 40 97.6  
     >  3 months 1 2.4  
*  =  no record of a test  or physical exam inat ion of oedema in medical notes 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of unknown data. 
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Other co-m orbid condit ions were gout  (6,  14% )  and cancer (3, 7% ) . Most  
respondents (n= 40, 98% )  were m onitored by a doctor at  least  every 3 m onths, 
so m edical records could be followed and assessed over t im e. Regarding 
laboratory exam inat ions in the year prior to the index date, 98%  of respondents 
had a serum  level tested for creat inine at  least  3 t im es per year;  whereas 78%  
provided at  least  3 values of serum  potassium  levels per year. Sixteen 
respondents (47% )  had at  least  3 values of serum  phosphate levels per year  
whilst  18 respondents (53% )  provided only 1 or 2 values. There was unknown 
data about  CKD com plicat ions -  hyperkalem ia (n= 2) , hyperphosphatem ia (n= 8) , 
peripheral oedem a (n= 7)  and exist ing proteinuria (n= 3)  because a doctor at  
SWU hospital did not  exam ine peripheral oedem a and did not  order pat ients to 
be tested for serum  levels of potassium , phosphate and urinary protein tested.   
This study found pat ients received on average 8 prescribed, convent ional 
m edicat ions. Fift y-seven percent  received renoprotect ive agents, i.e.  ACEIs or 
ARBs. Erythropoiet in, folic acid, ferrous com pounds and vitam in B1-6-12 were used 
for  support ive t reatm ent  of anem ia, see Table 7.3. Calcium  polystyrene sulfonate 
and phosphate binders were used for hyperkalem ia and hyperphosphatem ia, 
respect ively. Sodam int  was used for  t reatm ent  of m etabolic acidosis.  
Table 7.3 Medicines prescribed for respondents (n= 42)  
Types of medicat ions Number of respondents Percent 
Erythropoiet in 11 26.2 
Folic acid 24 57.1 
Ferrous compounds 13 31.0 
Vitam in B1-6-12 7 16.7 
Diuret ics 13 31.0 
Calcium polystyrene sulfonate 14 33.3 
Phosphate binders 11 26.2 
Sodamint  11 26.2 
Ant ihypertensive agents 41 97.6 
Dyslipidem ic agents 34 81.0 
Hypoglycem ic agents 19 45.2 
Ant ihyperur icem ic agents 14 33.3 
Aspir in 17 40.5 
Chapter 7:  Pilot  study 
109 
Thirteen respondents ( 31% )  were current ,  regular HDS users and 29 (69% )  
were non-users, see Table 7.4.  
Table 7.4 Pat ients reported use of alternat ive m edicines including HDS (n= 42)  
Types of alternat ive medicines Number of respondents Percent Missing data 
Herbal and dietary supplement  use   -  
     Current , regular usersa 13 31.0  
Non-users    
     Never usedb 14 33.3  
     Former usersc 10 23.8  
     Occasional usersd 5 11.9  
Other alternat ive medicines   1 (2.4% ) 
     No 33 80.5  
     Yes 8 19.5  
       Meditat ion 4 9.8  
       Massage 4 9.8  
a =  current , regular users were defined as pat ients taking herbal medicine or dietary supplements at 
least  three t imes a week in the month pr ior to the interview date 
b =  pat ients had never used HDS was defined as pat ients who did not  use HDS pr ior to the interview 
date 
c =  former users were defined as pat ients who had stopped using HDS before the month pr ior to the 
interview date 
d =  occasional users were defined as pat ients who had taken HDS less than three t imes a week in 
the month pr ior  to the interview date 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
There was the sam e proport ion of HDS users and non-users between CU and 
SWU hospitals. Twenty percent  of respondents reported using other alternat ive 
m edicines, i.e. m editat ion and m assage. 
Table 7.5 shows types and num ber of HDS used by in current , occasional or 
form er users (n= 28) . Two respondents in one hospital did not  report  to the 
interviewer that  they used HDS;  however they had inform ed their doctor about  
using HDS, as this was recorded in their m edical notes. One was a form er user 
and another was a current , regular user. This disparity m ay be because the 
interviewer had m et  respondents for the first  t im e, so they m ay not  have t rusted 
the interviewer. I t  also highlights one difficulty when conduct ing face to face 
research.  
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Table 7.5 Types and num ber of HDS used (n= 28)   
Pat terns of HDS use Number of respondents  Percent Missing data 
Type of HDS used   -  
     Herbal products 12 42.8  
     Dietary supplements 12 42.8  
     Both 4 14.4  
Number of different  HDS used   1 (3.6% ) 
     1 19 70.4  
     2 4 14.8  
     3 2 7.4  
     4 2 7.4  
     Total number of HDS used 41 100  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
The total num ber of HDS used was 41, see Table 7.5. Oral capsules or tablets 
were the m ost  frequent ly used form ulat ion of HDS in current , occasional or 
form er users (66% ) , see Table 7.6. Som e respondents used fresh herbal 
m edicines, such as leaves or stem s (11% ) . Missing data on the dosage form , 
durat ion and frequency of HDS use in Table 7.6 m ay be because respondents 
could not  rem em ber details of their HDS use, due to their using m any types of 
HDS.  
Chapter 7:  Pilot  study 
111 
Table 7.6 Pat terns of HDS used ( total num ber of HDS used= 41)  
 Number of HDS usage*  Percent Missing data 
Dosage form of HDS used    3 (7.3% ) 
     Oral capsules or tablets 25 65.8  
     Liquid form 6 15.8  
     Raw mater ial 4 10.5  
     Powder 3 7.9  
Durat ion of HDS use   10 (24.4% ) 
     Less than 1 year 23 74.2  
     1-2 year(s)  6 19.3  
     3-4 years 0 0  
     More than 5 years 2 6.5  
Frequency of HDS use   7 (17.1% ) 
     Daily 25 73.5  
     Once a week 5 14.7  
     2-3 t imes a week 2 5.9  
     Few t imes a year 2 5.9  
 *  Respondents reported for each product  they used so these total more than 28 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
Maintenance of well-being was the m ost  com m on indicat ion for using dietary 
supplem ent  reported by respondents (50% ) , whilst  m ore than a third of herbal 
products were taken for t reatm ent  of disorders (41% ) , see Table 7.7. Som e 
respondents used herbs for  relieving sym ptom s such as flatulence, pain, 
peripheral oedem a and loss of libido. Som e used HDS for t reatm ent  of their 
chronic diseases, such as diabetes and dyslipidaem ia.  
  
Chapter 7:  Pilot  study 
112 
Table 7.7 Reported indicat ions for herbal products and dietary supplem ents used 
(n= 28)  
 Number of HDS usage*  Percent Missing data 
I ndicat ions of herbal use    1 (3.6% ) 
     Well-being 8 29.6  
     Symptom relief 4 14.8  
     Treatment  of other chronic diseases 4 14.8  
     CKD treatment  3 10.1  
I ndicat ions of DS use    4 (14.3% ) 
     Well-being 12 50.0  
     Symptom relief 1 4.2  
     Treatment  of other chronic diseases 3 12.5  
     CKD treatment  1 4.2  
*  Respondents reported for each product  they used and one product  may have been reported more 
than one indicat ion 
Percent was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
Eighteen respondents (72% )  reported one reason for HDS use, whilst  the 
rem aining respondents provided 2 or 3 reasons. Sixty-eight  percent  of HDS 
users reported fam ily mem bers and fr iends influencing their HDS use, see Table 
7.8. Other reasons (20% )  were that  som e respondents believed in superst it ion 
and som e heard about  benefit s of HDS from  radio or t elevision. 
Table 7.8 Reasons why respondents use HDS (n= 28)  
Reasons for using HDS Number*  Percent 
Fam ily/ fr iend’s recommendat ion 17 68.0 
Belief that  HDS will work 4 16.0 
Decided to use HDS by themselves  3 12.0 
Other 5 20.0 
Wanted to t ry  2 8.0 
Safer than convent ional medicines 2 8.0 
Health care provider ’s recommendat ion 1 4.0 
*  Respondents were able to report  more than one reason, m issing data =  3 (10.7% ) 
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Percent was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
Over two- thirds did not  inform  their doctor about  using HDS because they were 
not  asked (10, 59% ) , see Table 7.9.  
Table 7.9 Report ing to their doctor about  HDS use (n= 28)  and reasons for  not  
report ing (n= 17)  
Categor ies Number of respondents Percent 
I nformed about  HDS use*    
     Yes 8 32 
     No 17 68 
Reasons Number of reasons* *  Percent 
Doctor did not ask about  HDS use 10 58.8 
There is no need to inform the doctor 5 29.4 
Doctors will blame pat ients for  using 4 23.5 
*  Percent  was calculated using an absolute number of respondents, which was not  included a 
number of m issing data. Missing data was 3 (10.7% ). 
* *  Respondents were able to report  more than one reason. 
Table 7.10 report s the nam e of the HDS used and their indicat ions. Respondents 
used 22 different  HDS. Six respondents could not  rem em ber the ingredients of 
the HDS they took (21% ) . 
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Table 7.10 Types of HDS used by respondents ( the total num ber of HDS 
used= 41)  
Types of HDS use Number*   I ndicat ions reported by respondents 
Herbal products   
     Chinese herbs 4 Promot ion for well-being and 
t reatment  of chronic diseases, 
including CKD 
     Turmeric (Curcuma Longa)  2 Flatulance 
     Thai herbs 2 Treatment  of chronic diseases, 
including CKD 
Holy mushroom (Garnoderma 
lucidum )  
1 Well-being 
     Boesenbergia (Boesenbergia spp.) 1 Well-being 
     Horse radish t ree (Moringa spp.)  1 Well-being 
     Butea Superba (Mucuna collet t ii)  1 I ncreasing libido 
     Curcuma xanthorrhiza 1 Diuret ic 
     Tradit ional m ixed herb powder 1 Prevent faint ing 
     Kar iyat (Andrographis paniculata)  1 Treatment  of the common cold 
Dietary supplements   
     Rice germ 3 Well-being (2)  Treatment  of CKD and 
diabetes (1) 
     Rice bran oil 3 Well-being (2) , to relieve pain (1) 
     Mult iv itam ins 2 Well-being 
     Evening pr im rose oil 1 Well-being 
Mixed vegetable and fruit  
beverage 
1 Treatment  of diabetes 
     Fish oil 1 Well-being 
     Co-Q10 1 Treatment  of heart  diseases 
     Glucosam ine 1 Treatment  of osteoarthr it is 
     Pollen 1 Treatment  of diabetes 
     Protein supplements 1 Well-being 
     Vitam in C 1 Well-being 
     Spirulina 1 Well-being 
*  Respondents were able to report  more than one product so these total more than 28. 
Missing data =  9 products that  pat ients could not remember the ingredients of the HDS they 
took 
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Most  HDS users (19, 68% )  thought  that  they gained benefit  from  taking HDS, 
see Table 7.11. Two perceived that  their diabetes had im proved and one 
reported im proved dyslipidaemia. Five respondents reported that  they had had 
side effects from  HDS. Three experienced increased serum  levels of lipid profiles, 
blood sugar levels or body weight , whilst  another one perceived it  worsening of 
her chronic disease. One thought  that  HDS was unsafe but  did not  report  
experiencing any specific side effects.  
Table 7.11 Percept ion of benefit s and adverse events of HDS reported by 
respondents (n= 28)  
Benefits and adverse effects  Number of benefits 
and adverse events 
Percent Missing 
data 
Benefits of HDS used   -   
     No 6 21.4  
     Yes 19 67.9  
     Do not  know 3 10.7  
Types of the benefit    -  
     Relieving symptoms 9 47.4  
     Well-being 6 31.6  
Treatment  of diabetes or dyslipidaem ia 3 15.8  
     Treatment  of chronic diseases 1 5.2  
Adverse effects of HDS used   3 (10.7% ) 
     No 20 80  
     Yes 5 20  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
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7 .4 .2  Validity and reliability 
The Thai version of the 8 - I tem  Morisky Medicat ion Adherence Scale®  
( MMAS- 8 - I tem ® )  
Respondents having a low level of adherence to prescribed, convent ional 
m edicat ion seem ed to have a decrease in m ean eGFR greater than those with a 
m edium  or high level of m edicat ion adherence, see Table 7.12. I t  would appear 
that  this relates to t he hypothesis that  if pat ients do not  adhere well to 
convent ional m edicat ions, their renal funct ion would decrease. However, the 
total num ber of respondents was not  sufficient  to est im ate the relat ionship with 
a stat ist ical significance of less than 0.05 level.   
The present  study yielded a Cronbach’s alpha score of 0.67, m eaning m oderate 
internal consistency (n= 42)  for the Thai version of the MMAS-8- I tem ® .  
Regarding test - retest  reliabilit y, the ICC of MMAS-8- I tem ®  was 0.73 (95% CI  
0.52-0.85, p <  0.01)  (n= 34, m issing data =  8) , m eaning this quest ionnaire had 
fair to good agreem ent . Due to severe flooding in Bangkok at  the t im e of this 
study, eight  respondents could not  be contacted by phone in order to be 
interviewed the second t im e.  
Table 7.12 The associat ion between the degree of convent ional m edicat ion 
adherence and change in m ean eGFR over 3 m onths (n= 42)  
MMAS-8- I tem ®  I ncreased mean eGFR Decreased mean eGFR 
Low medicat ion adherence 5 (41.7% ) 7 (58.3% ) 
Medium medicat ion adherence 9 (56.3% ) 7 (43.7% ) 
High medicat ion adherence 7 (50.0% ) 7 (50.0% ) 
-  Chi-squared tested the associat ion between low, medium or high medicat ion adherence and 
increased or decreased mean eGFR within 3 months.  
-  ǒ2 =  0.58, p-value =  0.75 
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The Rest r ict ion of Protein, Potassium , Phosphate  and Salt  diet  
quest ionnaire for  pre- dia lysis pat ients ( RPPPS)  
There were the expected t rends in associat ions between the degree of protein, 
potassium , phosphate and salt  consum pt ion and their target  t reatm ents, i.e. 
respondents consum ing low protein, potassium, phosphate and salt  diet  seem ed 
m ore able to m eet  the targets for their condit ion, than those with m oderate to 
high consum pt ion of protein, potassium , phosphate and salt  diet , see Table 7.13. 
Stat ist ically significant  associat ions between low potassium  intake and cont rolled 
m ean level of serum  potassium  were found (p- value <  0.05) . However, the total 
num ber of respondents is not  sufficient  to est im ate other associat ions with a 
stat ist ical significance of less than 0.05 level.   
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Table 7.13 Correlat ion between degree of protein, potassium , phosphate and salt  consum pt ion and their clinical outcom es (n= 42)  
Degree of food consumpt ion Clinical outcomes ǒ2 p-value Missing data 
Protein Decreased mean eGFR I ncreased mean eGFR 0.43 0.51 4 (9.5% ) 
     Low consumpt ion 7 (43.7% ) 9 (56.3% )    
     Moderate to high consumpt ion 12 (54.5% ) 10 (45.5% )    
Potassium Uncontrolled mean serum potassium 
levels 
Controlled mean serum potassium levels 5.51 0.02 7 (16.7% ) 
     Low consumpt ion 0 (0% ) 17 (100% )    
     Moderate to high consumpt ion 5 (27.8% ) 13 (72.2% )    
Phosphate Uncontrolled mean serum phosphate 
levels 
Controlled mean serum phosphate levels 0.368 0.54 10 (23.8% ) 
     Low consumpt ion 1 (6.2% ) 15 (93.8% )    
     Moderate to high consumpt ion 2 (12.5% ) 14 (87.5% )    
Salt  Uncontrolled blood pressure Controlled blood pressure 3.79 0.05 -  
     Low consumpt ion 5 (29.4% ) 12 (70.6% )    
     Moderate to high consumpt ion 15 (60% ) 10 (40% )    
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The test - retest  reliability of the RPPPS quest ionnaire was tested using Kappa. 
The reliabilit y of the quest ionnaire evaluat ing the degree of potassium  and salt  
consum pt ion had good agreem ent  (Kappa =  0.79 and 0.76, respect ively) , see 
Table 7.14. However, t he reliabilit y of the quest ionnaire assessing the degree of 
protein and phosphate consum pt ion had only fair agreem ent  (Kappa =  0.32 and 
0.27, respect ively) . The m issing data resulted from  both interviews was a result  
of respondents who were unable to answer the quest ions. 
Table 7.14 Test - retest  reliabilit y between the first  and the second interview 
regarding protein, potassium , phosphate and salt  consum pt ion (n= 42)  
First  interview Second interview Kappa p-value Missing 
data Degree of food intake Low intake High take   
Protein   0.32 0.07 12 (28.6% ) 
     Low intake 7 (23.3% ) 7 (23.3% )    
     High intake 3 (10.0% ) 13 (43.4% )    
Potassium   0.79 < 0.01 13 (31.0% ) 
     Low intake 11 (37.9% ) 2 (6.9% )    
     High intake 1 (3.5% ) 15 (51.7% )    
Phosphate   0.27 0.09 12 (28.6% ) 
     Low intake 13 (43.3% ) 2 (6.7% )    
     High intake 9 (30.0% ) 6 (20.0% )    
Salt    0.76 <  0.01 8 (19.0% ) 
     Low intake 12 (35.3% ) 1 (3.0% )    
     High intake 3 (8.8% ) 18 (52.9% )    
High intake =  Moderate to high intake 
7 .5  Results of the second pilot  study 
There was poor reliabilit y of the RPPPS quest ionnaire in the first  pilot  study, so 
this quest ionnaire was revised and tested for t est - retest  reliabilit y again, see 
Appendix 6. The durat ion between the first  and second interviews was 7 days. 
The reliabilit y of this quest ionnaire, designed to evaluate the degree of 
phosphate and salt  consum pt ion, had very good agreem ent ,  respect ively (Kappa 
=  0.81 and 0.81) , see Table 7.15. The reliabilit y of the quest ionnaire assessing 
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the degree of protein and potassium  consum pt ion also had good agreem ent  
(Kappa =  0.69 and 0.74, respect ively) .  
Table 7.15 Test - retest  reliabilit y of the revised RPPPS quest ionnaire between the 
first  and the second interviews regarding protein, potassium , phosphate and salt  
consum pt ion (n= 21)  
First  interview Second interview Kappa p-value 
Degree of food intake Low intake High intake   
Protein   0.69 0.01 
     Low intake 6 (28.6% ) 2 (9.5% )   
     High intake 1 (4.8% ) 12 (57.1% )   
Potassium   0.74 0.01 
     Low intake 4 (19.0% ) 1 (4.8% )   
     High intake 1 (4.8% ) 15 (71.4% )   
Phosphate   0.81 <  0.01 
     Low intake 10 (47.6% ) 0 (0.0% )   
     High intake 2 (9.5% ) 9 (42.9% )   
Salt    0.81 <  0.01 
     Low intake 8 (38.1% ) 1 (4.8% )   
     High intake 1 (4.8% ) 11 (52.4% )   
High intake =  Moderate to high intake 
This pilot  study assessed the understanding of the researcher adm inistered 
open-ended quest ions about  at t itudes towards the reasons for  HDS use in 
pat ients with CKD;  this part icular research inst rum ent  being designed by the 
author, see Appendix 4. All respondents understood and answered the quest ions 
fully (n= 6) . Six respondents using HDS current ly and regularly were 
interviewed;  each interview last ing between 5 to 10 m inutes. Five were audio-
recorded and the other did not  give perm ission to be recorded. Two relat ives of 
the pat ients who had decided that  the pat ients used HDS, were also interviewed. 
Half of the interviewees were wom en and m ost  respondents at tended the kidney 
clinic at  CU hospital (n= 5) . There were four them es about  their at t itudes towards 
the reasons for HDS use, which were ‘finding out  about  HDS’, ‘reasons for HDS 
use’, ‘at t itudes towards the benefit s of HDS’, and ‘concerns about  HDS’.  
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Finding out  about  HDS 
Pat ients found out  about  HDS in a variety of ways. Two pat ients and one relat ive 
took HDS based upon recom m endat ions from  their fr iends’ or  fam ily. 
Addit ionally, pat ient  A and a daughter of pat ient  F, who had decided her m other 
should use HDS, searched for HDS inform at ion by them selves via HDS 
conferences at  the School of Pharm acy, Mahidol University, or  via the internet . 
Another pat ient  found out  about  HDS from  television, fr iends who sold HDS, and 
a nurse.  
Reasons for HDS use 
There were several reasons for HDS use am ongst  the respondents. One pat ient  
was used to taking HDS. 
I  was using HDS when I  was young because my parents provided HDS for me when I  was 
ill, said pat ient  A 
Three pat ients said they took them  as they needed to t reat  their diseases or 
sym ptom s, i.e. CKD, diabetes, im m unocom prom ised disorder, or dyspepsia, or  
their fr iends or fam ily m em bers recom m ended.  
My wife wanted me to t ry them even though I  did not  want  to use them , said pat ient  E 
I  was not  well, so I  wanted to have well-being by using HDS, said pat ient  B  
Other people told me that  HDS was good, said pat ient  C  
Other factors related to HDS use were that  HDS is natural and has inform at ion 
about  benefit s. 
HDS did not contain chem ical substances, said pat ient  A  
Some HDS were supported by scient if ic evidence and some doctors produced HDS products 
and my fr iend recommended me to use it . However, I  wanted to ask a doctor or an expert 
on HDS before doing so, said pat ient  B. 
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Att itudes tow ards the benefits of HDS 
At t itudes towards the posit ive effects of HDS were that  three pat ients and one 
relat ive thought  that  they gained benefit s from  HDS.  
I  used HDS because my kidneys did not  work hard and t r ied to avoid or lim it  the use of 
convent ional medicines, such as pain killers, said pat ient  A 
One pat ient  did not  know whether or not  he gained benefit s from  using HDS, but  
cont inued using it .  
I  could not  assess the benefits of HDS, said pat ient  B  
However, one relat ive thought  that  a pat ient  did not  gain benefit s from  using 
HDS. 
My husband did not  gain any benefits from HDS, said wife of pat ient  E  
Regarding the com parison of the benefit s between HDS and CM, som e pat ients 
thought  that  they could not  com pare them . 
I  have never compared the benefits between HDS and CM, said pat ient  B 
The benefits between HDS and CM are not  possible to compare, said pat ient  C  
HDS and CM have different  benefits, said the relat ive of pat ient  F 
Som e could com pare different  benefit s between HDS and CM, which found that  
CM was superior t o HDS. 
CM prescr ibed by a doctor was more beneficial than HDS, said pat ient  E  
Two pat ients with CKD thought  that  they gained m ore benefit  from  HDS than 
what  they had expected.  
I  did not  expect  any benefits of HDS, said pat ient  B 
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Concerns about  HDS 
Two pat ients and two relat ives did not  have any concerns about  HDS;  whereas 
they were concerned that  CM m ay accum ulate in the body;  as a result , CM m ay 
cause harm .  
My kidneys may have to work harder if I  used high numbers of CM, said pat ient  A  
Dietary supplements are safe because they supplemented diet  and were not  medicat ions, 
said pat ient  C 
On the cont rary, one pat ient  was concerned about  both HDS and CM and another  
one was worried about  HDS as his fr iends had warned him  about  side effect s of 
HDS. 
I  had different concerns about  HDS and CM, and wanted to ask a doctor whether I  could use 
HDS or not , said pat ient  B 
High consumpt ion of HDS may not  be good so I  use HDS only occasionally , said pat ient  D 
Regarding warnings about  HDS use from  health professionals or other people, 
two respondents said no one had warned them  about  using HDS, as they knew 
how to use it  safely.  
My relat ives did not  have HDS knowledge, said pat ient  B 
I  knew how to use HDS, said pat ient  A  
I n cont rast , two pat ients were warned by their  doctor not  t o use HDS. One had 
stopped using them  whilst  the other did not . However, pat ient  C did not  obtain 
any warning from  her doctor,  although she did inform  her doctor about  her use 
of HDS.  
I t  would appear that  the pat ients using HDS had two characterist ics. First ly, 
som e pat ients t rusted in the benefit s from  HDS and had no concerns about  
them , as they thought  that  HDS did not  contain chem ical substances or were 
dietary. Secondly, others wanted to t ry HDS as their fr iends and fam ily had 
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recom m ended them ;  however, som e respondents quest ioned the efficacy and 
safet y of HDS and som e wanted to consult  their doctor.  
7 .6  Discussion 
The two pilot  studies tested the study inst rum ents and m ethods which were 
largely acceptable, although som e issues arose during the test ing. Regarding 
inform at ion about  household incom e, 48%  were not  able to provide household 
incom e because som e did not  know this inform at ion and others refused to 
disclose this inform at ion. As a result , this quest ion was deleted from  the 
quest ionnaire. The num ber of respondents who had never sm oked or consum ed 
alcoholic beverages was high:  the interviewer asked all respondents “Do you 
sm oke or drink alcoholic beverages?”  and the m ajority said “no” . Then the 
interviewer im proved the quest ion to “Have you ever sm oked or drunk alcoholic 
beverages?”  This quest ion seem ed to provide a m ore accurate answer than the 
original quest ion. Therefore, the new quest ion was used in the m ain study.  
The pat tern of HDS use am ongst  Thai pat ients with CKD, in this pilot  study, was 
sim ilar to the t rends found in the bus stop survey, see Appendix 1, which was 
conducted in the general populat ion in Bangkok. The bus stop survey found that  
the equal proport ion (40% )  between the use herbal m edicine and dietary 
supplem ent ;  the m ain purpose of herbal m edicine use was the t reatm ent  of 
illnesses, whilst  dietary supplem ents were used for  m aintaining well-being. There 
is the sam e proport ion of respondents using herbal products and dietary 
supplem ents with the sam e pat tern of usage in both the bus stop survey and the 
pilot  study.  
Regarding whether there are adequate num bers of laboratory results in pat ients’ 
notes for determ ining clinical outcom es, i.e. serum  levels of creat inine, 
potassium  and phosphate, were recorded, approxim ately 80%  had at  least  3 
values of serum  levels of serum  creat inine and potassium  in the previous year,  
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prior t o the index date. Half had at  least  3 values of serum  levels of phosphate. 
Therefore, the m ain study would have adequate inform at ion about  the study 
outcom es.  
Recruitm ent  rate was 10 respondents per week in the first  pilot  study, when only 
the principal invest igator approached and interviewed respondents. The sam ple 
size determ inat ion was at  least  420 pat ients for the cohort  study. This rate was 
too low;  therefore the recruitm ent  process m ay have taken at  least  11 m onths to 
achieve the required sam ple size for the baseline data. Given that  there is a 
planned 12 m onths follow-up, the cohort  study would then have taken at  least  2 
years, which is not  possible within the scope of 3-year PhD program m e. To 
im prove the recruitm ent  rate, in the second pilot  study, the m ain invest igator 
(MT)  and two research assistants t rained by MT, approached and interviewed 
pat ients, so the recruitm ent  rate was nearly doubled (15-20 respondents per 
week) . Therefore, the sam ple size of at  least  420 pat ients could be recruited 
within 6-7 m onths and this process was used in the m ain study.    
The Thai version of the MMAS-8- I tem ®  had already been tested for  validity and 
reliabilit y in Thai diabet ic pat ients by Sakthong et  al. (2009) .227 They found 0.61 
of Cronbach’s alpha and 0.83 of ICC. I n the present  study, the Thai version of 
MMAS-8- I t em ®  was tested for concurrent  validity, internal consistency and test -
retest  reliabilit y am ongst  CKD pat ients. Respondents with a low level of 
adherence to prescribed, convent ional m edicat ion had decreased m ean eGFR 
scores greater than those with m edium  or high m edicat ion adherence. However, 
the associat ion between the degree of m edicat ion adherence and the change of 
m ean eGFR was not  stat ist ically significant  due to the sm all num ber of 
respondents. Regarding reliabilit y, the present  study found 0.668 for Cronbach’s 
alpha and 0.728 for I CC, m eaning there was acceptable reliabilit y. I nternal 
consistency in the present  study was close to the previous study, whilst  the I CC 
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value in the present  study was slight ly lower than the value from  Sakthong’s 
study. Therefore, the MMAS-8- I tem ®  was used in the m ain study. 
The RPPPS quest ionnaire was adapted from  the dialysis diet  and fluid adherence 
quest ionnaire (DDFQ) .229 For the first  pilot  study, the RPPPS quest ionnaire was 
developed in order to assess dietary adherence, see Appendix 13;  however the 
m ajorit y of respondents (17, 77.3% )  found the quest ion about  “To what  degree 
did you deviate from  such recom m endat ion?”  was difficult  and hesitated for a 
m om ent  in order t o answer this quest ion. Therefore, this quest ion was revised to 
“How m uch did you com ply with your doctor’s recom m endat ion?”  when 
respondents could not  answer the original quest ion im m ediately.  
Most  respondents (19, 86.4% )  found it  difficult  to answer the quest ion “How 
m any days during the past  14 days didn’t  you follow recom m endat ion of your 
food rest r ict ion?” . None of the respondents could answer the quest ion about  
est im at ing the change of their diet  after they were neither diagnosed with CKD;  
nor could they accurately recall the am ount  of each t ype of food eaten, such as 
from  a high-protein diet , a high-potassium  diet  and a high-phosphate diet . 
Therefore, these quest ions were deleted and new quest ions based on the 
quest ionnaire of Vlam inck et  al. (2001)  were developed and used in the 
rem aining period of the pilot  study, see Appendix 3.   
The RPPPS quest ionnaire classified the degree of food consum pt ion into low and 
high food consum pt ion. Respondents answering ‘no’ or ‘very sm all am ounts’ 
were classified as low food consum pt ion;  m eanwhile those with m oderate or 
large am ounts of consum pt ion were high consum pt ion. Pat ients with 
com plicat ions of CKD, i.e. hyperkalem ia, hyperphosphatem ia and hypertension, 
have to rest r ict  the am ount  of protein, potassium , phosphate and salt  they eat .  
Although these pat ients consum ed a m oderate am ount  of these nut r ients in their 
diet , they m ay consum e m ore than their dietary recom m endat ions. Therefore, it  
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would seem  that  they reported eat ing m oderate am ounts, m eaning they were 
exceeding the recom m endat ions for their dietary intake. 
Regarding the validity of the RPPPS quest ionnaire, respondents with low protein 
consum pt ion had increased m ean eGFR, as com pared to those with high protein 
consum pt ion. Likewise, those with low potassium , phosphate and salt  
consum pt ion had cont rolled serum  levels of potassium  and phosphate, and 
cont rolled blood pressure, com pared to those with high potassium , phosphate 
and salt  consum pt ion. A stat ist ically significant  associat ion was found between 
low potassium  consum pt ion and cont rolled serum  potassium  levels. However, 
other correlat ions were not  stat ist ically significant , due to the sm all num ber of 
respondents. Other factors played their part  influencing these correlat ions, such 
as the severity of CKD and prescribed, convent ional m edicine for t reatm ent  of 
hyperkalem ia, hyperphosphatem ia or hypertension.  
Vlam inck et  al. (2001) , who developed the DDFQ, had one quest ion:  “To what  
degree did you deviate from  your diet  guidelines?”  which m easured the degree 
of dietary non-adherence, which is potassium  and phosphate intake. They 
conducted criterion validity of the DDFQ in order t o evaluate the correlat ion 
between the degree of dietary non-adherence and serum  levels of potassium  and 
phosphate. They found a posit ive correlat ion between the degree of dietary non-
adherence and serum  levels of phosphate, but  not  with potassium . I t  would 
seem  therefore, that  the RPPPS quest ionnaire direct ly m easures the degree of 
potassium  and phosphate consum pt ion, rather than the DDFQ doing so.   
The test–retest  reliabilit y of the RPPPS quest ionnaire assessing the degree of 
potassium  and salt  consum pt ion had good agreem ent  (Kappa=  0.79 and 0.76, 
respect ively) , m eaning acceptable reliabilit y. Therefore, these quest ions were 
used in the m ain study. I n cont rast , the reliabilit y of the quest ions assessing the 
degree of protein and phosphate consum pt ion had only fair agreem ent  (Kappa =  
0.32 and 0.27, respect ively) . This m ay be because the quest ions were not  
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specific;  at  least  a quarter  of respondents were not  able to assess the degree of 
protein and phosphate in their diet . High protein and phosphate diets consist  of 
several t ypes of food:  for instance, high phosphate foods are cereal, m ilk, 
chocolate, yogurt , ice-cream , etc. High protein diets contain pork, chicken, egg 
white, fish, etc. Therefore, only one quest ion assessing the degree of protein and 
phosphate consum pt ion m ay not  be suitable. These aspects of diet  should have 
m ore quest ions;  for exam ple, the quest ions about  high protein diet , ‘How often 
have you eaten pork in the last  14 days?’, ‘How often have you eaten chicken in 
the last  14 days?’, and ‘How often have you eaten egg white in the last  14 
days?’, etc. Addit ionally, doctor’s advice about  food rest r ict ions influenced a 
change in food consum pt ion in respondents. Therefore, these quest ions were 
revised, see Appendix 6 and the new quest ions were piloted again in Decem ber 
2011. Addit ionally, the poor reliabilit y of the RPPPS quest ionnaire in the first  pilot  
study m ay result  from  a change of respondents’ diet  behaviour under 
observat ion, which is known as the Hawthorne effect .  
Som e respondents found it  difficult  to est im ate their food consum pt ion, so the 
interviewer had to est im ate the food consum pt ion based on the respondent ’s 
inform at ion. To m easure the degree of food consum pt ion accurately, the 
definit ion of the degree of food consum pt ion needed to be put  forward. The 
degree of food consum pt ion was classified into 5 levels:  no, low, m oderate, high 
and very high, see Table 7.16.255  
Table 7.16 Definit ion of degree of food consum pt ion 
Degree of food consumpt ion Definit ion 
No No food consumed at  all  
Low Eat ing 1-2 days per week 
Medium Eat ing 3-4 days per week 
High Eat ing 5-6 days per week 
Very high Eat ing daily 
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Kappa values of test - retest  reliabilit y of the revised RPPPS quest ionnaire in the 
second pilot  study were acceptable. This m ay be because the quest ions in the 
second pilot  study were m ore specific and there was the short  period (7 days)  
between the first  and second interviews, so that  respondents m ay not  have 
changed their diet  behaviour. The reliabilit y of assessing protein, potassium , 
phosphate and salt  consum pt ion was im proved (Kappa =  0.69, 0.74, 0.81 and 
0.81, respect ively) . Appendix 6 shows the final version of the quest ionnaire 
em ployed for the survey.  
Regarding the researcher adm inistered open-ended quest ions, about  at t itudes 
towards the reasons for HDS use am ongst  pat ients with CKD, see Appendix 4, 
these quest ions were used in the qualitat ive study because all respondents in the 
second pilot  study understood the quest ions fully and the findings seem ed to 
relate to reasons for HDS use, which was the object ive of this qualitat ive study. 
Reasons for HDS use were percept ions of benefit s and safety of HDS. Sources of 
inform at ion influencing decision m aking of HDS use were fam ily m em bers, 
fr iends and the m edia supported by the literature.51,55,90 
7 .7  Conclusion 
The researcher adm inistered quest ionnaire in the survey and the researcher 
adm inistered open-ended quest ions about  at t itudes towards the reasons for  HDS 
use, in the qualitat ive study, were developed and piloted, and finally acceptable 
results were obtained. Both the Thai version of the MMAS-8- I t em ®  and the 
RPPPS quest ionnaire were tested for criterion validity and test - retest  reliabilit y, 
and found to have acceptable validity and reliabilit y. The final version of this 
quest ionnaire, which includes the RPPPS quest ionnaire, is shown in Appendix 6. 
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8 . The prevalence, pat terns and reasons for  
HDS use 
The object ives of this study were to determ ine 1)  the prevalence and pat terns of 
HDS use in Thai pat ients with CKD;  2)  the types and pat terns of HDS use 
am ongst  this populat ion;  3)  the dem ographic characterist ics relat ing to HDS use, 
com pared with the non-users;  4)  the associat ion between HDS use and a level of 
adherence to prescribed, convent ional m edicat ion;  5)  the reasons why Thai CKD 
pat ients use HDS;  6)  respondents’ experiences of benefit s and adverse effects 
from  using HDS;  and 7)  the rate of non-disclosure of HDS use to a doctor and it s 
reasons. 
8 .1  Methods 
A survey was perform ed in order to serve obj ect ives 1, 2, 3, 4, 6 and 7 whilst  
the fifth object ive was achieved using quant itat ive and qualitat ive m ethods, 
where quant itat ive and qualitat ive data were collected in parallel, analysed 
independent ly, and then com pared, see Flowchart  8.1.256  
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Flowchart  8.1 Diagram  of study m ethods 
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8 .1 .1  Choice of m ethod 
The survey collected data using a quest ionnaire, because ext ract ing data from  
m edical notes alone was considered unlikely to provide com plete inform at ion, 
part icularly in relat ion to HDS use. I n addit ion, the literature shows that  pat ients 
using HDS were unlikely to disclose their use to their doctor .15,16,51,58 Despite the 
high costs of an interview m ethod, com pared to a postal survey, there are m any 
advantages of face- to- face interviewing:  a high response rate, the abilit y to 
ensure all quest ions are answered, quest ions can be clarified by the interviewer 
to ensure inform ants understand the quest ions, the abilit y to probe for  
responses and sessions are not  lim ited to those with sufficient  reading abilit y to 
answer the quest ions.    
This survey was planned to collect  data for 6 m onths, as m ost  pat ients had to 
visit  their doctor every three m onths, so they all had an equal chance of being 
recruited during the six-m onth period. 
The third object ive:  ‘reasons why Thai CKD pat ients use HDS’, was designed to 
collect  data using a qualitat ive m ethod in order t o gain a greater insight  than 
would be obtained from  using the survey data alone.   
8 .1 .2  Definit ion of HDS use 
Herbal and dietary supplem ent  use was defined as use of products containing 
plant -derived m aterial, either raw or processed ingredients, from  one or m ore 
plants or containing dietary ingredients, such as vitam ins, m inerals, am ino acids 
and substances, such as, enzym es, organ t issues, glands and m etabolites.31,32 
This definit ion was used in this study because it  is sufficient ly wide to capture 
use in Thailand and an acceptable definit ion for  com parison with the literature. 
Addit ionally, the prevalence of HDS use was defined as it s use in the previous 12 
m onths, as m ost  studies which ascertain prevalence have used this per iod and it  
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is com m only used in prevalence studies10,25,36,40,42,43,45,46, thereby allowing 
com parisons to be m ade.  
The inclusion of both herbal m edicine and dietary supplem ents in this study was 
because 1)  both are frequent ly used;  and 2)  their definit ion overlaps in the 
literature. For exam ple, raw ginkgo can be defined as a herbal m edicine, 
part icularly in Asian studies, whilst  it s ext racts are com m only defined as dietary 
supplem ents, part icularly in US studies;  3)  the term  ‘dietary supplem ents’ is 
m ore likely to be used in the US, and this som et im es includes herbal products,10 
whilst  the term s ‘natural products’ or ‘natural herbs’ include both herbal 
m edicines and dietary supplem ents in the literature.15,28  
This study focused on HDS use for  the t reatm ent  of illnesses or health 
prom ot ion, rather than consum pt ion as daily food intake or cosm et ic purposes, 
which m ay affect  the study outcom es. I f the present  survey included all purposes 
of HDS use, the prevalence in Thailand m ay be overest im ated, com pared with 
prevalence in Western populat ions, as som e of the herbs are used in flavouring 
food in Thailand and are less likely to be used as frequent ly for  this purpose in 
Western populat ion. This assum pt ion is supported by the bus stop survey of the 
prevalence of HDS use in Thai general populat ion, where the definit ion of HDS 
use included the use of HDS for t reatm ent , dietary and cosm et ic purposes, see 
Appendix 1. Moreover, the definit ion of HDS usage in the present  survey did not  
include prescribed convent ional m edicat ions, such as calcium  supplem ents, folic 
acid, vitam in B com plex, iron supplem ents or Senokot ® , which are com m only 
prescribed for support ive t reatm ent  of CKD com plicat ions. 
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8 .1 .3  Quest ionnaire survey 
A cross-sect ional survey was recruited Thai outpat ients with stages 3 to 5 CKD 
at  two teaching hospitals from  January to June 2012.  
The five part s of the final version of the quest ionnaire consisted of dem ographic 
characterist ics, HDS use, experiences of benefit s and adverse effect s from  the 
HDS use, the Thai version of MMAS-8- I tem ®  and the RPPPS, see Appendix 6. 
Dem ographic character ist ics included age, sex, current  address, educat ion, 
occupat ion, sm oking status and alcohol consum pt ion. HDS usage included types, 
m edical purposes, dosage form s, doses and durat ion of HDS use, the reasons 
why respondents use HDS, their inform at ion sources and how they obtained the 
HDS. The RPPPS quest ionnaire m easured the degree of dietary intake for the 
cohort  study, see Chapter 9. 
All pat ients who m et  the inclusion criteria were approached in order to determ ine 
their willingness to part icipate in this survey. I f they consented, the 
quest ionnaire, with pictures of HDS sam ples and diets, was adm inistered in face-
to- face interviews, see Appendix 6. 
The principal invest igator (MT)  and two research assistants -  Ms. Panj it  
Chaiyasanit  and Mr. Piya Kaewkrachang interviewed respondents. The assistants 
were t rained to conduct  the interviews by MT and the first  respondent  
interviewed by them  was observed by MT in order to ensure the standardisat ion 
and conform ity of the interview procedures. 
Data were coded and entered into the IBM SPSS software version 19.0. This 
database was checked to ensure accuracy and com pleteness of data ent ry.  Ten 
per cent  of quest ionnaires (n =  42)  were random ly selected using Microsoft  Excel 
software and these quest ionnaires were checked against  the database. The 
quest ionnaire contained 28 quest ions and 103 variables. A total of 3 errors were 
found in 1,176 quest ions (4,326 variables) . These errors were rect ified. To check 
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consistency of the database, issues related to other variables were checked;  for 
exam ple, the total num ber of HDS used and the num ber of herbal m edicines and 
dietary supplem ents used. Such errors (1% )  found were rect ified.   
Data analysis consisted of sim ple frequencies with percentages, which were used 
to determ ine the prevalence of HDS use and descript ive results. Chi-squared 
tests were perform ed to determ ine the factors related to HDS use and any 
associat ions between HDS use and convent ional m edicat ion adherence. Mult iple 
logist ic regression analysis was undertaken to determ ine associat ions between 
HDS users and convent ional m edicat ion adherence, adjusted for  dem ographic 
characterist ics. Tests were 2- tailed, and a p-value <  0.05 was considered 
stat ist ically significant . I BM SPSS software version 19.0 was used for the 
stat ist ical analyses.  
8 .1 .4   Qualitat ive study 
HDS users from  the quest ionnaire survey, in both set t ings, who were willing to 
part icipate in the qualitat ive study were recruited. Addit ionally, part icipants who 
reported using HDS and provided reasons why they used HDS were chosen, as 
they were likely to have posit ive at t itudes towards HDS use. Respondents were 
interviewed face- to- face by MT, using eight  open-ended quest ions about  their 
reasons for HDS use, see Appendix 4, unt il the data was saturated. Therefore, 
16 respondents were recruited. The interv iews lasted approxim ately 5-10 
m inutes and were audio recorded.  
Open-ended quest ions were used in the qualitat ive study and were audio 
recorded, as this m ethod perm it ted inform ants to provide detailed answers and 
m inim ised the extent  to which these answers were influenced by the 
interviewers’ own perspect ives.257 An advantage of audio recording is that  
com plete and verbat im  data collect ion could be obtained, in com parison with 
writ ing notes, although som e inform ants m ay feel slight ly uncom fortable in being 
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recorded. Also, this m ethod lacks data regarding non-verbal aspects of 
com m unicat ion, such as body language and facial expressions. 
The audio recordings were t ranscribed verbat im  and the Thai t ranscr ipts were 
twice checked for accuracy against  the records, before start ing the process of 
forward t ranslat ion. Meaning-based t ranslat ion from  Thai language to English 
language was perform ed and English t ranscripts were twice checked with the 
Thai t ranscripts.253 Then five out  of sixteen t ranscripts were back t ranslated by 
Dr. Charoen Treesak, who is fluent  in both languages. This process was 
perform ed in order to validate the t ranscripts. One error out  of five t ranscript ions 
was found. The error was rect ified. 
Despite the fact  that  t he interviewer did not  ask about  their reasons for non-
disclosure of HDS use to a doctor, six respondents in the qualitat ive study 
provided this inform at ion. One respondent  m ent ioned disclosure of HDS use to 
her doctor by herself.  
The t ranscripts were analysed by the induct ive them at ic approach, with line-by-
line coding;  the Weft  QDA-a software program m e, for qualitat ive data analysis, 
was used for assist ing in the organisat ion of the t ranscripts.258,259 MT coded key 
words related to reasons for HDS use from  all t ranscripts, and then grouped 
them  under the sam e them e. Next , these were searched for characterist ics 
which were shared between the them es unt il there was consistency and them es 
em erging from  the inform at ion were ident ified. Com paring these them es with 
the t ranscripts again enabled new them es to em erge, which were not  included in 
the previous analyses. Finally, such processes were perform ed unt il the them es 
were consistent . 
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8 .2  Results 
The survey presents dem ographic characterist ics of respondents and HDS users, 
the prevalence and pat terns of HDS use, sources of inform at ion and HDS, 
experiences of benefit s and adverse effect s from  using HDS, disclosure of HDS 
use and reasons for  non-users. 
Reasons for HDS use were supported by both the survey (n= 189)  and the 
qualitat ive study (n= 16) . Six respondents who part icipated in the qualitat ive 
study provided m ore inform at ion about  reasons for  the non-disclosure of HDS 
use to their doctor and som e explained the reasons for  the disclosure. Reasons 
for non-adherence to convent ional m edicat ion em erged from  qualitat ive analysis. 
As there was overlap in the topics for  the researcher adm inistered quest ionnaire 
both in the survey and the open-ended quest ions in the qualitat ive study, the 
results are presented together.  
8 .2 .1  Descript ion of respondents 
The total num ber of potent ial respondents, who were approached to take part  in 
the survey, was 538. Pat ients at  SWU hospital did not  have eGFR calculated by 
the Thai MDRD equat ion and they were approached based on an increase in 
serum  creat inine levels. Subsequent ly after calculat ing eGFR, 94 respondents 
were excluded as they had stage 2 CKD. This left  a total of 444 pat ients of which 
23 (5.2% )  were excluded because they were receiving dialysis (n= 15) , were 
unable to provide inform at ion due to illnesses (n= 4) , or did not  give their 
consent  (n= 4) . Thus, 421 pat ients were recruited to the study. Dem ographic 
characterist ics are shown in Table 8.1. Som e pat ient  inform at ion (n= 60)  was 
provided by relat ives as the pat ients could not  provide the inform at ion due to 
their illness. Respondents had a m ean age of 66 years with a standard deviat ion 
(SD)  of 13, and 54%  were wom en. More than half of respondents had less than 
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a secondary school educat ion (56% ) , were ret ired (68% ) , were non-sm okers 
(64% )  and non-drinkers (57% ) , see Table 8.1. The m ajorit y of respondents had 
stage 3 CKD (71% )  and reported m oderate to high levels of prescribed, 
convent ional m edicine adherence (74% ) .  
Table 8.1 Dem ographics of respondents (n= 421)  
Demographics Frequency Percent Missing data 
Respondents from each hospital   -  
   CU hospital 238 56.5  
   SWU hospital 183 43.5  
I nterviewers   -  
   Main invest igator 349 82.9  
   Research assistants 72 17.1  
I nformat ion providers   1 
   Respondents 329 78.3  
   Pat ient ’s relat ives 60 14.3  
   Both 31 7.4  
Mean age and SD 66 +  13 years -  
Sex   -  
   Male 194 46.1  
   Female 227 53.9  
Current  address   -  
   Bangkok 148 35.2  
   Rural areas 273 64.8  
Educat ion   1 
   Less than secondary school 234 55.7  
   Secondary school 67 16.0  
   Vocat ional degree 29 6.9  
   Undergraduate degree 69 16.4  
   Higher degree 21 5.0  
Occupat ion   -  
   Ret ired 286 67.9  
   Employed 41 9.7  
   Self-employed/  business 39 9.3  
   Housewife/  house husband 19 4.5  
   Professional 13 3.1  
   Unemployed 11 2.6  
   Farmer 7 1.7  
   Pr iest 4 1.0  
   Student 1 0.2  
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Table 8.1 (cont inued)  
Demographics Frequency Percent Missing data 
Smoking status   -  
   Never smoked 269 63.9  
   Former smoker 131 31.1  
   Current  smoker 21 5.0  
Alcohol consumpt ion   2 
   Never  240 57.3  
   Former dr inker 156 37.2  
   Current  dr inker 23 5.5  
Stage of CKD   -  
   3 297 70.6  
   4 107 25.4  
   5 17 4.0  
Prescr ibed medicat ion adherence*    -  
   Low 108 25.7  
   Medium 201 47.7  
   High 112 26.6  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
*  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228. Low, medium and high adherence was defined as MMAS <  6, 6 <  MMAS <  
8, MMAS = 8, respect ively. 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772. 
8 .2 .2  Dem ographic var iables associated w ith herbal and 
dietary supplem ent  use 
The prevalence of herbal and dietary supplem ent  (HDS)  use in the previous 12 
m onths am ongst  Thai pat ients with CKD was 45%  (n= 189, 95% CI  40% -50% ) . 
Alm ost  all HDS users com bined these supplem ents with their prescribed, 
convent ional m edicines (n= 187, 99% ) . However, two (1% )  of the HDS users 
had stopped using their prescribed m edicines and had relied on HDS alone to 
relieve their sym ptom s. Addit ionally, alm ost  one third of the respondents used 
other com plem entary and alternat ive m edicines (CAM) , of which m assage was 
the m ain type of CAM use, reported by respondents (50% ) , see Table 8.2.  
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Table 8.2 The use of CAM (n= 421)  
 Frequency Percent Missing data 
CAM users   7 
   Yes 127 30.7  
   No 287 69.3  
Types of CAM used (n= 204)*   -  
   Massage 103 50.5  
   Meditat ion 57 27.9  
   Acupuncture 36 17.6  
   Yoga 5 2.5  
   Tai-chi 3 1.5  
*  Some respondents reported more than one type of CAM used 
Percent  was calculated using an absolute number of respondents, which was not  included a 
number of m issing data. 
Respondents who used HDS were m ore likely to use other CAMs (ǒ2 =  24.9, p <  
0.01) , see Table 8.3.  
Table 8.3 Relat ionship between HDS and CAM use (n= 421)    
 HDS users (n= 189 )  Non-users (n= 232 )  ǒ 2 p-value 
CAM users 81 (43.1% ) 46 (20.4% ) <  0.01*  
Non-users 107 (56.9% ) 180 (79.6% )  
Missing data 1 6  
*  Stat ist ically significant  at  p-value <  0.05. 
HDS users were m ore likely to have low adherence with prescribed, convent ional 
m edicines, com pared with non-users (ǒ2 =  8.46, p =  0.015) , see Table 8.4. 
There were no differences between HDS users and non-users regarding age, sex, 
educat ion levels, current  address, sm oking status, and the severity of CKD.  
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Table 8.4 Univariate analysis of factors associated with HDS use in pat ients with 
CKD (n= 421)  
Factors HDS user (n= 189) Non user 
(n= 232) 
X2 p-value 
Age   0.334 
   <  60 62 (32.8% ) 66 (28.4% )  
   >  60 127 (67.2% ) 166 (71.6% )  
Sex   0.708 
   Male 89 (47.1% ) 105 (45.3% )  
   Female 100 (52.9% ) 127 (54.7% )  
Educat ion   0.862 
   Less than secondary school 104 (55.3% ) 130 (56.0% )  
   Secondary school 27 (14.4% ) 40 (17.2% )  
   Vocat ional degree 14 (7.4% ) 15 (6.5% )  
   Undergraduate degree 34 (18.1% ) 35 (15.1% )  
   Higher than undergraduate 
     degree 
9 (4.8% ) 12 (5.2% )  
Address   0.186 
   Bangkok 60 (31.7% ) 88 (37.9% )  
   Rural areas 129 (68.3% ) 144 (62.1% )  
Smoking status   0.812 
   Never 122 (64.6% ) 147 (63.4% )  
   Former 59 (31.2% ) 72 (31.0% )  
   Current 8 (4.2% ) 13 (5.6% )  
Alcoholic consumpt ion   0.080 
   Never 119 (63.3% ) 121 (52.4% )  
   Former 60 (31.9% ) 96 (41.5% )  
   Current 9 (4.8% ) 14 (6.1% )  
Stages of CKD   0.936 
   3 133 (70.4% ) 164 (70.7% )  
   4 49 (25.9% ) 58 (25.0% )  
   5 7 (3.7% ) 10 (4.3% )  
Medicat ion adherence* *    0.015*  
   Low 61 (32.3% ) 47 (20.2% )  
   Medium 79 (41.8% ) 122 (52.6% )  
   High 49 (25.9% ) 63 (27.2% )  
     *  Stat ist ically significant  at p <  0.05 
* *  Medicat ion adherence was measured using the Thai version of the 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight  laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772. 
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The m ult iple logist ic regression analysis included all potent ial independent  
variables. Form er drinkers (adjusted odds rat io (OR)  0.43, 95%  CI  0.25-0.75)  
and respondents having m edium  adherence to prescribed, convent ional 
m edicines (adjusted OR 0.53, 95%  CI  0.32-0.87)  were m ore likely to use HDS. 
No other stat ist ically significant  associat ions with HDS use were found ( see Table 
8.5) .  
Table 8.5 Mult iple logist ic regression analysis of the associat ion between HDS 
use and dem ographics am ongst  pat ients with CKD (n= 421)  
Factors Adjusted odds rat io*  95%  CI  
Age   
   <  60 1.00  
   >  60 0.84 0.52-1.36 
Sex   
   Male 1.00  
   Female 0.77 0.47-1.29 
Educat ion   
   Less than secondary school 1.00  
   Secondary school 0.77 0.43-1.40 
   Vocat ional degree 1.11 0.48-2.52 
   Undergraduate degree 1.16 0.64-2.11 
   Higher than undergraduate degree 0.88 0.33-2.36 
Current  address   
   Bangkok 1.00  
   Rural address 1.38 0.90-2.12 
Smoking status   
   Never  smoked 1.00  
   Former sm oker  1.57 0.85-2.89 
   Current  sm oker  0.90 0.33-2.47 
Alcohol consum pt ion   
   Never  1.00  
   Former dr inker  0.43 0.25-0.75 
   Current  dr inker 0.52 0.20-1.33 
Stages of CKD   
   3 1.00  
   4 1.02 0.64-1.64 
   5 0.92 0.32-2.63 
Prescr ibed, convent ional medicat ion 
adherence* *  
  
   Low 1.00  
   Medium  0.53 0.32-0.87 
   High 0.68 0.39-1.20 
*  OR adjusted for all other var iables listed in the table 
* *  Medicat ion adherence was measured using the Thai version of the 8- I tem Morisky Medicat ion Adherence 
Scale®  227,228 
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Use of the © MMAS is protected by US copyr ight  laws. Perm ission for use is required.  A license agreement  is 
available from:  Donald E. Mor isky, ScD, ScM, MSPH, Professor, Department  of Com munity Health Sciences, 
UCLA School of Public Health,  650 Charles E. Young Dr ive South, Los Angeles, CA 90095-1772. 
With respect  to qualitat ive results, in term s of t he reasons for poor adherence to 
convent ional m edicat ion (CM)  am ongst  HDS users, only two respondents raised 
this issue. They either decreased doses of CM, or stopped using CM, as they 
were either concerned about  taking high numbers of CM, or had experiences of 
side effect s from  using CM.  
I  worry whether or not I ’ve taken too many medicat ions... I f I ’ve taken too many and feel it  
is wrong, I ’ll t ry to decrease the doses of the medicat ions. (R12, m age 75) 
 
I  had lots of side effects from convent ional medicines, so I  turned my thoughts to herbal use 
and used it ... I ’m normal at the moment although I  don’t  take my convent ional medicines. 
(R5, m age 43) 
Four out  of six interviewees who had negat ive at t itudes towards CM had poor 
adherence to CM, as m easured by the MMAS-8- I tem ® .  Their  negat ive at t itudes 
towards CM appeared to explain their poor adherence to CM. On the other hand, 
eight  out  of nine respondents who had m oderate or high levels of adherence did 
not  raise any concerns about  using CM and t rusted their doctor.   
8 .2 .3  Herbal and dietary supplem ent  usage 
Of the respondents using HDS (n= 189) , m ore than half of the respondents 
reported herbal use (64% , n= 138) , whilst  36%  (n= 77)  used dietary 
supplem ents;  of those 14%  used both (see Table 8.6) . The m ean num ber of 
different  HDS used was 1.6 (SD +  0.9)  products. The total num ber of different  
HDS used was 304, see Table 8.6.  
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Table 8.6 Pat terns of HDS use (n= 189)  
Pat terns Frequency Percent 
Types of HDS used   
   Herbal products 112 59.3 
   Dietary supplements 51 27.0 
   Both 26 13.7 
The number of different  HDS used   
   1 112 59.2 
   2 56 29.6 
   3 10 5.3 
   4 7 3.7 
   5 2 1.1 
   6 2 1.1 
   Total number of HDS used 304 100 
Am ongst  304 different  HDS used, capsules or tablets were the usual oral dosage 
form s (51% , n= 154)  of which 11%  (n= 17)  were t radit ional Thai or Chinese pills 
called ‘Luke Klon’,  which are a black round pill ( see Table 8.7) .  Nearly 10%  
(n= 22)  reported using unprocessed herbs, of which 64%  were collected from  the 
respondent ’s garden. Addit ionally, m ost  HDS products (71% , n =  213)  were 
used daily and around half of the products (52% , n =  153)  had been used for  
less than one year.   
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Table 8.7 Pharm aceut ical form s, frequency and durat ion of HDS use ( total 
num ber of HDS used= 304)*   
Pat terns Frequency Percent Missing data 
Oral dosage forms   1 
   Capsules or tablets 154 50.8  
   Liquid forms 94 31.0  
   Powder 33 10.9  
   Unprocessed herbs 22 7.3  
Frequency of use   4 
   Daily 213 71.0  
   Weekly 47 15.7  
   Few t imes a month 24 8.0  
   Few t imes a year  16 5.3  
Durat ion of use   9 
   Less than 1 year 153 51.9  
   1-2 year(s)  67 22.7  
   3-5 years 37 12.5  
   More than 5 years 38 12.9  
*  Respondents reported for each product  they used so these total more than the 189 
respondents who used HDS 
Percent  was calculated using an absolute number of respondents, which was not  included a 
number of m issing data. 
The purposes of using HDS were for m aintaining well-being (61% ) , followed by 
the t reatm ent  of other chronic diseases (40% ) , m inor ailm ents (33% ) , and 
kidney diseases (30% ) . I llnesses, including chronic disease, kidney disease, 
m inor ailm ents and leg oedem a, were the m ain purposes for  using herbs (92% , 
n= 171) , whist  m ost  dietary supplem ents were used for well-being (40% , n= 74) , 
see Table 8.8. Herbs used for  kidney stones (n= 2)  and diuret ic effect  ( n= 1)  were 
categorised as being taken to t reat  kidney diseases, and others were used for  
CKD (n= 46) . Chronic diseases t reated with herbs included diabetes, 
hypertension, dyslipidaem ia, cardiovascular diseases, gout , allergy, thyroid, and 
cancer. However, nine cases of HDS use reported using HDS for chronic disease, 
but  the diseases were not  specified. Minor ailm ents t reated with herbs included 
gast rointest inal sym ptom s (such as dyspepsia, flatulence, const ipat ion) , fever,  
com m on cold, pain, m igraine and haem orrhoids. I n Thai culture, m aintaining 
well-being was reported using various phrases, such as body detoxificat ion, 
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relieving fat igue or anxiety, increasing appet ite, m aintaining or balancing their 
body funct ion and having a good night ’s sleep.  
Table 8.8 Medical purposes of HDS use (n= 189) *  
 Frequency* *  Percent Missing data 
Purposes of herbal use   3 
   Chronic disease 64 34.4  
   Minor ailment  56 30.1  
   Kidney disease 49 26.3  
   Well-being 42 22.6  
   Leg oedema 2 1.1  
   Unknown 1 0.5  
Purposes of DS use   5 
   Well-being 74 40.2  
   Chronic disease 12 6.5  
   Supplement 8 4.3  
   Kidney disease 7 3.8  
   Minor ailment  6 3.3  
*  Respondent  reported using more than one herbal medicine and/ or dietary supplements  
* *  Respondents reported using more than one medical purpose per product  
Percent  was calculated using an absolute number of respondents, which was not  included a 
number of m issing data. 
8 .2 .4  Reasons for  and influences on herbal and dietary 
supplem ent  usage 
Most  frequent ly reported reasons for HDS use in the survey were fam ily or 
fr iends’ recom m endat ions, followed by the expectat ion of gaining benefit s from  
using HDS and a willingness to t ry HDS, see Table 8.9. This was sim ilar to the 
findings from  the qualitat ive study. Meanwhile, the safety of HDS and 
experiences of adverse effects of CM in the survey were reported by 5%  of 
respondents. The qualitat ive study supported this finding from  the survey, that  
pat ients who were concerned about  side effects from  using HDS were m ore likely 
to use them  with caut ion, such as taking lower doses than recom m ended, see 
Table 8.9.  
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Table 8.9 Reasons for  HDS use from  both quant itat ive (n= 189)  and qualitat ive 
(n= 16)  studies 
Quant itat ive results Qualitat ive results 
Quest ion Frequency (% )  
Reasons why HDS used*   
   Fam ily/ fr iend’s recommendat ion 111 (58.7)  I nfluenced by their social network 
who were health care professionals 
or teachers (n= 9) 
   HDS will work 71 (37.6) Percept ion of their  benefits (n= 11)  
x Health care needs (n= 7)   
x Willing to t ry (n= 4)  
x I ntent ion to use (n= 2) 
   Willing to try anything that  helps 61 (32.3) 
   Prefer to use HDS 34 (18.0) 
   Health care provider ’s  
      recommendat ion 
21 (11.1) No ment ion 
   Safer than CM 9 (4.8) Percept ion of their  safety (n= 5)  
x Their  character ist ics 
x No or lit t le side effects 
x Safer than CM 
Concerns about  side effects of HDS 
(n= 3)  
x Pat ients used HDS with caut ion 
   Easy access 5 (  2.6) No ment ion 
   Recommended by t radit ional 
   pract it ioners or HDS sellers  
2 (1.1) Their  fam ily recommended and then 
consulted Chinese herbal medicine 
pract it ioners (n= 1)   
   Exper ienced adverse effects 
   from convent ional medicines 
2 (1.1) Had exper iences or concerns about 
adverse effects of CM (n= 2) 
   Recommended by fellow 
   pat ients  
1 (0.5) I nfluenced by their social network 
(n= 9)  
*  Respondents reported more than one reason, so these total more than 189  
Most  respondents who part icipated in the qualitat ive study were fem ale and 
living in rural areas, see Table 8.10.  
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Table 8.10 Dem ographic characterist ics of respondents in the qualitat ive study 
(n= 16)  
Demographics Frequency (% ) 
Respondents from each hospital  
   CU hospital 11 (68.8) 
   SWU hospital 5 (31.2) 
Mean age and SD 62.5 +  12.3 years 
Sex  
   Male 6 (37.5) 
   Female 10 (62.5) 
Current  address  
   Bangkok 6 (37.5) 
   Rural areas 10 (62.5) 
Educat ion  
   Pr imary or secondary school 8 (50.0) 
   Higher educat ion 8 (50.0) 
 
The m ost  frequent ly reported inform at ion sources of HDS in the survey were 
fam ily and fr iends, and the m edia, e.g. t elevision, radio, internet , books and 
leaflets, see Table 8.11. These seem ed to influence decision-m aking regarding 
respondents using HDS. These findings were supported by the qualitat ive study. 
The five them es given as reasons for HDS use were:  1)  health care need, 2)  
percept ion of benefit s and 3)  safety of HDS, 4)  willingness to t ry HDS and 5)  
side effects of CM, see Figure 8.1. Addit ionally, two further them es, 
recom m endat ions via a respondent ’s social network and from  the m edia, were 
also reported as influencing their HDS use. This figure also shows the links 
between the them es. 
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Figure 8.1 Them es from  the qualitat ive study with 16 respondents about  their 
reasons for using HDS 
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Table 8.11 Reported inform at ion sources about  HDS and how they obtain HDS 
(n= 189)  
 Frequency*  Percent Missing data 
I nformat ion sources   1 
   Fam ily and fr iends 115 61.2  
   TV 20 10.6  
   Radio 18 9.6  
   I nternet 12 6.4  
   Health care providers 12 6.4  
   Books 11 5.9  
   Tradit ional pract it ioners 8 4.3  
   HDS companies 7 3.7  
   Leaflets from HDS companies 7 3.7  
   Own knowledge of HDS 7 3.7  
   Other pat ients with CKD 2 1.1  
   Scient if ic evidence 2 1.1  
   Newspapers 1 0.5  
HDS sources    -  
   Bought  in* *   128 67.7  
         Pharmacies, herbal or 
            Dietary supplement  shops  
56 43.8  
         Direct sale companies 41 32.0  
         Markets or stores 25 19.5  
         Hospitals 11 8.6  
         A temple 1 0.8  
         Bought  from abroad 1 0.8  
   Provided by fam ily and fr iends 54 28.6  
   Collected from own garden 19 10.1  
*  Respondents reported more than one source, so these total more than 189 
* *  Respondents reported more than one place they bought  HDS, so these total more than 128 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
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8 .2 .4 .1  The influence of fam ily and fr iends’ 
recom m endat ions 
I n the survey, fam ily or fr iends were reported as im portant  factors influencing 
HDS use (59% ) , see Table 8.9. I t  would appear that  they provided not  only HDS 
inform at ion (61% ) , but  also HDS products (29% ) , see Table 8.11. This finding 
was consistent  with the qualitat ive results, where fam ily and fr iends were 
reported as providing inform at ion about  the benefit s and safet y of HDS. 
Addit ionally, interviewees were willing to t ry HDS recom m ended by their fr iends, 
fam ily m em bers or fellow pat ients who experienced the benefit s and safety of 
HDS, see Figure 8.1. I t  would appear that  fr iends or fam ily m em bers who had 
posit ive at t itudes towards HDS influenced respondents to use HDS. Respondents 
also seem ed to respect  their educated fam ily m em bers, fr iends or 
acquaintances, such as doctors, nurses, and teachers.  
My younger brother confirmed that  it  is good and cleans the blood vessels so blood 
circulat ion is improved. He said “You should take it ”   “ I t  is no harm” . (R4, f age 56) 
 
He [ my older brother who has a wife working as a nurse and whose brother- in- law is a 
doctor]  said “You should eat  these herbs, which are good” . (R13, m age 70) 
8 .2 .4 .2  Desire to gain benefit  from  HDS 
The second m ost  frequent  reason for  HDS use was that ,  according to t he survey, 
respondents expected to gain benefit  from  HDS (38% ) . This result  was sim ilar to 
respondents’ health care needs, as reported in the qualitat ive study, and was 
related to their percept ion of HDS benefit s, see Figure 8.1. This seem ed to 
st rongly influence HDS use in pat ients with CKD. I t  appears that  som e 
respondents felt  hopeless and wanted to use any therapy which m ight  help 
them . Som e used HDS because they hoped to m aintain their health in order to 
be able to live their norm al daily life, such as being able to walk and cook. 
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Although others perceived that  CM was m ore effect ive than HDS, they wanted to 
use HDS. Thus, they concurrent ly used HDS and CM. 
I ’m  afraid of receiving dialysis... I  want  to use everything, which helps me to avoid receiving 
dialysis. (R8, m age 67)  
 
Convent ional medicines are more effect ive than any herb. Herbs supplement  convent ional 
medicines. (R12, m age 75) 
However, one respondent  did not  expect  t o gain any benefit  from  t rying HDS, 
when she used them  the first  t im e. She m erely wanted to t ry HDS due to being 
desperate to t ry anything that  m ight  work. 
8 .2 .4 .3  W illingness to t ry HDS 
Nearly one third of the reasons given for  HDS use were reported as willingness 
to t ry HDS in the survey. This was sim ilar to the qualitat ive results. The 
qualitat ive study found that  HDS users were m ainly influenced by their social 
network and the m edia, see Figure 8.1. Som e respondents perceived that  HDS 
did no harm , so they were willing to t ry HDS. Som e act ively sought  HDS 
inform at ion, part icularly about  their benefit s, and decided to use HDS by 
them selves.  
I  have to learn about  herbal informat ion by myself and know about  them from my 
colleagues’ or  fr iends’ exper ience of using herbs... I  have to think whether or not  herbs suit  
me and decide to use them by myself. (R11, f age 44) 
Respondents reported experim ent ing with HDS and m onitoring their effects. 
Where they not iced posit ive effects from  using HDS, they would cont inue using 
them  and, if no im provem ent , they would stop using them .  
I  wanted to try them. After t ry ing them, they were good. Thus, I  cont inue to use them. (R1, 
f age 59)  
 
However, one respondent  did not  want  to t ry HDS, but  he felt  he needed to use 
everything which m ight  help him  avoid dialysis;  as a result , he used it .  
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8 .2 .4 .4  Percept ion of the safety of HDS 
Although 5%  of the reasons for using HDS were reported as HDS being safer 
than CM in the survey, the qualitat ive study found respondents perceived HDS 
as safe:  in part icular, the absence of negat ive effects of HDS, or having lit t le 
concern about  adverse effects result ing from  HDS as com pared with CM. HDS 
were perceived by respondents as part  of t heir diet  or natural. Addit ionally, 
respondents were influenced by their social network and the m edia, which 
tended to provide inform at ion about  posit ive effect s of HDS, rather than their 
adverse effects.  
I  don’t  see their negat ive effects. (R12, m  age 75)  
 
... herbs are natural and not chem icals. I  think herbs are less accumulated in my body, 
compared to convent ional medicines. (R5, m age 43) 
The qualitat ive study found that  som e respondents were concerned, or sm all 
num bers of them , had received warnings about  renal adverse effects of HDS 
from  their social network, the m edia or their doctor and this m ay explain why 
warning inform at ion was rarely given as an answer. As a result , they tended to 
use HDS with caut ion and would consult  with their health care providers.    
I f I  take too many herbs, I ’m afraid of worsening liver and kidney funct ion. (R7, m age 67)  
 
...my fr iend said you should not  eat  “Hem”  [ Coscinium fenest ratum]  too much because 
another person who used it  died, and had his body cut  open and they found his stomach 
was dark yellow. Thus, I  don’t  want  to eat  it  at  all. (R12, m age 75) 
 
You know, there is marked lack of warning about taking herbs. (R11, f age 44)  
I t  would seem  that  the posit ive percept ion of HDS benefit s m ay not  have the 
sam e at t itude as the safety of HDS. Although the m ajorit y of HDS users had 
posit ive at t itudes towards benefits of HDS, it  does not  m ean that  they thought  
that  HDS are safe.  
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8 .2 .4 .5  Experiences w ith side effects from  using CM 
A few respondents reported experiences of adverse effect s from  using CM, as a 
reason for  HDS use in the survey. This was supported by the qualitat ive study, in 
which som e reported using HDS due to dissat isfact ion with CM, or because they 
had negat ive at t itudes towards CM.  
I  had lots of side effects from convent ional medicines, so I  turned my thoughts to herbal use 
and used it . (R5, m age 43) 
 
I ’m  afraid of worsening kidney funct ion. I f I  take lots of prescr ibed medicines, whether they 
will affect  kidneys or not? (R9, f age 46) 
8 .2 .4 .6  The m edia influence on HDS use 
The m edia, that  is television, radio, internet , books, leaflets, newspapers and 
m edical j ournals, were the second m ost  frequent ly reported source of HDS 
inform at ion (38% )  in the survey. From  the qualitat ive study part icipants 
reported the m edia dissem inat ing inform at ion about  the benefit s of HDS use, 
rather than the adverse effects. Addit ionally, HDS com panies advert ised benefit s 
and safety of their products via the m edia by indicat ing that  “ the product  is 
approved by the Thai FDA” .  
I  wonder whether I  should t ry it  or not  because I  listened on the radio and they said “ I t  was 
good”  .Thus, I  t r ied it . They also said “ I t  is to treat  kidney disease” . (R3, f age 67)  
 
... a herbal company advert ises on television that  the product  is approved by the Thai FDA 
for dietary supplement ... A herbal company advert ises “This herb is the best  sale product ”  
“ I t  is useful”  “You would not  be disappointed” . (R13, m age 70) 
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8 .2 .4 .7  HDS pract it ioners and health care providers 
influence on HDS use 
From  the survey, it  would seem  that  herbal pract it ioners in Thailand have a 
m inor im pact  on respondents’ decision-m aking regarding whether or  not  to use 
HDS am ongst  pat ients with CKD. Only one respondent  reported that  he used 
HDS recom m ended by a t radit ional pract it ioner,  and only 4%  of inform at ion 
about  HDS was provided by such pract it ioners ( see Tables 8.11) . This is 
consistent  with the sm all num ber of respondents report ing that  it  was health 
care providers who recom m ended HDS use (11% )  or provided HDS inform at ion 
(6% ) . The qualitat ive study suggests that  whilst  pat ients are largely influenced 
by non-health care professionals, som e did consult  them  before using HDS.  
8 .2 .4 .8  Availability of HDS 
Easy access to HDS was reported by fewer than 5%  as a reason for using HDS in 
the survey. Respondents reported that  m ost  HDS products were bought  from  
pharm acies, or herbal or dietary supplem ent  shops (44% ) , see Table 8.11. 
Thirty percent  of HDS products were direct ly bought  from  their com panies, which 
advert ised their products on satellite television or radio, and respondents bought  
them  by telephoning the com pany. Som e respondents reported that  the HDS 
com pany salesm an visited their house in order t o advert ise and sell their 
products. One respondent  reported obtaining their HDS at  a t em ple in Thailand. 
Som e priests are herbal pract it ioners and will provide herbal products for people 
consult ing them . 
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8 .2 .5  Types of HDS used  
Am ongst  304 different  reports of HDS being used, 199 herbal m edicines (see 
Table 8.12)  and 105 dietary supplem ents used (see Table 8.13) , 58 different  
herbal products and 18 dietary supplem ent  products were ident ified. Herbal 
products used (n= 58)  were as either a single herb (n= 38)  or a herbal 
com binat ion (n= 20) , including Thai herbal com binat ions (n= 15) , Chinese herbal 
com binat ions (n= 4) , and a m ixed botanical ext ract  (n= 1) . However, for 51 
(17% )  of the HDS products reported, the ingredients were unknown as 
respondents did not  either know or rem em ber their details. This group com prised 
of six Chinese herbs, nine Thai herbal com binat ions, 23 single Thai herbs and 13 
dietary supplem ent  products. Kariyat  (12% ) , turm eric (10% )  and horse radish 
t ree (8% )  were the three m ost  frequent ly reported herbs used, see Table 8.12.  
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Table 8.12 Types of herbs used, their purpose and adverse effects reported by respondents ( t otal num ber of herbal m edicines 
used= 199)*  
Types of herb used Frequency (% )  Main purpose as reported by respondents Adverse effects reported by respondents 
Kariyat  (Andrographis paniculata)  23 (11.6)  Com mon cold, fever,  sore throat , diabetes I ncreased SCr 
Turmeric (Curcuma longa)  19 (9.5)  Gast rointest inal symptoms* * ,  const ipat ion,  CKD -  
Horse radish t ree (Moringa oleifera)  16 (8.0)  Diabetes,  hypertension,  const ipat ion Unable t o stop bleeding 
Mixed botanical ext ract  or  fru it  dr ink 12 (6.0)  CKD, diabetes, well- being -  
Ginseng (Panax spp. )  7 (3.5)  Well-being -  
Holy mushroom (Garnoderma lucidum )  5 (2.5)  CKD Oedema 
River spiderwort  (Tradescant ia flum inensis)  4 (2.0)  CKD Increased SCr, fat igue 
Babbler ’s Bill Leaf (Thunbergia laur ifolia)  3 (1.5)  Detoxif icat ion,  diabetes -  
Senna (Senna alexandrina)  3 (1.5)  Const ipat ion -  
Ginkgo (Ginkgo biloba)  3 (1.5)  Im proved brain funct ion -  
Boesenbergia (Boesenbergia rotunda)  3 (1.5)  CKD -  
Garlic 3 (1.5)  Dyslipidaem ia -  
Mixed Thai t radit ional herbs called ‘Ya Hom’ 3 (1.5)  Well-being, faint ing,  dizziness -  
Heart - leaved moonseed (Tinospora cr ipa)  3 (1.5)  Diabetes,well- being -  
Coix seed (Semen Coicis)  3 (1.5)  CKD, well-being,  diabetes -  
Vap Ca (Hout tuynia cordata)  2 (1.0)  Kidney stones, CKD -  
Aloe (Aloe vera)  2 (1.0)  Diuret ic effect s, well- being -  
Blue Pea (Clitor ia ternatea)  2 (1.0)  CKD -  
Mixed 3 or  6 t ypes of mushrooms 2 (1.0)  CKD -  
Shiitake mushroom  (Lent inus edodes)  2 (1.0)  CKD, well-being -  
Cinnam on (Cinnamomum verum )  2 (1.0)  Diabetes -  
*    Respondents reported using m ore than one type of herb;  * *  Flatulance, dyspepsia and pept ic ulcers;  SCr =  Serum creat in ine  
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Table 8.12 (cont inued)  
Types of herb used Frequency (% )  Main purpose as reported by 
respondents 
Adverse effects reported by 
respondents 
Mixed Thai tradit ional herbs called ‘Ya Khom’ 2 (1.0) Fever -  
Mixed Thai tradit ional herbs called ‘Ka Sai’ 2 (1.0) Const ipat ion, well-being -  
Jujube (Zizyphus maurit iana)  and Roselle (Hibiscus sabdar iffa)  2 (1.0) CKD, dyslipidaem ia -  
Spirulina 2 (1.0) Detoxificat ion, diabetes -  
Lemongrass 1 (0.5) Dyslipidaem ia and CKD -  
Boesenbergia, sweet basil, honey and lime juice 1 (0.5) CKD Faint ing 
Boesenbergia, m int , ginger, galangal, lemongrass, kaffir lime leaves and shallots 1 (0.5) CKD -  
Spr ing bit ter cucumber (Momordica cochinchinensis)  1 (0.5) CKD -  
Chinese folk remedy -  Cordyceps, Lovage (Angelica sinensis) , deer ant ler velvet , 
cinnamon and Schisandra berry (Schisandra chinensis)  
1 (0.5) CKD -  
Lime 1 (0.5) Kidney stones -  
Chinese folk remedy -  Cordyceps, Lovage (Angelica sinensis) , deer ant ler velvet , 
cinnamon and Schisandra berry (Schisandra chinensis)  
1 (0.5) CKD -  
Paragrass roots (Brachiar ia mut ica)  and pomegranate leaves (Punica granatum )  1 (0.5) CKD -  
Leaves of Clerodendrum petasites 1 (0.5) CKD -  
Java tea 1 (0.5) Diuret ic effects -  
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Respondents reported a variety of uses for herbs:  kariyat  was used for com m on 
colds, including fever,  sore throats, and diabetes;  turm eric was used for 
flatulence, dyspepsia, pept ic ulcer and const ipat ion;  horse radish t ree was to 
t reat  diabetes, hypertension and to alleviate const ipat ion. 
Vitam ins and m inerals were com m on types of dietary supplem ents (DS)  reported 
(16% , n= 17) , of which vitam in C (n= 6)  and calcium  supplem ent  (n= 4)  were the 
m ost  com m only reported (see Table 8.13) , followed by essence of chicken drink 
(13% , n= 14)  and germ  oil (12% , n= 13) . All of these were used for m aintaining 
well-being.  
The thirty-one different  types of herbs and seven different  DS used were 
reported once, see Appendix 14.  
 
Chapter 8:  The prevalence, pat terns and reasons for HDS use 
160 
Table 8.13 Types of dietary supplem ents used, their purpose and adverse effects reported by respondents ( t otal num ber of DS 
used= 105)*  
Types of dietary supplement  used Frequency (% ) Purposes reported by respondents Adverse effects reported by respondents 
Vitam ins and m inerals 17 (16.2) Well-being Weight  gain 
Essence of chicken dr ink 14 (13.3) Well-being I ncreased blood sugar 
Germ oil 13 (12.4) Well-being -  
Rice Bran oil 9 (8.6) Well-being, CKD, diabetes -  
Fish oil 8 (7.6) Well-being, cardiovascular diseases -  
Protein 7 (6.7) Well-being Proteinur ia 
Chlorophyll 6 (5.7) Well-being, CKD, diabetes, hypertension -  
Swift let ’s nest  dr ink 5 (4.8) Well-being -  
Bee pollen 2 (1.9) Well-being -  
Wheatgrass 2 (1.9) Well-being I ncreased SCr 
Fibre 2 (1.9) Const ipat ion -  
Coconut  oil 1 (0.9) Well-being Diarrhoea 
*   Respondents reported more than one type of dietary supplement  used;  SCr =  Serum creat inine 
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8 .2 .6  Percept ion of beneficia l and det r im ental effects from  
HDS reported by respondents  
The percept ion of benefit s from  using HDS, based on data from  both the survey 
and the qualitat ive study are presented. 
Benefit s from  HDS were reported for around three quarters of the HDS used, see 
Table 8.14. The m ost  frequent ly reported types of perceived benefit s were the 
alleviat ion of m inor ailm ents, followed by enhanced well- being and slowed 
progression of CKD. In t he qualitat ive study, som e respondents reported benefit s 
to kidney funct ion based on their laboratory results and som e reported increased 
urine output  as a benefit . I t  appears that  they perceived benefit s based on 
m edical evidence. Som e reported that  the efficacy of HDS is superior t o 
convent ional m edicat ion.  
My creat inine level wasn’t  increased. Now, I  don’t  take it  [ herbal medicine] ;  my creat inine 
level increased, which is 1.6. (R14, f age 51)   
 
 ... they are more effect ive than convent ional medicat ions. (R6, f age 57) 
The survey found that  71%  of respondents who perceived benefit s from  HDS 
cont inued using HDS. Am ongst  those report ing “don’t  know about  HDS benefit s”  
(n= 31) , see Table 8.14, six respondents seem ed to hope that  HDS m ight  provide 
benefit s in the future, despite not  experiencing any at  the m om ent . Another 
reason offered by the rem aining respondents was that  they concurrent ly took 
both HDS and convent ional m edicat ion so they could not  ident ify effects 
result ing from  either HDS or CM. 
Because I ’ve taken the dietary supplement  and prescr ibed medicines together, I  don’t  know 
which one gives the benefit . (R14, f age 51)  
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Table 8.14 Benefit  and adverse effect s reported by pat ients from  their HDS use 
(n= 189)  
 Frequency Percent Missing data 
Benefit  exper ienced from HDS usea   2 
   Yes 147 78.6  
   No 15 8.0  
   Just  started using HDS and not  
      sufficient  t ime to gain benefits 
7 3.7  
   Don’t  know 31 16.6  
Types of benefit  (n=  147) b   -  
   Alleviated m inor ailments 54 36.7  
   Enhanced well-being 45 30.6  
   Slowed the progression of CKD 15 10.2  
   Treatment  of chronic disease  
      (unspecified)  
13 8.8  
   Reduced blood sugar  12 8.2  
   Desired diuret ic effect 10 6.8  
   Reduced blood pressure 5 3.4  
   I ncreased appet ite 4 2.7  
   Reduced serum lipid levels 2 1.4  
Adverse effects exper ienced from HDS use    -  
   Yes 19 10.0  
   No 169 89.5  
   Don’t  know 1 0.5  
Type of adverse effect (n= 19)    -  
   Progression of CKD 7 36.9  
   Gast rointest inal symptomsc 3 15.7  
   Neurological symptomsd 3 15.7  
   Oedema 2 10.5  
   Raised blood sugar 1 5.3  
   Rash 1 5.3  
   Weight  gain 1 5.3  
   Unable to stop bleeding 1 5.3  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data.     
a
  Respondents reported more than one benefit , so these total more than 189 
b
  Respondents reported more than one type of benefit , so these total more than 147    
c
  abdom inal pain, diarrhoea or vom it ing 
d
  dizziness, faint ing, or fat igue  
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From  the survey, the m ain benefit s from  HDS use were reported as alleviat ion of 
m inor ailm ents (n= 54, 37% ) , such as const ipat ion (24% , n= 13) , 
m usculoskeletal pain (18.5% , n= 10)  and flatulence (14.8% , n= 8) . Respondents 
reported using several different  types of HDS for const ipat ion, m any of which 
contain fibre;  for exam ple, senna, turm eric, horse radish t ree, Thai folk rem edies 
‘Tri pala’ and ‘Ka sai’, dietary supplem ents containing fibre and a m ixed fruit  
drink. Of ten products used to alleviate m usculoskeletal pain, five were Thai 
(n= 4)  or Chinese (n= 1)  folk rem edies where the ingredients were unknown;  
others were Boesenbergia, a m ixture of 23 botanical ext ract s, a m ixed fruit  
drink, a calcium  supplem ent , and a Chinese herbal com binat ion -  holy 
m ushroom , Cordyceps, ginseng and Chinese Wolfberry. Am ongst  the eight  HDS 
products used for flatulence, turm eric was the m ost  frequent ly reported act ive 
ingredient  (n= 5) .  
The effect  of their HDS use on the progression of their  CKD was reported, with 
around 10%  (n= 15)  of respondents report ing that  their CKD progress had 
slowed. Of these four were using herbs with unknown ingredients ( see Table 
8.14) . There were nine different  HDS reported to provide this benefit :  Holy 
m ushroom s (n= 3) , a herbal com binat ion – Boesenbergia, m int , ginger, galangal, 
lem ongrass, kaffir  lime leaves and shallots (n= 1) , a herbal com binat ion -  
Boesenbergia, onion, galangal, lem ongrass, kaffir  lim e leaves, lim e leaves and 
m int  (n= 1) , turm eric (n= 1) , Spring bit ter cucum ber (n= 1) , a Chinese folk 
rem edy -  Cordyceps, Angelica sinensis, Chinese Wolfberry, Ast ragalus 
(Ast ragalus m em branaceus) ,  Eucom m ia ulm oides,  Codonopsis pilosula and deer 
ant ler velvet  (n= 1) , Jujube, Roselle, Boesenbergia and m ixed 3 types of 
m ushroom s (n= 1) , spirulina (n= 1)  and m angosteen peel j uice (n= 1) . 
Ten percent  of respondents (n= 19)  reported problem s with HDS use, of which 
the progression of CKD was the m ost  frequent ly reported adverse effect  (37% , 
n= 7) , see Table 8.14. Types of HDS and pat ients’ reports of their adverse effects 
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are shown in Tables 8.12 and 8.13. Kariyat , r iver spiderwort , a protein product ,  
and wheatgrass were reported as being related to worsening CKD. However, 
eight  adverse effects were reported, i.e.  increased serum  creat inine (n= 3) , leg 
oedem a, stom ach ache, vom it ing, rash and dizziness, were all related to HDS 
with unknown ingredients.  
8 .2 .7  Disclosure of HDS use to doctors 
The survey presented the rate of non-disclosure of HDS use to their doctor and 
the reasons why HDS users did not  inform  them . Som e respondents in the 
qualitat ive study provided reasons for the non-disclosure and disclosure of HDS 
use to their doctor.  
Most  respondents reported that  they did not  inform  their doctor about  HDS use 
(72% , n= 145) , and alm ost  half reported that  this was because their doctors did 
not  ask them  (49% , n= 66) , see Table 8.15. A num ber of the reasons given 
seem ed to reflect  respondents preferr ing not  to discuss HDS use with their 
doctor (31% , n= 42) . They worried that  their doctor would disapprove of HDS 
use, did not  see a need to inform  their doctor about  HDS use, or did not  want  to 
tell their doctor.  These reasons were supported by som e part icipants in the 
qualitat ive research. One respondent  did not  want  to tell their doctor about  HDS 
use, although the doctor asked, as the pat ient  was worried about  a negat ive 
response from  their doctor.  
He [ their  doctor]  doesn’t  ask and these herbs are vegetables. (R16, f age 73) 
 
Even though my doctor asks me about  using herbs, I ’m  afraid of telling him ... I ’m  afraid 
that  he may blame me [ for any deter iorat ion in my condit ion]  (R8, m  age 67)  
There was a stat ist ically significant  difference in non-disclosure of HDS use 
between two set t ings (ǒ2 = 14.37, p <  0.01) , see Table 8.16. There was a 
difference in health care service between the CU and SWU hospitals. I n the CU 
kidney clinic, CKD pat ients were taken care of by m em bers of a health care 
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team , i.e.  doctors, pharm acists and diet it ians, whilst  the pat ients in the SWU 
hospital were m ainly serviced by a doctor.  The CU hospital (approxim ately 10 
nephrologists)  had a higher num ber of nephrologists than the SWU hospital 
(approxim ately 5) . Respondents who at tended the SWU hospital were less likely 
to disclose their HDS use, com pared with those who at tended the CU hospital. At  
the SWU hospital, 75 pat ients (55% )  did not  inform  their doctor,  com pared with 
61 pat ients (45% )  at  the CU hospital.  
Table 8.15 Inform ed doctors about  using HDS and reasons (n= 189)  
 Frequency Percent Missing data 
Whether HDS users informed their  doctor 
about  their HDS use   
  -  
   Yes 53 28.0  
   No 136 72.0  
Reasons for not report ing about  HDS use to 
their  health care providers (n=  136)*  
  1 
   Health care providers don’t  ask 66 48.9  
   Pat ients worr ied that  their  doctor 
      will disapprove of HDS use 
22 16.3  
   Short - term or occasional use 19 14.1  
   No need to inform their 
      pract it ioner  
18 13.3  
   Didn’t  see their doctor dur ing the 
      per iod of HDS use 
8 5.9  
   Just  started using HDS and no 
      opportunity 
4 3.0  
   Stopping or planning to stop 
      using HDS 
3 2.2  
   Don’t  want to tell them 2 1.5  
   HDS are safe 1 0.7  
   Doesn’t  influence their disease (s)  1 0.7  
*  Respondents reported more than one reason 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
Table 8.16 Associat ion of disclosure of HDS use am ongst  both set t ings 
 Don’t  inform  
(n= 136) 
I nform  (n= 53) X2 p-value 
CU hospital 61 (44.8% ) 40 (75.5% ) <  0.01*  
SWU hospital 75 (55.2% ) 13 (24.5% )  
     *  Stat ist ically significant  at p <  0.05 
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With respect  t o the reasons for the disclosure of HDS use to their doctor in the 
qualitat ive study, one respondent  had had a posit ive experience with their doctor 
who had explained whether or  not  the HDS could be used and why. I t  appears 
that  a respondent  discloses their HDS use to their doctor when they are 
confident  that  their doctor would not  disapprove of their use.  
After that  [ using HDS]  my doctor said “My creat inine level was reduced” .  I  was glad and 
asked my doctor can I  take these herbs? He said “They are fine”  and told me “ I f you want  to 
take any herbal and dietary supplements ..., you should tell me before taking them”  ... I ’ll 
not  take herbs that my doctor tells me “ I  should not  take because they will worsen your 
kidney funct ion”  (R6, f age 57)  
8 .2 .8  Reasons for  not  using HDS 
Am ongst  the non-HDS users (n= 232) , 87%  reported that  they were not  planning 
to use HDS in next  12 m onths (n= 202)  and gave their reasons (see Table 8.17) . 
I t  would seem  that  non-users’ reasons reflected not  only their posit ive at t itudes 
towards convent ional medicines (59% ) , but  also their negat ive at t itudes towards 
HDS (25% ) . The form er at t itudes were that  respondents t rusted their doctor 
(n= 24)  or  t rusted/ needed to use convent ional m edicines (n= 47) , followed by 
their doctor ’s recom m endat ion (n= 43)  and those CM users perceived that  the 
benefit s of convent ional m edicines were superior  to HDS (n= 5) . The lat ter  
at t itudes were that  respondents worried about  harm  from  HDS (n= 29) , doubts 
about  benefit s from  using HDS (n= 12) , and that  they had previously t r ied HDS 
but  had not  gained any benefit  (n= 6) , or had suffered from  harm  (n= 2) . 
However, 27 (12% )  respondents were not  able to decide whether they will use 
HDS or not .  Three respondents (1% )  are planning to start  using HDS because 
they either expect  t o gain benefit s from  HDS or can obtain HDS from  their 
fam ily. 
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Table 8.17 Reasons given for not  planning to use HDS (n= 202) a 
Reasons Frequency Percent 
x Pat ients t rusted their  doctor or trusted/ needed to use 
convent ional medicines  
71 35.1 
x Health care providersb advised that  the pat ient  should not 
use HDS  
44 21.8 
x Concerns about harm from HDSc 29 14.3 
x Don’t  want  to use HDS 16 7.9 
x Doubt about  benefits of HDS 12 5.9 
x Taking a high number of convent ional medicines  11 5.4 
x Don’t  know enough informat ion about  HDSd 9 4.5 
x Had renal insufficiency, so pat ients concerned about harm 
from HDS 
7 3.5 
x Previously tr ied and exper ienced no benefits from HDS 6 3.0 
x Benefits of convent ional medicines are super ior to HDS 5 2.5 
x Pat ient ’s relat ives recommended that  they should not  use 
HDS 
5 2.5 
x HDS are expensive 4 2.0 
x They perceived that  they are well 3 1.5 
x HDS are not  available in their area 2 1.0 
x Previously exper ienced a decrease in renal funct ion or other 
adverse effect  from  HDS 
2 1.0 
x Had many chronic diseases, so pat ients concerned about  
harm  from HDS 
2 1.0 
x A book about  k idney diseases indicated that  CKD pat ients 
should not use HDS 
1 0.5 
x A pat ient  need not  use HDS if (s)he adheres to medicat ion 
and dietary recommendat ions for CKD pat ients 
1 0.5 
a
 Respondents reported more than one reason;  b Doctors or Pharmacists 
c
 Adverse effects of HDS, contam inated HDS, or HDS-convent ional medicine interact ions 
d
 I ndicat ions, doses, benefits, or r isks of HDS  
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8 .3  Discussion 
8 .3 .1  Key findings 
The prevalence of HDS use am ongst  CKD pat ients in Thailand was 45%  (95% CI  
40% -50% ) . There is no clear pat tern of HDS usage with only a m edium  level of 
adherence to convent ional m edicines and being a form er alcohol consum er 
associated with HDS use. Herbal products used to t reat  illnesses were m ore 
frequent ly reported than dietary supplem ents, which were m ore frequent ly used 
for  well-being. The m ajority of respondents did not  disclose using HDS to their 
doctor;  the m ost  frequent ly reported reason being that  their doctor did not  ask 
them  about  their HDS use. Kariyat , turm eric, horse radish t ree, vitam ins and 
m inerals were the m ost  com m only reported HDS. Most  respondents reported 
gaining benefit  from  HDS, whilst  one- tenth reported adverse effect s. From  the 
survey and the qualitat ive study, the m ain reason why HDS were used by 
pat ients with CKD was an expectat ion of beneficial effects of HDS;  an 
expectat ion which was influenced by respondents’ social network and the m edia. 
Thus, they were willing to t ry HDS and when they did, if they perceived benefit s, 
they would cont inue using them . 
8 .3 .2  Com parison of the prevalence of HDS use betw een 
pat ients w ith CKD and the general populat ion 
After com paring dem ographics between the populat ion in this survey and the 
Thai general populat ion, there were no differences regarding sex, educat ion 
levels, living in urban or rural areas, sm oking and drinking status.260 However, 
respondents in the present  survey were older (m ean +  SD 66 +  13)  t han those 
in a study of the CKD pat ients in the Thai general populat ion (m ean +  SD 57 +  
15) .146 This m ay be because Ong-Ajyooth’s study screened people aged 15 or 
over, whilst  in pract ice younger people with asym ptom at ic CKD do not  seek a 
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diagnosis within the Thai Nat ional Health System . The m ean age in the present  
study, and in a survey of the prevalence of HDS use am ongst  pat ients with CKD 
in Canada, were sim ilar (HDS users 64 +  12;  non-users 60 +  15) .16 This m ay be 
because people who suffered from  CKD will go to see a doctor when they have 
sym ptom s, and such pat ients are m ore likely to be older. Therefore, it  would 
seem  that  there is no difference in age between these two count ries. This 
indicates that  the sam ple in the present  study is likely to represent  Thai pat ients 
with CKD. 
The prevalence of HDS use am ongst  Thai pat ients with CKD was 45% . This 
supports Spanner and Duncan’s survey (2005)  in Canada (45% ) , which studied 
the prevalence of dietary supplem ent  (DS)  use, including botanical ext racts in 
outpat ients with CKD.16 However, the researchers used a slight ly different  
definit ion of HDS use, i.e. current  daily intake. Although the prevalence in the 
current  study cannot  be direct ly com pared with previous surveys of HDS use in 
Thailand, due to the different  definit ions of HDS use and the different  
populat ions, the obtained prevalence is consistent  with a survey of HDS use in 
Thai pat ients with chronic diseases (45% ) .27 The prevalence am ongst  pat ients 
with advanced CKD, in the present  survey, was higher com pared with a Thai 
general populat ion survey (33% ) .5 However, the prevalence of HDS use am ongst  
pat ients with CKD (29% ) 15 was lower than the general populat ion (52 to 73% )  in 
the US.10,35  
8 .3 .3  Com parison of character ist ics betw een HDS users and 
non- users 
There were no differences in dem ographic characterist ics between HDS users 
and non-users regarding age, sex, sm oking status or  educat ion. This is 
consistent  with Spanner and Duncan’s survey (2005) , although the two surveys 
have different  ethnic dist r ibut ions in the populat ion.16 There was no associat ion 
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between the severity of CKD and HDS use. This differs from  Spanner and 
Duncan’s survey, which reported that  pat ients at  an early stage of CKD were 
m ore likely to use DS;  however, the survey did not  com pare the severity of CKD 
between Canadian HDS users and non-users. 
Although alm ost  all HDS users com bined HDS with their convent ional m edicines, 
there is a significant  associat ion between HDS use and adherence to 
convent ional m edicat ion. Respondents having a m edium  level of adherence to 
convent ional m edicat ion were less likely to use HDS, com pared with those with 
poor adherence (OR 0.53, 95% CI  0.32-0.87) . This result  is consistent  with 
Krousel-Wood et  al. (2010) 17 and Gohar et  al. ( 2008) 19 who conducted a study of 
pat ients with hypertension. The reason for t his associat ion, supported by the 
present  qualitat ive study, was due to the fact  that  som e HDS users had had 
experiences, or  concerns, regarding adverse effect s from  using convent ional 
m edicat ion, so they decreased their doses of convent ional m edicat ions or 
stopped using them . Rifkin et  al. found that  side effects of CM were a barrier t o 
adherence to CM in pat ients with CKD.261 Addit ionally, the current  qualitat ive 
study found that  four HDS users, who had negat ive at t itudes towards CM, had 
poor adherence to CM. However, the reasons why HDS users had poor  
adherence needs to be further invest igated before firm  conclusions can be m ade.  
I n cont rast , there was no relat ionship between HDS use and high adherence to 
convent ional m edicat ion in the current  survey. The present  qualitat ive study 
showed that  HDS users who reported that  they t rusted their doctor, and did not  
have concerns about  side effect s of CM, had a m oderate or high level of 
m edicat ion adherence. This is supported by a previous study, which also 
established the doctor-pat ient  relat ionship as an im portant  factor in adherence 
to convent ional m edicines.262 
Form er alcohol drinkers were less likely to use HDS. However, there is a lack of 
literature describing the associat ion between HDS use and drinking in pat ients 
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with chronic diseases. This finding in the present  survey cont rasts with the US 
nat ional surveys of com plem entary and alternat ive m edicine (CAM)  users 
am ongst  young adults in 2000, where it  was found form er drinkers were m ore 
likely to use CAM.28 This could be due to the differing ages of the populat ions. 
Further studies are required to exam ine this associat ion in pat ients with other 
chronic diseases, before firm  conclusion can be m ade. 
8 .3 .4  Pat terns and m edical purposes of HDS use in pat ients 
w ith CKD  
The m ajorit y of the respondents in this current  research reported using HDS 
daily and around one- fifth using them  long- term . This m ay raise concerns about  
interact ions between convent ional m edicat ion and HDS. Well-being was a 
frequent ly reported reason for using HDS in pat ients with CKD, part icularly DS 
use. This is consistent  with Spanner and Duncan’s survey16;  however, they did 
not  specify how m any of their pat ients used DS for CKD. The present  survey 
found that  the t reatm ent  of their CKD was not  a frequent ly reported reason for  
using HDS. This is sim ilar t o Yeh’s (2006)  research, which reported that  the m ain 
purposes of herbal use in pat ients with cardiovascular diseases were 
m usculoskeletal illnesses rather than their cardiovascular disease.58  
8 .3 .5  Percept ion of benefits and side effects from  using 
HDS 
Most  HDS users perceived that  they gained benefit  from  using HDS, whilst  10%  
reported adverse effect s. This is consistent  with Spanner and Duncan’s survey.16 
I t  would seem  that  HDS users are m ore interested in posit ive effects rather than 
negat ive effects.57 Furtherm ore, HDS users who perceived benefit s from  using 
HDS were m ore likely to cont inue using them . Nine different  HDS were reported 
to have im proved kidney funct ion, although there are lim ited clinical t r ials to 
dem onst rate their efficacy. Ast ragalus m em branaceus has been the only herb 
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which has been tested in clinical t r ials263,264 and which can slow the progression 
of diabet ic nephropathy and CKD. However,  these t r ials involved sm all num bers 
of people and were not  blinded. Ginger, onion, turm eric, cordyceps and 
Codonopsis pilosula have been t r ialled in anim al m odels to t est  potent ial for  
slowing the progression of either diabet ic nephropathy or CKD; 222,223,265-267 it  was 
found that  they had renoprotect ive effects via a decrease in lipid peroxidat ion 
(ginger and onion) 223,265, renal t r iglyceride accum ulat ion ( turm eric) 222,  and 
inhibit ion of the proinflam m atory cytokine TNF-Į UHOHDVH Codonopsis 
pilosula) .266 Although som e herbs have been reported as suitable for  CKD, 
supported by clinical t rials or anim al m odels, their m ain effect  is in slowing the 
progression of diabet ic nephropathy, which is only one cause of CKD. Therefore, 
their efficacy to t reat  CKD result ing from  other causes, such as 
glom erulonephrit is and hypertension, is unknown.  
Most  of the HDS, reported as being used to t reat  CKD, have no scient ific 
evidence in either hum an or anim al m odels to support  their  efficacy. 
Supplem ents include holy m ushroom s, boesenbergia, spring bit ter cucum ber, 
j ujube, roselle. Som e respondents used roselle for  t reat ing CKD;  however, this is 
a diuret ic and there is no evidence of any effect  on CKD.225 Health care providers 
need to ensure they provide factual inform at ion for  pat ients about  the lack of 
evidence of benefit s to t heir CKD, from  using som e HDS. 
Regarding renal adverse effects reported by respondents, proteinuria, which 
indicates worsening kidney funct ion, was reported as result ing from  using 
protein supplem ents. A high protein intake is related to a decrease in renal 
funct ion and this is likely to be why the protein supplem ents caused this adverse 
effect .268 River spiderwort , kariyat  and wheatgrass were reported by respondents 
to increase serum  creat inine. To date, there is no evidence in the literature to 
support  this reported effect . The Thai Nat ional List  of Essent ial Medicines (2011)  
suggests that , for pat ients with CKD, senna, j ava tea, roselle, Ya Hom  and Ka sai 
Chapter 8:  The prevalence, pat terns and reasons for HDS use 
173 
are not  recom m ended119;  however, the present  survey found som e pat ients 
reported using them . Addit ionally, turm eric, ginger and lem ongrass could 
potent ially harm  kidneys if the pat ients take them  at  high doses or long term . 
This is because they inhibit  cyclooxygenase-2, which increases blood pressure in 
glom erulus and leads to kidney injury269-272, although no pat ients reported this 
adverse effect  in the current  study. Both health care providers and pat ients with 
CKD should be aware of the benefit s and r isks of using HDS and report  any 
adverse effects t o the Health Product  Vigilance Center in Thailand, in order t o 
establish rigorous evidence. Further t r ials of the efficacy and safet y of HDS are 
required. 
8 .3 .6  Reasons for , and influences on HDS use  
From  both the survey and qualitat ive study, the m ost  frequent ly cited reason for  
HDS use in Thai pat ients with CKD was fam ily and fr iends’ recom m endat ions, 
followed by the desire to gain benefit  from  using HDS, a willingness to t ry HDS, 
safet y of HDS and experiences of adverse effects from  CM. Respondents’ social 
network and the m edia were m ost  frequent ly reported as an im portant  influence 
on their HDS use. 
Fam ily and fr iends influencing pat ients’ decision-m aking, regarding HDS use 
am ongst  Asian populat ions, is sim ilar to other studies of CAM use in pat ients 
with chronic diseases in Thailand, Malaysia, Japan and Turkey.14,50,51,54,57,61 This 
is also consistent  with CAM use am ongst  t he general populat ion in South 
Korea.45 Such behaviour could be a result  of the close knit  fam ily culture in Asian 
count ries. I n Western count ries, both pat ients with chronic illnesses and the 
general populat ion used HDS, as their health care providers suggested it .16,25,58 
This m ay be why high num bers of HDS users with CKD in Western count ries 
inform  their health care providers about  using HDS (55 to 67% ) .15,16  
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The second reason for  using HDS was that  HDS was perceived as support ing 
respondents’ health care needs, such as avoiding dialysis t reatm ent .  Such usage 
is because they felt  hopeless, used HDS as a last  resort , and expected that  HDS 
would solve their health concerns, as suggested in the qualitat ive study. This is 
consistent  with the literature.63,90,93,96 Using HDS as a last  resort , and due to 
feelings of hopelessness, were m ore frequent ly reported in pat ients with chronic 
diseases than the general populat ion.87,96 
Want ing to t ry HDS was a frequent ly reported reason for  using HDS, which has 
been reported in the current  survey and other surveys of CAM use am ongst  
pat ients with chronic illnesses, in both Asian and Western count r ies.58,61,99 
Studies have suggested that  the personalit y t rait  of “having an open m ind”  is 
linked to pat ients being willing to t ry HDS.61,99 Som e respondents wanted to t ry 
HDS as they perceived that  HDS was safe and they hoped to gain benefit  as 
reported in the qualitat ive study. I t  should be em phasised that  although pat ients 
want  to t ry HDS, they would also m onitor any HDS effects. I f they perceived a 
benefit ,  they would cont inue using them ;  if not , they would stop using them . 
Moreover, such pat ients are m ore likely to act ively search for  inform at ion from  
several sources, such as the m edia and their social network, to decide whether 
or not  to use HDS by them selves;  a conclusion supported by data from  the 
present  qualitat ive study, and also supported by the literature.97  
Both the current  survey and qualitat ive study found that  the percept ion of HDS 
safet y was less likely to influence decision-m aking regarding HDS use, com pared 
to the percept ion of t heir benefit s am ongst  pat ients with CKD. This m ay be 
because respondents were concerned about  adverse effects of HDS. This is 
consistent  with the literature.16,56,57,66,93,98 I n the present  qualitat ive study, 
pat ients with CKD, who were concerned about  adverse effects of HDS, seem ed 
to want  to have consultat ions with their health care providers.   
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Both the survey and qualitat ive study found that  som e respondents experienced 
adverse effects from  using CM, so this drove them  to use HDS. This situat ion is 
sim ilar to that  cited in the literature, which explained that  som e pat ients were 
likely to use HDS, as they either had side effects from  CM or wanted to decrease 
them .61,66 
Both the survey and qualitat ive study reported that  the m edia, such as 
television, radio, etc. was a second influence on decision-m aking regarding HDS 
use, aft er fam ily and fr iends’ recom m endat ions. The qualitat ive study also 
showed that  the m edia was likely to report  benefit s of HDS, rather than warn 
about  their adverse effects, and that  HDS com panies used the m edia in order to 
advert ise their products in term s of their benefit s, rather than m ent ioning 
anything about  their possible adverse effects. This is consistent  with Bubela et  
al. (2008)  who found that  90%  of newspapers in Western count ries reported the 
benefit s of herbal m edicine.107 I n addit ion, a system at ic review showed that  the 
m ass m edia reported posit ive effects of CAM, rather than any of their negat ive 
effect s.108 This m ay explain why a large num ber of Thai respondents buy HDS 
products from  HDS com panies.  
8 .3 .7  Reasons for  non- users 
Respondents who either t rusted their doctor, or were advised by their doctor t o 
avoid using HDS, were less likely to use HDS. I t  would seem  that  t he doctor-
pat ient  relat ionship influences decision-m aking regarding non-HDS use am ongst  
Thai pat ients with CKD. The rem aining reasons for  non-use were that  non-users 
were scept ical about  the benefit  of HDS, as well as being concerned about  their 
adverse effects. This is consistent  with the reasons for non-use of herbal 
m edicine or CAM, based on the literature:  products are ineffect ive, pat ients 
worry about  their side effects and there is a lack of inform at ion about  
them .55,57,60  
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8 .3 .8  The non- disclosure of HDS use to their  doctor 
Most  HDS users in the present  survey did not  disclose HDS use to their doctor 
(72% ) . This cont rasted with Western pat ients with CKD, where m ost  inform ed 
their doctor about  their HDS use (55 to 67% ) .15,16 This high am ount  of non-
disclosure found in the current  survey has also been found in other Asian 
populat ions.98,110,111 Most  frequent ly reported reasons of non-disclosure were 
that  their doctor did not  enquire, concern that  the doctor m ay disapprove of their  
HDS use or they felt  the doctor did not  need to know about  HDS use. These 
findings are consistent  with a previous system at ic review of the disclosure of 
CAM use to health care providers.273 
The qualitat ive study showed that  although doctors asked pat ients about  HDS 
use, one pat ient  reported he did not  want  to tell his doctor about  his HDS use 
because he worried about  a negat ive response from  that  doctor. Another 
respondent ,  who had experienced such a response from  his doctor in the past ,  
refused to disclose HDS use to his doctor in the future. Therefore, it  would seem  
that  health care providers’ com m unicat ion is an im portant  factor influencing 
whether pat ients would disclose their HDS use to those providers.53,109 This is 
also supported by reasons for  the disclosure of HDS use to a doctor;  respondents 
were willing to inform  their doctor about  their use where they experienced a 
posit ive response from  their doctor or were confident  that  their HDS use would 
not  be disapproved of.        
To com pare reasons for non-disclosure of HDS use between SWU and CU 
hospitals, 53%  (n= 40)  of respondents at tending the SWU hospital reported a 
reason – ‘their doctor did not  ask’ -  m ore than respondents at  the CU kidney 
clinic (43 % , n= 26)  (p- value <  0.01) . This could be because the form er hospital 
had a sm all num ber of kidney consultants, so their pat ients were less likely to be 
asked about  HDS use than the lat ter;  where a health care team  service consisted 
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of a kidney consultant , a pharm acist  and a diet ician, therefore, giving m ore 
opportunit ies to be asked or discuss HDS use. 
8 .3 .9  HDS availability in Thailand 
Pharm acies were frequent ly reported as places selling HDS;  a finding sim ilar to 
Grabe and Garrison’s study (2004)  in the US, so pharm acists should be aware 
that  CKD could be a cont raindicat ion for  som e HDS. I t  is im portant  t o note that  
direct  sale com panies were frequent ly reported as a place for selling HDS in 
Thailand. There are lim ited reports about  such com panies selling HDS in previous 
studies in other count r ies.14,15 I t  would be a problem  in HDS dist r ibut ion in 
Thailand if those com panies provided inaccurate inform at ion about  benefit s and 
r isks of HDS. The Thai Health Body should closely m onitor their advert ising and 
enforce the m edicine advert ising law if com panies violate that  law.   
8 .4  Strengths and w eaknesses 
8 .4 .1  St rengths 
This survey is the first  survey of HDS use am ongst  Thai pat ients with advanced 
CKD and therefore provides, to som e extent , fundam ental knowledge about  
prevalence, pat terns and reasons for HDS use. Both quant itat ive and qualitat ive 
m ethods provide m ore understanding of the reasons why these pat ients used 
HDS. There was the large sam ple size in the current  survey (n= 421) , com pared 
with form er surveys am ongst  pat ients with CKD (n= 100-250) .15,16 Advantages of 
the researcher-adm inistered quest ionnaire were a high response rate (98% )  and 
a low rate of m issing data ( less than 5% ) .   
The sam ple in this survey represented an Asian populat ion, so this finding can be 
generalised to such populat ions. This is due to the fact  that  Asian count ries share 
their self- care behaviour,  part icularly that  people are m ore likely to use herbal 
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m edicines, and their at t itudes to health m anagem ent . Several findings in the 
current  survey were sim ilar to the literature in Asian count ries. For exam ple, 
fr iends and fam ily m em bers were the m ain influence on HDS use.54,57,61 Also, the 
high am ount  of non-disclosure in the present  survey was sim ilar to the literature 
in other Asian populat ions.98,110,111  
8 .4 .2  W eaknesses 
The sam ple populat ion in this survey was not  random ly selected from  pat ients 
with advanced CKD across Thailand, but  was recruited at  two hospitals for  six 
m onths. This m ay m ean that  the sam ple is not  representat ive of the general 
CKD pat ient  populat ion. However, dem ographic characterist ics of the sam ple in 
this survey were sim ilar to the Thai census in 2007 260 and the literature.16 Most  
pat ients with CKD in the two set t ings were likely to visit  their doctor every 3 
m onths, so this period seem ed to be sufficient  t im e to approach alm ost  all of the 
target  populat ion. 
I nform at ion about  HDS use in this study relied on self- report  so this approach 
m ay be subject  t o social desirabilit y bias, such as pat ients not  disclosing their 
HDS use as they felt  it  m ight  be disapproved of.  
The use of three people to collect  data m ay have led to differences in the way 
quest ions were asked;  however, the assistant  researchers were t rained by the 
m ain researcher (MT)  who observed the collect ion of their first  data to ensure 
consistency. 
A cross-sect ional study cannot  determ ine the incidence of HDS use, com pared 
with a cohort  study. 
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8 .5  Conclusions and im plicat ions 
The prevalence of HDS use in Thai pat ients with CKD was 45%  (95% CI  40% -
50% ) , which is greater than the general populat ion. This is sim ilar to Western 
populat ions. Although there was no clear pat tern of associat ions between HDS 
use and convent ional m edicat ion adherence, respondents with poor adherence 
were m ore likely to use HDS. This m ay be because they had exper iences of 
adverse effects from  using CM. The m ost  frequent ly reported reason for using 
HDS was to m aintain well-being rather than t reatm ent  of CKD. However, m ost  
HDS reported as being used for  CKD, other than Ast ragalus m em branaceus,  
have no scient ific evidence to support  their efficacy from  clinical t rials. 
Furtherm ore, r iver spiderwort , kariyat  and wheatgrass were reported to increase 
serum  creat inine, but  there is no literature to indicate their  adverse effects. 
Therefore, further studies are needed to invest igate both efficacy and adverse 
effect s of HDS on renal funct ion. 
I n Thailand, the pat ient ’s social network and the m edia seem  to influence their  
decision m aking regarding HDS use, rather than HDS pract it ioners or health care 
providers. Most  reasons for HDS use in pat ients with CKD were based on hoping 
to gain benefit s from  using HDS, and did not  involve concern about  HDS safety. 
Although the pat ients were willing to t ry HDS, they were likely to evaluate their 
benefits. I f they did not  gain any benefit , they would stop using them .  
The doctor-pat ient  relat ionship appears to be a crucial factor related to non-use 
of HDS. Frequent ly reported reasons of the non-disclosure about  HDS use were 
that  their doctor did not  ask about  HDS use, or that  HDS users were concerned 
about  a negat ive response from  their doctor. Addit ionally, pharm acies were 
involved in HDS dist r ibut ion. Thus, health care providers should acknowledge the 
high prevalence of HDS use in pat ients with CKD, and therefore should always 
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ask them  about  HDS use, recom m end and discuss whether they should use HDS, 
or not , when the pat ients go to see a doctor or buy HDS at  pharm acies.  
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9 . The associat ion of HDS, the progression of 
CKD and its com plicat ions 
The prim ary and secondary object ives of this study were to determ ine any 
associat ions between HDS use and the fast  progression of CKD, and any 
associat ions between HDS use and CKD’s com plicat ions, i.e. uncont rolled 
hyperkalem ia and hyperphosphatem ia. Another object ive was to determ ine 
pat terns of any other r isk factors influencing CKD progression. 
9 .1  Method 
9 .1 .1  Choice of m ethod 
A prospect ive, cohort  study was designed in order to determ ine any associat ions 
between exposure to HDS and the prim ary outcom e of this study, i.e. the fast  
progression of CKD m easured by a decline in est im ated glom erular filt rat ion rate 
(eGFR)  over 12 m onths. The m easurem ent  of this outcom e requires at  least  3 
m onths.145 The present  study was designed to follow this outcom e over 12 
m onths, as the longer t he follow-up period in which eGFR is m easured, the m ore 
valid the data.11 The length of follow-up was lim ited by the scope of t his 3-year 
PhD program m e. There are advantages of this m ethod, com pared with a case-
cont rol study;  data about  exposure is collected before the m easurem ent  of 
outcom e and therefore is less likely to be subject  to recall bias, com pared with a 
case-cont rol study.274 However, the cohort  study is cost ly, t im e-consum ing and 
has a high rate of loss to follow-up, as part icipants need to be followed up over 
long t im e periods. 
The target  populat ion in this cohort  study was defined as Thai outpat ients with 
stages 3 to 5 CKD. This study recruited from  ent ire sam ples in the selected 
set t ings, at  baseline, as these set t ings m ight  not  have been able to provide a 
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sufficient  num ber of the target  populat ion, based on sam ple size determ inat ion, 
if sam ples were random ly selected.  
9 .1 .2  Study design 
The prospect ive cohort  study was conducted from  January 2012 to July 2013. I n 
the recruitm ent  process, 421 Thai adult  outpat ients with CKD, at  kidney clinics in 
two teaching hospitals, were approached and consented to be research 
part icipants, see Chapter 8. However, it  was found that  three pat ients had 
received dialysis prior to the recruitm ent , and 12 pat ients had stage 2 CKD 
(approxim ately eGFR of 60-65 m l/ m in/ 1.73m 2)  at  baseline. These pat ients 
(n= 15)  did not  m eet  the inclusion criteria;  therefore, 406 pat ients were enrolled 
for  this one-year follow-up study, see Flowchart  9.1. 
9 .1 .3  Definit ion of var iables and outcom es 
Exposure and non- exposure to HDS 
The index date was defined as the day that  the survey took place. The exposed 
group was defined as current , regular herbal users and/ or dietary supplem ent  
users, i.e. pat ients taking herbs and/ or dietary supplem ents at  least  three t im es 
a week in the last  m onth before the index date. There was no literature defining 
how the frequency of exposure is linked to a decline in kidney funct ion, so this 
definit ion was adapted from  literature on convent ional m edicat ion- induced 
nephropathy, where non-steroidal ant i- inflamm atory drugs lead to end-stage 
renal disease.275,276 The exposed group included the use of all t ypes of HDS, 
rather than specific ones, due to the lim ited num ber of pat ients in the exposed 
group and the lim ited evidence regarding which Thai herbal m edicines m ay affect  
kidney funct ion.  
The unexposed group was defined as those who had never taken herbs and/ or 
dietary supplem ents (non-users of herbal and dietary supplem ents) , or who had 
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stopped using them  before the m onth prior to the index date ( form er users of 
herbal and dietary supplem ents) , or who had taken them  less than three t im es 
per week in the previous m onth prior  t o the index date (occasional or rare users 
of herbal and dietary supplem ents) . 
Flowchart  9.1 Schem at ic diagram  of the cohort  study  
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The prim ary outcom e 
The prim ary outcom e of this study, the dependent  variable, was classified as 
‘fast  progression of CKD’. Fast  progression of CKD was defined as either a 
decline in eGFR of at  least  5 m l/ m in/ 1.73m 2/ year11,145 or init iated renal 
replacem ent  therapy during the follow-up period. Dichotom ous variables of the 
dependent  variable were ‘yes’ m eaning pat ients having the fast  progression of 
CKD and ‘no’. This definit ion differed from  the first  definit ion in sam ple size 
determ inat ion, see Chapter 6, because the init iat ion of renal replacem ent  
therapy during the follow-up is likely to be due to the fast  progression of CKD.  
There are various definit ions of ‘fast  progression’ in clinical pract ice and 
literature11,158,161,184, which related to, and were based upon, -3, -4 or -5 
m l/ m in/ 1.73 m 2/ year. To test  the robustness of the results, sensit ivit y analyses 
regarding various cut -off points of a decline in eGFR over a year were perform ed. 
An eGFR level was calculated from  serum  creat inine using the Thai Modificat ion 
of Diet  in Renal Disease (MDRD)  equat ion, including the Thai coefficient , which is 
1.129.183 This equat ion was 375.5 X serum  creat inine( -0.848)  X Age( -0.364)  X 0.712 
( if fem ale) . This equat ion est im ated eGFR has been recom m ended by the 
Nat ional Kidney Disease Educat ion Program  in the US, the NI CE guideline for 
CKD in the UK and the Thai guidelines for CKD.12,145,181 The level of serum  
creat inine related to acute kidney injury, as reported by a doctor,  was excluded 
as the MDRD equat ion precisely est im ates GFR under stable kidney funct ion. This 
equat ion should be used with caut ion when pat ients are aged over 70, due to 
underest im ate GFR. 
Measurem ent  of serum  creat inine in the current  study was part  of t he norm al 
care of CKD pat ients, and was analysed by the hospital laboratory service as 
usual. The test ing was therefore subject  to the norm al qualit y standards in the 
hospitals and can be considered valid m easures of the outcom e. 
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A rate of decline in eGFR over 12 m onths, for an individual, was est im ated using 
a slope of a best  fit  linear regression line, which was plot ted on a graph, i.e.  
eGFR levels and t im e, for each respondent  as recom m ended by the KDOQI  
guideline (2002) .158 At  least  three m easures of eGFR over a year,  for each 
respondent ,  were plot ted in order to m inim ise im precise rates of decline in 
eGFR.145,158   
The secondary outcom es 
Uncont rolled hyperkalem ia and hyperphosphatem ia were the secondary 
outcom es in this study. These outcom es were chosen as som e HDS contains 
potassium  or phosphate, which m ay cause such com plicat ions. Uncont rolled 
hyperkalem ia was defined as pat ients having m ore than 5.0 m Eq/ L (m m ol/ l)  of 
m ean level of serum  potassium  over a year .277 A cut -off point  of uncont rolled 
hyperphosphatem ia is shown in Table 9.1.186 A m ean of this level over a year,  
which was m ore than such values in this table, was defined as uncont rolled 
hyperphosphatem ia.  
Table 9.1 Definit ion of uncont rolled hyperphosphatem ia 
Stages of CKD Serum levels of phosphate 
3-4 >  4.6 mg/ dL (0.87-1.49 mmol/ L)  
5  >  5.5 mg/ dL (1.13-1.78 mmol/ L)  
Variables know n to influence the progression of CKD and the secondary 
outcom es 
Known risk factors for t he progression of CKD are:  being m ale, obesity,  sm oking, 
exist ing proteinuria, uncont rolled blood pressure, hypertension, diabetes, 
hyperlipidaemia, high protein consum pt ion, and taking nephrotoxic agents,  such 
as nonsteroidal ant i- inflam m atory drugs (NSAI Ds) , cyclo-oxygenase-2 inhibitors 
(COX-2 inhibitors) , and aspir in.157,158,167 Factors related to uncont rolled 
hyperkalem ia and hyperphosphatem ia are:  high potassium  and phosphate 
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intake, or  received t reatm ent  of hyperkalem ia and hyperphosphatem ia, together 
with their associated m edicat ion- induced com plicat ions, such as angiotensin-
convert ing enzym e inhibitors (ACEI s)  and/ or angiotensin I I  receptor antagonists 
(ARBs)  related to hyperkalem ia.278 These variables are defined below. 
Age was defined as aged 60 years and over. This cut -off point  influences a 
suscept ibilit y to CKD, because people aged 60 years and older have a decrease 
in renal funct ion com pared to those aged less than 60 years.279 
Obesity at  baseline was defined in the Thai populat ion as 27 kg/ m 2 of body m ass 
index (BMI ) , or over,  in m en and 25 kg/ m 2 of BMI , or over,  in wom en280 in the 
last  3 m onths before the index date. This definit ion differs from  the cut -off 
values for obesity in Caucasian populat ions, which is defined as 30 kg/ m 2 or  
m ore.281 This is because the Thai populat ion has a different  body fat  dist ribut ion 
com pared with Western populat ions. 
Sm oking status at  baseline was classified as current , form er or non-sm okers. 
Current  sm oking was defined as a person who had sm oked in the last  5 years 
before the index date;  m eanwhile form er sm oking was defined as a person who 
had quit  m ore than 5 years before the index date.282 A non-sm oker was a person 
who had never sm oked. These criteria were chosen because Yacoub’s study 
defined current  sm oking as above and found it  associated with CKD.282 
Exist ing proteinuria at  baseline was defined based on the Thai guideline for CKD 
m anagem ent  in 2009 and the Nat ional Kidney Foundat ion Kidney Disease 
Outcom es Qualit y I nit iat ive (NKF-KDOQI TM)  in 2002 and 2007 as follows.12,187,283 
A person who has one of these criteria is defined as having proteinuria.  
1. 24-hour urinary protein excret ion rate over 300 m g/  24 hour in the last  3-6 
m onths before the index date.12 
2. A protein and creat inine rat io (PCR)  m ore than 500 m g/ g creat inine in the 
last  3-6 m onths before the index date.12 
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3. An albumin and creat inine rat io (ACR)  m ore than 300 m g/ g.12,187 
4. At  least  2+  urine dipst ick protein m easurem ents for diabet ic pat ients in the 
last  3-6 m onths before the index date or at  least  1+  of urine dipst ick protein 
m easurem ent  for non-diabet ic pat ients in the last  3-6 m onths before the 
index date.12,283  
The Thai guideline for  CKD m anagem ent  has recom m ended test ing proteinuria 
every 6 m onths for pat ients with stage 3 CKD and every 3 m onths for pat ients 
with stages 4 to 5 CKD.12 The m easurem ent  of proteinuria using a dipst ick test , 
recom m ended by the NKF-KDOQI TM in 2002 and the Thai guideline for  CKD 
m anagem ent  in 2009, differs from  the NI CE guideline for CKD in 2008 which 
preferred using the album in- to-creat inine rat io (ACR) .145 This is because the Thai 
guideline was established based on m edical facilit ies in Thailand, evidence of 
cost -effect iveness and clinical outcom es.  
Uncont rolled blood pressure at  baseline was defined as pat ients having blood 
pressure of m ore than 130/ 80 m m Hg in the last  3 m onths before the index 
date.12,284 Hypertension was defined as either hypertension diagnosed by a 
doctor or  receiving ant ihypertensive agents.  
Dyslipidaem ia or diabetes was defined as pat ients who have been diagnosed with 
dyslipidaem ia or diabetes. Uncont rolled low-density lipoprotein (LDL)  cholesterol 
was defined as m ore than 100 m g/ dl (2.59 m m ol/ l)  of a LDL cholesterol level, 
which related to the progression of CKD. Likewise, m ore than 7%  of glycated 
haem oglobin (A1C)  is associated with CKD progression.11 A level of A1C and LDL 
cholesterol at  baseline were defined as such levels m easured in the last  3 -  6 
m onths before the index date because these levels are m easured every 6 
m onths, as recom m ended by the Thai guideline for CKD (2009) .12 
Moderate to high protein consum pt ion at  baseline was defined as pat ients taking 
a m oderate to high protein diet , as m easured in the last  14 days before the 
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index date, by using the Rest r ict ion of Protein, Potassium , Phosphate and Salt  
diet  quest ionnaire in pre-dialysis pat ients (RPPPS) . This approach yielded a 
m easurem ent  of m oderate to high potassium  and phosphate consum pt ion at  
baseline, which were factors related to the secondary outcom es.  
Exposure and non-exposure to nephrotoxic agents at  baseline, i.e. NSAIDs, COX-
2 inhibitors or aspir in, was defined as follows. The exposed group was defined as 
a person taking them  in the last  m onth before the index date (current  users) 276;  
whilst  the unexposed group were defined as those taking 20 tablets or less 
during their lifet im e (non-users) , or  those who stopped taking them  for at  least  a 
m onth before the index date ( form er users) .285,286  
The use of loop diuret ics, ACEIs or ARBs at  baseline, was defined as a person 
who had been prescribed such m edicines in the last  3 m onths before the index 
date. These m edicat ions are likely to be prescribed for pat ients with CKD and 
m ay induce hypokalem ia or hyperkalem ia. Receiving t reatm ent  for  hyperkalem ia 
at  baseline was defined as those who had received prescribed sodium  or calcium 
polystyrene sulfonate in the last  3 m onths before the index date. Receiving 
t reatm ent  for hyperphosphatem ia, at  baseline, was defined as those who had 
received prescribed phosphate binders in the last  3 m onths before the index 
date. 
9 .1 .4  Data collect ion 
At  baseline, r isk factors related to the outcom es and the outcom e data were 
collected by surveying and ext ract ing data from  m edical notes using the 
researcher-adm inistered quest ionnaire and data ext ract ion sheet ,  see 
Appendices 5 and 6. I ndependent  variables, including the exposure, t ested for a 
relat ionship with the progression of CKD and it s com plicat ions are:  age, sex, 
obesity, sm oking status, history of diabetes, and hypertension, exist ing 
proteinuria, NSAI Ds, COX-2 inhibitors, and aspir in, blood pressure, A1C, and LDL 
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cholesterol levels, degree of protein, potassium , and phosphate intake, use of 
loop diuret ics, ACEI s, or  ARBs, and t reatm ent  of hyperkalem ia, and 
hyperphosphatem ia. The outcom es of this study, i.e.  eGFR levels, serum  levels 
of potassium  and phosphate, were ext racted from  m edical notes.  
I n the follow-up period, data of the outcom es were ext racted from  m edical notes 
over a year using a st ructured quest ionnaire, see Appendix 7. All respondents 
were interviewed over the telephone regarding their HDS use in the twelfth 
m onth of their involvem ent , using a quest ionnaire, see Appendix 7. This 
inform at ion was to support  the results of any associat ions between HDS use and 
the progression of CKD. Telephone interviews were used, as they were m ore 
convenient , cheaper and took less t im e than face- to- face interviews. Telephone 
interviews are suitable for  short  quest ions on non-sensit ive subjects.287 I n this 
case, the respondents had already taken part  in the baseline data collect ion and 
had com pleted a short ened version of the quest ionnaire, which asked about  their 
HDS use since the baseline survey. The respondents had supplied their 
telephone num bers for t he purpose of further contact . 
Data was coded and entered into IBM SPSS software version 19.0. To validate 
this process, frequencies of categorical variables were perform ed and checked in 
order t o ident ify inaccurate codes. A total of 5 errors were found in 16,422 
variables (46 variables and 357 respondents)  and these errors were rect ified. 
Num erical variables were checked according to their range. Som e num bers fell 
outside the expected range, which were checked against  the original records, 
and no errors were found. Ten percent  of the quest ionnaires (n =  33)  were 
random ly selected using Microsoft  Excel software and these quest ionnaires were 
checked against  the database in the I BM SPSS software version 19.0. This 
database had 100 variables per respondent . A total of 17 errors were found in 
35,700 variables (0.05% ) . These errors were rect ified.  
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Regarding consistency checks, variables related to other variables were checked 
for  their consistency. For instance, body m ass index and obesity. Sixteen errors 
(0.12% )  were found in 12,852 variables (36 variables and 357 respondents)  and 
were rect ified.  
9 .1 .5  Stat ist ical analyses 
Descript ive analyses were perform ed and presented as frequencies and 
percentages. Potent ial confounding factors related to the exposure or the 
prim ary outcom e – the fast  progression of CKD based on literature, step one:  
univariate analyses between the exposure and the potent ial confounding factors 
at  baseline were tested using Chi-squared tests in order to ascertain any 
associat ions between the exposure and the potent ial confounding factors. These 
factors at  baseline were age, sex, sm oking status, obesity, proteinuria, degree of 
protein intake, hypertension, diabetes, dyslipidaem ia, severity of CKD, cont rolled 
blood pressure, A1C, LDL cholesterol, use of NSAIDs, aspir in or COX-2 inhibitors, 
and the level of adherence to prescribed convent ional m edicat ion.  
Step two, univariate analyses between the exposure at  baseline, including the 
potent ial confounding factors and the dependent  variable – the fast  progression 
of CKD at  the end point  were perform ed using Chi-squared tests and calculat ing 
unadjusted odds rat ios. Tests were 2- tailed and a p-value <  0.05 was considered 
stat ist ically significant . This step aim ed to ident ify the potent ial confounding 
factors related to the dependent  variable.  
The final step, that  of m ult iple logist ic regression analysis, was included the 
exposure and the stat ist ically significant  confounding factors from  the step one 
and two in order to select  the potent ial confounding factors. This step is 
presented as adjusted odds rat io of the exposure after  cont rolling each potent ial 
confounding factor from  step one and two. I f a difference between the 
unadjusted odds rat io of the exposure associated with the outcom e from  step 
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two and the adjusted odds rat io from  m ult iple logist ic regression analysis is at  
least  10% , this m eans that  such factors are likely to be confounding factors in 
the associat ion between the exposure and the outcom e. As a result , that  factor 
was included in building the m odel of associat ion between the exposure and the 
outcom e in order to cont rol the confounding factor.288 
I f the dataset , a decline in eGFR over 12 m onths, had norm al dist r ibut ion, a 
com parison of m ean decline in eGFR am ongst  variables using a t - test  was 
perform ed in respondents who had not  received dialysis during the follow-up 
period. Those with init iated renal replacem ent  therapy could not  be tested on 
this outcom e as their eGFR did not  represent  their kidney funct ion. 
The secondary outcom es, i.e. uncont rolled hyperkalem ia and 
hyperphosphatem ia, were analysed only am ongst  respondents who did not  
init iate dialysis therapy as this therapy increases excret ion of potassium  and 
phosphate from  the body. Univariate analyses tested any associat ions between 
the exposure and dichotom ous dependent  variables – cont rolled and 
uncont rolled hyperkalem ia and hyperphosphatem ia -  using Chi-squared tests. 
Potent ial confounding factors related to these dependent  variables were tested 
using Chi-squared tests and unadjusted odds rat ios. Factors related to worsening 
hyperkalem ia, based on the literature, were m oderate to high potassium  intake, 
t reatm ent  of hyperkalem ia, use of loop diuret ics and use of ACEIs or ARBs. 
Factors related to worsening hyperphosphatem ia, based on literature, were 
m oderate to high phosphate intake and t reatm ent  of hyperphosphatem ia. 
Mult iple logist ic regression analyses of associat ion between the exposure and the 
secondary outcom es included the exposure and all potent ial confounding factors, 
based on the literature as above, in order to explore effects of each factor. The 
unadjusted and adjusted odds rat ios of the exposure related to the outcom es 
were com pared. I f they have a difference of at  least  10% , this m eans that  such 
Chapter 9:  The associat ion of HDS, the progression of CKD and its complicat ions 
192 
factors are confounding factors of the associat ions between the exposure and the 
outcom es.   
Mult iple sensit ivit y analyses were perform ed in order to t est  the robustness of 
the associat ion between HDS and the prim ary outcom e. First ly, four cut -off 
points of a decline in eGFR over a year , defined as ‘fast  progression of CKD’ were 
classified based on literature and the nature of the dataset  in this study, which 
were m ean plus a quarter  of the standard deviat ion (SD) , m ean plus a half of the 
SD, and m ean plus the SD. Univariate analyses between variables and these cut -
off points were perform ed by Chi-squared tests and were com pared. Secondly, 
different  causes of CKD influenced the various rates of a decline in eGFR over a 
year.158 For exam ple CKD result ing from  glom erular diseases, HIV, cir rhosis and 
cancer had a different  rate of a decline in eGFR over a year, com pared with CKD 
caused by diabetes and hypertension. This m ay affect  the prim ary outcom e – the 
fast  progression of CKD. Associat ions of the fast  progression of CKD with the 
exposure between all respondents and those who did not  have glom erular 
diseases, HIV, cirrhosis and cancer were analysed using Chi-squared test s and 
com pared.  
Finally, both exposed and unexposed groups m ay have changed their HDS use 
during the follow-up period, so whether there was consistent  exposure or non-
exposure to HDS over a year needed to be explored, together with their 
associat ion with the prim ary outcom e, com pared with both groups at  baseline.  
The telephone interview in the twelfth m onth collected data about  t he use of 
HDS during the follow-up, and inform at ion was then classified into consistent  
exposure and non- exposure to HDS. Consistent  exposure was defined as 
respondents exposed to HDS at  least  three t im es a week at  baseline and over 12 
m onths. Consistent  non-exposure was defined as the non-users, form er HDS 
users or the occasional users of HDS at  baseline and over 12 m onths.  
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Associat ions of the fast  progression of CKD between the consistent  exposure and 
non-exposure were perform ed using Chi-squared tests and com pared. 
9 .2  Results 
9 .2 .1  Dem ographic character ist ics 
Four hundred and six pat ients were enrolled in this one-year follow-up study. 
Forty-nine pat ients (12% )  left  the study:  30 (7.4% )  due to deaths;  16 (3.9% )  
loss to follow-up and 3 (0.7% )  being referred to another hospital. Reasons for  
death were unknown. Three-hundred and fift y- seven pat ients were followed-up 
over 12 m onths and 27 pat ients (8% )  started to receive dialysis during the 
follow-up period. Respondents had a m ean age of 66 years with a standard 
deviat ion (SD)  of 13, and 55%  were wom en, see Table 9.2. Mean BMI  and m ean 
eGFR at  baseline were 25.0 +  4.9 kg/ m 2 and 39 +  12 m l/ m in/ 1.73 m 2. Thirty-
two respondents aged over 70 years (8% )  had eGFR at  baseline of 50 – 59 
m l/ m in/ 1.73m 2, which m ay be underest im ated due to a lim itat ion of t he MDRD 
equat ion. At  least  60%  had diabetes and hypertension. Seventeen percent  
(n= 62)  had glom erular disease. A sm all num ber of the pat ients had polycyst ic 
kidney disease (n= 7, 1.9% ) , cirrhosis (n= 7, 1.9% )  or hum an im munodeficiency 
virus (HIV)  infect ion (n= 4, 1.1% ) .  
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Table 9.2 Characterist ics of respondents at  baseline (n= 357)  
Character ist ics Frequency Percent Missing data 
Age   -  
   <  60 114 31.9  
   >  60 243 68.1  
Male 162 45.4 -  
Smoking   -  
   Never smoked 233 65.3  
   Former smoker 106 29.7  
   Current  smoker 18 5.0  
Alcohol consumpt ion   1 (0.3% ) 
   Never  207 58.1  
   Former dr inker 130 36.5  
   Current  dr inker 19 5.3  
Obesitya 139 40.6 15 (4.2% ) 
Stage of CKDb   -  
   3 a (eGFR =  45-59)  125 35.0  
   3 b (eGFR =  30-44) 138 38.7  
   4 (eGFR =  15-29) 85 23.8  
   5 (eGFR <  15) 9 2.5  
Comorbidit ies   -  
   Hypertension 333 93.3  
   Dyslipidaem ia 313 87.7  
   Diabetes 213 59.7  
   Heart disease 100 28.0  
   Cancer 31 8.7  
Exist ing proteinur ia 163 52.1 44c (12.3% ) 
Degree of protein intaked   -  
   Low 203 56.9  
   Medium 129 36.1  
   High 25 7.0  
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data.  
a
 Obesity was defined in the Thai populat ion as 27 kg/ m2 of body mass index (BMI )  or over in men 
and 25 kg/ m2 of BMI  or over in women.280 
b
 Stage of CKD was defined based on the KDI GO guideline 201211 and the NI CE guideline for CKD 
2008.145 
c
 Respondents were not measured.  
d
 Protein intake was assessed using the Restr ict ion of Protein, Potassium, Phosphate and Salt  diet  
quest ionnaire    
At  baseline, pat ients were taking an average of 8 +  3 prescribed, convent ional 
m edicat ions ( range 2-20) . At  least  half of the pat ients received both ant i-diabet ic 
m edicat ions and lipid- lowering drugs, whilst  at  least  a quarter  took ACEIs and/ or 
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ARBs, which can slow the progression of CKD, part icularly in diabet ic 
nephropathy and kidney diseases with proteinuria, see Table 9.3. Regarding the 
use of nephrotoxic agents, a sm all num ber of pat ients took NSAIDs (6% )  or 
COX-2 inhibitors (3% ) . Only one pat ient  regularly and current ly took NSAI Ds 
(0.3% ) , whilst  6%  reported interm it tent  use. Forty percent  received aspir in for 
cardiovascular diseases and m ost  of them  took aspir in 81 m g daily (89% ) , which 
is available in Thailand. 
There were three pat terns of HDS use in the present  study. First ly, respondents 
who have always taken HDS;  this study shows 17%  of all pat ients (n= 62)  
cont inued to regularly take HDS during the follow-up. Secondly, 50%  (n= 177)  
did not  take them  at  all. Finally, som e respondents took HDS on and off. Twenty-
nine percent  of respondents current ly and regularly took HDS at  baseline, which 
was the exposed group (n= 102) . Of this group, 26 pat ients (25% )  stopped using 
supplem ents during the follow-up period. Am ongst  the unexposed group 
(n= 255) , 10 pat ients (4% )  started using HDS regularly during the follow-up 
period.  
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Table 9.3 HDS and m edicat ion use at  baseline (n= 357)  
The use Frequency Percent 
HDS use   
   Non-use 191 53.5 
   Current  and regular use 102 28.6 
   Current  and occasional use 34 9.5 
   Former use 30 8.4 
The use of NSAI Ds   
   Non-use 298 83.5 
   Current  use 21 5.9 
   Former use 38 10.6 
The use of COX-2 inhibitors   
   Non-use 330 92.4 
   Current  use 11 3.1 
   Former use 16 4.5 
Aspir in use   
   Non-use 207 58.0 
   Current  use 141 39.5 
   Former use 9 2.5 
Prescr ibed medicat ion adherence*    
   Low 89 24.9 
   Medium 172 48.2 
   High 96 26.9 
Use of prescr ibed medicat ions related to CKD management and its complicat ions 
   ACEI s 86 24.1 
   ARBs 125 35.0 
   Lipid- lowering drugs 278 77.9 
   Ant i-diabet ic medicat ions 175 49.0 
   Erythropoiet in 73 20.4 
   I ron supplement 114 31.9 
   Folic acid 159 44.5 
   Vitam in B 1-6-12 66 18.5 
   Loop diuret ics 97 27.2 
   Kayexalate or calcium polystyrene sulfonate 70 19.6 
   Phosphate binders 112 31.4 
   Sodam int  86 24.1 
   Hypour icem ic agents 113 31.7 
*  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772. 
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Am ongst  the 330 respondents who were not  init iated into dialysis therapy during 
the follow-up period, the m edian num ber of eGFR m easurem ent  over a year was 
5 t im es ( range 3-12)  and the m edian follow-up period was 12 m onths ( range 9-
16) . Mean decline in eGFR and SD was 2.09+ 7.58 m l/ m in/ 1.73m 2/ year, see 
Figure 9.1. The dist r ibut ion of change in eGFR over 12 m onths was not  norm al 
as tested by Kolm ogorov-Sm irnov analysis (p- value <  0.01) , so com parison of 
m ean change in eGFR over one year, between the exposed and unexposed 
groups, was not  perform ed. Median change in eGFR over one year, between the 
exposed and unexposed groups, was -2.32 and -1.86 m l/ m in/ 1.73 m 2/ year, 
respect ively. There was no difference in these m edian between two groups (p-
value =  0.72)  tested by Mann Whitney U test .  
Figure 9.1 The dist r ibut ion of change in eGFR over a year (n= 330)  
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Table 9.4 Dist r ibut ion of changes in rates of eGFR over a year (n= 330)  
Changes in rates of eGFR over a year 
(m l/ m in/ 1.73m 2/ year)  
Frequency Percent 
   >  -10 31 9.4 
   -6 to -10 59 17.9 
   -1 to -5 107 32.4 
   0 28 8.5 
   1 to 5 73 22.1 
   6 to 10 20 6.1 
   >  10 12 3.6 
 
Table 9.5 Laboratory results at  baseline (n= 357)  
Laboratory results at baseline Frequency Percent Non-
measurement  
Controlled blood pressure (BP <  130/ 80) 114 32.2 3*  (0.9% ) 
A1C* *    142 (39.8% ) 
   <  7%  117 54.4  
   >  7%  98 45.6  
LDL cholesterol* *    43 (12.0% ) 
   <  100 mg/ dl 155 49.4  
   >  100 mg/ dl 159 44.5  
Hyperkalem ia 61 17.7 12 (3.4% ) 
Hyperphosphatem ia 18 7.0 100 (28.0% ) 
Percent  was calculated using an absolute number of respondents, which was not  included a number 
of m issing data. 
*  m issing data 
* *  The cut -off point  based on KDI GO guideline 201211 
Less than half of the pat ients achieved their t arget  of blood pressure and low-
density lipoprotein (LDL)  cholesterol at  baseline, see Table 9.5. Less than 20%  
had hyperkalem ia or hyperphosphatem ia at  baseline. There was a high num ber 
of the non-m easurem ent  of serum  levels of phosphate at  baseline (28% ) :  60 
(18% )  respondents had the non-  m easurem ent  of such elect rolytes over one 
year. The total num ber of respondents regarding such m easurem ent  over one 
year was 330, as dialysis influences excret ion of potassium  and phosphate. As a 
result , pat ients receiving dialysis had invalid serum  levels of potassium  and 
phosphate and these pat ients were not  included in the analyses of the 
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outcom es of this study, uncont rolled hyperkalem ia and hyperphosphatem ia. 
Com paring between the exposure and the non-m easurem ent  of serum  levels of 
potassium  and phosphate tested by Chi-squared test s is shown in Tables 9.6 and 
9.7.  
Table 9.6 Com parison between the exposure and the non-m easurem ent  of 
serum  levels of potassium  
Exposure to HDS The non-measurement  of serum levels of 
potassium at baseline (n= 357)  
X2 value p-value 
 Yes No   
Yes 8 (66.7% ) 94 (27.2% ) 8.83 <  0.01*  
No 4 (33.3% ) 251 (72.8% )   
 The non-measurement  of serum levels of 
potassium over one year (n= 330) 
  
 Yes No   
Yes 1 (50.0% ) 97 (29.6% ) 0.40 0.53 
No 1 (50.0% ) 231 (70.4% )   
*  Stat ist ical significance at  p-value <  0.05 
The exposed group had a higher num ber of the non-m easurem ent  of serum  
potassium  levels at  baseline (67% )  than the unexposed group (33% )  (p- value <  
0.01) ;  however,  there was no difference in such data over one year,  see Table 
9.6.  
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Table 9.7 Com parison between the exposure and the non-m easurem ent  of 
serum  levels of phosphate 
Exposure to HDS The non-measurement  of serum levels 
of phosphate at  baseline (n= 357) 
X2 value p-value 
 Yes No   
Yes 30 (30% ) 72 (28% ) 0.14 0.71 
No 70 (70% ) 185 (72% )   
 The non-measurement  of serum levels 
of phosphate over one year (n= 330) 
  
 Yes No   
Yes 18 (30% ) 80 (29.6% ) 0.003 0.96 
No 42 (70.0% ) 190 (70.4% )   
 
There was no difference in the non-m easurem ent  of serum  phosphate levels 
between the exposed and unexposed groups at  baseline and over one year, see 
Table 9.7.  
There were 65 different  types of HDS am ongst  the exposed group, see Tables 
9.8 and 9.9. Ten respondents in the exposed group (10% )  did not  rem em ber or 
know the ingredients of their HDS. The three m ost  frequent ly used HDS were 
turm eric, a m ixture of botanical ext ract s, and horse radish t ree. Regarding the 
dosage regim en of HDS, senna was used in the recom m ended dose for  a general 
populat ion, as well as the two Thai folk rem edies:  ‘Ka sai’ and ‘Ya hom ’. One 
pat ient  used a high dose vitam in C and others used 250-500 m g/ day of vitam in 
C.   
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Table 9.8 Types of herbal m edicine used in the exposed group (n= 102)  
Name of HDS Frequency 
Turmeric (Curcuma longa)  12 
A m ixture of botanical extracts*  9 
Horse radish tree (Moringa oleifera)  8 
Ginseng or coffee contained ginseng 6 
Boesenbergia (Boesenbergia rotunda)  5 
Different  types of mushrooms, such as holy or shiitake mushrooms 4 
Garlic 4 
River spiderwort  (Tradescant ia flum inensis)  4 
Mixed Thai tradit ional herbs called  ‘Ka sai’ 3 
Tea for diuret ic effects, such as java tea, babbler ’s bill leaves 3 
Tinospora cr ispa 3 
Aloe vera 2 
Bamboo grass (Tiliacora t r iandra)  2 
A m ixture of Jujube and roselle 2 
Mixed Thai tradit ional herbs called  ‘Ya hom ’ 2 
A m ixture of Boesenbergia, ocimum and honey 1 
Cinnamon 1 
Veld grape (Cissus quadrangular is)  1 
Clerodendrum petasites 1 
Echinochloa spp. 1 
Gynura procumbens 1 
Kaffir lime 1 
Lemongrass 1 
Blue plea (Clitor ia ternatea)  1 
Malva nut  (Scaphium scaphigerum )  1 
A m ixture of bamboo grass, blue plea and pandanus palm 1 
Mixed Thai tradit ional herbs called  ‘Ya khom ’ 1 
Spirulina 1 
Senna 1 
Gac fruit  (Momordica cochinchinensis)  1 
Chinese folk remedy -  Cordyceps, Angelica sinesis, deer ant ler  velvet , 
f ive flavour berry (Schisandra chinensis)  and cinnamon 
1 
Chinese folk remedy -  Holy mushroom, cordyceps, ginseng, goj i berry 1 
Helicteres isora 1 
Kar iyat  (Andrographis paniculata)  1 
Lotus seed 1 
I vy gourd (Coccinia grandis)  1 
A m ixture of boesenbergia, m int , galanga, onion, lemongrass, kaffir 
lime leaves and lime leaves 
1 
Lemongrass, kaffir  lime leaves, mango, yardlong bean, carrot , 
wildbetal leafbush (Piper sarmentosum )  and pomelo 
1 
Thai folk remedy called ‘Tr i pala’ – Phyllanthus emblica, Term inalia 
beler ica and Term inalia chebula  
1 
*  some products contained cereal 
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Table 9.9 Types of dietary supplem ent  used in the exposed group (n= 102)  
Name of dietary supplements Frequency Name of dietary supplements Frequency 
Fish oil  7 Calcium supplement   2 
Protein supplement 7 Vitam in B 2 
Germ oil 6 Beta -  glucan 1 
Essence of chicken dr ink  5 Bee pollen  1 
Rice bran oil 5 Chlorophyll 1 
Vitam in C 5 Cod liver oil 1 
Gingko 4 Chondroit in  1 
Mult iple vitam in  3 CoQ10 1 
Swift let ’s nest  dr ink 3 Glucosam ine 1 
Vitam in E 3 Omega-3 1 
Wheatgrass 3 Lecithin 1 
Virgin cold pressed coconut  oil  2 Zinc 1 
A product contained vitam ins, 
m inerals and botanical 
ext racts 
3 A product  contained vitam ins, 
m inerals and cereal 
1 
To com pare the dem ographics between the included group and the group of 
drop-out ,  including deaths, the group of drop-out  cont rolled their blood pressure 
bet ter  than the included group (p- value <  0.05) , see Table 9.10. Any differences 
of other factors, in either group, were not  found. 
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Table 9.10 Sim ilarit ies and differences of dem ographics at  baseline between the 
included group and the group of drop-out  (n= 406)   
Variables The included group 
(n= 357) 
The group of drop-out  
(n= 49) 
X2 value p-value 
Exposure to HDS   2.26 0.13 
   Yes 102 (28.6% ) 9 (18.4% )   
   No 255 (71.4% ) 40 (81.6% )   
Age   3.75 0.05 
   <  60 114 (31.9% ) 9 (18.4% )   
   >  60 243 (68.1% ) 40 (81.6% )   
Sex   0.22 0.63 
   Male 162 (45.4% ) 24 (49.0% )   
   Female 195 (54.6% ) 25 (51.0% )   
Current  smoking   0.10 0.75 
   No 339 (95.0% ) 46 (93.9% )   
   Yes 18 (5.0% ) 3 (6.1% )   
Obesity (n= 342) (n= 44) 1.27 0.26 
   No  203 (59.4% ) 30 (68.2% )   
   Yes 139 (40.6% ) 14 (31.8% )   
Exist ing proteinur ia (n= 313) (n= 38) 0.30 0.58 
   No 150 (47.9% ) 20 (52.6% )   
   Yes 163 (52.1% ) 18 (47.4% )   
Degree of protein intake   2.78 0.09 
   Low 203 (56.9% ) 34 (69.4% )   
   Moderate to high 154 (43.1% ) 15 (30.6% )   
Hypertension   0.79 0.37 
   No 24 (6.7% ) 5 (10.2% )   
   Yes 333 (93.3% ) 44 (89.8% )   
Diabetes   0.04 0.83 
   No 144 (40.3% ) 19 (38.8% )   
   Yes 213 (59.7% ) 30 (61.2% )   
Dyslipidaem ia   0.18 0.67 
   No 44 (12.3% ) 5 (10.2% )   
   Yes 313 (87.7% ) 44 (89.8% )   
eGFR (m l/ m in)    2.88 0.41 
   45-59 125 (35.0% ) 21 (42.9% )   
   30-44 138 (38.6% ) 13 (26.5% )   
   15-29 85 (23.8% ) 14 (28.6% )   
   <  15 9 (2.6% ) 1 (2.0% )   
Controlled blood 
pressure 
(n= 354) (n= 49) 5.48 0.02*  
   No 234 (66.1% ) 24 (49.0% )   
   Yes 120 (33.9% ) 25 (51.0% )   
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Table 9.10 (cont inued)  
Variables The included group 
(n= 357) 
The group of drop-out  
(n= 49) 
X2 
value 
p-value 
A1C (n= 215) (n= 34) 0.23 0.63 
   <  7 117 (54.4% ) 20 (58.8% )   
   >  7 98 (45.6% ) 14 (28.6% )   
LDL cholesterol (n= 314) (n= 48) 0.79 0.37 
   <  100 155 (49.4% ) 27 (56.3% )   
   >  100 159 (50.6% ) 21 (43.7% )   
Current  use of NSAI Ds or COX-2 inhibitors  0.26 0.61 
   Yes 21 (5.9% ) 2 (4.1% )   
   No 336 (94.1% ) 47 (95.9% )   
Current  use of aspir in   1.61 0.20 
   Yes 141 (39.5% ) 24 (49.0% )   
   No 216 (60.5% ) 25 (51.0% )   
Prescr ibed, convent ional medicat ion adherence* *   0.30 0.58 
   Low 89 (24.9% ) 14 (28.6% )   
   Medium to high 268 (75.1% ) 35 (71.4% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
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9 .2 .2  The associat ion betw een r isk  factors and the 
progression of CKD 
To test  the potent ial confounding factors at  baseline related to the exposure 
using Chi-squared test s, indicated there were no differences in the factors 
between people exposed and unexposed to HDS at  baseline, with two 
except ions:  the use of NSAI Ds or COX-2 inhibitors, and adherence to prescribed, 
convent ional m edicat ion, see Table 9.11. The exposed group was m ore likely to 
take NSAI Ds or COX-2 inhibitors (unadjusted OR 3.64, 95% CI  1.49-8.94)  and 
have a low level of prescribed m edicat ion adherence, as com pared to the 
unexposed group (unadjusted OR 1.7, 95% CI  1.02-2.83) .     
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Table 9.11 Com parison of dem ographics and factors related to the progression of 
CKD between exposed and unexposed groups at  baseline (n= 357)  
Variables at  baseline Exposure to HDS 
(n= 102) 
Non-exposure 
(n= 255) 
X2 value p-value 
Age   0.74 0.39 
   <  60 36 (35.3% ) 78 (30.6% )   
   >  60 66 (64.7% ) 177 (69.4% )   
Sex   <  0.01 0.95 
   Male 46 (45.1% ) 116 (45.5% )   
   Female 56 (54.9% ) 139 (54.5% )   
Current  smoking   0.21 0.65 
   No 96 (94.1% ) 243 (95.3% )   
   Yes 6 (5.9% ) 12 (4.7% )   
Obesity (n= 99) (n= 243) 0.83 0.36 
   No  55 (55.6% ) 148 (60.9% )   
   Yes 44 (44.4% ) 95 (39.1% )   
Exist ing proteinur ia (n= 84) (n= 229) 1.47 0.23 
   No 45 (53.6% ) 105 (45.9% )   
   Yes 39 (46.4% ) 124 (54.1% )   
Degree of protein intake   0.50 0.48 
   Low 55 (53.9% ) 148 (58.0% )   
   Moderate to high 47 (46.1% ) 107 (42.0% )   
Hypertension   3.26 0.07 
   No 3 (2.9% ) 21 (8.2% )   
   Yes 99 (97.1% ) 234 (91.8% )   
Diabetes   <  0.01 0.97 
   No 41 (40.2% ) 103 (40.4% )   
   Yes 61 (59.8% ) 152 (59.6% )   
Dyslipidaem ia   0.31 0.57 
   No 11 (10.8% ) 33 (12.9% )   
   Yes 91 (89.2% ) 222 (87.1% )   
eGFR (m l/ m in)    1.88 0.59 
   45-59 40 (39.2% ) 85 (33.3% )   
   30-44 39 (38.2% ) 99 (38.8% )   
   15-29 20 (19.6% ) 65 (25.5% )   
   <  15 3 (3.0% ) 6 (2.4% )   
Controlled blood pressure (n= 101) (n= 253) 0.65 0.42 
   No 70 (69.3% ) 164 (64.8% )   
   Yes 31 (30.7% ) 89 (35.2% )   
A1C (n= 64) (n= 151) 0.42 0.51 
   <  7 37 (57.8% ) 80 (53.0% )   
   >  7 27 (42.2% ) 71 (47.0% )   
LDL cholesterol (n= 86) (n= 228) 0.02 0.89 
   <  100 43 (50.0% ) 112 (49.1% )   
   >  100 43 (50.0% ) 116 (50.9% )   
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Table 9.11 (cont inued)  
Variables at  baseline Exposure to HDS 
(n= 102) 
Non-exposure 
(n= 255) 
X2 value p-value 
Current  use of NSAI Ds or COX-2 inhibitors  8.92 <  0.01*  
   Yes 12 (11.8% ) 9 (3.5% )   
   No 90 (88.2% ) 246 (96.5% )   
Current  use of aspir in   0.03 0.86 
   Yes 41 (40.2% ) 100 (39.2% )   
   No 61 (59.8% ) 155 (60.8% )   
Prescr ibed, convent ional medicat ion adherence* *   4.20 0.04*  
   Low 33 (32.4% ) 56 (22.0% )   
   Medium to high 69 (67.6% ) 199 (78.0% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
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Analysing associat ions between the exposure, including the potent ial 
confounding factors at  baseline and the fast  progression of CKD at  the end point , 
which was the dependent  variable and defined as either a decline in eGFR of at  
least  -5 m l/ m in/ 1.73m 2/ year or receipt  of dialysis therapy were perform ed using 
a Chi-squared test  and calculat ing unadjusted OR, see Tables 9.12 and 9.13. No 
associat ion was found between the exposure to HDS and the fast  progression of 
CKD (unadjusted OR 0.81, 95% CI  0.50 – 1.32) . 
To explore associat ions between other factors at  baseline, and the fast  
progression of CKD at  the end point , there were posit ive associat ions between 
this dependent  variable and being a younger age ( r isk rat io 1.69, 95%  CI  1.29 – 
2.20) , being m ale ( r isk rat io 1.42, 95%  CI  1.08 – 1.87) ,  having exist ing 
proteinuria ( r isk rat io 2.64, 95%  CI  1.87 – 3.72) , or having poor adherence to 
prescribed m edicat ion ( r isk rat io 1.42, 95%  CI  1.08 – 1.88) , see Table 9.12. No 
associat ions between this outcom e and other variables were found, including the 
use of NSAIDs, aspir in or COX-2 inhibitors.   
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Table 9.12 Univariate analyses of the fast  progression of CKD at  the end point  
and variables at  baseline (n= 357)  
Variables at  baseline Fast  progression 
(n= 131) 
Slow progression 
(n= 226) 
X2 value p-value 
HDS use   0.69 0.40 
   Exposure 34 (26.0% ) 68 (30.1% )   
   Non-exposure 97 (74.0% ) 158 (69.9% )   
Age   14.50 <  0.01*  
   <  60 58 (44.3% ) 56 (24.8% )   
   >  60 73 (55.7% ) 170 (75.2% )   
Sex   6.49 0.01*  
  Male  71 (54.2% ) 91 (40.3% )   
  Female 60 (45.8% ) 135 (59.7% )   
Current  smoking   0.04 0.84 
   Yes 7 (5.3% ) 11 (4.9% )   
   No 124 (94.7% ) 215 (95.1% )   
Obesity (n= 124) (n= 218) 0.13 0.71 
   Yes 52 (41.9% ) 87 (39.9% )   
   No  72 (58.1% ) 131 (60.1% )   
Sever ity of CKD   2.63 0.11 
   Stage 4-5 41 (31.3% ) 53 (23.5% )   
   Stage 3 90 (68.7% ) 173 (76.5% )   
Exist ing proteinur ia (n= 120) (n= 193) 38.05 < 0.01*  
   Yes 89 (74.2% ) 74 (38.3% )   
   No 31 (25.8% ) 119 (61.7% )   
Degree of protein intake  0.59 0.44 
   Moderate to high 60 (45.8% ) 94 (41.6% )   
   Low 71 (54.2% ) 132 (58.4% )   
Hypertension   0.63 0.43 
   Yes 124 (94.7% ) 209 (92.5% )   
   No 7 (5.3% ) 17 (7.5% )   
Diabetes   0.87 0.35 
   Yes 74 (56.5% ) 139 (61.5% )   
   No 57 (43.5% ) 87 (38.5% )   
Dyslipidaem ia   0.91 0.34 
   Yes 112 (85.5% ) 201 (88.9% )   
   No 19 (14.5% ) 25 (11.1% )   
Controlled blood pressure (n= 129) (n= 225) 3.25 0.07 
   No 93 (72.1% ) 141 (62.7% )   
   Yes 36 (27.9% ) 84 (37.3% )   
A1C (% ) (n= 73) (n= 142) 0.04 0.83 
   >  7 34 (46.6% ) 64 (45.1% )   
   <  7 39 (53.4% ) 78 (54.9% )   
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Table 9.12 (cont inued)  
Variables at  baseline Fast  progression 
(n= 131) 
Slow progression 
(n= 226) 
X2 value p-value 
LDL cholesterol (mg/ dl)  (n= 109) (n= 205) 3.42 0.06 
   >  100 63 (57.8% ) 96 (46.8% )   
   <  100 46 (42.2% ) 109 (53.2% )   
Current  use of NSAI Ds or COX-2 inhibitors  0.02 0.89 
   Yes 8 (6.1% ) 13 (5.8% )   
   No 123 (93.9% ) 213 (94.2% )   
Current  use of aspir in   3.85 0.05 
   Yes 43 (32.8% ) 98 (43.4% )   
   No 88 (  67.2% ) 128 (56.6% )   
Prescr ibed, convent ional medicat ion adherence* *   5.62 0.02*  
   Low 42 (32.1% ) 47 (20.8% )   
   Medium to high 89 (67.9% ) 179 (79.2% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
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Table 9.13 The associat ion of the fast  progression of CKD at  the end point  and 
the independent  variables at  baseline (n= 357)  
Variables  Unadjusted OR 95%  Confidence interval 
HDS use   
   Exposure 0.81 0.50 – 1.32 
   Non-exposure  1.00  
Age   
   <  60 2.41 1.53 – 3.81 
   >  60 1.00  
Sex   
   Male 1.76 1.14 – 2.71 
   Female    1.00  
Current  smoking   
   Yes 1.10 0.42 – 2.92 
   No 1.00  
Obesity   
   Yes 1.09 0.70 – 1.70 
   No  1.00  
Sever ity of CKD   
   Stage 4-5 1.49 0.92 -  2.41 
   Stage 3 1.00  
Exist ing proteinur ia   
   Yes 4.62 2.80 – 7.62 
   No 1.00  
Protein intake   
   Moderate to high 1.19 0.77 – 1.83 
   Low 1.00  
Hypertension   
   Yes 1.44 0.58 – 3.57 
   No 1.00  
Diabetes   
   Yes 0.81 0.53 – 1.26 
   No 1.00  
Dyslipidaem ia   
   Yes 0.73 0.39 – 1.39 
   No 1.00  
Controlled blood pressure   
   No 1.54 0.96 – 2.46 
   Yes    1.00  
A1C (% )   
   >  7 1.06 0.60 – 1.87 
   <  7 1.00  
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Table 9.13 (cont inued)  
Variables at  baseline  Unadjusted OR 95%  Confidence interval 
LDL cholesterol (mg/ dl)    
   >  100 1.56 0.97 – 2.49 
   <  100  1.00  
Current  use of NSAI Ds or COX-2 inhibitors  
   Yes 1.07 0.43 – 2.64 
   No  1.00  
Current  use of aspir in   
   Yes 0.64 0.41 -1.00 
   No  1.00  
Prescr ibed, convent ional medicat ion adherence* *   
   Low 1.80 1.10 – 2.93 
   Moderate to high 1.00  
* *  Medicat ion adherence was measured using the Thai version of the 8-I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
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To ident ify the confounding factors related to the associat ion between exposure 
and the prim ary outcom e, m ult iple logist ic regression analysis was perform ed. 
Com paring unadjusted OR of the associat ion between the exposure and the 
outcom e (unadjusted OR 0.81, 95% CI  0.50 -1.32)  with it s adjusted OR, 
result ing from  m ult iple logist ic regression analysis, found only proteinuria as a 
confounding factor related to this associat ion. This was because there was m ore 
than 10%  of the difference between unadjusted and adjusted OR of such 
relat ionship (adjusted ORproteinuria 1.21, 95% CI  0.70 – 2.10) . Age, sex, 
m edicat ion adherence and the use of NSAI Ds or COX-2 inhibitors were not  
confounding factors as less than 10%  of the differences in unadjusted and 
adjusted OR of the associat ion between the exposure and the outcom e (adjusted 
ORage 0.77, 95% CI  0.47 – 1.27;  adjusted ORsex 0.81, 95% CI  0.50 – 1.32;  
adjusted ORm edicat ion adherence 0.76, 95% CI  0.46 – 1.24;  adjusted ORuse of NSAI Ds or COX-
2 inhibitors 0.81, 95% CI  0.49 – 1.32) .  
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Therefore, the m odel of the associat ion between the exposure and to the fast  
progression of CKD was step by step included each of the factor:  the exposure, 
age, sex, and proteinuria based on this order,  see Table 9.14. The finding 
indicated that  the associat ion between the exposure and the outcom e was not  
found (adjusted OR 1.16, 95% CI  0.66 – 2.03) .  I n cont rast ,  exist ing proteinuria 
at  baseline and younger age were associated with the fast  progression of CKD 
(adjusted odds rat io (OR)  4.22, 95%  CI  2.52 – 7.05;  adjusted OR 1.91, 95%  CI  
1.14 – 3.18, respect ively) , see Table 9.14. The total num ber of m ult iple logist ic 
regression analysis was 313, as 44 respondents were not  m easured for 
proteinuria.  
Table 9.14 Mult iple logist ic regression analysis of the fast  progression of CKD 
and variables at  baseline ( total num ber of analysis=  313)  
Variables Adjusted odds rat io*  95%  Confidence interval 
HDS use   
   Non-exposure  1.00  
   Exposure 1.16 0.66 – 2.03 
Age   
   >  60 1.00  
   <  60 1.91 1.14 – 3.18 
Sex   
   Female  1.00  
   Male 1.57 0.96 – 2.58  
Exist ing proteinur ia   
   No 1.00  
   Yes 4.22 2.52 – 7.05 
*  OR adjusted for all other var iables listed in the table 
9 .2 .3  Pat ients experiencing renal adverse effects and 
benefits from  HDS and analgesic use 
Medical notes am ongst  the exposed group were reviewed in order to exam ine 
HDS induced acute kidney injury (AKI )  reported by a doctor . Reported renal 
adverse effects in the m edical notes showed that  two pat ients, who were using 
herbal m edicine, suffered from  AKI  in addit ion to CKD, as diagnosed by a doctor.  
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The incidence of herbal m edicine- induced AKI  was 0.6%  in this cohort  study. 
After  the concerned pat ients stopped using the m edicine, their eGFR im proved. 
The first  pat ient  used a m ixture of 10 unknown Chinese herbal m edicines and his 
eGFR im proved from  26 to 41 m l/ m in/ 1.72m 2 ( serum  creat inine changed from  
4.15 to 2.45 m g/ dl)  after stopping them . The second pat ient  took both r iver 
spiderwort  and diclofenac;  aft er  stopping both the herbal m edicine and the 
NSAI D, his eGFR increased from  18 to 25 m l/ m in/ 1.72m 2 ( serum  creat inine 
changed from  8.36 to 5.64 m g/ dl) . These pat ients exposed such herbal 
m edicines within one m onth before worsening their kidney funct ion, a situat ion 
which is likely to associate with the onset  of herbal m edicine- induced AKI . After  
they stopped using suspected herbal m edicines and NSAID, their kidney funct ion 
returned to their baseline of kidney funct ion within 3 m onths. Addit ionally, other 
factors, which m ay be related to worsening kidney funct ion, were less likely to 
change during this period. This was the process of assessing causality of these 
suspected adverse events, using World Health Organisat ion’s Uppsala Monitoring 
Cent re causalit y categories289 analysed by MT. Therefore, AKI  were likely to be 
related to such herbal m edicines, and both the herbal m edicine and the NSAI D 
could be associated with AKI  in the second pat ient .  
Medical notes of all respondents who used NSAI Ds or COX-2 inhibitors during the 
study were reviewed to collect  data regarding a report  of these m edicat ions 
related to AKI  diagnosed by a doctor.  Sixteen pat ients (4.8% )  had AKI , in 
addit ion to CKD, due to taking NSAI Ds, COX-2 inhibitors or an analgesic dose of 
aspir in;  their renal funct ion was im proved by between 8%  to 36% , after  
stopping them . 
Regarding benefit s of HDS use, 8 pat ients out  of 62 pat ients, who regularly used 
HDS for 12 m onths (13% ) , reported that  their kidney funct ion did not  worsen, 
which was related to their rate of decline in eGFR per year. Most  of t hem  were 
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not  obese, or had proteinuria, and could cont rol their blood pressure, which are 
m ain factors- related to the progression of CKD, see Table 9.15.  
Chapter 9:  The associat ion of HDS, the progression of CKD and its complicat ions 
214 
Table 9.15 Pat ients reported gaining benefit  from  HDS use and their r isk factors 
Pat ient  
no.  
HDS use Age Stages 
of CKD 
Co-m orbidit ies Obesit y Analgesic or 
aspir in use  
Proteinur ia Cont rolled 
BP 
Cont rolled A1C Cont rolled 
LDL 
1 Spring bit ter cucum ber (Mom ordica 
cochinchinensis)  
67 4 Diabetes,  HTN Yes Aspir in 81 m g Yes Yes No Yes 
2 Jujube combined with roselle,  
boesenbergia’s ju ice and a m ixture of three 
types of mushroom s’ ju ice 
57 4 HIV, HBV No No No No -  No 
3 A Chinese folk remedy -   
Cordyceps, Angelica sinensis,  deer ant ler  
velvet ,  f ive f lavour  berry (Schisandra 
chinensis)  and cinnamon 
67 3a HTN No NSAID use No Yes Yes No 
4 Unknown Chinese folk remedy for CKD 42 3a HTN No Aspir in 81 m g No Yes -  Yes 
5 Boesenbergia’s ju ice and unknown Chinese 
folk remedy for  CKD 
43 3b Chronic 
glomerulonephrit is 
No No Yes No -  No 
6 A herbal combinat ion – Boesenbergia, m int ,  
ginger, galangal,  lemongrass,  kaff ir  lime 
leaves and shallots 
79 4 Diabetes,  HTN No Aspir in 81 m g No Yes Yes Yes 
7 Wheatgrass and a m ixture of 60  botanical 
agents 
54 4 Diabetes,  HTN No Aspir in 81 m g No Yes Uncont rolled 
FBS 
No 
8 Turmeric (Curcuma longa)  64 4 Diabetes,  HTN No Aspir in 81 m g No No Yes Yes 
Note:  BP =  Blood pressure;  HTN =  Hypertension;  FBS =  Fast ing blood sugar  
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9 .2 .4  The associat ion betw een exposure to HDS and CKD 
com plicat ions 
Three-hundred and thirty pat ients who did not  receive dialysis during the follow-
up study were analysed to ascertain any correlat ions of uncont rolled 
hyperkalem ia and hyperphophatem ia between exposed and unexposed groups. 
Only two pat ients had over 5.5 m Eq/ l of a m ean serum  level of potassium  over 
one year. There was a stat ist ically significant  associat ion between uncont rolled 
hyperphosphatem ia and exposure to HDS ( risk rat io 3.05, 95%  CI  1.18 – 7.92) ,  
whilst  an associat ion between uncont rolled hyperkalem ia and exposure was not  
found ( r isk rat io 0.62, 95%  CI  0.29 – 1.29) , see Table 9.16.  
There were no differences in num bers of the non-m easurem ent  of serum  levels 
of potassium  or phosphate over one year in each independent  variable at  
baseline, except  the non-m easurem ent  of serum  levels of phosphate between 
respondents receiving t reatm ent  of hyperphosphatem ia and those who did not  
receive it  (X2 value 14.67, p- value <  0.01)  and such non-m easurem ent  between 
CKD stage 3 and stages 4 to 5 (X2 value 12.48, p- value <  0.01) .  Fift y- four 
respondents (90% )  who were not  t reated for  hyperphosphatem ia had the non-
m easurem ent  of serum  levels of phosphate over one year, com pared with those 
receiving t reatm ent  of hyperphosphatem ia (6 respondents, 10% ) . Respondents 
with stage 3 CKD had the non-m easurem ent  of such elect rolyte (57 respondents, 
95% ) , rather m ore than those with stages 4 to 5 CKD (3 respondents, 5% ) . 
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Table 9.16 Univariate analyses between the secondary outcom es, exposure to HDS and related factors at  baseline (n= 330)  
Variables at  baseline Uncont rolled hyperkalem ia over one year Missing data X2 value p-value Unadjusted OR (95% CI )  
 Yes (n= 39)  No (n= 289)  (n= 2)     
HDS use    1.75 0.19 0.58 (0.26 -  1.31)  
   Exposure 8 (20.5% )  89 (30.8% )  1 (50.0% )     
   Non-exposure 31 (79.5% )  200 (69.2% )  1 (50.0% )     
Age    0.38 0.54 0.79 (0.37 -  1.69)  
   <  60 10 (25.6% )  88 (30.4% )  0 (0.0% )     
   >  60 29 (74.4% )  201 (69.6% )  2 (100.0% )     
Sex    0.82 0.37 1.36 (0.70 -  2.66)  
   Male 20 (51.3% )  126 (43.6% )  1 (50.0% )     
   Female 19 (48.7% )  163 (56.4% )  1 (50.0% )     
Severity  of CKD    4.76 0.03*  2.18 (1.07 – 4.46)  
   Stage 4-5 14 (35.9% )  59 (20.4% )  0 (0.0% )     
   Stage 3 25 (64.1% )  230 (79.6% )  2 (100.0% )     
Degree of high potassium  intake* *    0.77 0.38 0.73 (0.36 -  1.48)  
   Moderate t o high 25 (64.1% )  205 (70.9% )  2 (100.0% )     
   Low  14 (35.9% )  84 (29.1% )  0 (0.0% )     
Treatment  of hyperkalem ia* * *    10.57 <  0.01*  3.14 (1.53 -  6.42)  
   Yes 15 (38.5% )  48 (16.6% )  0 (0.0% )     
   No 24 (61.5% )  241 (83.4% )  2 (100.0% )     
Use of loop diuret ics     1.46 0.23 0.59 (0.25 -  1.40)  
   Yes 7 (17.9% )  78 (27.0% )  0 (0.0% )     
   No 32 (82.1% )  211 (73.0% )  2 (100.0% )     
Use of ACEIs or  ARBs    0.01 0.92 1.04 (0.53 -  2.04)  
   Yes 23 (59.0% )  168 (58.1% )  1 (50.0% )     
   No 16 (41.0% )  121 (41.9% )  1 (50.0% )     
Prescr ibed, convent ional medicat ion adherence   3.18 0.08 1.89 (0.93 – 3.85)  
   Low 14 (35.9% )  66 (22.8% )  1 (50.0% )     
   Medium  to high 25 (64.1% )  223 (77.2% )  1 (50.0% )     
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Table 9.16  (cont inued)  
Variables at  baseline Uncontrolled hyperphosphatem ia over one year Missing data X2 value p-value Unadjusted OR (95% CI ) 
 Yes (n= 16) No (n= 254) (n= 60)    
HDS use    5.78 0.02*  3.31 (1.19 -  9.24) 
   Exposure 9 (56.3% ) 71 (28.0% ) 18 (30.0% )    
   Non-exposure 7 (43.7% ) 183 (72.0% ) 42 (70.0% )    
Age    3.54 0.06 2.58 (0.93 – 7.13) 
   <  60 8 (50.0% ) 71 (28.0% ) 19 (31.7% )    
   >  60 8 (50.0% ) 183 (72.0% ) 41 (68.3% )    
Sex    1.70 0.19 0.49 (0.17 – 1.46) 
   Male 5 (31.2% ) 122 (48.0% ) 20 (33.3% )    
   Female 11 (68.8% ) 132 (52.0% ) 40 (66.7% )    
Sever ity of CKD     2.81 0.09 2.36 (0.84 – 6.59) 
   Stage 4-5 7 (43.8% ) 63 (24.8% ) 3 (5.0% )    
   Stage 3 9 (56.3% ) 191 (75.2% ) 57 (95.0% )    
Degree of high phosphate intake* *    1.63 0.20 0.44 (0.12 -  1.60) 
   Moderate to high 3 (18.8% ) 87 (34.3% ) 19 (31.7% )    
   Low  13 (81.2% ) 167 (65.7% ) 41 (68.3% )    
Treatment  of hyperphosphatem ia   0.12 0.73 0.83 (0.28 -  2.46) 
   Yes 5 (31.3% ) 90 (35.4% ) 6 (10.0% )    
   No 11 (68.7% ) 164 (64.6% ) 54 (90% )    
Prescr ibed, convent ional medicat ion 
adherence 
  0.03 0.87 1.10 (0.34 – 3.54) 
   Low 4 (25.0% ) 59 (23.2% ) 18 (30.0% )    
   Medium to high 12 (75.0% ) 195 (76.8% ) 42 (70.0% )    
Missing data =  the non-measurement  of serum levels of potassium or phosphate over one year, *  Stat ist ical significance at  p-value <  0.05 
* *  measured by the rest r ict ion of protein, potassium, phosphate and salt  diet quest ionnaire, * * *  received sodium or calcium polystyrene sulfonat
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Mult iple logist ic regression analysis included exposure and all independent  
variables of hyperkalem ia or hyperphosphatem ia in order to exam ine the effect  
of each variable on the dependent  variable – uncont rolled hyperkalem ia or 
hyperphosphatem ia. Based on the literature, independent  variables which m ay 
be related to uncont rolled hyperkalem ia were the degree of high potassium  
intake, t reatm ent  of hyperkalem ia, the use of loop diuret ics, ACEI s or ARBs. 
I ndependent  variables related to hyperphosphatem ia, based on the literature, 
were the degree of high phosphate intake and t reatm ent  of hyperphosphatem ia. 
Age, sex, the severity of CKD and prescribed, convent ional m edicat ion 
adherence were also included in the m ult iple logist ic regression analysis, as 
these variables m ay influence the dependent  variables.  
Com paring unadjusted and adjusted OR of the relat ionship between HDS and the 
secondary outcom es, in order to exam ine potent ial confounding factors, found 
no differences in both outcom es (unadjusted OR of uncont rolled hyperkalem ia 
0.58, 95% CI  0.26 – 1.31;  it s adjusted OR
 
0.59, 95% CI  0.25 – 1.38;  unadjusted 
OR of uncont rolled hyperphosphatem ia 3.31, 95% CI  1.19 – 9.24;  and its 
adjusted OR
 
3.53, 95% CI  1.20 – 10.43) , see Tables 9.16-9.17. Exam ining 
potent ial confounding factors related to the associat ion between HDS and 
uncont rolled hyperkalem ia, i.e. age, sex, the severity of CKD and t reatm ent  of 
hyperkalem ia, found no differences between unadjusted and adjusted OR when 
cont rolling such factors (unadjusted OR 0.58, 95% CI  0.26 – 1.31;  adjusted 
ORage 0.59, 95% CI  0.26 – 1.33;  adjusted ORsex 0.58, 95% CI  0.26 – 1.32;  
adjusted ORseverity  of CKD 0.59, 95% CI  0.26 – 1.34;  and adjusted ORt reatm ent  of 
hyperkalem ia 0.63, 95% CI  0.28 – 1.44) .  Likewise, there was no difference in the 
associat ion between HDS and uncont rolled hyperphosphatem ia after  cont rolling 
for  age or sex (unadjusted OR 3.31, 95% CI  1.19 – 9.24;  adjusted ORage 3.33, 
95% CI  1.19 – 9.38;  and adjusted ORsex 3.49, 95% CI  1.24 – 9.82) .  
. .  
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Table 9.17 Mult iple logist ic regression analyses between the secondary outcom es 
over one year, exposed group and other factors at  baseline  
Variables at  baseline Adjusted OR*  95%  CI  
Uncontrolled hyperkalem ia over one year (n= 328)   
   HDS use   
      Non-exposure  1.00  
      Exposure 0.59 0.25 -  1.38 
   Age   
     >  60 1.00  
     <  60 0.59 0.26 – 1.37 
   Sex   
     Female 1.00  
     Male 1.72 0.83 – 3.57 
   Sever ity of CKD   
     Stage 3 1.00  
     Stage 4-5 2.90 1.28 – 6.55 
   Degree of potassium intake  
      Low 1.00  
      Moderate to high 0.84 0.40 -  1.77 
   Treatment  of hyperkalem ia   
      No 1.00  
      Yes 3.02 1.43 -  6.40 
   Use of loop diuret ics   
      No 1.00  
      Yes 0.41 0.16 – 1.05 
   Use of ACEI s or ARBs   
     No 1.00  
     Yes 1.14 0.54 – 2.41 
   Prescr ibed, convent ional medicat ion adherence   
     Medium to high 1.00  
     Low 2.16 1.00 – 4.70 
*  OR adjusted for all other var iables listed in the table 
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Table 9.17  ( cont inued)  
Var iables at  baseline Adjusted OR*  95%  CI  
Uncontrolled hyperphosphatem ia over one year 
(n= 270) 
  
   HDS use   
      Non-exposure  1.00  
      Exposure 3.53 1.20 – 10.43 
   Age   
     >  60 1.00  
     <  60 3.01 0.99 – 9.13 
   Sex   
     Female 1.00  
     Male 0.59 0.18 – 1.88 
   Sever ity of CKD   
     Stage 3 1.00  
     Stage 4-5 2.22 0.71 – 6.91 
   Degree of phosphate intake  
      Low 1.00  
      Moderate to high 0.43 0.11 – 1.64 
   Treatment  of hyperphosphatem ia   
      No 1.00  
      Yes 1.11 0.32 – 3.80 
   Prescr ibed, convent ional medicat ion adherence   
     Medium to high 1.00  
     Low 0.78 0.22 – 2.77 
*  OR adjusted for all other var iables listed in the table 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772. 
Stages 4 to 5 CKD was associated with uncont rolled hyperkalem ia or 
hyperphosphatem ia, com pared with stage 3 CKD (adjusted OR of uncont rolled 
hyperkalem ia 2.90, 95% CI  1.28 – 6.55;  adjusted OR of uncont rolled 
hyperphosphatem ia 2.22, 95% CI  0.71 – 6.91) . Pat ients receiving t reatm ent  for  
hyperkalem ia or hyperphosphatem ia at  baseline st ill had uncont rolled 
hyperkalem ia or hyperphosphatem ia at  the end point  (adjusted OR of 
uncont rolled hyperkalem ia 3.02, 95% CI  1.43 – 6.40;  adjusted OR of 
uncont rolled hyperphosphatem ia 1.11, 95% CI  0.32 – 3.80) ,  see Table 9.17.  
Regarding cont rolling m edicat ion adherence, those receiving t reatm ent  of 
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hyperkalem ia or hyperphosphatem ia and having poor adherence were m ore 
likely to be uncont rolled hyperkalem ia or hyperphosphatem ia than those with 
m oderate to high adherence (adjusted ORm edicat ion adherence of uncont rolled 
hyperkalem ia 2.63, 95% CI  0.79-8.77;  adjusted ORm edicat ion adherence of uncont rolled 
hyperphosphatem ia 1.64, 95% CI  0.26 – 10.40) . I t  would seem  that  pat ients 
receiving the t reatm ent  st ill had uncont rolled hyperkalem ia or 
hyperphosphatem ia due to poor m edicat ion adherence. 
Pat ients who had m oderate to high potassium or phosphate intake at  baseline 
were likely to cont rol their serum  levels of potassium  or phosphate over one 
year, com pared with those with low intake (adjusted OR of uncont rolled 
hyperkalem ia 0.84, 95% CI  0.40 – 1.77;  adjusted OR of uncont rolled 
hyperphosphatem ia 0.43, 95% CI  0.11 – 1.64) . This could be influenced by 
standard pract ice for  pat ients with uncont rolled hyperkalem ia or 
hyperphosphatem ia. Health care providers i.e. doctors, pharm acists or  diet icians 
advised the pat ients to avoid consum ing high potassium  or phosphate intake 
when they had uncont rolled hyperkalem ia or hyperphosphatem ia.  
Poor convent ional m edicat ion adherence seem ed to be associated with 
uncont rolled hyperkalem ia (adjusted OR 2.16, 95% CI  1.00 – 4.70) . I n cont rast , 
pat ients with poor adherence were able to cont rol their serum  levels of 
phosphate over one year (adjusted OR 0.78, 95% CI  0.22 – 2.77) .  Regarding 
cont rolling phosphate intake, pat ients with poor adherence and low phosphate 
intake cont rolled hyperphosphatem ia m ore than those with poor adherence and 
m oderate to high phosphate intake (adjusted ORphosphate intake 0.37, 95% CI  0.05 – 
2.87) . I t  would appear that  pat ients with poor adherence had cont rolled 
hyperphosphatem ia as they cont rolled their phosphate intake. 
Chapter 9:  The associat ion of HDS, the progression of CKD and its complicat ions 
222 
9 .2 .5  Sensit ivity analyses 
To test  the robustness of the associat ion between exposure to HDS and the fast  
progression of CKD, m ult iple sensit ivit y analyses were perform ed. The first  
analysis was to com pare the associat ions between various classificat ions of cut -
off points for the fast  progression of CKD and related factors. Secondly, there 
were analyses of any associat ions between risk factors and this outcom e 
between all pat ients, and those with glom erular disease, cancer, hepat it is, 
cirrhosis or HIV -  related to various rates of the progression, com pared with 
those with diabetes or hypertension. Finally, there was the invest igat ion of such 
associat ions between consistent  exposed and unexposed groups over one year,  
which were excluded pat ients who stopped using HDS, and those who started 
using HDS during the follow-up period, see Appendix 15.     
Of the 330 pat ients who did not  start  receiving dialysis during the follow-up 
period, four cut -off points of decline in eGFR per year were:  at  least  -5 
m l/ m in/ 1.72m 2/ year based on literature;  at  least  -4 m l/ m in/ 1.72m 2/ year based 
on m ean decline in eGFR in this study and plus a quarter of SD;  at  least  -6 
m l/ m in/ 1.72m 2/ year based on such m ean plus half SD;  and at  least  -10 
m l/ m in/ 1.72m 2/ year based on such m ean plus SD. Univariate analyses were 
perform ed at  these cut -off points and results were as follows.    
An associat ion between the exposure to HDS and the outcom e was not  found at  
any of the cut -off points. However, there were stat ist ically significant  
associat ions between this outcom e and being younger, having exist ing 
proteinuria, uncont rolled LDL cholesterol, or having poor adherence to prescribed 
convent ional m edicat ion at  all cut -off points. These factors are known as r isk 
factors in the fast  progression of CKD. There were inconsistent  associat ions 
between sex and this outcom e at  som e cut -off points. This outcom e at  -5 and -6 
cut -off points was related to gender, but  not  at  -4 and -10. 
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Causes of CKD affect  the rate of CKD progression. For exam ple, polycyst ic 
kidney disease and glom erulonephrit is have faster  rates of progression. The rate 
of CKD progression am ongst  pat ients with HIV, cirrhosis and cancer differs from  
pat ients with diabetes or hypertension. To test  whether or not  these confounding 
factors influenced the outcom e, pat ients with glom erular diseases, HIV, cirrhosis 
or cancer were excluded. Then univariate analyses between variables and the 
progression of CKD were perform ed. As a result , there was no difference 
between all respondents and those who did not  have such diseases. 
The exposed and unexposed groups at  baseline changed their exposure to HDS 
during the follow-up period, so this m ay have affected the findings. Sixty- two 
pat ients cont inued regularly taking HDS for 12 m onths and were defined as the 
exposed group, whilst  177 pat ients did not  take them  at  all, i.e. the unexposed 
group. These groups were analysed to establish the effects on the CKD 
outcom es, and it  was found that  there was no difference from  the originally 
defined groups. 
9 .3  Discussion 
9 .3 .1  Key findings 
Three-hundred and fift y-seven Thai pat ients with CKD were followed for 12 
m onths and less than 10%  died or received dialysis therapy. Mean age and SD in 
this cohort  study was 66 and 13, and 55%  of the part icipants were fem ale. At  
least  60%  of the research populat ion had com orbid diabetes and hypertension. 
Mean BMI  in this study was 25 kg/ m 2 at  baseline. Mean eGFR (SD)  at  baseline 
was 39 (12)  m l/ m in and 74%  had stage 3 CKD. Twenty-nine percent  regularly 
used HDS at  baseline.  
There were no differences in dem ographic characterist ics between exposed and 
unexposed groups, except  that  the exposed group was m ore likely to use 
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NSAI Ds or COX-2 inhibitors;  levels of adherence to prescribed, convent ional 
m edicat ion were lower in the exposed group. A relat ionship between HDS use 
and the fast  progression of CKD in Thai pat ients with CKD was not  found 
(adjusted OR 1.16, 95% CI  0.66 – 2.03) .  There were associat ions between the 
fast  progression of CKD, and exist ing proteinuria (adjusted OR 4.22, 95% CI  2.52 
– 7.05)  and younger age (adjusted OR 1.91, 95% CI  1.14 – 3.18) .  
I n the 330 pat ients who did not  init iate dialysis therapy, there was a stat ist ically 
significant  associat ion between HDS use and uncont rolled hyperphosphatem ia 
(adjusted OR 3.53, 95% CI  1.20 – 10.43) . However, no associat ion between HDS 
use and uncont rolled hyperkalem ia was found (adjusted OR 0.59, 95%  CI  0.25 – 
1.38) . 
9 .3 .2  Character ist ics of respondents 
There was no difference in the m ean age (66)  in the present  study and the 
stages 2 to 4 CKD populat ion in Thailand (65) .290 The proport ion of wom en in the 
present  study was higher than m en (55% ) , which is inconsistent  with 
Chartsrisak’s study in Thailand, where 44%  of the populat ion were fem ale.290 A 
sm all num ber of respondents aged over 70 years m ay have underest im ated GFR 
at  baseline due to a lim itat ion of the MDRD equat ion (n= 32, 8% ) . 
Pat ients in the present  study showed no difference in a prevalence of 
hypertension (93% )  and diabetes (60% ) , com pared to the Thai CKD populat ion 
(91%  and 56% , respect ively) . 
The high num ber with hypertension in the current  study m ay be due to this 
dataset  including both the history of hypertension, and hypertension caused by 
CKD, in the definit ion of hypertension, as this was not  separately ident ified in the 
m edical notes. The sam ple in this study represented CKD result ing from  
hypertension and diabetes. Nine percent  had cancer and registered a decline in 
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kidney funct ion156 in the present  study, and this does not  differ great ly from 
Goeij ’s study (2011)  in the Netherlands (11% ) .172  
The num ber of current  sm okers (5% )  and m ean BMI  (25 kg/ m 2)  in the present  
study were lower than other cohort  studies am ongst  pat ients with stages 3 to 5 
CKD in European count ries (current  sm oking 13-56% , m ean BMI  26-27 
kg/ m 2) .172,291,292 However, these pat ients in both Thai and Western populat ions 
are overweight , which is defined as at  least  23 kg/ m 2 of BMI  in a Thai 
populat ion293 and at  least  25 kg/ m 2 of BMI  in a Western populat ion.281 Sm oking 
status in the current  study (5% )  is also lower than Thai pat ients with CKD in the 
Thai nat ional health survey (26% ) 146, whilst  the m ean BMI  in the present  study 
was not  different ,  com pared to the Thai CKD populat ion (25 kg/ m 2)  290 and 
cohort  studies in Japan (23-24 kg/ m 2) .150,294 There was a different  proport ion of 
sm oking status between the current  study and data from  the literature, due to 
the different  populat ions. The Thai nat ional health survey recruited people aged 
15 or over and who were not  diagnosed with CKD at  recruitm ent , whilst  the 
current  study recruited pat ients diagnosed with CKD. Pat ients with CKD were 
m ore likely to have stopped sm oking, com pared with the general populat ion. 
A m ortalit y rate (7% ) , and pat ients who reached end-stage renal disease (8% )  
in the present  study, are consistent  with Landray’s study in the UK (6%  and 
12% )  and Nicola’s study in I taly (6%  and 8% ) .171,292 I t  would seem  that  
respondents in the current  study had less severe CKD than those pat ients cited 
in other studies170,171,291,292,294 as m ost  of them  had stage 3 CKD (74% ) . The 
m ean eGFR at  baseline in the current  study (39 m l/ m in/ 1.73m 2/ year)  was higher 
than other studies ( range 22-31 m l/ m in/ 1.73m 2/ year) .170,171,291,292,294 The 
proport ion of pat ients with cont rolled blood pressure (<  130/ 80 m m Hg)  in the 
current  study (35% )  was lower than Muntner’s study in the US (47% ) 295,  but  it  
is higher than Nicola’s study in I taly  (13% ) 171 and Mart inez-Castelao’s study in 
Spain (17.4% ) .151 Less than 35%  received ACEIs or ARBs in the current  study, 
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which is lower than other studies in Western count ries (at  least  60% ) .44,291 
However, this is not  great ly different  from  a cohort  study in Japan (ACEIs 21%  
and ARBs 40% ) .294  
Regarding the proport ion of exist ing proteinuria (52% ) , and hyperphosphatem ia 
at  baseline (7% ) , data are consistent  with the CKD populat ion in Western 
count ries (60%  and 9-11% , respect ively) 151,171 and the Thai CKD populat ion 
(hyperphosphatem ia 8% ) .290 There was a very sm all num ber of respondents that  
were current ly using NSAIDs or COX-2 inhibitors ( less than 10% ) , which is lower 
than Kuo’s study am ongst  CKD pat ients in Taiwan (NSAIDs 19%  and COX-2 
inhibitors 1% ) 174 and I ngsathit ’s survey in the Thai general populat ion (NSAIDs 
45% ) .5 
I t  would appear therefore that  respondents in the current  study represent  Thai 
pat ients with CKD stages 3 to 5, despite having less severe CKD than Western 
populat ions. The populat ion in the present  study had low rates of sm oking and 
use of NSAIDs or COX2- inhibitors.  
9 .3 .3  The associat ion betw een r isk  factors and the 
progression of CKD 
To com pare dem ographic characterist ics between the drop-out  group (death and 
lost  to follow-up)  and the included groups, there were no differences between 
the groups, except  cont rol of blood pressure. The included group was less likely 
to have cont rolled blood pressure than the drop-out  group (p- value <  0.05) . This 
was unlikely to affect  t he prim ary outcom e in this study as the drop-out  group 
did not  intent ionally leave the study based on faster progression of CKD, 
com pared with the included group. 
There were no differences in dem ographic characterist ics between exposed and 
unexposed groups. The only difference between these groups was the use of 
NSAI Ds or COX-2 inhibitors, and the degree of adherence to prescribed, 
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convent ional m edicat ion. Exposure to HDS was m ore likely to result  in a low 
level of prescribed convent ional m edicat ion adherence (unadjusted OR 1.7, 
95% CI  1.02-2.83) , which was discussed in Chapter 8. However, these factors 
did not  influence the associat ion between HDS use and the fast  progression of 
CKD. Only exist ing proteinuria was a confounding factor in this associat ion.  
There was no associat ion between the fast  progression of CKD over a year and 
HDS use, as analysed by univariate and m ult iple variate analyses, which was 
also tested for  robustness using sensit ivit y analyses. No differences were found. 
This m ay be because HDS, used by Thai pat ients with CKD, were m ore likely to 
be dietary, such as m ushroom s, garlic, cinnam on, lem ongrass, kaffir  lim e leaves, 
j ujube and dietary supplem ents. There was also no report  of renal adverse 
effect s from  the HDS used by respondents, i.e. turm eric, ginseng, garlic, veld 
grape, senna, kariyat  and gingko. This finding is supported by the Thai Health 
Product  Vigilance Center database from  2000 to 2008.128  
Despite lim ited case reports on the renal adverse effects of m any herbal 
m edicines, used by the Thai populat ion in the present  study, there are several 
anim al studies of acute and sub-chronic toxicity. Most  studies, in rats, report  no 
acute and/ or sub-chronic renal toxicit y from  consum ing Moringa oleifera296, Thai 
folk rem edy – ‘Ka sai’297, Tiliacora t r iandra298, Cissus quadrangularis299, Gynura 
procum bens300, Cordyceps301 or Coccinia gradis.302 
However, som e pat ients (n= 11)  in the present  study used HDS, which should be 
avoided i.e.  aloe, senna, ginseng and ‘Ya hom ’;  avoidance recom m ended by the 
Nat ional Kidney Foundat ion in the US and the Thai Nat ional List  of Essent ial 
Medicines.119,194,208 Both aloe and senna contain anthraquinones, which could 
accum ulate in renal t issues and induce elect rolyte im balance.303 Ginseng could 
lead to an increase in blood pressure.208 The Thai folk rem edy – ‘Ya hom ’ caused 
renal failure and death in a 2-year-old gir l,  as it  contained Magnolia officinalis 
which can cause renal failure.196  
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There was one case report , and several anim al studies (n= 5) , in which spirulina, 
Tinospora crispa and ‘Tri pala’ were found to be related to renal toxicit y. A dose 
(1 g/ day)  of spirulina induced acute rhabdom yolysis in a 28-year-old m an, which 
could have led to acute renal failure.304 Prolonged high doses of Tinospora crispa 
can induce renal toxicit y in rats.305 A high dose ‘Tri pala’ in rats caused 
nephrocalcinosis, chronic pyelonephrit is and renal hydrocalyx because it  contains 
tannin, which is m etabolised into gallic acid, result ing in renal toxicity.306 
Therefore, pat ients with CKD should avoid these herbal m edicines. 
The finding of ‘no relat ionship’ between HDS and the fast  progression of CKD in 
the present  study is inconsistent  with cross-sect ional studies in Thailand and 
Taiwan4,5, which found herbal m edicines were related to CKD and a case-cont rol 
study in Taiwan7 indicated an associat ion between Chinese herbal m edicine and 
end-stage renal disease.  
There are several reasons to support  the present  finding, as follows. First ly, the 
Thai populat ion in the present  study m ight  have used different  t ypes of herbal 
m edicine com pared with the part icipants in the above studies;  a sm all num ber of 
them  were using Chinese herbal m edicine (n= 5) , com pared with studies in 
Taiwan. However, such previous studies did not  provide the types of herbal 
m edicine used, and populat ions in two out  of t hree of the studies used Chinese 
herbal m edicines, which are likely to induce nephrotoxic effects.307 Secondly, all 
previous studies speculated about  negat ive effects of herbal m edicines based on 
evidence, despite unknown types of herbal m edicines being included. Finally, the 
study in Thailand5 showed a weak associat ion between herbal m edicine and CKD 
(adjusted OR 1.2, 95%  CI  1.02-1.42) ,  whilst  the case cont rol study in Taiwan 
found a st rong associat ion between Chinese herbal m edicine and end-stage renal 
disease (crude OR 6.26, 95%  CI  3.85-10.19) .7 These findings suggest  that  Thai 
herbal m edicine m ay be less likely to be associated with adverse effect s on 
kidney funct ion than Chinese herbal m edicine, due to the fact  that  Chinese 
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herbal m edicine is likely to be contam inated with NSAIDs related to acute kidney 
injury.7 
No associat ion between HDS use and the fast  progression of CKD m ay be 
because the effect  size in this study was sm aller than the expected effect  on 
kidney funct ion, when calculat ing sam ple size determ inat ion. As a result , the 
num ber of part icipants m ay not  be sufficient  to detect  the effect . However, this 
study was the first  study to determ ine this associat ion, so the finding in the 
present  study will inform  further research.  
Medical notes in the present  study showed two respondents, who were using 
herbal m edicine, suffered from  acute kidney injury in addit ion to their CKD 
(0.6% ) . Unfortunately, the first  person did not  know ingredients in the Chinese 
herbal m edicine he used;  the other used r iver spiderwort  com bined with 
diclofenac. These herbal m edicines were likely to be related to AKI ;  a conclusion 
reached when they were assessed using World Health Organisat ion’s Uppsala 
Monitoring Cent re causalit y categories.289 There is no evidence to support  
whether or  not  r iver spiderwort  is related to AKI . However, this incidence 
indicated an exam ple of the infrequent , albeit  serious, adverse effects of herbal 
m edicine on worsening kidney funct ion.308 I t  is reasonable to conclude that  
health care providers should be aware of herbal m edicine use am ongst  Thai 
pat ients with CKD, part icularly Chinese herbal m edicine and r iver spiderwort ,  
and therefore that  they should closely m onitor adverse effect s of herbal 
m edicine. Further studies are required to explore what  type of Thai herbal 
m edicine leads to AKI  am ongst  pat ients with CKD.     
There was no associat ion between NSAIDs, COX-2 inhibitors or aspir in and the 
fast  progression of CKD, analysed by univariate and m ult ivariate analyses in the 
current  study. This is inconsistent  with Kuo’s study (2010)  in Taiwan, which 
found that  the use of these m edicat ions was related to end stage renal 
disease.174 There are several reasons to explain the finding in the current  study. 
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A sm all num ber of respondents took NSAIDs (6% )  or COX-2 inhibitors (3% )  in 
the present  study, com pared to Kuo’s study (19% , 1% , respect ively)  and those 
taking aspirin took a lower dose (m edian dose 81 m g/ day) , com pared to Kuo’s 
study (m edian dose 113 m g/ day) . These are inconsistent  associat ions between 
low doses of aspir in and the progression of CKD. Perneger et  al. ( 1994)  found no 
associat ion between aspirin and the developm ent  of end stage renal disease190,  
whilst  Evans et  al. in 2009 found slower progression of CKD in a group of aspir in 
users, com pared with non-users.191 Sixteen pat ients using NSAI Ds, COX-2 
inhibitors or aspir in in the present  study suffered from  AKI , in addit ion to CKD. 
After stopping them  taking the herbal m edicines their kidney funct ion im proved,  
so this m ay have interfered with the prim ary outcom e of the present  study. This 
result  m ay reflect  that  health care providers in the two teaching hospitals 
advised their pat ients to avoid using NSAIDs and COX-2 inhibitors.  
Proteinuria and younger age were associated with the fast  progression of CKD 
(adjusted OR 4.22, 95% CI  2.52 – 7.05 and adjusted OR 1.91, 95% CI  1.14 – 
3.18) . This is consistent  with the literature, which shows exist ing proteinuria is 
associated with the fast  progression of CKD.157,169-171,173   
The associat ion between m oderate to high protein, potassium  and phosphate 
intake, and the fast  progression of CKD, uncont rolled hyperkalem ia and 
uncont rolled hyperphosphatem ia was not  found in the present  study. This is 
inconsistent  with theoret ical knowledge.157 There are several reasons to explain 
this result . First ly, there are m any factors related to these outcom es. High 
protein intake has a weak associat ion with CKD progression176 whilst  proteinuria 
is st rongly related to this progression.169-171 At  least  20%  of the pat ients received 
loop diuret ics, a t reatm ent  of hyperkalem ia and hyperphosphatem ia, so these 
m ay have interfered with the associat ions between high potassium  and 
phosphate intake, and uncont rolled hyperkalem ia and hyperphosphatem ia. 
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Secondly, respondents m ay have changed the degree of such dietary intake, 
after  visit ing their doctor during the follow-up period. 
Assessm ent  of the degree of such dietary intake was m easured by the 
Rest r ict ion of Protein, Potassium , Phosphate and Salt  Diet  (RPPPS)  quest ionnaire 
in pre-dialysis pat ients, which was adapted from  Vlaminck’s study229, and piloted 
for  validity in the present  study. The validity of this quest ionnaire had a 
tendency related to the progression of CKD, uncont rolled hyperkalem ia and 
uncont rolled hyperphosphatem ia, but  there was no stat ist ical significance due to 
the lim ited sam ple size (n= 42) . This was a lim itat ion of using this quest ionnaire 
and it  is st rongly suggested re-validat ion of t his quest ionnaire is required for 
further studies.  
Sensit ivit y analyses determ ined the effects of two confounding factors on the 
prim ary outcom e, which were causes of CKD and inconsistent  exposure, or non-
exposure, to HDS during the follow-up period. There was no difference between 
HDS use and the prim ary outcom e. 
9 .3 .4  The associat ion betw een HDS and CKD com plicat ions 
This is the first  study to report  on the associat ion between HDS and uncont rolled 
hyperkalem ia and hyperphosphatem ia. Am ongst  pat ients who did not  receive 
dialysis therapy, HDS use was associated with uncont rolled hyperphosphatem ia 
(adjusted OR 3.53, 95%  CI  1.20 – 10.43) .  This m ay be because som e of the 
HDS used contained phosphate, such as bee pollen, m ult ivitam ins, swift let ’s nest  
drink, and som e products which contained cereal or coffee, that  are r ich sources 
of phosphate, as well as wheatgrass.165 Moreover,  som e dietary supplem ents 
contained vitam in D which increases absorpt ion of phosphate in gast rointest inal 
t ract  and can lead to hyperphosphatem ia in pat ients with CKD165, i.e.  
m ult ivitam ins, r ice bran oil, cod liver oil, bee pollen, and a product  containing 
vitam ins, m inerals and botanical ext racts. Uncont rolled hyperphosphatem ia, 
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com bined with calcium in the blood, can lead to the calcificat ion of soft  t issue 
and vascular t issue in pat ients with CKD.162  
An associat ion between HDS and uncont rolled hyperkalem ia was not  found 
(adjusted OR 0.59, 95%  CI  0.25 – 1.38)  as the HDS used m ay have contained 
only sm all am ounts of potassium  and som e HDS m ay even increase excret ion of 
potassium , such as tea for  diuret ic effects.  
The non-m easurem ent  of serum  levels of potassium  (n= 2)  or  phosphate (n= 60)  
over one year did not  affect  the associat ion of HDS use with uncont rolled 
hyperkalem ia or hyperphosphatem ia, as no differences in numbers of the non-
m easurem ent  of such elect rolytes, between the exposed and unexposed groups, 
were found. Further studies are required to exam ine such associat ions before 
any conclusions can be m ade, because there were sm all num bers of pat ients 
with hyperkalem ia or hyperphosphatem ia in the current  study.  
A lim itat ion of the current  study is that  uncont rolled hyperkalem ia was defined 
as over 5.0 m Eq/ l of a serum  level of potassium , in order t o create early 
detect ion of this problem . However, in pract ice hyperkalem ia is defined as over 
5.5 m Eq/ l of a serum  level of potassium 185 and only two pat ients in the current  
study had over 5.5 m Eq/ l of a serum  level of potassium . Therefore, t he finding 
regarding associat ion between HDS use and uncont rolled hyperkalem ia, in the 
present  study, should be used with caut ion. This issue needs to be invest igated 
by involving a high num ber of part icipants when using a definit ion of 
hyperkalem ia which is clinically significant . 
Peripheral oedem a, one of the CKD com plicat ions which m ay be affected by HDS 
containing sodium , was not  exam ined, as a m easure of oedem a in clinical 
pract ice is inconsistent  and relies on subject ive data. 
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9 .3 .5  Methodological considerat ions 
Sam ple size determ inat ion was calculated by the com parison of two m eans 
because this was the best  way to analyse a cont inuous variable of t he prim ary 
outcom e in the present  study, i.e. a decline in eGFR over a year. However the 
dist ribut ion of change in eGFR over a year was not  norm al, so a com parison of 
the two m eans cannot  be m ade, as it  violates the assum pt ion of a t - test . Despite 
the fact  that  a t - test  was not  perform ed, it  would appear that  there was no 
difference in m edian change in eGFR over 12 m onths between exposed ( -2.32 
m l/ m in/ 1.73m 2/ year)  and unexposed groups ( -1.86 m l/ m in/ 1.73m 2/ year)  (p-
value =  0.72 tested by Mann Whitney U test ) .  
This outcom e was am ended based on the dataset  which found that  the 
dist ribut ion of change in eGFR over a year was not  norm al and som e 
respondents had init iated renal replacem ent  therapy, which was likely to 
represent  the fast  progression of CKD. The prim ary outcom e, the effect  size, was 
thus newly defined as either at  least  -5 m l/ m in/ 1.73m 2/ year of eGFR, or having 
reached renal replacem ent  therapy. The dichotom ous outcom es were defined as 
having fast  progression of CKD and no fast  progression. The finding showed that  
there was no associat ion between the exposure of HDS and the fast  progression 
of CKD when analysed by Chi-squared test , which was sim ilar to com paring the 
m edian change in eGFR, over 12 m onths, between exposed and unexposed 
groups.  
Therefore, univariate analyses between the exposure and the fast  progression of 
CKD were conducted using Chi-squared tests and m ult iple logist ic regression 
analysis in order to cont rol for confounding factors. Post  hoc determ inat ion of the 
sam ple size for non-param et ric stat ist ical analyses, using the com parison of two 
proport ions of the fast  progression of CKD,230,231 indicated at  least  72 and 144 
num bers of the exposed and unexposed groups, respect ively. Therefore, 
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num bers of respondents in the present  study were a sufficient  sam ple size in this 
study for the analysis which took place. 
9 .4  Strengths and w eaknesses 
9 .4 .1  St rengths 
This is the first  prospect ive, cohort  study to ascertain the associat ion between 
exposure to HDS and the fast  progression of CKD, and it s com plicat ions, 
am ongst  Thai pat ients with CKD stages 3 to 5. Advantages of a prospect ive 
cohort  study are to determ ine a causal relat ionship and to m inim ise the recall 
bias of exposure, as the respondents were interviewed about  their current  HDS 
use. I n cont rast , a ret rospect ive study collects data in the past , such as last  
year, so this m ay increase recall bias. There was a low rate of loss to follow-up 
(5% )  in this study and no significant  differences in dem ographic characterist ics 
between the included group and the group of drop-outs. Object ive data were 
collected for  the outcom es in the present  study and the quant it y of exposure to 
HDS was m easured, which prevented inform at ion and m isclassificat ion bias. 
There was unlikely to be select ion bias as clinical characterist ics between 
exposed and unexposed groups were not  significant ly different , such as age, sex, 
severity of CKD, com orbidit ies and uncont rolled blood pressure, A1C and LDL 
cholesterol. The sam ple in the present  study seem ed to represent  the populat ion 
of pat ients with CKD, stages 3 to 5, as there were no significant  differences in 
dem ographic characterist ics between the present  study and those cited in the 
literature. 
The findings in this study can be generalised to Asian pat ients with CKD, who 
tend to use the sam e types of herbal m edicines as those ident ified in the present  
study, because the dem ographic characterist ics of respondents in this study are 
consistent  with the Asian populat ion as a whole.294 Som e types of t ropical herbal 
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m edicine in the current  study are shared across Asian count ries, part icularly in 
Southeast  Asian count ries, such as Gac fruit , I vy ground and Gynura 
procum bens and som e herbal m edicines used in the present  study are influenced 
by India, China or Japan, such as Shiitake m ushroom s. 
9 .4 .2  W eaknesses 
Exposure to HDS was defined as the use of all t ypes of HDS. This m ay have 
diluted the effects on kidney funct ion, as each HDS m ay have a posit ive or 
negat ive influence on k idney funct ion or no effect  at  all. Therefore, t his study 
was likely to indicate only a crude associat ion between HDS and the fast  
progression of CKD. Addit ionally, this research has exam ined the short - term  
effect s (a year)  of HDS on kidney funct ion. This period m ay not  be sufficient  to 
exam ine or ident ify any long- term  effects of HDS on kidney funct ion.  
Further studies are required to exam ine effect s of specific herbal m edicines on 
kidney funct ion. The present  findings suggest  that  r iver spiderwort  and Chinese 
herbal m edicines should be invest igated for any det r im ental effects on kidneys. 
A cohort  study of the associat ion between HDS and the progression of CKD 
should be followed up for m ore than a year, in order to invest igate long- term  
effect s on kidney funct ion.  
Of concern are the m ult iple confounding factors. Data for the large num ber of 
variables related to the prim ary outcom e was collected, such as age, obesity,  
sm oking status, degree of protein intake, uncont rolled blood pressure, A1C and 
LDL cholesterol, exposure to NSAI Ds or COX-2 inhibitors, and prescribed, 
convent ional m edicat ion adherence. Confounding effect s were exam ined using 
m ult iple logist ic regressions and it  was found that  exist ing proteinuria was a 
confounding factor in the present  study. 
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Medical notes were not  always com prehensive, with som e biom et ric data not  
recorded. This is likely to have been because the clinician did not  consider the 
tests necessary, rather than they were done but  not  recorded. However, there 
was sufficient  sam ple size of such variables to analyse the findings.   
9 .5  Conclusions and im plicat ions 
Despite no associat ion between HDS and the fast  progression of CKD am ongst  
Thai pat ients with CKD evident  from  the present  cohort  study, a sm all num ber of 
pat ients suffered from  acute kidney injury, which m ay be related to using r iver 
spiderwort  com bined with diclofenac or unknown Chinese herbal m edicines. This 
does not  m ean that  HDS can be safely used am ongst  pat ients with CKD, because 
som e pat ients with CKD, in the present  study, used HDS, which should be 
avoided;  as noted in case reports or anim al studies of renal toxicit y, i.e. aloe, 
senna, ginseng, ‘Ya Hom ’, ‘Tripala’, Tinospora crispa and spirulina. Moreover, 
there was a significant  associat ion between HDS use and uncont rolled 
hyperphosphatem ia, although no relat ionship between HDS and uncont rolled 
hyperkalem ia was found.  
These findings provide scient ific evidence of HDSs’ effects on kidney funct ion, 
and uncont rolled hyperkalem ia and hyperphosphatem ia am ongst  Thai pat ients 
with CKD stages 3 to 5 in order to inform  health care providers who take care of 
CKD pat ients who plan to use HDS. Health care providers in Thailand should 
acknowledge these findings, and closely m onitor kidney funct ion and elect rolytes 
am ongst  pat ients using HDS. 
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1 0 . Thesis discussion 
This final chapter sum m arises the findings presented in the previous chapters, in 
order t o dem onst rate how this work achieved the object ives of this thesis. 
Regarding the cohort  study (presented in Chapter 9) , the first  obj ect ive was to 
determ ine any associat ions between HDS use and the progression of CKD. The 
second object ive was to determ ine any associat ion between HDS use and CKD 
com plicat ions, i.e. uncont rolled hyperkalem ia or uncont rolled hyperphosphatem ia 
and the final object ive was to determ ine pat terns of any other r isk factors of 
CKD progression and it s com plicat ions. Regarding the survey and qualitat ive 
study (presented in Chapter 8) , the object ives were to determ ine 1)  the 
prevalence, types and pat terns of HDS use in Thai pat ients with CKD;  2)  the 
dem ographic characterist ics of Thai pat ients with CKD using HDS, com pared with 
the non-users;  3)  the associat ion between HDS use and a level of adherence to 
prescribed, convent ional m edicat ion;  4)  the reasons why Thai outpat ients with 
CKD use HDS;  5)  pat ients’ experiences of the beneficial and adverse effect s from  
using HDS;  and 6)  the rate of non-disclosure of HDS use to a doctor and it s 
reasons.  
A survey provided background inform at ion regarding HDS use in Thai pat ients 
with CKD. The reasons for  HDS use in pat ients with CKD were explored by both a 
survey and qualitat ive study, due to lim ited prior  published evidence in this area 
am ongst  pat ients with CKD. The prospect ive, cohort  study determ ined any 
associat ion between HDS use and the fast  progression of CKD in Thai pat ients, 
including any associat ions with uncont rolled hyperkalem ia or 
hyperphosphatem ia. 
Key findings are now presented, t ogether with an overview of the research 
results from  the survey, the qualitat ive study and the prospect ive, cohort  study. 
A sum m ary of this discussion will show that  the findings are robust , when 
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com pared with previous literature. Finally im plicat ions for pract ice and policy and 
recom m endat ions for further research are discussed. 
1 0 .1  Key findings 
Respondents in both the survey and the prospect ive, cohort  study were from  the 
sam e sam ple and their dem ographic character ist ics were as follows. Mean age 
(SD)  was 66 (13)  and the rat io between m ale and fem ale was 0.8. There were a 
sm all num ber of current  sm okers (5% ) , and dr inkers (5% ) . At  least  60%  of the 
respondents had diabetes and hypertension. Approxim ately 70%  of the 
respondents had stage 3 CKD. At  baseline, pat ients were taking an average of 8 
+  3 prescribed, convent ional m edicat ions, which were ant i-hypertensive agents 
(ACEIs 24% ;  ARBs 35% ) , ant i-diabet ic m edicines (49% ) , lipid- lowering drugs 
(78% ) , low dose aspir in (40% ) , and m edicat ions for CKD com plicat ions (at  least  
20% ) . Less than 10%  took NSAIDs or COX-2 inhibitors. A quarter  had a low 
level of adherence to prescribed, convent ional m edicat ion. Alm ost  all HDS users 
com bined them  with their prescribed, convent ional m edicine (99% ) . The 
prospect ive, cohort  study, over one year, found a 7%  rate of death and that  8%  
init iated dialysis therapy. 
The prevalence of herbal and dietary supplem ent  (HDS)  use over 12 m onths 
am ongst  Thai pat ients with stages 3 to 5 CKD was 45%  (95% CI  40% -50% ) . I n 
the survey, form er alcohol drinking (adjusted OR 0.43, 95%  CI  0.25-0.75)  or 
those with a m edium  level of convent ional m edicine adherence (adj usted OR 
0.53, 95%  CI  0.32-0.87)  were less likely to use HDS, com pared with non-  
drinking or those with poor adherence to prescribed, convent ional medicat ion. 
However, there was inconsistency in associat ions between the degree of 
m edicat ion adherence and HDS use. I n the cohort  study, current  and regular 
HDS users, i.e. the exposed group, were m ore likely to have a low level of 
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adherence (unadjusted OR 1.7, 95% CI  1.02-2.83)  com pared to the unexposed 
group. 
The m ost  frequent ly reported purposes for  using HDS were to m aintain well-
being (61% ) , whilst  HDS use for kidney diseases was also reported (30% ) . Thai 
pat ients with CKD used various types of HDS (304 and 65 different  HDS used in 
the survey and the cohort  study, respect ively) . The m ost  frequent ly reported 
HDS used in both the survey and the cohort  study were kariyat , turm eric, horse 
radish t ree, m ixed botanical ext ract s, vitam ins and m inerals, essence of chicken 
drink, germ  oil, fish oil, protein supplem ent , and r ice bran oil. Pharm acies and 
the m edia were frequent ly reported as sources of HDS and it s inform at ion, 
respect ively. 
Most  frequent ly reported influences on HDS use, from  both the survey and the 
qualitat ive study, were fam ily m em bers and fr iends’ recom m endat ions, followed 
by a percept ion of HDS benefit s and a willingness to t ry them . Alm ost  three 
quarters reported non-disclosure of their HDS use to their doctor;  reasons for  
secrecy being that  their doctor did not  ask (49% ) , or the pat ient  had concerns 
about  disapproval of HDS use from  their doctor (16% ) .  
The survey showed that  nearly 80%  of respondents reported perceived benefit  
from  HDS, such as alleviat ing m inor ailm ents (37% ) , m aintaining well-being 
(31% ) , and slowing the progression of CKD (10% ) . However,  one- tenth reported 
experiencing adverse events from  HDS use, such as progression of CKD (37% ) , 
gast rointest inal sym ptom s (16% )  and neurological sym ptom s (16% ) . Kariyat , 
r iver spiderwort  and wheatgrass were reported by respondents t o increase 
serum  creat inine in the survey. Reviewing m edical notes am ongst  the exposed 
group revealed two respondents had developed acute kidney injury, on top of 
their CKD, which m ay be related to the use of unknown Chinese herbal 
m edicines, or r iver spiderwort  com bined with diclofenac diagnosed by a doctor.  
However, the cohort  study did not  find an associat ion between current  and 
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regular HDS use, and the fast  progression of CKD, when defined as either a 
decline in eGFR of at  least  5 m l/ m in/ 1.73m 2/ year or reaching end-stage renal 
disease over one year (adjusted OR 1.16, 95% CI  0.66 -  2.03) . Proteinuria 
showed the highest  r isk for  the fast  progression of CKD (adjusted OR 4.22, 95%  
CI  2.52 – 7.05) , followed by younger age (adjusted OR 1.91, 95%  CI  1.14 – 
3.18) . Exist ing proteinuria was found to be a confounding factor related to the 
associat ion between HDS use and the fast  progression of CKD. 
Regarding HDS being related to CKD com plicat ions, the cohort  study found an 
associat ion between HDS use and uncont rolled hyperphosphatem ia (adjusted OR 
3.53, 95% CI  1.20 -  10.43) . This m ay be because som e HDS used in the exposed 
group contain phosphate or vitam in D, such as m ult ivitam ins, cod liver oil, bee 
pollen, r ice brand oil, wheatgrass, botanical ext racts and swift let ’s nest  drink. 
Meanwhile there was no relat ionship between HDS use and uncont rolled 
hyperkalem ia (adjusted OR 0.59, 95%  CI  0.25 – 1.38) .  
1 0 .2  Com parison w ith the literature 
Dem ographic characterist ics of the sam ple in the survey and the cohort  study 
represent  the populat ion of Thai pat ients with CKD, as there were no differences 
in the proport ions by sex, educat ion levels, living in urban or rural areas, 
sm oking and drinking status between respondents in the present  study and the 
Thai general populat ion in the Thai Nat ional census (2007) .260 There was no 
difference in the m ean age and sex between the present  study and the Thai CKD 
populat ion.290  
The prevalence of HDS use over 12 m onths, am ongst  Thai pat ients with CKD in 
the present  survey (45% ) , is consistent  with pat ients with CKD in Canada 
(45% ) 16, and higher than reported in the Thai general populat ion survey (33% ) .5 
Form er drinking and m edium  adherence to prescribed, convent ional m edicat ion 
were less likely to use HDS, com pared with non-drinking and poor adherence. 
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However, there were no clear pat terns for  these factors and only lim ited 
evidence to support  these associat ions.  
There were no differences in the reasons for HDS use between the present  
studies and literature.63,87,90,93,96 However, fr iends and fam ily m em bers were the 
m ost  frequent ly reported influence on HDS use am ongst  Thai pat ients in the 
present  studies;  data which is consistent  with the literature concerning other 
Asian populat ions, such as Malaysia and Japan.54,57,61 I n cont rast ,  Western 
populat ions are m ore likely to use HDS which have been suggested by their 
health care providers.16,25,58 Most  Thai HDS users in the present  survey reported 
non-disclosure of their use to their doctor (72% ) , which is consistent  with other 
Asian populat ions.98,110,111 On the other hand, Western populat ions are m ore 
likely to inform  their doctor (55-67% ) .15,16 
There are a lack of clinical t rials to ident ify which types of HDS, reported to be 
used for kidney diseases in the present  survey, are effect ive. Reported renal 
adverse effects from  HDS in the present  survey and the cohort  study, also had 
only lim ited scient ific evidence to support  them .  
An associat ion between HDS use and the fast  progression of CKD was not  found 
in the present  cohort  study. This is inconsistent  with previous surveys and a 
case-cont rol study in Thailand and Taiwan4,5,7, which found that  herbal m edicine, 
is related to CKD or end-stage renal disease. However, the respondents in the 
Taiwanese studies m ainly used Chinese herbal m edicine, which was likely to be 
contam inated with NSAIDs7,  whilst  one survey in Thailand found a weak 
associat ion between herbal m edicine and CKD. Another reason for  there being no 
associat ion between HDS use and the fast  progression of CKD in the current  
study m ay be due to t he lim ited sam ple size to detect  the sm all effect  size of 
HDS use. 
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Various types of HDS were used am ongst  Thai pat ients with CKD in the present  
cohort  study, and therefore such an equivocal situat ion challenges a researcher 
to invest igate renal effects from  a specific type of HDS, whilst  sim ultaneously 
achieving a sufficient  sam ple size to determ ine such associat ion.  
Exist ing proteinuria and younger age were associated with the fast  progression 
of CKD in the present  cohort  study, which are known risk factors.157,169-171,173  
There is a significant  associat ion between HDS and uncont rolled 
hyperphosphatem ia;  the first  t im e this link has been found. This m ay be due to 
the use of several HDS products containing phosphate or vitam in D, such as 
m ult ivitam ins, cod liver oil, bee pollen, r ice brand oil, wheatgrass, botanical 
ext racts and swift let ’s nest  drink. However, an associat ion between HDS use and 
uncont rolled hyperkalem ia was not  found in the present  cohort  study. There are 
several reasons to support  this finding;  HDS m ay contain a sm all am ount  of 
potassium ;  and som e HDS, such as tea for diuret ic effects m ay increase 
excret ion of potassium . 
1 0 .3  Strengths and w eaknesses 
Strengths 
There are several st rengths of this thesis. First  of all, this is the first  prospect ive 
cohort  study to invest igate any causal relat ionship between HDS and the fast  
progression of CKD in Thai pat ients with advanced CKD, including the 
associat ions with the com plicat ions of CKD. The findings from  both the survey 
and the qualitat ive study also provide the com prehensive inform at ion about  HDS 
use am ongst  Thai pat ients with advanced CKD. This study had a high response 
rate to the survey, as well as only sm all num bers of m issing data in the survey, 
since inform at ion was gathered using face- to- face interviews. There was also a 
low rate of drop out  in the cohort  study, although interviews can result  in social 
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desirabilit y bias. The validity and reliabilit y of the quest ionnaire in this thesis was 
acceptable, and helped to m inim ise inform at ion bias. Obj ect ive data was 
m easured for the outcom e in the cohort  study, whilst  the quant it y of exposure to 
HDS was m easured. Therefore, these procedures could prevent  inform at ion and 
m isclassificat ion bias. Finally, sensit ivit y analyses were perform ed for the 
prim ary outcom e of the cohort  study;  they revealed the sam e findings as the 
original results. This could cont r ibute to the robust  findings. 
W eaknesses 
Lim itat ions of this thesis are that  all t ypes of HDS use were defined as ‘the 
exposure’ so this m ay have resulted in the inconclusive findings, because each 
HDS m ay have either different  effects on the renal system  or no effect .  However, 
as the types of HDS used are unknown, this seem s to be a sensible way to 
achieve the prim ary aim  of this thesis. I f only one type of HDS was defined as 
the exposure, then it  is likely a larger sam ple size would be needed, which was 
not  feasible within the scope of a 3-year PhD program m e. Also it  was unknown 
which HDS would be an appropriate choice to study, as the different  types of 
HDS used by pat ients with advanced CKD were unknown. The findings in the 
present  study provide suitable individual herbal m edicines, into which further 
research would be valuable in order to understand their effects on CKD 
progression. I f findings were to show a st rong associat ion between HDS use and 
the progression of CKD, individual ingredients should be invest igated to 
determ ine which is responsible for  the effect  on CKD progression. Sim ilarly, if 
any were suspected of being beneficial in slowing the progression of CKD, these 
would also be worthy of further invest igat ion. Whilst  no HDS were found to be 
im plicated in the fast  progression of CKD, the findings do suggest  that  r iver 
spiderwort  should be exam ined for it s potent ial negat ive effect  in term s of acute 
kidney injury. HDS use in this study was self- reported, so som e pat ients m ay not  
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disclose their HDS use;  therefore the findings related to this issue should be 
used with caut ion. 
Select ing two teaching hospitals for the recruitm ent  m ay have resulted in 
select ion bias and doubts as to whether t he sam ple can be generalised. 
However, the dem ographics of respondents in this study, i.e.  gender, educat ion 
levels and living in urban or rural areas, and sm oking and drinking status, are 
consistent  with the Thai general populat ion. The m ean age of respondents in this 
study was also sim ilar to the CKD general populat ion in Thailand.  
Despite the determ inat ion of sam ple size in this study calculated by a 
com parison of the m eans of the outcom e, eGFR over one year, between two 
groups, Chi-squared tests and m ult iple logist ic regressions were perform ed as 
the dist r ibut ion of the outcom e was not  norm al. Addit ionally, during the follow-
up period som e pat ients init iated dialysis, which seem ed to indicate the fast  
progression of CKD. Therefore, the definit ion of the dependent  var iable was 
newly defined as either having or not  having fast  progression of CKD over one 
year -  a dichotom ous variable. The fast  progression of CKD was defined as either 
a decline in eGFR of at  least  5 m l/ m in/ 1.73m 2/ year or  init iated dialysis over one 
year.  However, post  hoc determ inat ion of the sam ple size, for  non-param et ric 
stat ist ics, confirm ed there was sufficient  sam ple size in this study for the 
analysis to be conducted.  
There were three invest igators who interviewed respondents, which can lead to 
differences in responses and recording of data. To ensure consistency in data 
collect ion, the invest igators were t rained how to ask respondents the quest ions 
in a standardised way. The m ain researcher (MT) , by observing the conduct  of 
their first  interview, confirm ed the data collect ion procedure was consistent .  
Ext ract ing inform at ion from  m edical notes can result  in m issing data, as data 
m ay not  have been recorded, or som e parts of the m edical notes m ay have been 
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m isplaced or used for another purpose. However, there were lit t le m issing data 
in this study. 
To exam ine potent ially confounding factors in the cohort  study, such factors, 
such as dem ographics, were tested using Chi-squared test s and m ult iple logist ic 
regressions in order to ident ify whether such factors related to an associat ion 
between the exposure and the outcom es. This found that  exist ing proteinuria 
was a confounding factor  in the associat ion between HDS use and the fast  
progression of CKD. Therefore, this variable was included in the m ult iple logist ic 
regression analysis to cont rol for it . 
1 0 .4  I m plicat ions for pract ice and policy  
The findings suggest  that  health care providers, part icularly in Thailand, should 
acknowledge that  alm ost  half of their  Thai pat ients with CKD stages 3 to 5 are 
likely to use HDS and they m ay not  inform  their doctor about  this use. They 
should also be aware that  pat ients with a m edium  level of adherence to 
prescribed, convent ional m edicat ion are less likely to use HDS than those with 
poor adherence. However, there was an inconsistent  associat ion between HDS 
use and the degree of m edicat ion adherence.  Thus, doctors and other health 
care professionals should regularly inquire about  HDS use, as standard pract ice 
for  m anaging CKD in Thailand. Pharm acists, in part icular, should fur ther study 
the relat ionship between HDS use and the degree of m edicat ion adherence 
before standard pract ice can be em ployed. 
To date there is lim ited scient ific evidence to provide inform at ion for  health care 
providers, upon which to base decisions about  which type of HDS should be 
avoided by pat ients with CKD. The findings in the present  cohort  study aim ed to 
establish such knowledge. Even though an associat ion between HDS and the fast  
progression of CKD was not  found in the short - term , it  would appear that  
unknown Chinese herbal m edicine or r iver spiderwort  com bined with diclofenac 
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m ay be related to acute kidney injury, as reported by a doctor in pat ients’ 
m edical notes. HDS use was also associated with uncont rolled 
hyperphosphatem ia in the current  cohort  study. This m ay be because som e HDS 
used in this study contain phosphate or vitam in D. Thus, health care providers 
should closely m onitor their pat ients using such products.  
There are m any m odified r isk factors related to the progression of CKD, such as 
obesity, sm oking, proteinuria, uncont rolled blood pressure, raised blood sugar 
and raised lipid levels, based on evidence in the relevant  literature. Given the 
findings from  the present  cohort  study, it  can be seen that  exist ing proteinuria is 
m ore likely to be associated with the fast  progression of CKD than other factors 
in Thai pat ients, which is consistent  with findings presented in previous 
literature. Cont rolling for  this factor  should be the m ain priority for  the 
prevent ion of fast  progression of CKD. I t  would appear that  this factor  is m ore 
st rongly associated with worsening kidney funct ion than HDS use. 
Most  frequent ly reported as a supply source of HDS are pharm acies. Com m unity 
pharm acists should therefore play an im portant  role in educat ing their custom ers 
how to properly use HDS. They should also m onitor any adverse effect s of HDS, 
part icularly in people with kidney insufficiency. 
The Thai Health Product  Vigilance Center has intensively m onitored eight  herbal 
m edicines on the Thai Nat ional List  of Essent ial Medicines, including Kariyat  and 
turm eric125 and has established, since 1997, a spontaneous report ing system  in 
order t o m onitor adverse effect s from  other HDS products in Thailand.126 Under 
this surveillance there has been lim ited evidence to provide inform at ion 
regarding the safety of HDS use in pat ients with CKD. Som e HDS used in the 
present  studies are not  on the list , such as r iver spiderwort . Wheatgrass 
products have been registered as a food so they have not  been rest r icted, nor 
has their safet y been m onitored under post -m arket ing surveillance, the sam e as 
m edicines. River spiderwort  was reported by a doctor to be related to acute 
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kidney injury in the m edical note and wheatgrass was reported by a pat ient  in 
the present  survey to increase serum  creat inine. These issues should be 
intensively m onitored by Thai Health Product  Vigilance Center. This center 
should also encourage health care providers and consum ers in Thailand to report  
adverse events, part icularly in pat ients with CKD, who are m ore vulnerable to 
adverse effect s on their kidneys. Further studies of the HDS safety profile, in 
pat ients with CKD, need to be carried out  by governm ent  bodies, researchers, 
and m anufacturers of herbal or dietary supplem ent  products.  
The research findings showed that  the m edia, such as television and radio, plays 
an im portant  part  in dissem inat ing HDS inform at ion and influencing pat ients to 
use HDS. The Thai Food and Drug Adm inist rat ion should inspect  HDS advert ising 
in order to ensure that  HDS com panies provide proper inform at ion, due to the 
reported HDS use for unproven indicat ions in the present  survey. This body 
should provide a fact  sheet  of HDS inform at ion for  consum ers, in order to 
prevent  unnecessary or inappropriate use of HDS.  
1 0 .5  Recom m endat ions for further study 
There has been a scarcity of safety inform at ion about  HDS use in pat ients with 
CKD so research, part icularly phase I  clinical t r ials, in this field needs to be 
conducted in order to provide safety profiles of HDS. This is because m any HDS 
have been registered as a diet , so they are not  required to be studied for  toxicit y 
in hum ans. The associat ion between HDS and the fast  progression of CKD needs 
to be invest igated for  its long- term  effect s on kidney funct ion and renal adverse 
effect s, according to the specific herbal m edicine used, such as r iver spiderwort .  
No associat ion between HDS use and the fast  progression of CKD was found in 
the present  cohort  study, due to lim ited sam ple size, so a populat ion-based 
cohort  study needs to confirm  this finding before a conclusion can be m ade. I t  
would seem  that  sm all num bers of herbal m edicines m ay be related to  acute 
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kidney injury (AKI )  in Thai pat ients with stages 3 to 5 CKD as found in the 
results. Therefore, the causes of AKI  apparent ly related to HDS use am ongst  
pat ients diagnosed as acute renal failure, need to be exam ined.  
The present  studies were not  aim ed at  invest igat ing beneficial effects of HDS on 
kidney funct ion and there is a significant  lack of scient ific evidence in this area, 
which needs to be exam ined. Som e HDS used in this study appear to have 
beneficial effects on kidney funct ion, in both anim al and hum an m odels, such as 
spring bit ter cucum ber, a m ixture of boesenbergia, m int , ginger,  galangal, 
lem ongrass, kaffir  lime leaves and shallots, and holy m ushroom s. This 
potent ially beneficial associat ion needs further invest igat ion. Alm ost  all pat ients 
reported using HDS together with prescribed, convent ional m edicine in the 
present  survey. This raises the quest ion of how to integrate HDS use with 
convent ional m edicines, in order t o use them  m ore effect ively and safely in 
pat ients with CKD. This m at ter  needs to be invest igated, with part icular focus on 
the effects of HDS-drug interact ion.  
The research results show an inconsistent  associat ion between HDS use and 
degree of adherence to prescribed, convent ional m edicat ion. This should be 
further exam ined before any firm  conclusions can be m ade. This could assist  in 
understanding this relat ionship and guide health care providers in dealing with 
this issue. 
The finding that  there is a high am ount  of non-disclosure of HDS use to their 
doctors in Thai pat ients with CKD, requires qualitat ive studies to ascertain the 
root  causes of this problem , and what  st rategies could be em ployed to resolve it .  
1 0 .6  Thesis conclusion 
Alm ost  half of Thai pat ients with CKD stages 3 to 5 in the current  survey were 
likely to use HDS together with prescribed, convent ional m edicat ion, although 
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there is lim ited scient ific evidence to support  t heir beneficial effects on kidney 
funct ion and their safety. The findings in the present  cohort  study seem  to 
provide safety inform at ion for  using HDS in Thai pat ients with CKD. No 
associat ion between HDS use and the fast  progression of CKD in Thai patents 
with stages 3 to 5 CKD was found, due to lim ited sam ple size to detect  the sm all 
effect  size of using HDS. I t  would appear that  proteinuria is likely to influence 
the fast  progression of CKD m ore than HDS use. HDS use was also associated 
with uncont rolled hyperphosphatem ia in the present  cohort  study. Health care 
providers should closely m onitor pat ients who are using Chinese herbal m edicine 
or r iver spiderwort  which, as cases suggest , m ay be related to acute kidney 
injury in pat ients with stages 3 to 5 CKD. They should also m onitor serum  levels 
of phosphate am ongst  pat ients using products containing phosphate or vitam in 
D. Further studies are needed to invest igate the associat ion between HDS use 
and the fast  progression of CKD, greater than one year, and to ident ify any 
beneficial and/ or det r im ental effects of specific herbal m edicines on kidney 
funct ion. 
References 
250 
References 
1. World Health Organizat ion. WHO t radit ional m edicine st rategy 2002-2005. 
Geneva:  World Health Organizat ion, 2002. 
2. Jha V. Herbal m edicines and chronic kidney disease. Nephrology  
2010; 15(Suppl S2) : 10-17. 
3. Luyckx VA. Nephrotoxicity of alternat ive m edicine pract ice. Adv Chronic 
Kidney Dis 2012; 19(3) : 129-41. 
4. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the 
r isk of CKD in adults not  using analgesics in Taiwan. Am  J Kidney Dis 
2007; 49(5) : 626-33. 
5. I ngsathit  A, Thakkinst ian A, Chaiprasert  A, Sangthawan P, Gojaseni P, 
Kiat t isunthorn K, et  al. Prevalence and r isk factors of chronic kidney 
disease in the Thai adult  populat ion:  Thai SEEK study. Nephrol Dial 
Transplant  2010; 25(5) : 1567-75. 
6. Hsieh CF, Huang SL, Chen CL, Chen WT, Chang HC, Wu ML, et  al. I ncreased 
risk of chronic kidney disease am ong users of non-prescribed Chinese 
herbal m edicine in Taiwan. Prev Med  2012; 55(2) : 155-59. 
7. Tsai SY, Tseng HF, Tan HF, Chien YS, Chang CC. End-stage renal disease in 
Taiwan:  a case-cont rol study. J Epidem iol 2009; 19(4) : 169-76. 
8. De Sm et  P. Health r isks of herbal rem edies:  an update. Clin Pharm acol Ther  
2004; 76(1) : 1-17. 
9. Kozyrskyj  A. Herbal products in Canada:  How safe are they? Can Fam  
Physician  1997; 43: 697-702. 
10. Tim bo BB, Ross MP, McCarthy PV, Lin C-TJ. Dietary supplem ents in a 
nat ional survey:  prevalence of use and report s of adverse events. J Am 
Diet  Assoc 2006; 106(12) : 1966-74. 
11. Kidney Disease:  I m proving Global Outcom e (KDI GO)  CKD Work Group. 
KDI GO 2012 clinical pract ice guideline for the evaluat ion and 
m anagem ent  of chronic kidney disease. Kidney I nt  Suppl 2012; 3(1) : 1-
150. 
12. The Nephrology Society of Thailand. Clinical pract ice guidelines for pre-
dialysis pat ients in 2009. 1st  ed. Bangkok:  The Nephrology Society of 
Thailand, 2009. 
13. Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et  al. All- cause 
m ortalit y at t ributable to chronic kidney disease:  a prospect ive cohort  
study based on 462293 adults in Taiwan. Lancet  2008; 371(9631) : 2173-
82. 
14. Kara B. Herbal product  use in a sam ple of Turkish pat ients undergoing 
haem odialysis. J Clin Nurs 2009; 18(15) : 2197-205. 
15. Grabe DW, Garrison GD. Com parison of natural product  use between prim ary 
care and nephrology pat ients. Ann Pharm acother  2004; 38(7) : 1169-72. 
16. Spanner ED, Duncan AM. Prevalence of dietary supplem ent  use in adults with 
chronic renal insufficiency. J Ren Nut r  2005; 15(2) : 204-10. 
17. Krousel-Wood MA, Muntner P, Joyce CJ, I slam  T, Stanley E, Holt  EW, et  al. 
Adverse effects of com plem entary and alternat ive m edicine on 
ant ihypertensive m edicat ion adherence:  findings from  the cohort  study of 
m edicat ion adherence am ong older adults. J Am  Geriat r Soc 
2010; 58(1) : 54-61. 
18. Weizm an AV, Ahn E, Thanabalan R, Leung W, Croitoru K, Silverberg MS, et  
al. Characterisat ion of com plem entary and alternat ive m edicine use and 
it s im pact  on m edicat ion adherence in inflam m atory bowel disease. 
Alim ent  Pharm acol Ther  2012; 35(3) : 342-49. 
References 
251 
19. Gohar F, Greenfield SM, Beevers DG, Lip GYH, Jolly K. Self-care and 
adherence to m edicat ion:  a survey in the hypertension outpat ient  clinic. 
BMC Com plem ent  Altern Med 2008; 8(8) : 4-12. 
20. Caspi O, Sechrest  L, HC P, CL M, IR B, M N. On the definit ion of 
com plem entary, alternat ive, and integrat ive m edicine:  societal m ega-
stereotypes vs. the pat ients' perspect ives. Altern Ther Health Med  
2003; 9(6) : 58-62. 
21. Payyappallim ana U. Role of t radit ional m edicine in prim ary health care:  an 
overview of perspect ives and challenges. Yokoham a J Soc Sci 
2010; 14(6) : 57-77. 
22. Nat ional Center for Com plem entary and Alternat ive Medicine. What  is 
com plem entary and alternat ive m edicine? 2010. 
ht tp: / / nccam .nih.gov/ sites/ nccam .nih.gov/ files/ D347_05-25-2012.pdf 
(accessed 12 October 2010) . 
23. House of Lords. Com plem entary and alternat ive m edicine:  science and 
technology, sixth report . 2000. 
ht tp: / / www.publicat ions.parliam ent .uk/ pa/ ld199900/ ldselect / ldsctech/ 12
3/ 12301.htm  (accessed 11 October 2010) .  
24. Minist ry of Public Health. Tradit ional m edicine in Kingdom  of Thailand. 2013. 
ht tp: / / herbalnet .healthrepository.org/ bitst ream / 123456789/ 2288/ 10/ 09-
p.97-120.pdf (accessed 26th March 2013) .  
25. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Com plem entary and 
alternat ive m edicine use am ong adults:  United States, 2002. Advance 
Data 2004; 343: 1-19. 
26. The Role of Thai t radit ional m edicine in health prom ot ion. 6GCHP Bangkok 
Thailand 2005;  2005;  Bangkok, Thailand. 
27. Jiaranaikajorn T, Panthawangkul J, Tham likit kul V. Use of alternat ive 
m edicines am ong m edical pat ients at  Sir iraj  hospital. Siriraj  Medical 
Journal 2002; 54(10) : 603-10. 
28. Gardiner P, Kem per KJ, Legedza A, Phillips RS. Factors associated with herb 
and dietary supplem ent  use by young adults in the United States. BMC 
Com plem ent  Altern Med  2007; 7: 39. 
29. Kennedy J. Herb and supplem ent  use in the US adult  populat ion. Clin Ther  
2005; 27(11) : 1847-58. 
30. Laliberte M-C, Norm andeau M, Lord A, Lam arre D, Cant in I , Berbiche D, et  
al. Use of over- the-counter m edicat ions and natural products in pat ients 
with m oderate and severe chronic renal insufficiency. Am  J Kidney Dis 
2007; 49(2) : 245-56. 
31. World Health Organizat ion. General guidelines for m ethodologies on research 
and evaluat ion of t radit ional m edicine. 2000. 
ht tp: / / whqlibdoc.who.int / hq/ 2000/ WHO_EDM_TRM_2000.1.pdf (accessed 
11 October 2010) .  
32. U.S. Food and Drug Adm inist rat ion. Q&A on dietary supplem ents. 2009. 
ht tp: / / www.fda.gov/ Food/ DietarySupplem ents/ QADietarySupplem ents/ de
fault .htm # what_is (accessed 25 October 2010) . 
33. Minist ry of Public Health. Public health law. 2014. 
ht tp: / / www.m oph.go.th/ ops/ m inister_06/ laws.htm  (accessed 21st  April 
2014) . 
34. Stys T, Stys A, Kelly P, Lawson W. Trends in use of herbal and nut r it ional 
supplem ents in cardiovascular pat ients. Clin Cardiol 2004; 27(2) : 87-90. 
35. Radim er K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary 
supplem ent  use by US adults:  data from  the Nat ional Health and Nut rit ion 
Exam inat ion Survey, 1999-2000. Am  J Epidem iol 2004; 160(4) : 339-49. 
36. Aydin S, Bozkaya AO, Mazicioglu M, Gem alm az A, Ozcakir A, Ozturk A. What  
influences herbal m edicine use?-  Prevalence and related factors. Turk J 
Med Sci 2008; 38(5) : 455-63. 
References 
252 
37. Guo X, Willows N, Kuhle S, Jhangri G, Veugelers PJ. Use of vitam in and 
m ineral supplem ents am ong Canadian adults. Can J Public Health 
2009; 100(4) : 357-60. 
38. Hess S, De Geest  S, Halter  K, Dickenm ann M, Denhaerynck K. Prevalence 
and correlates of selected alternat ive and com plem entary m edicine adult  
renal t ransplant  pat ients. Clin Transplant  2009; 23(1) : 56-62. 
39. Nowack R, Balle C, Birnkam m er F, Koch W, Sessler R, Birck R.  
Com plem entary and alternat ive m edicat ions consum ed by renal pat ients 
in Southern Germ any. J Ren Nut r  2009; 19(3) : 211-19. 
40. Al-Windi A, Elm feldt  D, Svardsudd K. The relat ionship between age, gender, 
well-being and sym ptom s, and the use of pharm aceut icals, herbal 
m edicines and self- care products in a Swedish m unicipalit y. Eur J Clin 
Pharm acol 2000; 56(4) : 311-17. 
41. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitam in and m ineral 
supplem ent  use in the United States:  results from  the Third Nat ional 
Health and Nut rit ion Exam inat ion Survey. Arch Fam  Med 2000; 9(3) : 258-
62. 
42. Singh V, Raidoo DM, Harries CS. The prevalence, pat terns of usage and 
people's at t itude towards com plem entary and alternat ive m edicine (CAM) 
am ong the Indian com m unity in Chatsworth, South Afr ica. BMC 
Com plem ent  Altern Med  2004; 4: 3. 
43. Xue CC, Zhang AL, Lin V, Da Costa C, Story DF. Com plem entary and 
alternat ive m edicine use in Aust ralia:  a nat ional populat ion-based survey. 
J Altern Com plem ent  Med 2007; 13(6) : 643-50. 
44. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, et  al. 
Prevalence and characterist ics of vitam in or dietary supplem ent  users in 
Lausanne, Switzerland:  the CoLaus study. Eur J Clin Nut r  
2009; 63(2) : 273-81. 
45. Ock SM, Choi JY, Cha YS, Lee J, Chun MS, Huh CH, et  al. The use of 
com plem entary and alternat ive m edicine in a general populat ion in South 
Korea:  results from  a nat ional survey in 2006. J Korean Med Sci 
2009; 24(1) : 1-6. 
46. Aziz Z, Tey NP. Herbal m edicines:  prevalence and predictors of use am ong 
Malaysian adults. Com plem ent  Ther Med 2009; 17(1) : 44-50. 
47. Hunt  KJ, Coelho HF, Wider B, Perry R, Hung SK, Terry R, et  al. 
Com plem entary and alternat ive m edicine use in England:  results from  a 
nat ional survey. I nt  J Clin Pract  2010; 64(11) : 1496-502. 
48. Thom son P, Jones J, Evans JM, Leslie SJ. Factors influencing the use of 
com plem entary and alternat ive m edicine and whether pat ients inform  
their prim ary care physician. Com plem ent  Ther Med 2012; 20(1-2) : 45-53. 
49. Mat thees BJ, Anantachot i P, Kreitzer MJ, Savik K, Hertz MI , Gross CR. Use of 
com plem entary therapies, adherence, and qualit y of life in lung t ransplant  
recipients. Heart  Lung 2001; 30(4) : 258-68. 
50. Moolasarn S, Sripa S, Kuesir ikiet  V, Sutawee K, Huasary J, Chaisila C, et  al.  
Usage of alternat ive m edicine in cancer pat ients. Siriraj  Medical Journal 
2003; 55(6) : 307-23. 
51. Moolasarn S, Sripa S, Kuessir ikiet  V, Sutawee K, Huasary J, Chaisila C, et  al. 
Usage of and cost  of com plem entary/ alternat ive m edicine in diabet ic 
pat ients. J Med Assoc Thai 2005; 88(11) : 1630-37. 
52. Lee G, Charn T, Ng T. Com plem entary and alternat ive m edicine use in 
pat ients with chronic diseases in prim ary care is associated with 
perceived qualit y of care and cultural beliefs. Fam  Pract  2004; 21(6) : 654-
60. 
53. Barraco D, Valencia G, Riba AL, Nareddy S, Draus CBSN, Schwartz SM. 
Com plem entary and alternat ive m edicine (CAM)  use pat terns and 
disclosure to physicians in acute coronary syndrom es pat ients. 
Com plem ent  Ther Med  2005; 13(1) : 34-40. 
References 
253 
54. Hyodo I ,  Am ano N, Eguchi K, Narabayashi M, Im anishi J, Hirai M, et  al. 
Nat ionwide survey on com plem entary and alternat ive m edicine in cancer 
pat ients in Japan. J Clin Oncol 2005; 23(12) : 2645-54. 
55. Molassiot is A, Fernadez-Ortega P, Pud D, Ozden G, Scot t  JA, Panteli V, et  al. 
Use of com plem entary and alternat ive m edicine in cancer pat ients:  a 
European survey. Ann Oncol 2005; 16(4) : 655-63. 
56. Kum ar D, Bajaj  S, Mehrot ra R. Knowledge, at t itude and pract ice of 
com plem entary and alternat ive m edicines for diabetes. Public Health 
2006; 120(8) : 705-11. 
57. Saw JT, Bahari MB, Ang HH, Lim  YH. Herbal use am ongst  m ult iethnic m edical 
pat ients in Penang hospital:  pat tern and percept ions. Med J Malaysia 
2006; 61(4) : 422-32. 
58. Yeh GY, Davis RB, Phillips RS. Use of com plem entary therapies in pat ients 
with cardiovascular disease. Am  J Cardiol 2006; 98(5) : 673-80. 
59. Hori S, Mihaylov I ,  Vasconcelos JC, McCoubrie M. Pat tern of com plem entary 
and alternat ive m edicine use am ongst  outpat ients in Tokyo, Japan. BMC 
Com plem ent  Altern Med  2008; 8: 14. 
60. Rossi P, Torelli P, Lorenzo CD, Sances G, Manzoni GC, Tassorelli C, et  al. Use 
of com plem entary and alternat ive m edicine by pat ients with cluster 
headache:  results of a m ult i- cent re headache clinic survey. Com plem ent  
Ther Med  2008; 16(4) : 220-27. 
61. Hasan SS, Ahm ed SI ,  Bukhari NI , Loon WCW. Use of com plem entary and 
alternat ive m edicine am ong pat ients with chronic diseases at  outpat ient  
clinics. Com plem ent  Ther Clin Pract  2009; 15(3) : 152-57. 
62. Wilkinson JM, Jelinek H. Com plem entary m edicine use am ong at tendees at  a 
rural health screening clinic. Com plem ent  Ther Clin Pract  2009; 15(2) : 80-
84. 
63. Lam bert  TD, Morrison KE, Edwards J, Clarke CE. The use of com plem entary 
and alternat ive m edicine by pat ients at tending a UK headache clinic. 
Com plem ent  Ther Med 2010; 18(3-4) : 128-34. 
64. Ogbera AO, Dada O, Adeleye F, Jewo PI .  Com plem entary and alternat ive 
m edicine use in diabetes m ellitus. West  Afr J Med 2010; 29(3) : 158-62. 
65. Braun LA, Cohen M. Use of com plem entary m edicines by cardiac surgery  
pat ients;  undisclosed and undetected. Heart  Lung Circ 2011; 20(5) : 305-
11. 
66. Ali-Shtayeh MS, Jam ous RM, Jam ous RM. Com plem entary and alternat ive 
m edicine use am ongst  Palest inian diabet ic pat ients. Com plem ent  Ther 
Clin Pract  2012; 18(1) : 16-21. 
67. Shorofi SA, Arbon P. Com plem entary and alternat ive m edicine (CAM)  am ong 
hospitalised pat ients:  an Aust ralian study. Com plem ent  Ther Clin Pract  
2010; 16(2) : 86-91. 
68. St rej ilevich SA, Sarm iento MJ, Scapola M, Gil L, Mart ino DJ, Gil JF, et  al. 
Com plem entary and alternat ive m edicines usage in bipolar pat ients from  
Argent ina and Colom bia:  associat ions with sat isfact ion and adherence to 
t reatm ent . J Affect  Disord 2013; 149(1-3) : 393-7. 
69. Satyapan N, Patarakitvanit  S, Tem boonkiet  S, Vudhironarit  T, Tankanit lert  J. 
Herbal m edicine:  affect ing factors and prevalence of use am ong Thai 
populat ion in Bangkok. J Med Assoc Thai 2010; 93(Suppl. 6) : S139-44. 
70. Barnes J, Ernst  E. Com plem entary m edicine. Brit  J Gen Pract  
1997; 4(418) : 329. 
71. Zollm an C, Vickers A. What  is com plem entary m edicine? Br Med J 
1999; 319(7211) : 693-96. 
72. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. 
Unconvent ional m edicine in the United States -  prevalence, costs, and 
pat terns of use. N Engl J Med 1993; 328(4) : 246-52. 
References 
254 
73. Ernst  E, Resch KL, Mills S, Hill R, Mitchell A, Willoughby M, et  al. 
Com plem entary m edicine -  a definit ion. Br J Gen Pract  
1995; 45(398) : 506. 
74. Cheung CK, Wym an JF, Halcon LL. Use of com plem entary and alternat ive 
therapies in com m unity-dwelling older adults. J Altern Com plem ent  Med 
2007; 13(9) : 997-1006. 
75. Qato DM, Alexander C, Cont i RM, Johnson M, Schum m  P, Lindau ST. Use of 
prescript ion and over- the-counter m edicat ions and dietary supplem ents 
am ong older adults in the United States. JAMA 2008; 300(24) : 2867-78. 
76. Levine MAH, Xu S, Gaebel K, Brazier N, Bedard M, Brazil K, et  al. Self-
reported use of natural health products:  a cross-sect ional telephone 
survey in older Ontarians. J Geriat r  Pharm acother  2009; 7(6) : 383-92. 
77. Gunther S, Pat terson RE, Kristal AR, St rat ton KL, White E. Dem ographic and 
health- related correlates of herbal and specialty supplem ent  use. J Am 
Diet  Assoc 2004; 104(1) : 27-34. 
78. Honda K, Jacobson JS. Use of com plem entary and alternat ive m edicine 
am ong United States adults:  the influences of personalit y, coping 
st rategies, and social support . Prev Med  2005; 40(1) : 46-53. 
79. Araz A, Harlak H, Mese G. Factors related to regular use of 
com plem entary/ alternat ive m edicine in Turkey. Com plem ent  Ther Med 
2009; 17(5-6) : 309-15. 
80. Im ai T, Nakam ura M, Ando F, Shim okata H. Dietary supplem ent  use by 
com m unity- living populat ion in Japan:  data from  the Nat ional I nst itute for  
Longevity Sciences Longitudinal Study of Aging (NI LS-LSA) . J Epidem iol 
2006; 16(6) : 249-60. 
81. Lee JS, Kim  J. Factors affect ing the use of dietary supplem ents by Korean 
adults:  data from  the Korean Nat ional Health and Nut rit ion Exam inat ion 
Survey I I I .  J Am  Diet  Assoc 2009; 109(9) : 1599-605. 
82. Chung VCH, Ma PHX, Tang TSK, Lau CH, Kim  JH, Griffiths SM. Do pat ients 
tell their clinicians they are using both prescribed and over the counter 
allopathic and t radit ional m edicines? Eur J I ntegr Med 2011; 3(4) : e289-
98. 
83. Conner M, Kirk SF, Cade JE, Barret t  JH. Why do wom en use dietary 
supplem ents? The use of the theory of planned behaviour t o explore 
beliefs about  their use. Soc Sci Med 2001; 52(4) : 621-33. 
84. Bruno JJ, Ellis JJ. Herbal use am ong US elderly:  2002 Nat ional Health 
I nterview Survey. Ann Pharm acother  2005; 39(4) : 643-48. 
85. McFadden KL, Hernandez TD, I to TA. At t itudes toward com plem entary and 
alternat ive m edicine influence it s use. Explore 2010; 6(6) : 380-88. 
86. Sm ith BW, Dalen J, Wiggins KT, Christopher PJ, Bernard JF, Shelley BM. Who 
is willing to use com plem entary and alternat ive m edicine. Explore 
2008; 4(6) : 359-67. 
87. Vickers KA, Jolly KB, Greenfield SM. Herbal m edicine:  wom en's views, 
knowledge and interact ion with doctors:  a qualitat ive study. BMC 
Com plem ent  Altern Med  2006; 6: 40. 
88. Thom as K, Colem an P. Use of com plem entary or alternat ive m edicine in a 
general populat ion in Great  Britain. results from  the Nat ional Om nibus 
Survey. J Public Health  2004; 26(2) : 152-57. 
89. Ast in JA. Why pat ients use alternat ive m edicine:  results of a nat ional study. 
JAMA 1998; 279(19) : 1548-53. 
90. Yu H, Wang S, Liu J, Lewith G. Why do cancer pat ients use Chinese 
m edicine? -  a qualitat ive interview. Eur J I ntegr Med 2012; 4(2) : e197-
203. 
91. Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer 
B, et  al. Com plem entary and alternat ive m edicine:  use and disclosure in 
radiat ion oncology com m unity pract ice. Support  Care Cancer  
2011; 19(4) : 521-29. 
References 
255 
92. Sewitch MJ, Yaffe M, Maisonneuve J, Prchal J, Ciam pi A. Use of 
com plem entary and alternat ive m edicine by cancer pat ients at  a Mont real 
hospital. I ntegr Cancer Ther  2011; 10(4) : 305-11. 
93. Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and 
characterist ics associated with com plem entary and alternat ive m edicine 
use am ong adult  cancer pat ients:  a system at ic review. I ntegr Cancer 
Ther  2005; 4(4) : 274-86. 
94. Wilkinson S, Gom ella LG, Sm ith JA, Brawer MK, Dawson NA, Wajsm an Z, et  
al. At t itudes and use of com plem entary m edicine in m en with prostate 
cancer. J Urol 2002; 168(6) : 2505-09. 
95. Chen W-T, Shiu C-S, Sim oni J, Fredriksen-Goldsen K, Zhang F, Starks H, et  
al. At t itudes toward ant iret roviral therapy and com plem entary and 
alternat ive m edicine in Chinese pat ients infected with HIV. J Assoc Nurses 
AI DS Care 2009; 20(3) : 203-17. 
96. Rawsthorne P, Shanahan F, Cronin NC, Anton PA, Lofberg R, Bohm an L, et  
al. An internat ional survey of the use and at t itudes regarding alternat ive 
m edicine by pat ients with inflam m atory bowel disease. Am  J 
Gast roenterol 1999; 94(5) : 1298-303. 
97. Bishop FL, Yardley L, Lewith GT. A system at ic review of beliefs involved in 
the use of com plem entary and alternat ive m edicine. J Health Psychol 
2007; 12(6) : 851-67. 
98. Kuo GM, Hawley ST, Todd WL, Balkrishnan R, Volk RJ. Factors associated 
with herbal use am ong urban m ult iethnic prim ary care pat ients:  a cross-
sect ional survey. BMC Com plem ent  Altern Med  2004; 4: 18. 
99. Sirois FM, Gick ML. An invest igat ion of the health beliefs and m ot ivat ions of 
com plem entary m edicine clients. Soc Sci Med 2002; 55(6) : 1025-37. 
100. Klepser TB, Doucet te WR, Horton MR, Buys LM, Ernst  ME, Ford JK, et  al. 
Assessm ent  of pat ients' percept ions and beliefs regarding herbal 
therapies. Pharm acotherapy  2000; 20(1) : 83-87. 
101. Kappauf H, Leykauf-Am m on D, Bruntsch U, Horneber M, Kaiser G, Buschel 
G, et  al. Use of and at t itudes held towards unconvent ional m edicine by 
pat ients in a departm ent  of internal m edicine /  oncology and 
haem atology. Support  Care Cancer  2000; 8(4) : 314-22. 
102. Eisenberg DM, Kessler RC, Van Rom pay MI , Kaptchunk TJ, Wilkey SA, Appel 
S, et  al. Percept ions about  com plem entary therapies relat ive to 
convent ional therapies am ong adults who use both:  results from  a 
nat ional survey. Ann I ntern Med 2001; 135(5) : 344-51. 
103. McCrea CE, Pritchard ME. Concurrent  herb-prescript ion m edicat ion use and 
health care provider disclosure am ong university students. Com plem ent  
Ther Med  2011; 19(1) : 32-36. 
104. Alkhateeb FM, Doucet te WR, Ganther-Urm ie JM. I nfluences on consum er 
spending for herbal products. Res Social Adm  Pharm  2006; 2(2) : 254-65. 
105. Ryan A, Wilson S, Taylor A, Greenfield S. Factors associated with self- care 
act ivit ies am ong adults in the United Kingdom :  a system at ic review. BMC 
Public Health  2009; 9: 96-106. 
106. Howell L, Kochhar K, Saywell R, Zollinger T, Koehler J,  Mandzuk C, et  al.  
Use of herbal rem edies by Hispanic pat ients:  Do they inform  their 
physician? J Am  Board Fam  Med  2006; 19(6) : 566-78. 
107. Bubela T, Boon H, Caulfield T. Herbal rem edy clinical t rials in the m edia:  a 
com parison with the coverage of convent ional pharm aceut icals. BMC 
Medicine 2008; 6: 35. 
108. Weeks LC, St rudsholm  T. A scoping review of research on com plem entary 
and alternat ive m edicine (CAM)  and the m ass m edia:  looking back, 
m oving forward. BMC Com plem ent  Altern Med  2008; 8: 43. 
109. Farooqui M, Hassali MA, Shatar AKA, Shafie AA, Farooqui MA, Saleem  F, et  
al. Com plem entary and alternat ive m edicines (CAM)  disclosure to the 
References 
256 
health care providers:  a qualitat ive insight  from  Malaysian cancer 
pat ients. Com plem ent  Ther Clin Pract  2012; 18(4) : 252-56. 
110. Chao MT, Wade C, Kronenberg F. Disclosure of com plem entary and 
alternat ive m edicine to convent ional m edical providers:  variat ion by 
race/ ethnicity and type of CAM. J Nat l Med Assoc 2008; 100(11) : 1341-49. 
111. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary 
supplem ent  disclosure to health care providers by individuals with chronic 
condit ions. J Altern Com plem ent  Med 2008; 14(10) : 1263-69. 
112. Peltzer K, Preez NF-d, Ram lagan S, Fom undam  H, Anderson J. Tradit ional 
com plem entary and alternat ive m edicine and ant iret roviral t reatm ent  
adherence am ong HIV pat ients in Kwazulu-Natal, South Afr ica. Afr J Trad 
CAM 2010; 7(2) : 125-37. 
113. Cherniack EP. Com plem entary m edicine use is not  associated with non-
adherence to convent ional m edicat ion in the elderly:  a ret rospect ive 
study. Com plem ent  Ther Clin Pract  2011; 17(4) : 206-08. 
114. Bailey GR, Barner JC, Weem s JK, Leckbee G, Solis R, Montem ayor D, et  al. 
Assessing barriers to m edicat ion adherence in underserved pat ients with 
diabetes in Texas. Diabetes Educ 2012; 38(2) : 271-79. 
115. Jiratchariyakul W, Mahady GB. Overview of botanical status in EU, USA, and 
Thailand. Evid Based Com plem ent  Alternat  Med 2013; 21: 480128. 
116. Chuthaput t i A. Nat ional t radit ional system  of m edicine recognized by the 
Thai governm ent , 2007. 
117. The Inst itute of Thai Tradit ional Medicine. Missions of the Inst itute of Thai 
Tradit ional Medicine. 2013. 
ht tp: / / it tm .dtam .m oph.go.th/ index.php?opt ion= com _content&view= featu
red&I tem id= 152 (accessed 17th February 2014) . 
118. Medicinal Plant  Research Inst itute. Missions of Medicinal Plant  Research 
Inst itute. 2013. 
ht tp: / / dm sc2.dm sc.m oph.go.th/ webroot / Plant / Mpri2013/ index.shtm  
(accessed 17th February 2014) .  
119. Nat ional Drug Com m it tee. Nat ional list  of herbal m edicine products. 1st  ed. 
Bangkok:  Minist ry of Public Health Thailand, 2011. 
120. Thai Food and Drug Adm inist rat ion. The food and m edicine law. 2010. 
www2.fda.m oph.go.th/ law (accessed 8 October 2010) . 
121. Thai Bureau of Food. Rules of regist rat ion of dietary supplem ents. 2010. 
ht tp: / / newsser.fda.m oph.go.th/ food/  (accessed 9th January 2013) .  
122. Gulat i OP, Ot taway PB. Legislat ion relat ing to nut raceut icals in the 
European Union with a part icular focus on botanical-sources products. 
Toxicology  2006; 221(1) : 75-87. 
123. European Food Safety Authority. Guidance on safety assessm ent  of 
botanicals and botanical preparat ions intended for  use as ingredients in 
food supplem ents. EFSA Journal 2009; 7(9) : 1249-67. 
124. Nat ional Drug Com m it tee. Lists of herbal m edicinal products A.D. 2006. 1st  
ed. Bangkok:  Minist ry of Public Health Thailand, 2006.  
125. Oppam ayun Y, Rungapirum nan W, Suwanakaesawong W, Uerchaikul C. 
Recent  study on safet y m onitoring herbal m edicines of Thai Nat ional 
Essent ial Drug List  (NEDL) . Planta Med 2009; 75: 26. 
126. Biswas P. Pharm acovigilance in Asia. JPP 2013; 4(Suppl 1) : S7-19. 
127. I nt rasook J. Regulat ion of food supplem ents (vitam ins and m inerals)  in EU, 
US, and Thailand:  a com parat ive study. Wageningen University, 2013. 
128. Saokaew S, Suwankesawong W, Perm suwan U, Chaiyakunapruk N. Safety 
of herbal products in Thailand:  an analysis of report s in the Thai health 
product  vigilance center database from  2000 to 2008. Drug Saf 
2011; 34(4) : 339-50. 
129. Thai Food and Drug Adm inist rat ion. The declarat ion of health products. 
2010. ht tp: / / www.fda.m oph.go.th/ www_fda/ newweb/ index.php 
(accessed 9 Novem ber 2010) . 
References 
257 
130. Minist ry of Public Health. Thailand health profile (2001-2004) . I n:  
Wilbulpolprasert  S, editor. Bangkok:  Pr int ing Press, Express 
Transportat ion Organisat ion, 2005. 
131. Vongprajan T, editor. Situat ions and problem s of prescribed herbal 
m edicines in public hospitals. The 5 t h Annual Northeast  Pharm acy 
Research Conference of 2013 "Pharm acy Profession:  Moving Forward to 
ASEAN Harm onizat ion";  2013;  Thailand. 
132. I nst itute of Thai Tradit ional Medicine. Research on Thai Tradit ional 
Medicines. 2008. ht tp: / / it tm .dtam .m oph.go.th (accessed 27 October 
2010) . 
133. Departm ent  of Herbal Database Mahidol University. Med plant . 2010. 
ht tp: / / www.m edplant .mahidol.ac.th/ index.asp (accessed 8 Novem ber 
2010) . 
134. Chuengsam arn S, Rat tanam ongkolgul S, Luechapudiporn R, Phisalaphong 
C, Jirawatnotai S. Curcum in ext ract  for  prevent ion of type 2 diabetes. 
Diabetes Care 2012; 35(11) : 2121-27. 
135. Sangsuwan C, Udom panthurak S, Vannasaeng S, Tham likitkul V. 
Random ized cont rolled t r ial of Tinospora crispa for addit ional therapy in 
pat ients with type 2 diabetes m ellitus. J Med Assoc Thai 2004; 87(5) : 543-
46. 
136. Cherdshewasart  W, Nim sakul N. Clinical t r ial of Butea superba,  an 
alternat ive herbal t reatm ent  for erect ile dysfunct ion. Asian J Androl 
2003; 5(3) : 243-46. 
137. Sam appito S, Srichaikul B, Viroj  J, Bakker G. Com parat ive study of double 
blind clinical t r ial in side-effects am ong Areca catechu  I .,Thai t radit ional 
herbal form ula and m ebendazole. Trop Parasitol 2012; 2(2) : 116-18. 
138. Lim kul N, Aram wit  P, Chaiprasert  A. Efficacy and safet y of senna tablets for  
t reatm ent  of chronic const ipat ion in pat ients with end-stage renal 
disease. Thai Pharm  Health Sci J 2010; 5(1) : 31-36. 
139. Palaniswam y UR, editor. Cassia siam ea induced hepat it is, a case report  of 
phytom edicine side effect .  The 3 rd World Congress on Medicinal and 
Aram at ic Plants:  t radit ional m edicine and nut raceut icals;  2003;  Thiland. 
I nternat ional Society for  Hort icultural Science. 
140. Thailand Library I ntegrated System . Thai digital collect ion. 2010. 
ht tp: / / tdc.thailis.or.th/ tdc/  (accessed 13 Decem ber 2010) .  
141. Pylypa J. Healing herbs and dangerous doctors:  " fruit  fever"  and com m unity 
conflicts with biom edical cre in Northeast  Thailand. Med Anthropol Q 
2007; 21(4) : 349-68. 
142. Sanguansak A. Media exposure, knowledge and at t itude towards Thai herbs 
am ong people in Bangkok. Tham m asat  University, 2004.  
143. Srisupakwong S. Factory worker at t itude towards consum ing Thai's herbs in 
Mueang dist r ict , Sam ut  Sakhon province. Chiang Mai University, 2003.  
144. Nat ional Kidney Foundat ion. Definit ion and classificat ion of stages of chronic 
kidney disease. Am  J Kidney Dis 2002; 39(2 Suppl 1) : S46-75. 
145. The Nat ional Collaborat ing Cent re for Chronic Condit ions (Great  Britain) . 
Chronic kidney disease:  nat ional clinical guideline for  early ident ificat ion 
and m anagem ent  in adults in prim ary and secondary care.  1st  ed. 
London:  Royal College of Physicians, 2008. 
146. Ong-Ajyooth L, Vareesangthip K, Khonputsa P, Aekplakorn W. Prevalence of 
chronic kidney disease in Thai adults:  a nat ional health survey. BMC 
Nephrol 2009; 10: 35. 
147. Perkovic V, Cass A, Patel AA, Suriyawongpaisal P, Barzi F, Chadban S, et  al. 
High prevalence of chronic kidney disease in Thailand. Kidney I nt  
2008; 73(4) : 473-79. 
148. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in 
populat ion-based studies:  system at ic review. BMC Public Health 
2008; 11(8) : 117-30. 
References 
258 
149. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et  al. Prevalence of 
chronic kidney disease in China:  a cross-sect ional survey. Lancet  
2012; 379(9818) : 815-22. 
150. Im ai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nit ta K, et  al. Chronic 
kidney disease Japan cohort  study:  baseline characterist ics and factors 
associated with causat ive diseases and renal funct ion. Clin Exp Nephrol 
2010; 14(6) : 558-70. 
151. Mart inez-Castelao A, Gorriz JL, Portoles JM, de Alvaro F, Cases A, Luno J, et  
al. Baseline characterist ics of pat ients with chronic kidney disease stage 3 
and stage 4 in Spain:  the MERENA observat ional cohort  study. BMC 
Nephrol 2011; 12: 53. 
152. Jha V, Garcia-Garcia G, I seki K, Li Z, Naicker S, Plat tner B, et  al. Chronic 
kidney disease:  global dim ension and perspect ives. Lancet  
2013; 382(9888) : 260-72. 
153. Nilwarangkur S, Nim m annit  S, Chaovakul V, Susaengrat  W, Ong- Ajyooth S, 
Vasuvat takul S, et  al. Endem ic prim ary distal renal tubular acidosis in 
Thailand. Q J Med 1990; 74(275) : 289-301. 
154. Gupta SK, Eustace JA, Winston JA, Boydstun I I , Ahuja TS, Rodriguez RA, et  
al. Guidelines for the m anagem ent  of chronic kidney disease in HIV-
infected pat ients:  recom m endat ions of the HIV m edicine associat ion of 
the Infect ious Diseases Society of Am erica. Clin I nfect  Dis 
2005; 40(11) : 1559-85. 
155. Rem uzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I ,  et  al. 
Kidney failure:  aim s for  the next  10 years and barriers to success. Lancet  
2013; 382(9889) : 353-62. 
156. Stengel B. Chronic kidney disease and cancer:  a t roubling connect ion. J 
Nephrol 2010; 23(3) : 253-62. 
157. Greenberg A, editor.  Prim er on kidney diseases.  5th ed. Philadelphia:  
Saundes Elsevier, 2009. 
158. Nat ional Kidney Foundat ion. St rat ificat ion of r isk for  progression of kidney 
disease and developm ent  of cardiovascular disease. Am  J Kidney Dis 
2002; 39(2 Suppl1) : S170-S212. 
159. Cam pbell LJ, I brahim  F, Fisher M, Holt  SG, Hendry BM, Post  FA. Spect rum  
of chronic kidney disease in HIV- infected pat ients. HI V Med 
2009; 10(6) : 329-36. 
160. Nat ional Kidney Foundat ion. About  chronic kidney disease. 2013. 
ht tp: / / www.kidney.org/ kidneydisease/ aboutckd.cfm # sym ptom s 
(accessed 17th January 2013) . 
161. Levey AS, Coresh J. Chronic kidney disease. Lancet  2012; 379(14) : 165-80. 
162. Nat ional Kidney Foundat ion. Associat ion of level of GFR with com plicat ions 
in adults. Am  J Kidney Dis 2002; 39(2 Suppl 1) : S111-69. 
163. Nyirenda MJ, Tang JI , Padfield PL, Seckl JR. Hyperkalaem ia. Br Med J 
2009; 339. 
164. Sarafidis PA, Blacklock R, Wood E, Rum jon A, Sim m onds S, Fletcher-Rogers 
J, et  al. Prevalence and factors associated with hyperkalem ia in 
predialysis pat ients followed in a low-clearance clinic. Clin J Am  Soc 
Nephrol 2012; 7(8) : 1234-41. 
165. Uribarri J. Phosphorus hom eostasis in norm al health and in chronic kidney 
disease pat ients with special em phasis on dietary phospharus intake. 
Sem in Dialysis 2007; 20(4) : 295-301. 
166. Kidney Disease:  I m proving Global Outcom e (KDI GO) . Diagnosis of CKD-
MBD:  biochem ical abnorm alit ies. Kidney I nt  2009; 76(Suppl 113) : S22-
S49. 
167. Taal MW, Brenner BM. Predict ing init iat ion and progression of chronic 
kidney disease:  developing renal r isk scores. Kidney I nt  
2006; 70(10) : 1694-705. 
References 
259 
168. Chit t inandana A, Chailim pam ont ree W, Chaloeiphap P. Prevalence of 
chronic kidney disease in Thai adult  populat ion. J Med Assoc Thai 
2006; 89(Suppl 2) : S112-20. 
169. Levin A, Djurdjev O, Beaulieu M, Er L. Var iabilit y and r isk factors for kidney 
disease progression and death following at tainm ent  of stage 4 CKD in a 
referred cohort .  Am  J Kidney Dis 2008; 52(4) : 661-71. 
170. Obi Y, Kim ura T, Nagasawa Y, Yam am oto R, Yasuda K, Sasaki K, et  al. 
Im pact  of age and overt  proteinuria on outcom es of stage 3 to 5 chronic 
kidney disase in a referred cohort . Clin J Am  Soc Nephrol 
2010; 5(9) : 1558-65. 
171. Nicola LD, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Lorio BD, et  al. 
Prognosis of CKD pat ients receiving outpt ient  nephrology care in I t aly. 
Clin J Am  Soc Nephrol 2011; 6(10) : 2421-28. 
172. Goeij  MCd, Voorm olen N, Halbesm a N, Jager DJd, Boeschoten EW, Sijpkens 
YW, et  al. Associat ion of blood pressure with decline in renal funct ion and 
t im e unt il the start  of renal replacem ent  therapy in pre-dialysis pat ients:  
a cohort  study. BMC Nephrol 2011; 12: 38. 
173. Eriksen B, I ngebretsen O. The progression of chronic kidney disease:  a 10-
year populat ion-based study of the effects of gender and age. Kidney I nt  
2006; 69(2) : 375-82. 
174. Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee I M. Analgesic use and the r isk for  
progression of chronic kidney disease. Pharm acoepidem iol Drug Saf 
2010; 19(7) : 745-51. 
175. Sam uelsson O, Mulec H, Knight -Gibson C, At tm an PO, Kron B, Larsson R, et  
al. Lipoprotein abnorm alit ies are associated with increased rate of 
progression of hum an chronic renal insufficiency. Nephrol Dial Transplant  
1997; 12(9) : 1908-15. 
176. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et  al. The 
effect s of dietary protein rest r ict ion and blood-pressure cont rol on the 
progression of chronic renal disease. N Engl J Med 1994; 330(13) : 877-84. 
177. Aljadhey H, Tu WZ, Hansen RA, Blalock S, Brater C, Murray MD. Risk of 
hyperkalem ia associated with select ive COX-2 inhibitors. 
Pharm acoepidem iol Drug Saf 2010; 19(11) : 1194-98. 
178. Weir MR, Rolfe M. Potassium  hom eostasis and renin-angiotensin-
aldosterone system  inhibitors. Clin J Am  Soc Nephrol 2010; 5(3) : 531-48. 
179. Gut ierrez OM, Wolf M. Dietary phosphorus rest r ict ion in advanced chronic 
kidney disease:  m erits, challenges, and em erging st rategies. Sem in. Dial. 
2010; 23(4) : 401-06. 
180. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, et  al. 
Serum  potassium  and outcom es in CKD:  insights from  the RRI -CKD 
cohort  study. Clin J Am  Soc Nephrol 2010; 5(5) : 762-69. 
181. Nat ional Kidney Disease Educat ion Program . Est im at ing GFR. 2013. 
ht tp: / / nkdep.nih.gov/ lab-evaluat ion/ gfr/ est im at ing.shtm l (accessed 21st  
January 2013) .  
182. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et  al. Modified glom erular 
filt rat ion rate est im at ing equat ion for  Chinese pat ients with chronic kidney 
disease. J Am  Soc Nephrol 2006; 17(10) : 2937-44. 
183. Praditpornsilpa K, Townam chai N, Chawatanarat  T, Tiranathanagul K, 
Katawat in P, Susant itaphong P, et  al. The need for  robust  validat ion for 
MDRD-based glom erular filt rat ion rate est im at ion in various CKD 
populat ions. Nephrol Dial Transplant  2011; 26(9) : 2780-85. 
184. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newm an AB, Siscovick DS, et  
al. Relat ionship of uric acid with progression of kidney disease. Am  J 
Kidney Dis 2007; 50(2) : 239-47. 
185. Dipiro JT, Talbert  RL, Yee GC, Matzke GR, Wells BG, Posey LM. Chronic 
kidney disease:  m anagem ent  of com plicat ions. I n:  8th, editor.  
References 
260 
Pharm acotherapy:  a pathophysiologic approach . stam ford:  Appleton & 
Lange, 2011. 
186. Nat ional Kidney Disease. K/ DOQI  clinical pract ice guidelines for bone 
m etabolism  and disease in chronic kidney disease. Am  J Kidney Dis 
2003; 42(4 Suppl 3) : S1-201. 
187. Nat ional Kidney Foundat ion Kidney Disease Outcom es Qualit y I nit iat ive 
(NKF KDOQI ) . Clinical pract ice guidelines and clinical pract ice 
recom m endat ions for  diabetes and chronic kidney disease. Am  J Kidney 
Dis 2007; 49(2) : S42. 
188. Fouque D, M L. Low protein diets for chonic kidney disease in non diabet ic 
adults. Cochrane Database Syst  Rev  2009; 8(3) : CD001892. 
189. Fored CM, Ej erblad E, Lindblad P, Fryzek J, Dickm an PW, Signorello LB, et  
al. Acetam inophen, aspirin, and chronic renal failure. N Engl J Med 
2001; 345(25) : 1801-08. 
190. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with 
the use of acetam inophen, aspir in, and nonsteroidal ant iinflam m atory 
drugs. N Engl J Med  1994; 331(25) : 1675-79. 
191. Evans M, Fored CM, Bellocco R, Fitzm aurice G, Fryzek JP, McLaughlin JK, et  
al. Acetam inophen, aspirin and progression of advanced chronic kidney 
disease. Nephrol Dial Transplant  2009; 24(6) : 1908-18. 
192. Nat ional Toxicology Program . CAS regist ry num ber:  76-22-2 toxicity 
effect s. 2013. ht tp: / / ntp.niehs.nih.gov/ ?obj ect id= E882C9CF-BDB5-82F8-
F4949C8A2D8C8B01 (accessed 6th February 2014) . 
193. Departm ent  of Medical Sciences. Warning about  Aristolochia contained a 
carcinogenic agent . 2013. 
ht tp: / / www.m oph.go.th/ show_hotnew.php?idHot_new= 52540 (accessed 
26th February 2014) .  
194. Nat ional Kidney Foundat ion. Use of herbal supplem ents in chronic kidney 
disease. 2013. ht tp: / / www.kidney.org/ atoz/ content / herbalsupp.cfm  
(accessed 17th Decem ber 2013) .  
195. Wechwithan S, Sriphirom ya P, Suwankesawong W. Report  of potent ial 
signals from  Thaivigibase during year 2007-2008. Drug Saf 
2010; 33(10) : 954. 
196. WHO collaborat ing cent re for  internat ional drug m onitoring. Nat ional drug 
m onitoring cent res -  drug safety issues. Adverse React ion Newslet ter .  
Uppsala, 1999: 4. 
197. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney failure 
associated with consum pt ion of herbal products containing Mu Tong or 
Fangchi:  a populat ion-based case-cont rol study. Am  J Kidney Dis 
2010; 55(3) : 507-18. 
198. Lin MY, Chiu YW, Lee CH, Yu HY, Chen HC, Wu MT, et  al. Factors associated 
with CKD in the elderly and nonelderly populat ion. Clin J Am  Soc Nephrol 
2013; 8(1) : 33-40. 
199. Terris MK, I ssa MM, Tacker JR. Dietary supplem entat ion with cranberry 
concent rate tablets m ay increase the r isk of nephrolothiasis. Urology  
2001; 57(1) : 26-29. 
200. Galera SC, Fechine FV, Teixeira MJ, Coelho ZCB, de Vasconcelos RC, de 
Vasconcelos PRL. The safet y of oral use of L-glutam ine in m iddle-aged 
and elderly individuals. Nut rit ion 2010; 26(4) : 375-81. 
201. Traxer O, Huet  B, Poindexter J, Pak CYC, Pearle MS. Effect  of ascorbic acid 
consum pt ion on urinary stone r isk factors. J Urol 2003; 170(2 Pt  1) : 397-
401. 
202. Gualano B, Ferreira DC, Sapienza MT, Seguro AC, Lancha AH. Effect  of 
short - term  high-dose creat ine supplem entat ion on m easured GFR in a 
young m an with a single kidney. Am  J Kidney Dis 2010; 55(3) : e7-9. 
203. Gualano B, Ugrinowitsch C, Novaes RB, Art ioli GG, Shim izu MH, Seguro AC, 
et  al. Effects of creat ine supplem entat ion on renal funct ion:  a 
References 
261 
random ized, double-blind, placebo-cont rolled clinical t r ial. Eur J Appl 
Physiol 2008; 103(1) : 33-40. 
204. Prit chard NR, Kalra PA. Renal dysfunct ion accom panying oral creat ine 
supplem ents. Lancet  1998; 351(9111) : 1252-53. 
205. Thorsteinsdot t ir  B, Grande JP, Garovic VD. Acute renal failure in a young 
weight  lifter taking m ult iple food supplem ents, including creat ine 
m onohydrate. J Ren Nut r  2006; 16(4) : 341-45. 
206. Mueller BA, Scot t  MK, Sowinski KM, Prag KA. Noni j uice (Morinda cit r ifolia) :  
hidden potent ial for hyperkalem ia? Am  J Kidney Dis 2000; 35(2) : 310-12. 
207. Kolasani A, Xu H, Millikan M. Evaluat ion of m ineral content  of Chinese 
m edicinal herbs used to im prove kidney funct ion with chem om et rics. Food 
Chem  2011; 127(4) : 1465-71. 
208. Cooke J. Prat ical aspects of herbal supplem ent  use in chronic kidney 
disease. J Renal Nut r  2004; 14(1) : e1-4. 
209. Johns C. Glycyrrhizic acid toxicity caused by consum pt ion of licor ice candy 
cigars. CJEM 2009; 11(1) : 94-96. 
210. Abt  AB, Oh JY, Hunt ington RA, Burkhart  KK. Chinese herbal m edicine 
induced acute renal failure. Arch I ntern Med 1995; 115(2) : 211-12. 
211. Braithwaite R. Heavy m etals and herbal m edicines. I n:  Watson RR, Preedy 
VR, editors. Botanical Medicine in Clinical Pract ice. Trowbridge:  
Crom wellpress, 2008: 851-57. 
212. Chan K. Som e aspects of toxic contam inants in herbal m edicines. 
Chem osphere 2003; 52(9) : 1361-71. 
213. Yu CC, Lin JL, Lin-Tan DT. Environm ental exposure to lead and progression 
of chronic renal diseases:  a four-year prospect ive longitudinal study. J Am 
Soc Nephrol 2004; 15(4) : 1016-22. 
214. Kosalec I , Cvek J, Tom ic S. Contam inat ions of m edicinal herbs and herbal 
products. Arh Hig Rada Toksikol 2009; 60(4) : 485-501. 
215. Thai Food and Drug Adm inist rat ion. Sum m ary report  on the surveillance of 
health products in 2012. Bangkok:  Thai Food and Drug Adm inist rat ion 
2013: 17-18. 
216. Departm ent  of Medical Sciences. A report  on herbal products contam inated 
with convent ional m edicine. 2013. ht tp: / / tum dee.org/ alert /  (accessed 
10th February 2014) .  
217. Nowack R, Nowak B. Herbal teas interfere with cyclosporin levels in renal 
t ransplant  pat ients. Nephrol Dial Transplant  2005; 20(11) : 2554-56. 
218. Hu Z, Yang X, Ho PCL, Chan SY, Heng PWS, Chan E, et  al. Herb-drug 
interact ions. Drugs 2005; 65(9) : 1239-82. 
219. Chavez ML, Jordan MA, Chavez PI .  Evidence-based drug-herbal 
interact ions. Life Sci 2006; 78(18) : 2146-57. 
220. Zhong Y, Deng Y, Chen Y, Chuang PY, He JC. Therapeut ic use of t radit ional 
Chinese herbal m edicat ions for chronic kidney diseases. Kidney I nt  
2013; 84(6) : 1108-18. 
221. Li X, Wang H. Chinese herbal m edicine in the t reatm ent  of chronic kidney 
disease. Adv Chronic Kidney Dis 2005; 12(3) : 276-81. 
222. Soet ikno V, Sari FR, Sukum aran V, Lakshm anan AP, Harim a M, Suzuki K, et  
al. Curcum in decreases renal t r iglyceride accum ulat ion through AMPK-
SREBP signaling pathway in st reptozotocin- induced type 1 diabet ic rats. J 
Nut r Biochem  2013; 24(5) : 796-802. 
223. Babu PS, Srinivasan K. Renal lesions in st reptozotocin- induced diabet ic rats 
m aintained on onion and capsaicin containing diets. J Nut r Biochem  
1999; 10(8) : 477-83. 
224. Pat ten GS, Abeywardena MY, Head RJ, Bennet te LE. Processed dietary 
plants dem onst rate broad capacity for  angiotensin convert ing enzym e and 
angiotensin I I  receptor binding inhibit ion in vit ro. J Funct  Foods 
2012; 4(4) : 851-63. 
References 
262 
225. Wright  CI , Van-Buren L, Kroner CI ,  Koning MMG. Herbal m edicines as 
diuret ics:  a review of the scient ific evidence. J Ethnopharm acol 
2007; 114(1) : 1-31. 
226. Prasongwatana V, Woot t isin S, Sriboonlue P, Kukongvir iyapan V. Uricosuric 
effect  of Roselle (Hibiscus sabdariffa)  in norm al and renal-stone form er 
subjects. J Ethnopharm acol 2008; 117(3) : 491-95. 
227. Sakthong P, Chabunthom  R, Charoenvisuthiwongs R. Psychom et ric 
propert ies of the Thai version of the 8- item  Morisky m edicat ion adherence 
scale in pat ients with type 2 diabetes. Ann Pharm acother  
2009; 43(5) : 950-57. 
228. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predict ive validity of a 
m edicat ion adherence m easure in an outpat ient  set t ing. J Clin Hypertens 
2008; 10(5) : 348-54. 
229. Vlam inck H, Jacobs A, Reynt jens S, Evers G. The dialysis diet  and fluid non-
adherence quest ionnaire:  validit y test ing of a self- report  inst rum ent  for  
clinical pract ice. J Clin Nurs 2001; 10(5) : 707-15. 
230. Kirkwood BR, Sterne JAC. Essent ial m edical stat ist ics.  2nd ed. Oxford:  
Blackwell Science, 2003. 
231. Fleiss JL. Stat ist ical Methods for Rates and Proport ions New York:  John 
Wiley, 1981. 
232. Cohen HW, Shm ukler C, Ullm an R, Rivera CM, Walker EA. Educat ion and 
psychological aspects m easurem ents of m edicat ion adherence in diabet ic 
pat ients with poorly cont rolled HbA1C. Diabet  Med 2010; 27(2) : 210-16. 
233. Gabriel A, Violato C. Knowledge of and at t itudes towards depression and 
adherence to t reatm ent :  the Ant idepressant  Adherence Scale (AAS) . J 
Affect  Disord 2010; 126(3) : 388-94. 
234. Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I ,  et  al. 
Validat ion of a sim plified m edicat ion adherence quest ionnaire in a large 
cohort  of HIV- infected pat ients:  the GEEMA study. AI DS 2002; 16(4) : 605-
13. 
235. Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. 
Challenge of phosphorus cont rol in hem odialysis pat ients:  a problem  of 
adherence? J Nephrol 2010; 23(5) : 525-34. 
236. Thom pson K, Kulkarni J, Sergejew AA. Reliabilit y and validity of a new 
Medicat ion Adherence Rat ing Scale (MARS)  for the psychoses. Schizophr 
Res 2000; 42(3) : 241-47. 
237. Kim  MT, Hill MN, Bone LR, Levine DM. Developm ent  and test ing of the Hill-
Bone com pliance to high blood pressure therapy scale. Prog Cardiovasc 
Nurs 2000; 15(3) : 90-96. 
238. McHorney CA. The adherence est im ator:  a brief, proxim al screener for  
pat ient  propensity to adhere to prescript ion m edicat ions for chronic 
disease. Curr Med Res Opin  2009; 25(1) : 215-38. 
239. Sriwarakorn S, Krit t iyanunt  S, Sakulbum rungsil R. Sensit ivit y and specificity 
of Thai-Version brief m edicat ion quest ionnaire. J Health Res 
2010; 24(3) : 129-34. 
240. Osterberg L, Blaschke T. Adherence to m edicat ion. N Engl J Med 
2005; 353(5) : 487-97. 
241. Bross R, Noori N, Kovesdy CP, Murali SB, Benner D, Block G, et  al. Dietary 
assessm ent  of individuals with chronic kidney disease. Sem in Dialysis 
2010; 23(4) : 359-64. 
242. Caspi O, Koithan M, Criddle MW. Alternat ive m edicine or "alternat ive"  
pat ients:  a qualitat ive study of pat ient -oriented decision-m aking 
processes with respect  to com plem entary and alternat ive m edicine. Med 
Decis Making 2004; 24(1) : 64-79. 
243. Bradburn NM, Sudm an S, Wansink B. Asking quest ions:  the definit ive guide 
to quest ionnaire design -  for m arket  research, polit ical polls, and social 
References 
263 
and health quest ionnaires, revised edit ion .  San Francisco:  A Wiley 
Im print , 2004. 
244. St reiner DL, Norm an GR. Health m easurem ent  scales:  a pract ical guide to 
their developm ent  and use. Fourth ed. Oxford:  Oxford University Press, 
2008. 
245. Cinot t i GA, Zucchelli PC. Effect  of lisinopril on the progression of renal 
insufficiency in m ild proteinuric non-diabet ic nephropathies. Nephrol Dial 
Transplant  2001; 16(5) : 961-66. 
246. Ruggenent i P, Perna A, Gherardi G, Garini G, Zoccali C, Salvador i M, et  al. 
Renoprotect ive propert ies of ACE- inhibit ion in non-diabet ic nephropathies 
with non-nephrot ic proteinuria. Lancet  1999; 354(9176) : 359-64. 
247. Chan JCN, Wat  NMS, So WY, Lam  KSL, Chua CT, Wong KS, et  al. Renin 
angiotensin aldosterone system  blockade and renal disease in pat ients 
with type 2 diabetes. Diabetes Care 2004; 27(4) : 874-79. 
248. Clausen T. Horm onal and pharm acological m odificat ion of plasm a potassium 
hom eostasis. Fundam  Clin Pharm acol 2010; 24(5) : 595-605. 
249. Wright  JA, Cavanaugh KL. Dietary sodium  in chronic kidney disease:  a 
com prehensive approach. Sem in Dialysis 2010; 23(4) : 415-21. 
250. Shrout  PE, Fleiss JL. I nt raclass correlat ions:  uses in assessing rater 
reliabilit y. Psychol Bull 1979; 86(2) : 420-28. 
251. Rosner B. Fundam entals of biostat ist ics. Fifth ed. Pacific Grove:  Duxbury 
Thom son Learning, 2000. 
252. Brennan P, Silm an A. Stat ist ical m ethods for  assessing observer variability 
in clinical m easures. Br Med J 1992; 304(6) : 1491-94. 
253. Larson ML. Meaning-based t ranslat ion:  a guide to cross- language 
equivalence. 2nd ed. Oxford:  University Press of Am erica, 1998.  
254. WHO expert  consultat ion. Appropriate body-m ass index for  Asian 
populat ions and it s implicat ions for policy and intervent ion st rategies. 
Lancet  2004; 363(9403) : 157-63. 
255. Nut rit ionquest . Food quest ionnaire -  dialysis. 2005. 
www.nut r it ionquest .com  (accessed 20 January 2011) . 
256. Creswell JW, Clark VLP. Designing and conduct ing m ixed m ethods research .  
London:  SAGE Publicat ions, 2011. 
257. Sim  J, Wright  C. Research in health care:  concepts, designs and m ethods.  
1st  ed. Cheltenham :  Nelson Thornes Ltd, 2000. 
258. Guest  G, MacQueen KM, Nam ey EE. Applied them at ic analysis. 1st  ed. 
California:  SAGE Publicat ions, 2012. 
259. Braun V, Clarke V. Using them at ic analysis in psychology. Qual Res Psychol 
2006; 3(2) : 77-101. 
260. Nat ional Stat ist ical Office. Populat ion and society. 2007. 
ht tp: / / web.nso.go.th/ en/ stat_them e_socpop.htm  (accessed 27th March 
2013) . 
261. Rifkin DE, Laws MB, Rao M, Balakrishnan V, Sarnak MJ, Wilson IB. 
Medicat ion adherence behavior and priorit ies am ong older adults with 
CKD:  a sem i-st ructured interview study. Am  J Kidney Dis 
2010; 56(3) : 439-46. 
262. Stavropoulou C. Non-adherence to m edicat ion and doctor-pat ient  
relat ionship:  evidence from  a European survey. Pat ient  Educ Couns 
2011; 83(1) : 7-13. 
263. Li M, Wang W, Xue J, Gu Y, Lin S. Meta-analysis of the clinical value of 
Ast ragalus m em branaceus in diabet ic nephropathy. J Ethnopharm acol 
2011; 133(2) : 412-19. 
264. Okuda M, Horikoshi S, Matsum oto M, Tanim oto M, Yasui H, Tom ino Y. 
Beneficial effect  of Ast ragalus m em branaceus on est im ated glom erular 
filt rat ion rate in pat ients with progressive chronic kidney disease. Hong 
Kong J Nephrol 2012; 14(1) : 17-23. 
References 
264 
265. Afshari AT, Shirpoor A, Farshid A, Saadat ian R, Rasm i Y, Saboory E, et  al. 
The effect  of ginger on diabet ic nephropathy, plasm a ant ioxidant  capacity 
and lipid peroxidat ion in rats.  Food Chem  2007; 101(1) : 148-53. 
266. Li Z, Zhu L, Zhang H, Yang J, Zhao J, Du D, et  al. Protect ive effect  of a 
polysaccharide from  stem  of Codonopsis pilosula against  renal 
ischem ia/ reperfusion injury in rats. Carbohydr Polym  2012; 90(4) : 1739-
43. 
267. Wang Y, Yin H, Lv X, Wang Y, Gao H, Wang M. Protect ion of chronic renal 
failure by a polysaccharide from  Cordyceps sinensis. Fitoterapia 
2010; 81(5) : 397-402. 
268. Knight  EL, Stam pfer MJ, Hankinson SE, Spiegelm an D, Curhan GC. The 
im pact  of protein intake on renal funct ion decline in wom en with norm al 
renal funct ion or m ild renal insufficiency. Ann I ntern Med 
2003; 138(6) : 460-67. 
269. Shakibaei M, John T, Schulze-Tanzil G, Lehm ann I , Mobasheri A. 
Suppression of NF-kB act ivat ion by curcum in leads to inhibit ions of 
expression of cyclo-oxygenase-2 and m at rix m etalloproteinase-9 in 
hum an art icular chondrocytes:  im plicat ions for the t reatm ent  of 
osteoarthrit is. Biochem  Pharm acol 2007; 73(9) : 1434-45. 
270. van Breem en RB, Tao Y, Li W. Cyclooxygenase-2 inhibitors in ginger 
(Zingiber officinale) .  Fitoterapia 2011; 82(1) : 38-43. 
271. Katsukawa M, Nakata R, Takizawa Y, Hori K, Takahashi S, I noue H. Cit ral, a 
com ponent  of lem ongrass oil, act ivates PPARD and J and suppress COX-2 
expression. Biochim  Biophys Acta 2010; 1801(11) : 1214-20. 
272. Rios A, Vargas-Robles H, Gam ez-Mendez AM, Escalante B. Cyclooxygenase-
2 and kidney failure. Prostaglandins Other Lipid Mediat  2012; 98(3-4) : 86-
90. 
273. Robinson A, McGrail MR. Disclosure of CAM use to m edical pract it ioners:  a 
review of qualitat ive and quant itat ive studies. Com plem ent  Ther Med 
2004; 12(2-3) : 90-98. 
274. Friis RH, Sellers TA. Epidem iology for  public health pract ice. 3rd ed. 
Massachuset ts:  Jones and Bart let t  Publishers, 2009. 
275. I banez L, Morlans M, Vidal X, Mart inez MJ, Laporte JR. Case-cont rol study 
of regular analgesic and nonsteroidal ant i- inflam m atory use and end-
stage renal disease. Kidney I nt  2005; 67(6) : 2393-98. 
276. Plant inga L, Grubbs V, Sarkar U, Hsu C-y, Hedgem an E, Robinson B, et  al. 
Nonsteroidal ant i- inflam m atory drug use am ong persons with chronic 
kidney disease in the United States. Ann Fam  Med 2011; 9(5) : 423-30. 
277. Brophy DF, Gehr TW. Disorders of potassium  and m agnesium  hom eostasis. 
I n:  Dipiro JT, Talbert  RL, Yee GC, Matzke GR, Wells BG, Posey LM, 
editors. Pharm acotherapy:  a pathophysiologic approach .  7th ed. New 
York:  The McGraw-Hill Com panies, 2008: 877. 
278. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et  al. The 
frequency of hyperkalem ia and it s significance in chronic kideny disease. 
Arch I ntern Med 2009; 169(12) : 1156-62. 
279. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahm an M, et  al. Chronic Renal 
I nsufficiency Cohort  (CRIC)  study:  baseline characterist ics and 
associat ions with kidney funct ion. Clin J Am  Soc Nephrol 2009; 4(8) : 1302-
11. 
280. Pongchaiyakul C, Nguyen T, Kosulwat  V, Roj roongwasinkul N, 
Charoenkiatkul S, Pongchaiyakul C, et  al. Defining obesity by body m ass 
index in the Thai populat ion:  an epidem iologic study. Asia Pac J Clin Nut r  
2006; 15(3) : 293-99. 
281. World Health Organizat ion. Obesity:  Prevent ing and Managing the Global 
Epidem ic. Report  of a WHO consultat ion. World Health Organ Tech Rep 
Ser  2000; 894: 1-253. 
References 
265 
282. Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, et  al. 
Associat ion between sm oking and chronic kidney disease:  a case cont rol 
study. BMC Public Health  2010; 25(10) : 731-36. 
283. Nat ional Kidney Foundat ion. Evaluat ion of laboratory m easurem ents for 
clinical assessm ent  of k idney disease. Am  J Kidney Dis 2002; 39(2 Suppl 
1) : S76-S110. 
284. Kidney Disease:  Im proving Global Outcom e (KDI GO) . KDIGO clinical 
pract ice guideline for the m anagem ent  of blood pressure in chronic kidney 
disease. Kidney I nt  Suppl 2012; 2(5) : 340-97. 
285. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickm an PW, Signorello LB, et  
al. Acetam inophen, aspirin, and chronic renal failure. N Engl J Med 
2001; 345(25) : 1801-08. 
286. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et  al. NSAI D 
use and progression of chronic kidney disease. Am  J Med 
2007; 120(3) : 280.e1-7. 
287. Powell R. Surveys. I n:  Walker DM, editor.  An int roduct ion to health services 
research.  London:  SAGE, 2014: 189. 
288. Greenland S, Rothm an KJ. I nt roduct ion to st rat ified analysis. I n:  Rothm an 
KJ, Greenland S, Lash TL, editors. Modern epidem iology . Philadelphia:  
Lippincot t  William s & Wilkins, 2008: 260-63. 
289. Edwards IR, Aronson JK. Adverse drug react ions:  definit ions, diagnosis, and 
m anagem ent . Lancet  2000; 356(9237) : 1255-59. 
290. Chart srisak K, Vipat tawat  K, Assanatham  M, Nongnuch A, I ngsathit  A, 
Dom rongkitchaiporn S, et  al. Mineral m etabolism  and outcom es in chronic 
kidney disease stage 2-4 pat ients. BMC Nephrol 2013; 14: 14. 
291. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, et  al.  
Factors associated with kidney disease progression and m ortalit y in a 
referred CKD populat ion. Am  J Kidney Dis 2010; 56(6) : 1072-81. 
292. Landray MJ, Em berson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, 
et  al. Predict ion of ESRD and death am ong people with CKD:  the Chronic 
Renal Im pairm ent  in Birm ingham  (CRIB)  prospect ive cohort  study. Am  J 
Kidney Dis 2010; 56(6) : 1082-94. 
293. Thaikruea L, Seetam anotch W, Seetam anotch S. Appropriate cut -off level of 
BMI  for screening in Thai adults. J Med Assoc Thai 2006; 89(12) : 2123-8. 
294. Yam ashita T, Yoshida T, Ogawa T, Tsuchiya K, Nit ta K. Clinical outcom es in 
pat ients with chronic kidney disease:  a 5- year ret rospect ive cohort  study 
at  a University hospital in Japan. Clin Exp Nephrol 2011; 15(6) : 831-40. 
295. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et  al. 
Hypertension awareness, t reatm ent , and cont rol in adults with CKD:  
results from  the Chronic Renal I nsufficiency Cohort  (CRIC)  study. Am  J 
Kidney Dis 2010; 55(3) : 441-51. 
296. Asare GA, Gyan B, Bugyei K, Adjei S, Maham a R, Addo P, et  al. Toxicity 
potent ials of the nut raceut ical Moringa oleifera at  supra- supplem entat ion 
levels. J Ethnopharm acol 2012; 139(1) : 265-72. 
297. Sireeratawong S, Nanna U, Vannasir i S, Chiruntanat  N, Srithiwong S, 
Subcharoen P, et  al. Acute and subchronic toxicity study of Tud-Rak-Ka-
Sai-Puu recipe in rats. Afr J Tradit  Com plem ent  Alt ern Med  
2013; 10(1) : 142-48. 
298. Sireeratawong S, Lertprasertsuke N, Srisawat  U, Thuppia A, Ngam jariyawat  
A, Suwanlikhid N, et  al. Acute and subchronic toxicity study of the water 
ext ract  from  Tiliacora t r iandra (Colebr.)  Diels in rats. Songklanakarin J Sci 
Technol 2008; 30(5) : 611-19. 
299. Kothari SC, Shivarudraiah P, Venkataram aiah SB, Koppolu KP, Gavara S, 
Jairam  R, et  al. Safety assessm ent  of Cissus quadrangularis ext ract  (CQR-
300) :  subchronic toxicity and m utagenicity studies. Food Chem  Toxicol 
2011; 49(12) : 3343-57. 
References 
266 
300. Rosidah, Yam  MF, Sadikun A, Ahm ad M, Akowuah GA, Asm awi MZ. 
Toxicology evaluat ion of standardized m ethanol ext ract  of Gynura 
procum bens.  J Ethnopharm acol 2009; 123(2) : 244-49. 
301. Meena H, Singh KP, Negi PS, Ahm ed Z. Sub-acute toxicity of cultured 
m ycelia of Him alayan entom ogenous fungus Cordyceps sinensis (Berk.)  
Sacc. in rats. I ndian J Exp Biol 2013; 51(5) : 381-87. 
302. At tanayake AP, Jayat ilaka K, Pathirana C, Kum ari L, Mudduwa B. Efficacy 
and toxicological evaluat ion of Coccinia grandis (Cucurbitaceae)  ext ract  in 
m ale wistar rats.  Asian Pac J Trop Dis 2013; 3(6) : 460-66. 
303. Foote J, Cohen B. Medicinal herb use and the renal pat ient . J Ren Nut r  
1998; 8(1) : 40-42. 
304. Mazokopakis EE, Karefilakis CM, Tsartsalis AN, Milkas AN, Ganotakis ES. 
Acute rhabdom yolysis caused by spirulina (Arthrospira platensis) . 
Phytom edicine 2008; 15(6-7) : 525-27. 
305. Chavalit tum rong P, At tawish A, Chuthaput t i A, Chuntapet  P. Toxicological 
study of crude ext ract  of Tinospora crispa Mier ex Hook F.&Thom s. Thai J 
Pharm  Sci 1997; 21(4) : 199-210. 
306. Chavalit tum rong P, At tawish A, Rugsam on P, Chuntapet  P. Subacute 
toxicity of t radit ional m edicinal Tripala. Bull Dept  Med Sci 
1996; 38(3) : 169-91. 
307. Colson CRD, De Broe ME. Kidney injury from  alternat ive m edicines. Adv 
Chronic Kidney Dis 2005; 12(3) : 261-75. 
308. The Uppsala Monitoring Cent re. Glossary of term s used in 
pharm acovigilance. 2011. ht tp: / / who-um c.org/ Graphics/ 24729.pdf 
(accessed 16th Decem ber 2013) .  
 
 
 
Appendices 
267 
Appendices 
 
Appendix 1:  Bus stop survey 
268 
Appendix 1 : Bus stop survey 
 
 
Appendix 1:  Bus stop survey 
269 
 
  
Appendix 1:  Bus stop survey 
270 
 
  
Appendix 1:  Bus stop survey 
271 
 
  
Appendix 1:  Bus stop survey 
272 
 
  
Appendix 1:  Bus stop survey 
273 
 
  
Appendix 1:  Bus stop survey 
274 
 
  
Appendix 1:  Bus stop survey 
275 
 
  
Appendix 1:  Bus stop survey 
276 
 
 
Appendix 2:  Common use of herbal medicines in Thailand 
277 
Appendix 2 : Com m on use of herbal m edicines 
in Thailand 
Types of herbal medicine Picture Part  of the t ree for 
herbal medicine use 
Medical purposes*  
Kar iyat  (Andrographis 
paniculata)  
 
 
Leaf Common cold 
Turmeric (Curcuma longa)  
  
Rhizome Flatulence 
Horse radish t ree 
(Moringa spp.)  
 
Leaf I nsomnia 
Laxat ive and 
diuret ic effects 
River spiderwort 
(Tradescant ia flum inensis)  
 
All parts No evidence 
Babbler ’s Bill Leaf 
(Thunbergia laur ifolia)  
-  Leaf Fever 
Boesenbergia 
(Boesenbergia rotunda)  
 
Rhizome Flatulence and 
diarrhoea 
Heart - leaved moonseed 
(Tinospora cr ipa)  
-  Stem Fever, expectorant 
and muscle pain 
Vap Ca (Hout tuynia 
cordata)  
 
Leaf Diuret ic effect  and 
cough 
Blue Pea (Clitor ia 
ternatea)  
 
Flower Topical use:  hair 
loss and good hair 
health  
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Types of herbal 
medicine 
Picture Part  of the t ree for 
herbal medicine use 
Medical purposes*  
Roselle (Hibiscus 
sabdar iffa)  
 
Flower Diuret ic effect 
Spr ing bit ter  cucumber 
(Momordica 
cochinchinensis)  
 
Fruit  No evidence 
Java tea 
 
Leaf Diuret ic effect 
Types of Thai folk 
remedy 
Picture Main ingredients Medical purposes*  
 ‘Ya hom ’ 
 
Licor ice, nutmeg, clove, 
cinnamon, I ndian small 
civet , saffron, camphor, 
aglia, Magnolia officinalis 
Faint  
‘Ka sai’ -  Rhubarb, senna, 
asafet ida, aloe, Garcinia 
hanburyi 
Const ipat ion 
 ‘Ya khom ’ -  Turmeric, Tinospora 
cr ipa, Aristolochia, 
Gymnopetalum 
cochinchinense 
fever 
Reference:  Nat ional Drug Commit tee. Nat ional list  of herbal medicine products. 1st  ed. Bangkok:  
Minist ry of Public Health Thailand, 2011. 
Department  of Herbal Database Mahidol University. Med plant , 2010. 
*  Approved by Thai FDA    
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Appendix  4 :  Open- ended quest ions about  
at t itudes tow ards the reasons for  HDS use 
Translat ion version 
This quest ionnaire is to gather inform at ion about  reasons for  HDS use in pre-
dialysis pat ients in order to understand HDS users. 
CU /  SWU Hospital 
Part icipant  num ber……………………....    
Date of data collect ion………/ …………/ …………. 
Inform at ion provider  Ŀ Pat ient  (0)   Ŀ Care giver (1)  
1. How and when were you int roduced to HDS? 
2. Why do you use HDS? 
3. What  led you to start  using HDS? 
4. Did anything influence you to start  using HDS, e.g. advice from  fr iends, 
doctor,  news reports, etc?           
5. Are there benefit s of HDS com pared with convent ional m edicines? Please 
explain why you think this. 
6. What  did you hope taking HDS would achieve? 
7. Do you have any concerns about  using HDS? I f yes, what? Then please 
com pare with convent ional m edicines. 
8. Have you had any warnings about  taking the HDS such as from  doctors, 
fr iends? I f yes, has it  influenced your use in anyway? 
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The or iginal version of data ext ract ion sheet  for  outpat ient  
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The or iginal f inal version of quest ionnaire  
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Appendix 7 : Data  sheet  for  telephone 
interview  and data  ext ract ion sheet  for  the 
follow - up study 
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Appendix 7:  Data sheet for the follow-up study 
326 
 
  
Appendix 7:  Data sheet for the follow-up study 
327 
 
  
Appendix 7:  Data sheet for the follow-up study 
328 
 
  
Appendix 7:  Data sheet for the follow-up study 
329 
 
  
Appendix 7:  Data sheet for the follow-up study 
330 
The or iginal version of data sheet  for  the follow - up study 
 
  
Appendix 7:  Data sheet for the follow-up study 
331 
 
  
Appendix 7:  Data sheet for the follow-up study 
332 
 
  
Appendix 7:  Data sheet for the follow-up study 
333 
 
 
Appendix 8:  I nformat ion sheet  for  research part icipant  
334 
Appendix 8 : I nform at ion sheet  for  research 
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Translat ion version 
62 Mu 7 Ongkharak 
Nakhon-Nayok 26120 
Tel. 0-3739-5085-6  ext . 60428 
 
Cert ificate of Approval by I nst itut ional Review  Board  
( Expedited Review )   
Faculty of Medicine, Sr inakharinw irot  University 
SWUEC/ EX IRB No. 43/ 2554 
Study Tit le The associat ion between herbal and dietary supplem ent  
use and the progression of chronic kidney disease (CKD)  
and it s com plicat ions am ong pat ients with chronic 
kidney disease in Thailand 
Principal I nvest igator  
I nst itut ion 
Miss Mayuree  Tangkiatkum jai 
Faculty of Pharm acy, Sr inakharinwirot  University 
SWUEC code SWUEC/ Ex 
Docum ent  Reviewed 1. Protocol version 5 May 2011 
2. The docum ent  of quest ions answering on 8 
August  2011 
3. Consent  form  
4. St ructured quest ionnaire 
5. The data from  pat ient  m edical records 
Approval by Inst itut ional Review Board (Ex)  
Date of Approval 9 August  2011 
Approval Expire Date 8 August  2012 
 
The Inst itut ional Review Board of the Faculty of Medicine, Srinakharinwirot  
University has approved this study which is to be carried out  in com pliance with 
the Internat ional guidelines for hum an research protect ion as Declarat ion of 
Helsinki. 
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Translat ion version 
62 Mu 7 Ongkharak 
Nakhon-Nayok 26120 
Tel. 0-3739-5085-6  ext . 60428 
 
Cert ificate of Approval by I nst itut ional Review  Board  
( Expedited Review )   
Faculty of Medicine, Sr inakharinw irot  University 
SWUEC/ EX IRB No. 43/ 2555 (First  extension)  
Study Tit le The associat ion between herbal and dietary supplem ent  
use and the progression of chronic kidney disease (CKD)  
and it s com plicat ions am ong pat ients with chronic 
kidney disease in Thailand 
Principal I nvest igator  
I nst itut ion 
Assist . Prof. Mayuree  Tangkiatkum jai 
Faculty of Pharm acy, Sr inakharinwirot  University 
SWUEC code SWUEC/ Ex 43/ 2555 
Docum ent  Reviewed 1. Protocol version 5 May 2011 
2. Cert ificate of ethics approval SWUEC/ EX 43/ 2554 
Approval by Inst itut ional Review Board (Ex)  
Date of Approval 9 August  2012 
Approval Expire Date 8 August  2013 
 
The Inst itut ional Review Board of the Faculty of Medicine, Srinakharinwirot  
University has approved this study which is to be carried out  in com pliance with 
the Internat ional guidelines for hum an research protect ion as Declarat ion of 
Helsinki. 
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quest ionnaire 
Translat ion version 
 
Appendix 13:  First  version of dietary quest ionnaire 
351 
 
Appendix 13:  First  version of dietary quest ionnaire 
352 
 
  
Appendix 13:  First  version of dietary quest ionnaire 
353 
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Appendix 1 4 : Different  HDS used in the 
present  survey reported by one respondent  
Thirty-one different  types of herbal m edicines and seven different  dietary 
supplem ents used were reported once, see table below. 
Types of HDS used 
Black galingale (Kaem pferia parviflora)  Roselle j uice  
Lem ongrass Lim e 
An herbal com binat ion – Boesenbergia, 
sweet  basil, honey and lim e juice 
Spring bit ter cucum ber (Mom ordica 
cochinchinensis)  
An herbal com binat ion – Boesenbergia, 
m int , ginger, galangal, lem ongrass, 
kaffir  lim e leaves and shallots 
Lotus (Nelum bo nucifera)  
An herbal com binat ion -  Boesenbergia, 
sweet  basil, honey, lim e juice and 
Asiat ic Pennywort  (Centella asiat ica)  
I vy gourd leaves (Coccinia grandis)  
An herbal com binat ion – Boesenbergia 
and Asiat ic Pennywort  
Bam boo grass leaves (Tiliacora 
t r iandra)  
Sweet  basil and pineapple Alfafa 
An herbal com binat ion -  Boesenbergia, 
onion, galangal, lem ongrass, kaffir  lim e 
leaves, lim e leaves and m int  
An herbal com binat ion – paragrass 
roots (Brachiaria m ut ica)  and 
pom egranate leaves (Punica 
granatum )  
A Chinese folk rem edy – holy 
m ushroom , Cordyceps (Cordyceps 
sinessis) , ginseng and Chinese 
Wolfberry (Lycium  Chinese)  
A Chinese folk rem edy -  Cordyceps, 
Lovage (Angelica sinensis) ,  deer 
ant le velvet ,  cinnam on and 
Schisandra berry (Schisandra 
chinensis.)  
Java tea (Orthosiphon aristatus)  Mim osa pudica 
An herbal com binat ion – garlic, leaves 
of Cassod t ree (Cassia siam ea) , piper 
and aloe vera 
An herbal com binat ion -  green tea, 
pepper and garcinia. 
A stem  from  Coscinium  fenest ratum  Echinochloa spp.  
Leaves of Palm ae (Corypha lecom tei)  Algae 
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Types of HDS used 
Leaves of Clerodendrum  petasites Gynura procum bens 
A Thai folk rem edy called “Tri Pla”  – 
Chebulic m yrobalans (Term inalia 
chebula) , Beleric m yrobalan 
(Term inalia bellir ica)  and Em blic 
m yrablan (Phyllanthus em blica)  
A Chinese folk rem edy -  Cordyceps, 
Angelica sinensis,  Chinese 
Wolfberry, Ast ragalus (Ast ragali 
radix) , Eucom m ia ulm oides,  
Codonopsis pilosula and deer ant ler  
velvet  
Cissus quadrangularis Sesam e oil 
Coconut  oil Collagen 
Glucosam ine Chondroit in sulphate 
Lecithin A soy bean ext ract  and beta-glucan 
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Appendix 1 5 : Sensit ivity analyses 
Table 1:  Univariate analyses of the progression of CKD at  the cut -off point  of a 
decline in eGFR over a year at  least  5 m l/ m in/ 1.73m 2/ year and variables 
(n= 330)  
Variables Fast  progression 
(n= 104) 
Slow progression 
(n= 226) 
X2 value p-value 
HDS use   0.05 0.82 
   Exposure 30 (30.6% ) 68 (69.4% )   
   Non-exposure 74 (31.9% ) 158 (68.1% )   
Age   8.31 <  0.01*  
   <  60 42 (40.4% ) 56 (24.8% )   
   >  60 62 (59.6% ) 170 (75.2% )   
Sex   5.32 0.02*  
  Male  56 (53.8% ) 91 (40.3% )   
  Female 48 (46.2% ) 135 (59.7% )   
Current  smoking   <  0.01 0.98 
   Yes 5 (4.8% ) 11 (4.9 % )   
   No 99 (95.2% ) 215 (95.1% )   
Obesity (n= 98) (n= 218) 0.69 0.40 
   Yes 44 (44.9% ) 87 (39.9% )   
   No  54 (55.1% ) 131 (60.1% )   
Exist ing proteinur ia (n= 98) (n= 193) 25.07 <  0.01*  
   Yes 68 (69.4% ) 74 (38.3% )   
   No 30 (30.6% ) 119 (61.7% )   
Degree of protein intake  1.22 0.27 
   Moderate to high 50 (48.1% ) 94 (41.6% )   
   Low 54 (51.9% ) 132 (58.4% )   
Hypertension   0.84 0.36 
   Yes 99 (95.2% ) 209 (92.5% )   
   No 5 (4.8% ) 17 (7.5% )   
Diabetes   0.68 0.41 
   Yes 59 (56.7% ) 139 (61.5% )   
   No 45 (43.3% ) 87 (38.5% )   
Dyslipidaem ia   0.02 0.89 
   Yes 92 (88.5% ) 201 (88.9% )   
   No 12 (11.5% ) 25 (11.1% )   
Controlled blood pressure (n= 102) (n= 225) 1.94 0.16 
   No 72 (70.6% ) 141 (62.7% )   
   Yes 30 (29.4% ) 84 (37.3% )   
A1C (% ) (n= 59) (n= 142) 0.28 0.59 
   >  7 29 (49.2% ) 64 (45.1% )   
   <  7 30 (50.8% ) 78 (54.9% )   
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Table 1:  ( cont inued)  
Variables Fast  progression 
(n= 104) 
Slow progression 
(n= 226) 
X2 value p-value 
LDL cholesterol (mg/ dl)  (n= 88) (n= 205) 6.05 0.01*  
   >  100 55 (62.5% ) 96 (46.8% )   
   <  100 33 (37.5% ) 109 (53.2% )   
Current  use of NSAI Ds or COX-2 inhibitors  0.45 0.50 
   Yes 8 (7.7% ) 13 (5.8% )   
   No 96 (92.3% ) 213 (94.2% )   
Current  use of aspir in   2.79 0.09 
   Yes 35 (33.7% ) 98 (43.4% )   
   No 69 (66.3% ) 128 (56.6% )   
Prescr ibed, convent ional medicat ion adherence* *   5.44 0.02*  
   Low 34 (32.7% ) 47 (20.8% )   
   Medium to high 70 (67.3% ) 179 (79.2% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772. 
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Table 2:  Univariate analyses of the progression of CKD at  the cut -off point  of a 
decline in eGFR over a year at  least  4 m l/ m in/ 1.73m 2/ year and variables 
(n= 330)  
Variables Fast  progression 
(n= 121) 
Slow progression 
(n= 209) 
X2 value p-value 
HDS use   <  0.01 0.99 
   Exposure 36 (29.8% ) 62 (29.7% )   
   Non-exposure 85 (70.2% ) 147 (70.3% )   
Age   7.65 <  0.01*  
   <  60 47 (38.8% ) 51 (24.4% )   
   >  60 74 (61.2% ) 158 (75.6% )   
Sex   3.47 0.06 
  Male  62 (51.2% ) 85 (40.7% )   
  Female 59 (48.8% ) 124 (59.3% )   
Current  smoking   <  0.01 0.94 
   Yes 6 (5.0% ) 10 (4.8% )   
   No 115 (95.0% ) 199 (95.2% )   
Obesity (n= 115) (n= 201) 0.62 0.43 
   Yes 51 (44.3% ) 80 (39.8% )   
   No  64 (55.7% ) 121 (60.2% )   
Exist ing proteinur ia (n= 113) (n= 178) 25.19 <  0.01*  
   Yes 76 (67.3% ) 66 (37.1% )   
   No 37 (32.7% ) 112 (62.9% )   
Degree of protein intake  1.43 0.23 
   Moderate to high 58 (47.9% ) 86 (41.1% )   
   Low 63 (52.1% ) 123 (58.9% )   
Hypertension   <  0.01 0.98 
   Yes 113 (93.4% ) 195 (93.3% )   
   No 8 (6.6% ) 14 (6.7% )   
Diabetes   0.14 0.71 
   Yes 71 (58.7% ) 127 (60.8% )   
   No 50 (41.3% ) 82 (39.2% )   
Dyslipidaem ia   0.78 0.38 
   Yes 105 (86.8% ) 188 (90.0% )   
   No 16 (13.2% ) 21 (10.0% )   
Controlled blood pressure (n= 119) (n= 208) 1.75 0.19 
   No 83 (69.7% ) 130 (62.5% )   
   Yes 36 (30.3% ) 78 (37.5% )   
A1C (% ) (n= 71) (n= 130) 0.40 0.52 
   >  7 35 (49.3% ) 58 (44.6% )   
   <  7 36 (50.7% ) 72 (55.4% )   
LDL cholesterol (mg/ dl)  (n= 105) (n= 188) 5.81 0.02*  
   >  100 64 (61.0% ) 87 (46.3% )   
   <  100 41 (39.0% ) 101 (53.7% )   
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Table 2:  ( cont inued)  
Variables Fast  progression 
(n= 121) 
Slow progression 
(n= 209) 
X2 value p-value 
Current  use of NSAI Ds or COX-2 inhibitors  1.16 0.28 
   Yes 10 (8.3% ) 11 (5.3% )   
   No 111 (91.7% ) 198 (94.7% )   
Current  use of aspir in   1.23 0.27 
   Yes 44 (36.4% ) 89 (42.6% )   
   No 77 (63.6% ) 120 (57.4% )   
Prescr ibed, convent ional medicat ion adherence* *   6.09 0.01*  
   Low 39 (32.2% ) 42 (20.1% )   
   Medium to high 82 (67.8% ) 167 (79.9% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
agreement  is available from:  Donald E. Morisky, ScD, ScM, MSPH, Professor, Department  of 
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Table 3:  Univariate analyses of the progression of CKD at  the cut -off point  of a 
decline in eGFR over a year at  least  6 m l/ m in/ 1.73m 2/ year and variables 
(n= 330)  
Variables Fast  progression 
(n= 90) 
Slow progression 
(n= 240) 
X2 value p-value 
HDS use   <  0.01 0.94 
   Exposure 27 (29.3% ) 71 (29.6% )   
   Non-exposure 63 (70.7% ) 169 (70.4% )   
Age   7.72 <  0.01*  
   <  60 37 (41.1% ) 61 (25.4% )   
   >  60 53 (58.9% ) 179 (74.6% )   
Sex   7.36 <  0.01*  
  Male  51 (56.7% ) 96 (40.0% )   
  Female 39 (43.3% ) 144 (60.0% )   
Current  smoking   0.13 0.71 
   Yes 5 (5.6% ) 11 (4.6% )   
   No 85 (94.4% ) 229 (95.4% )   
Obesity (n= 85) (n= 231) 0.94 0.33 
   Yes 39 (45.9% ) 92 (39.8% )   
   No  46 (54.1% ) 139 (60.2% )   
Exist ing proteinur ia (n= 86) (n= 205) 23.93 <  0.01*  
   Yes 61 (70.9% ) 81 (39.5% )   
   No 25 (29.1% ) 124 (60.5% )   
Degree of protein intake  0.03 0.86 
   Moderate to high 40 (44.4% ) 104 (43.3% )   
   Low 50 (55.6% ) 136 (56.7% )   
Hypertension   0.98 0.32 
   Yes 86 (95.6% ) 222 (92.5% )   
   No 4 (4.4% ) 18 (7.5% )   
Diabetes   1.02 0.31 
   Yes 50 (55.6% ) 148 (61.7% )   
   No 40 (44.4% ) 92 (38.3% )   
Dyslipidaem ia   0.13 0.72 
   Yes 79 (87.8% ) 214 (89.2% )   
   No 11 (12.2% ) 26 (10.8% )   
Controlled blood pressure (n= 88) (n= 239) 0.93 0.34 
   No 61 (69.3% ) 152 (63.6% )   
   Yes 27 (30.7% ) 87 (36.4% )   
A1C (% ) (n= 51) (n= 150) 0.21 0.65 
   >  7 25 (49.0% ) 68 (45.3% )   
   <  7 26 (51.0% ) 82 (54.7% )   
LDL cholesterol (mg/ dl)  (n= 75) (n= 218) 10.94 <  0.01*  
   >  100 51 (68.0% ) 100 (45.9% )   
   <  100 24 (32.0% ) 118 (54.1% )   
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Table 3:  ( cont inued)  
Variables Fast  progression 
(n= 90) 
Slow progression 
(n= 240) 
X2 value p-value 
Current  use of NSAI Ds or COX-2 inhibitors  0.41 0.52 
   Yes 7 (7.8% ) 14 (5.8% )   
   No 83 (92.2% ) 226 (94.2% )   
Current  use of aspir in   2.49 0.11 
   Yes 30 (33.3% ) 103 (42.9% )   
   No 60 (66.7% ) 137 (57.1% )   
Prescr ibed, convent ional medicat ion adherence* *   9.82 <  0.01*  
   Low 33 (36.7% ) 48 (20.0% )   
   Medium to high 57 (63.3% ) 192 (80.0% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
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Table 4:  Univariate analyses of the progression of CKD at  the cut -off point  of a 
decline in eGFR over a year at  least  10 m l/ m in/ 1.73m 2/ year and variables 
(n= 330)  
Variables Fast  progression 
(n= 40) 
Slow progression 
(n= 290) 
X2 value p-value 
HDS use   2.05 0.15 
   Exposure 8 (20.0% ) 90 (31.0% )   
   Non-exposure 32 (80.0% ) 200 (69.0% )   
Age   8.99 <  0.01*  
   <  60 20 (50.0% ) 78 (26.9% )   
   >  60 20 (50.0% ) 212 (73.1% )   
Sex   3.09 0.08 
  Male  23 (57.5% ) 124 (42.8% )   
  Female 17 (42.5% ) 166 (57.2% )   
Current  smoking   2.62 0.11 
   Yes 4 (10.0% ) 12 (4.1% )   
   No 36 (90.0% ) 278 (95.9% )   
Obesity (n= 36) (n= 280) 0.11 0.74 
   Yes 14 (38.9% ) 117 (41.8% )   
   No  22 (61.1% ) 163 (58.2% )   
Exist ing proteinur ia (n= 40) (n= 251) 12.74 <  0.01*  
   Yes 30 (75.0% ) 112 (44.6% )   
   No 10 (25.0% ) 139 (55.4% )   
Degree of protein intake  1.38 0.24 
   Moderate to high 14 (35.0% ) 130 (44.8% )   
   Low 26 (65.0% ) 160 (55.2% )   
Hypertension   0.05 0.82 
   Yes 37 (92.5% ) 271 (93.4% )   
   No 3 (7.5% ) 19 (6.6% )   
Diabetes   0.12 0.73 
   Yes 23 (57.5% ) 175 (60.3% )   
   No 17 (42.5% ) 115 (39.7% )   
Dyslipidaem ia   0.08 0.78 
   Yes 35 (87.5% ) 258 (89.0% )   
   No 5 (12.5% ) 32 (11.0% )   
Controlled blood pressure (n= 38) (n= 289) 2.37 0.12 
   No 29 (76.3% ) 184 (63.7% )   
   Yes 9 (23.7% ) 105 (36.3% )   
A1C (% ) (n= 23) (n= 178) 1.09 0.29 
   >  7 13 (56.5% ) 80 (44.9% )   
   <  7 10 (43.5% ) 98 (55.1% )   
LDL cholesterol (mg/ dl)  (n= 36) (n= 257) 9.05 <  0.01*  
   >  100 27 (75.0% ) 124 (48.2% )   
   <  100 9 (25.0% ) 133 (51.8% )   
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Table 4:  ( cont inued)  
Variables Fast  progression 
(n= 40) 
Slow progression 
(n= 290) 
X2 value p-value 
Current  use of NSAI Ds or COX-2 inhibitors  1.01 0.31 
   Yes 4 (10.0% ) 17 (5.9% )   
   No 36 (90.0% ) 273 (94.1% )   
Current  use of aspir in   2.01 0.16 
   Yes 12 (30.0% ) 121 (41.7% )   
   No 28 (70.0% ) 169 (58.3% )   
Prescr ibed, convent ional medicat ion adherence* *   7.92 <  0.01*  
   Low 17 (42.5% ) 64 (22.1% )   
   Medium to high 23 (57.5% ) 226 (77.9% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
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Table 5:  Univariate analyses of the fast  progression of CKD and variables 
am ongst  respondents who did not  have glomerular diseases, cancer, HIV, and 
cirrhosis (n= 258)  
Variables Fast  progression 
(n= 84) 
Slow progression 
(n= 174) 
X2 value p-value 
HDS use   <  0.01 0.98 
   Exposure 24 (28.6% ) 50 (28.7% )   
   Non-exposure 60 (71.4% ) 124 (71.3% )   
Age   6.07 0.01*  
   <  60 27 (32.1% ) 32 (18.4% )   
   >  60 57 (67.9% ) 142 (81.6% )   
Sex   5.24 0.02*  
  Male  47 (56.0% ) 71 (40.8% )   
  Female 37 (44.0% ) 103 (59.2% )   
Current  smoking   2.05 0.15 
   Yes 7 (8.3% ) 7 (4.0% )   
   No 77 (91.7% ) 167 (96.0% )   
Obesity (n= 78) (n= 166) 0.59 0.44 
   Yes 37 (47.4% ) 70 (42.2% )   
   No  41 (52.6% ) 96 (57.8% )   
Exist ing proteinur ia (n= 75) (n= 144) 22.94 <  0.01*  
   Yes 51 (68.0% ) 49 (34.0% )   
   No 24 (32.0% ) 95 (66.0% )   
Degree of protein intake  0.88 0.35 
   Moderate to high 37 (44.0% ) 66 (37.9% )   
   Low 47 (56.0% ) 108 (62.1% )   
Hypertension   0.45 0.50 
   Yes 82 (97.6% ) 167 (96.0% )   
   No 2 (2.4% ) 7 (4.0% )   
Diabetes   0.14 0.70 
   Yes 54 (64.3% ) 116 (66.7% )   
   No 30 (35.7% ) 58 (33.3% )   
Dyslipidaem ia   <  0.01 0.94 
   Yes 77 (91.7% ) 159 (91.4% )   
   No 7 (8.3% ) 15 (8.6% )   
Controlled blood pressure (n= 83) (n= 173) 0.01 0.91 
   No 56 (67.5% ) 118 (68.2% )   
   Yes 27 (32.5% ) 55 (31.8% )   
A1C (% ) (n= 57) (n= 118) <  0.01 0.93 
   >  7 26 (45.6% ) 53 (44.9% )   
   <  7 31 (54.4% ) 65 (55.1% )   
LDL cholesterol (mg/ dl)  (n= 75) (n= 164) 5.27 0.02*  
   >  100 44 (58.7% ) 70 (42.7% )   
   <  100 31 (41.3% ) 94 (57.3% )   
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Table 5:  ( cont inued)  
Variables Fast  progression 
(n= 84) 
Slow progression 
(n= 174) 
X2 value p-value 
Current  use of NSAI Ds or COX-2 inhibitors  0.35 0.55 
   Yes 7 (8.3% ) 11 (6.3% )   
   No 77 (91.7% ) 163 (93.7% )   
Current  use of aspir in   0.97 0.33 
   Yes 37 (44.0% ) 88 (50.6% )   
   No 47 (56.0% ) 86 (49.4% )   
Prescr ibed, convent ional medicat ion adherence* *   6.27 0.01*  
   Low 26 (31.0% ) 30 (17.2% )   
   Medium to high 58 (69.0% ) 144 (82.8% )   
*  Stat ist ical significance at  p-value <  0.05 
* *  Medicat ion adherence was measured using the Thai version of 8- I tem Morisky Medicat ion 
Adherence Scale®  227,228 
Use of the © MMAS is protected by US copyr ight laws. Perm ission for use is required. A license 
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Table 6:  Univariate analysis of the fast  progression of CKD between the exposed 
group who current ly and regularly used HDS at  baseline and during the follow-up 
period (n= 62)  and the unexposed group who was non-users, form er users or 
occasional users at  baseline and during the follow-up period (n= 177)  
Variables Fast  progression 
(n= 85) 
Slow progression 
(n= 154) 
X2 value p-value 
HDS use   2.42 0.12 
   Exposure 17 (20.0% ) 45 (29.2% )   
   Non-exposure 68 (80.0% ) 109 (70.8% )   
 
 
